<SEC-DOCUMENT>0001628280-20-008534.txt : 20200528
<SEC-HEADER>0001628280-20-008534.hdr.sgml : 20200528
<ACCEPTANCE-DATETIME>20200528161611
ACCESSION NUMBER:		0001628280-20-008534
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		51
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200528
DATE AS OF CHANGE:		20200528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adverum Biotechnologies, Inc.
		CENTRAL INDEX KEY:			0001501756
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				205258327
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36579
		FILM NUMBER:		20921255

	BUSINESS ADDRESS:	
		STREET 1:		800 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		650-272-6269

	MAIL ADDRESS:	
		STREET 1:		800 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Avalanche Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20100921
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>advm-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a,d:6cc84e466e2441dcb07b49b4c9803a6d--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20200331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>advm-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV80LTEtMS0xLTA_06ecddaa-0918-4429-96f0-8fa68005c7a0">false</ix:nonNumeric><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV82LTEtMS0xLTA_7e304b32-ef21-4903-b217-5839690777d9">2020</ix:nonNumeric><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV83LTEtMS0xLTA_1eb30538-08d3-40ce-a780-3be4f08fb2e2">Q1</ix:nonNumeric><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV8xMC0xLTEtMS0w_215e18ce-e9f1-4433-849e-1bbc684c6359">0001501756</ix:nonNumeric><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV8xMS0xLTEtMS0w_fc4fdb89-8588-48be-9c05-13b1415fa547">12-31</ix:nonNumeric><ix:nonNumeric contextRef="i7a217f3fdd144ea6b634832732d7d3db_I20200331" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM0Nw_17c69df5-37f9-4e40-b044-a43f7f4fa76d">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="advm-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ib3b5cb04ce03418782a7afb3b064fa24_I20200522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-05-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e35996fd934b90add7c64de848251a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacf2abccc1834cb1bdaab10d8de21ca0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia816f302506f4971bff3c5020987ffa0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67edce6e02864aa48bab4d1c16e87715_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7321fa80e56a46d986877106f9f44748_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c01bdf8459643d8a68ef8c51b769185_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093bc26ce2354e49aecd7233bb878cbd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e8cce64cab4c6e9d91184e4d15997c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a23c9af1b9940d09d585b851026690a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idaf6e1fd67294be9a4ce6f1605da8ebf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05a0800f62f84a1f83badb8e82cff328_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieecaee0157b64ef9ba48e56e97f43459_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3969f7d77a94b91b93ebc11fb4d9a86_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie296a832075d46d2b88ab3bca1eecd12_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idefba8ae62c94026a09f3f5f81761591_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib67d336e80f142c7ad1f135676f4b5f4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0984d4527bd849dea64c0968d781c858_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e2950d05d944066bb3c8f6b9541befb_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ba61405a18e48f09259ca56e8354dab_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ebb645f5e3746168957a7ff7640900b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff64a4df71714cc2b301cd15fa17cac9_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15463bcc9ee04802abd38ead29ea3887_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i833ac88809664274ab22787623b8d238_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93fd01d998494aca846c6d58c36d0dcc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8240d35edaef41478472c5ad37bc778a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a217f3fdd144ea6b634832732d7d3db_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342bf0ef26dc49da8828fe5944816454_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedc52aa3b04946a0a0eef67548681e3e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707559898d544e9bb307731a2ae13d5f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e71d13a2174d099753799db973fd83_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i621486e661ba4c8b85b23a96dfe63109_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8729f4de91b34c2d919e7cf785fff591_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01f564a1a87d437f9d0b3f17d3bac012_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fefcb42e1542bd867592dab7eee895_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idce7caa83b044c50a6c225417896fd78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6384f75152d49f38ebf15724aca6383_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa66768ec34c4f83b89a84a802763883_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11acc5e392074f6aa619a7caf4b0e38b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747bceb18b5d4106adeb8f39000b9982_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dff8015a05449eda49c8fb0645749d9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife518f866ce14a03be135a52d4f9429c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6e4fe498c24ec5abb76f172e87c141_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64910ab1df99412c876858849bf70e6f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib286c4189e9142e595e64dd9e87b795b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78c5e96cfeb4a7ba9d2f8f09386b78f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i067845b9bbc441dca466c83c3266762f_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2550dd60ce2c49f19a995e351a4d4e99_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ebb3283ddf14932b74fbf553fe5f243_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2be7ba555c8443369db8b32a5b5a90b0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73b815ac0dad4ea7937de1d62295b3f1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advm:TrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib89a5f94a6544269b3729160754cd23d_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001501756</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advm:TrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_1"></div><div style="height:45pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">WASHINGTON</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">, DC 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">___________________________________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%;">FORM <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM1_032c5a79-1869-4f80-b6f5-921891331526">10-Q</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">___________________________________________________________________</span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:2.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:93.162%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MDAzMmQ4NTNhMTFhNGIxMzkwNGVmZGUyMDcwMjRhNjcvdGFibGVyYW5nZTowMDMyZDg1M2ExMWE0YjEzOTA0ZWZkZTIwNzAyNGE2N18wLTAtMS0xLTEyNDY_2df007cd-c468-4e65-bc99-d92ca2284a67">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM18xMDk5NTExNjMwMjU4_2c665882-7ddd-4681-8c4c-d4f3f70a4b2f">March&#160;31, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">or</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:2.838%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:93.162%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6YzM3YTg3NDIyMzcwNDkwODk4ZTkwMWQ5ZWZhZjFjYzYvdGFibGVyYW5nZTpjMzdhODc0MjIzNzA0OTA4OThlOTAxZDllZmFmMWNjNl8wLTAtMS0xLTEyNDg_896ef8f8-50ed-4025-96cd-8a38f4d66c7d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center;margin-top:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> to </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission File Number: <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDUw_f5728d29-562a-4ea1-ba63-e253afb62cc2">001-36579</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">___________________________________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM2_1d001eb4-6d1e-4120-8902-d1d847e363ff">Adverum Biotechnologies, Inc.</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">___________________________________________________________________</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:46.538%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.723%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.539%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MzY2ZjE5NTZkYzRhNDdiMWFhYzZkMzI5YmUwZDU1OGUvdGFibGVyYW5nZTozNjZmMTk1NmRjNGE0N2IxYWFjNmQzMjliZTBkNTU4ZV8wLTAtMS0xLTExOTg_cacbf85f-15b6-446c-a868-2a9f8d0471cf">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MzY2ZjE5NTZkYzRhNDdiMWFhYzZkMzI5YmUwZDU1OGUvdGFibGVyYW5nZTozNjZmMTk1NmRjNGE0N2IxYWFjNmQzMjliZTBkNTU4ZV8wLTItMS0xLTExOTk_61dab842-4343-4c6f-a27e-3df334daf8e5">20-5258327</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(State or other jurisdiction of</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">incorporation or organization)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(I.R.S. Employer</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Identification No.)</span></div></td></tr></table></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDUx_e7017e20-0b85-46e1-b235-b2ea33277816">800 Saginaw Drive,</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180Mzk4MDQ2NTEzNzM5_0da3548c-ef7b-4eba-8cd8-0618fc8f7873">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU1_54fafea0-3c08-4ec9-ab67-e25e4291b16e">CA</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Address of principal executive offices)</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM4_238593cb-0ae0-4e41-926a-354e374c5260">94063</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Zip Code)</span></div><div style="text-align:center;margin-top:5pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">(<ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDQ1_fabc4ee0-ac4f-4d92-9b0d-ffc5cd301a31">650</ix:nonNumeric>) <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDQ5_815ba500-d98f-46be-ab25-caa2fe67fb16">656-9323</ix:nonNumeric></span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;">___________________________________________________________________</span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:32.407%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.185%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.408%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">Title of each class</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">Trading symbol</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;text-decoration: underline;">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTAtMS0xLTEyMjA_9023f726-3502-4872-ab7d-5d65731a4158">Common Stock, $0.0001 par value</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTEtMS0xLTEyMjI_ab16952c-2ee7-417a-9f73-8694777848f6">ADVM</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTItMS0xLTEyMjM_1fb16e40-8451-42fc-9148-21d71e8220be">The Nasdaq Global Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU2_43cb6c58-440b-44f2-bbc6-96377987d520">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#168;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU3_cbe43331-f58c-4575-9434-344ca22ae26a">Yes</ix:nonNumeric>&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">x</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#168;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:29.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.723%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:25.339%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:33.087%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.219%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Large accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#168;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8wLTMtMS0xLTEyNDI_b76e7019-0497-468e-b15d-45a34da8fa5a">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">x</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Non-accelerated filer</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#168;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Smaller reporting company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Wingdings',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8xLTQtMS0xLTEyMzY_02435210-2fb8-49ac-940b-482f74196c5a">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Emerging growth company</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8yLTQtMS0xLTEyNDQ_a5b9e0f8-a02c-426b-a663-30a52daf0d9e">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#168;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NTgw_6488e276-dd65-403a-8ddc-c1eebdd8f2d3">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">x</span></div><div style="margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">As of May&#160;22, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ib3b5cb04ce03418782a7afb3b064fa24_I20200522" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU5_451ebfb7-7b5a-4807-b551-cc1876d8627c">80,295,560</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, outstanding.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span><br/></span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center;margin-top:24pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:90.228%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:5.772%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Page</span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_10">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_10">3</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_13">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">Condensed Consolidated Balance Sheets as of </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16"> and December 31, 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16"> (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">Condensed Consolidated Statements of Operations and Comprehensive Loss for the three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19"> (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">Condensed Consolidated Statements of Stockholders&#8217; Equity for the three </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">March</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25"> (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">Condensed Consolidated Statements of Cash Flows for the </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">thre</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">e months ended </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">Ma</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">r</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">ch</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28"> 3</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">1</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28"> and 201</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">9</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28"> (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_31">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_76">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_76">11</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_97">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_97">16</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_100">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_100">17</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_103">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_103">18</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_106">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_106">18</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_109">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_109">18</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_112">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_112">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_115">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_115">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_118">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_118">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_121">Item 5. Other Information</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_121">53</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_124">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_124">54</a></span></div></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_127">SIGNATURES</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: none;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_127">56</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_13"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;Financial Statements</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_16"></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Current assets:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMy0xLTEtMS0w_ae2770ad-4131-456c-b43c-6f4d97b9bc4d">130,162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMy0zLTEtMS0w_8397d4a1-0ecd-437c-9911-2d4bf1b31de1">65,897</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Short-term investments</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNC0xLTEtMS0w_e89419e0-9b18-4629-bf59-654e797cb494">166,904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNC0zLTEtMS0w_e701f616-09a4-40df-bee4-d33ee6bb89c3">100,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNS0xLTEtMS0w_c09b0d24-c6e2-4f5b-bc1b-27f498cb7ede">3,382</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNS0zLTEtMS0w_83b8602e-674e-48d5-bb4c-cdeb654314f8">9,835</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNi0xLTEtMS0w_0c41daf1-f1af-41d5-b33c-c798097cb1f1">300,448</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNi0zLTEtMS0w_95ea5ddc-d8dc-464b-ba73-078cac247fe6">175,870</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNy0xLTEtMS0w_d225ec48-007a-43d8-a919-a8e1e0c6bb42">20,406</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNy0zLTEtMS0w_5c6619a1-1b41-41eb-965e-178406d9e12a">20,963</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOC0xLTEtMS0w_87594c57-cf6b-47a8-b9a0-5cd25ab25e16">26,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOC0zLTEtMS0w_c5c96a46-4a96-4b6d-85f6-eaae605cd077">24,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOS0xLTEtMS0w_da745cc4-3c9f-49fb-bbfb-c4dc9e3d18cc">999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOS0zLTEtMS0w_16a81349-41c9-4004-9ecb-b341897945bb">999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Deposit and other long-term assets</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTAtMS0xLTEtMA_db6037e2-484e-4532-a7b4-e7539db266b7">19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTAtMy0xLTEtMA_2963378e-8089-4460-b9a9-227c65d86fc9">11</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTEtMS0xLTEtMA_f94c2d12-c786-4841-a867-516e7f50cb8a">348,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTEtMy0xLTEtMA_fc3e76f4-b312-4d3c-ac0d-d7094df6214b">222,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liabilities and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accounts payable</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTQtMS0xLTEtMA_4496ee14-5466-4d56-b964-ace2868d421d">4,663</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTQtMy0xLTEtMA_b7c6a8f5-e994-49f0-8f15-e419a6cd048e">4,103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTUtMS0xLTEtMA_3c37184d-1090-4b4d-afe4-c173ff327839">8,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTUtMy0xLTEtMA_e7c83ec2-037d-4b6d-941f-ead5edb5e35d">11,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease liability, current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTYtMS0xLTEtMA_30b924e4-4fde-49e3-8456-313a049056f9">4,025</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTYtMy0xLTEtMA_c04ce3c5-5f65-4101-b20f-d64ad651c269">4,034</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total current liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTgtMS0xLTEtMA_9fa47114-655d-467e-91cb-837cc79df19c">16,767</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTgtMy0xLTEtMA_4da690cb-73a8-4cf7-a594-53d2efe41838">19,408</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease liability, net of current portion</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjAtMS0xLTEtMA_55389f6e-a720-4672-8dda-3d3f6fbf9437">27,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjAtMy0xLTEtMA_b5da4aa1-e0ce-4756-a9ab-9870fdd1d9da">28,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjEtMS0xLTEtMA_22a0fec1-3c66-485f-953f-009b2d5ad38c">126</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjEtMy0xLTEtMA_5530dd07-7e9e-4e6b-a597-e962faa6005a">148</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total liabilities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjItMS0xLTEtMA_fedca108-c483-453e-9c38-8655c33eea51">44,646</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjItMy0xLTEtMA_17b519d6-4122-42eb-95ce-9f98de9a7fe5">47,770</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjUtMS0xLTEtMA_99ef0ca0-e403-4642-94f1-4b2111f32a6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjUtMy0xLTEtMA_1c9d62cb-62f5-49b2-96a2-b0d21601434f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Common stock</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjYtMS0xLTEtMA_6c9c4cfa-8f18-4e11-850a-a14e53c54b26">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjYtMy0xLTEtMA_d1c9df00-626b-4283-8417-376b8bde0000">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjctMS0xLTEtMA_897de7d8-276d-4f05-9482-50a73955369a">712,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjctMy0xLTEtMA_34674bb4-10c8-453e-a0fd-5a914f67f811">560,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjgtMS0xLTEtMA_bad6ad02-f885-4fec-a7ca-15d23a96b367">833</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjgtMy0xLTEtMA_8acc055b-358d-4a54-afb5-ec672efa47cf">725</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjktMS0xLTEtMA_32c6de5d-14d0-4a97-a2ae-c80e459c5924">407,935</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjktMy0xLTEtMA_47d49429-a6e3-4832-b61e-961e0d1526fc">385,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzAtMS0xLTEtMA_4a75cf05-64b7-4b41-8d36-e69907519064">303,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzAtMy0xLTEtMA_739c3ce5-dd6c-472f-9ff0-691bc7663393">174,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities and stockholders' equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzEtMS0xLTEtMA_ac4a3313-9590-492d-9c69-b3002c21f12b">348,599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzEtMy0xLTEtMA_9bafb627-2661-4e1d-a358-9d06a707c158">222,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_19"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands except per share data)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:72.415%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.426%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.429%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNS0xLTEtMS0w_82d14a36-36dc-4bb1-b1f7-b35186cd3a68">14,751</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNS0zLTEtMS0w_79c3adc8-7974-44f0-a851-1bdc9bada42a">10,131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNi0xLTEtMS0w_ae7b3abc-0f28-47a5-830c-2ba5f4583133">9,040</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNi0zLTEtMS0w_7fc347a2-c854-49b7-9c4d-10887155cf1b">5,576</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOC0xLTEtMS0w_0e7ea70f-fe2a-43f7-96ec-ee52bbff68bf">23,791</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOC0zLTEtMS0w_3e9a8f13-05e7-4fdb-a16f-ab5fdcf06f97">15,707</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOS0xLTEtMS0w_e37cd496-b2fd-49af-a077-cc1f3146a67b">23,791</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOS0zLTEtMS0w_056c8e17-68f3-4f67-a29c-eaeedfd33aae">15,707</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTAtMS0xLTEtMA_74796613-c5d8-471a-bdc4-33a169136d2c">885</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTAtMy0xLTEtMA_2bef6822-f590-432e-a429-6df0180d5395">1,218</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTMtMS0xLTEtMA_af2f1add-cfb5-49a9-a9df-2e1ef73fab3a">22,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTMtMy0xLTEtMA_c26c71b4-73db-4e9a-9cb7-29b0a8d86c7f">14,489</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net unrealized (loss) gain on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTUtMS0xLTEtMA_f178c64a-c88e-4e8f-8493-e17d58f16516">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTUtMy0xLTEtMA_f41975f0-4d14-4506-8a53-9169d85539d1">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTYtMS0xLTEtMA_47c2f6f3-27ab-49e0-bf2f-401cb2ea592a">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTYtMy0xLTEtMA_0caa177d-9a6e-4332-9d39-a0bb13ea1ff7">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTctMS0xLTEtMA_75c3528e-f9f3-41c8-b149-005629f82c75">23,014</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTctMy0xLTEtMA_fa1e408d-a713-4961-aaa6-5960403a0304">14,444</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss per share &#8212; basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTgtMS0xLTEtMA_b7eebfe7-fba0-4424-8220-f5a7ca21b940">0.31</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTgtMy0xLTEtMA_ac7b1b9a-9070-4995-bb7a-df744507b7df">0.23</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Weighted-average common shares used to compute net loss per share - basic and diluted</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTktMS0xLTEtMA_5a3af2bc-d52a-46da-9689-8ac2b9948d54">73,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTktMy0xLTEtMA_e484ef95-19b6-4dd3-b789-1b6b3e96c452">63,125</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(Unaudited)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:28.847%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.134%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.681%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated Other<br/>Comprehensive<br/>(Loss)/Income</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0xLTEtMS0w_732601b2-6a45-4c5c-a2ed-6702ccea316d">67,329</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0zLTEtMS0w_21145d8f-e379-4a5c-9f75-b02de645cce3">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iacf2abccc1834cb1bdaab10d8de21ca0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi01LTEtMS0w_004fce56-3a6b-48ce-9482-db1ba81016b9">560,704</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia816f302506f4971bff3c5020987ffa0_I20191231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi03LTEtMS0w_da785afd-ba75-4e66-b248-37c7171a325b">725</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i67edce6e02864aa48bab4d1c16e87715_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi05LTEtMS0w_d7038570-e049-4e71-9791-5a1f8b767d2f">385,029</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0xMS0xLTEtMA_11c981e8-23ac-45a6-88ac-6d7dfb438f53">174,957</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMy01LTEtMS0w_482e2cec-0aaa-447e-97c7-f1c766537edb">3,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMy0xMS0xLTEtMA_6bc5d5ca-79ab-41dd-a100-426cf1d20115">3,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Issuance of common stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0wLTEtMS0xNjYwL3RleHRyZWdpb246YzcxZGNkZDUzYjg2NDIyODhjNzYwNDMwMWM5NmE2NWFfNDk0NzgwMjMyNTA1NA_0a4f548f-8551-4a18-8324-895a5276d01a">332</ix:nonFraction></span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xLTEtMS0xNjc5_24a5d928-ce28-4bd4-a45f-6ce75c157391">10,925</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0zLTEtMS0xNjc5_75943967-e08d-4a81-ad21-b584b2eba56c">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC01LTEtMS0xNjc5_2cb70d17-3f14-45f6-b825-7128fb5b1f64">140,872</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xMS0xLTEtMTY3OQ_b707834a-cb5a-4ebf-b846-cbd725941b71">140,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock issued upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xLTEtMS0w_3d803367-272d-4e08-92d7-e1cb02e13d04">1,310</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC01LTEtMS0w_c6495b47-849f-4bba-bdc4-221559d8a9f3">9,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xMS0xLTEtMA_e8d86afd-352e-4c4d-8916-127f3f411866">9,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock issued upon exercise of warrants</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="INF" name="advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xLTEtMS0yMjQy_f3f14321-558a-44b6-9a96-9c63413ffe7b">7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock issued upon release of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNS0xLTEtMS0w_3d849306-ac4a-4621-8a37-74ce2ade51e5">462</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock surrendered for taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xLTEtMS0w_972f1e87-1fee-4c77-a3b8-3bb68056f8e9">155</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:StockPaidValueForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi01LTEtMS0w_d08c990d-9cb3-4caa-92e0-18e6bc81a34d">1,922</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:StockPaidValueForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xMS0xLTEtMA_06e3c7ff-4bed-4ef3-8f8f-e1cbf5ec050f">1,922</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustments     </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOC03LTEtMS0w_40c16113-14ff-46d6-a3b9-48b12befcd04">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOC0xMS0xLTEtMA_a6a558f6-e56b-405a-a113-71dccfb14947">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized loss on marketable securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOS03LTEtMS0w_4ef01261-9a26-4a84-a5bc-7b77e83afddd">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOS0xMS0xLTEtMA_2a8d7d3f-1c39-4cc7-b676-9e4761ac0d5f">54</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4c01bdf8459643d8a68ef8c51b769185_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTAtOS0xLTEtMA_3d0278f5-eb56-4f60-8578-6f9c92ef2f75">22,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTAtMTEtMS0xLTA_69cbd87b-0e65-4f88-910d-f5d7c1e66ff7">22,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i093bc26ce2354e49aecd7233bb878cbd_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMS0xLTEtMA_c10f8098-aa4e-4bc0-b3c9-bcbf1d808432">79,878</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i093bc26ce2354e49aecd7233bb878cbd_I20200331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMy0xLTEtMA_1b4313d5-35a4-424f-9510-a2a29dca6b80">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i24e8cce64cab4c6e9d91184e4d15997c_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtNS0xLTEtMA_10603458-f60b-4a36-8cbd-0a980829ad11">712,713</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a23c9af1b9940d09d585b851026690a_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtNy0xLTEtMA_3b847605-1d9f-499f-91b4-daf13f898c24">833</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idaf6e1fd67294be9a4ce6f1605da8ebf_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtOS0xLTEtMA_a305b062-36d2-474a-ae08-57bf012ba4f1">407,935</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMTEtMS0xLTA_a2fd9f3a-f7d6-412f-8f23-b58e752db676">303,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.415%;"><tr><td style="width:1.0%;"></td><td style="width:28.441%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.205%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.735%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.535%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0xLTEtMS0w_c7165eca-a1d7-4e45-bff0-9a6824603f1a">62,965</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0zLTEtMS0w_da734e4d-3e9c-41db-a874-672b21a339e8">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05a0800f62f84a1f83badb8e82cff328_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi01LTEtMS0w_774defef-ede3-4a43-bb6b-2612f174c685">522,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ieecaee0157b64ef9ba48e56e97f43459_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi03LTEtMS0w_c8599c85-6048-4c0c-b011-b3456b945c8d">799</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie3969f7d77a94b91b93ebc11fb4d9a86_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi05LTEtMS0w_96b3a653-9c1c-4b23-8564-40671655a273">320,543</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0xMS0xLTEtMA_6c6d9fb7-ff62-446f-b7be-851effa5bc5a">201,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMy01LTEtMS0w_6fd2717e-1ba6-4755-a291-3703a6bb8a30">1,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMy0xMS0xLTEtMA_d99eb101-5ef1-4c69-80c8-8b8183d30a57">1,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock issued upon exercise of stock options</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi0xLTEtMS0w_65b4034b-9fca-4e69-a8bd-eb3bc8481e00">119</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi01LTEtMS0w_7c2920f6-d174-4a28-b9b5-766d4b1ed5f5">162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi0xMS0xLTEtMA_cf7d4e87-ec87-455f-97fe-cbd4fd6f7f23">162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:20.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Common stock issued upon release of restricted stock units</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNy0xLTEtMS0w_f286b135-d1cd-433d-981f-41b79fbd26a4">397</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock surrendered for taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331" decimals="INF" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOC0xLTEtMS0w_edca8979-55e3-4f50-b8e2-3e6ee607307d">145</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="advm:StockPaidValueForTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOC0xMS0xLTEtMA_bd2b10d2-b794-4dda-ae2d-4a8b077938b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes paid for RSUs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOS01LTEtMS0w_f762673c-816f-4dff-95d6-17e6e41e452b">504</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOS0xMS0xLTEtMA_1c9aa557-c649-4112-b64c-75b5b0aedd0d">504</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTAtNy0xLTEtMA_b0e1e16b-8355-45ec-83fd-b5eaccd17750">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTAtMTEtMS0xLTA_b1912e92-7943-44b3-9719-267337e95587">42</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized gain on marketable securities, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTEtNy0xLTEtMA_b4200914-6636-4d8f-a774-599b10f3ff3f">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTEtMTEtMS0xLTA_9ebd2ea7-c074-44a6-89f6-a67bb16de466">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie296a832075d46d2b88ab3bca1eecd12_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTItOS0xLTEtMA_865d45b9-9e52-4942-88d9-113555683ac2">14,489</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTItMTEtMS0xLTA_c4330857-bbc8-4f8d-a26d-7e693753178a">14,489</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="idefba8ae62c94026a09f3f5f81761591_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMS0xLTEtMA_b1ef46f1-601b-40ed-82e0-959251bab93d">63,336</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idefba8ae62c94026a09f3f5f81761591_I20190331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMy0xLTEtMA_e4747633-a95f-4d2d-8260-eb933e06ad1c">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib67d336e80f142c7ad1f135676f4b5f4_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtNS0xLTEtMA_310a18ab-b210-44d1-ae96-1120455e06dd">523,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0984d4527bd849dea64c0968d781c858_I20190331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtNy0xLTEtMA_25a7dac2-21eb-4fa0-866d-40d7bc2c1768">754</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i6e2950d05d944066bb3c8f6b9541befb_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtOS0xLTEtMA_fd688192-1d4d-4645-a35e-4a56bd7e4f9a">335,032</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ba61405a18e48f09259ca56e8354dab_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMTEtMS0xLTA_86fd3ad7-5417-4e82-95cc-eab3a51e4658">188,143</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_28"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">(In thousands)</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Unaudited</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:69.994%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.636%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.637%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMy0xLTEtMS0w_c4527d53-1399-4b60-b289-de17dd7e873d">22,906</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMy0zLTEtMS0w_1267f495-d69b-4027-aa60-5e3771cacc11">14,489</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNS0xLTEtMS0w_205670ca-a706-4628-8da2-8ed76c10d8ac">599</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNS0zLTEtMS0w_1fb7d53d-2404-4f33-b62b-2332f4c9667e">426</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNi0xLTEtMS0w_f1499d1a-b689-47f3-9a9e-6e861b1ee3ec">3,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNi0zLTEtMS0w_c63c5a6d-3069-46b4-81b7-45c37f153db6">1,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of premium and accrued interest on marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNy0xLTEtMS0w_02062a84-a563-4dc2-9d4e-49ac348c16cf">179</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNy0zLTEtMS0w_6e9c3e88-c28f-4c26-9e26-f279d83a2fa2">129</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTAtMS0xLTEtMA_3070e035-b192-480d-bc10-999fcd0b7773">48</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTAtMy0xLTEtMA_0737d838-efd7-45d4-bd2c-170fc1fa51f5">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMS0xLTEtMA_6767a071-abc7-4709-a004-964b3339b9e5">6,345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMy0xLTEtMA_ff1ffbab-ca7f-456d-987d-96482c2ebc9a">91</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:23.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTEtMS0xLTEtMTQwMw_ce4ebe0a-0703-4359-9adb-6492e991d7d1">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTEtMy0xLTEtMTQwNQ_cc3a3b1b-83cf-4975-b22d-1f201d600e88">18</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:23.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMS0xLTEtMTM5OQ_6cd4cf9e-97ee-41d5-aa5f-9198363120f7">557</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" name="advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMy0xLTEtMTQwMA_4878794e-a2ca-460b-8560-040201f68e71">539</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTMtMS0xLTEtMA_0eb0617d-634c-44c0-83c1-519f06d11e04">2,514</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTMtMy0xLTEtMA_33babb31-08e7-4b9f-ac9e-70d03489ac97">136</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTQtMS0xLTEtMA_b903d5f6-8155-4f0e-837e-dbbc3aaac749">3,429</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTQtMy0xLTEtMA_45acda95-bfbb-4716-9def-5df2fd8cbdf2">2,363</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24.75pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" name="advm:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTctMS0xLTEtMA_55818488-667e-451b-bffe-c06f43a61ccd">470</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="advm:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTctMy0xLTEtMA_2022a6b3-1969-4ac7-afa9-773dc69b8eaf">1,242</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTktMS0xLTEtMA_9770458a-29c1-47db-9cc0-15237854290a">13,616</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTktMy0xLTEtMA_9c4790a2-a368-48af-b63f-a31f511c095f">13,217</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjEtMS0xLTEtMA_efc7ced1-e060-4ab2-abaf-dff0a8df12cc">127,733</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjEtMy0xLTEtMA_00c8020f-2702-4b1c-b83c-08d64f393a3e">22,454</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Maturities of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjItMS0xLTEtMA_76d86260-5ac1-412c-864b-ce2de3403a8e">61,200</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjItMy0xLTEtMA_4968123e-91bc-4da7-9548-2404469f7887">27,385</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjMtMS0xLTEtMA_84b20f66-3a6f-4498-aeec-e7341676ada8">4,210</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjMtMy0xLTEtMA_58aa9010-e198-4e97-b1cc-44f79e41477c">2,186</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjQtMS0xLTEtMA_036463c7-29b9-451b-96a0-23d4af3e92e2">70,743</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjQtMy0xLTEtMA_06f784e7-78c9-4aaf-a0c3-89cb12288c5b">2,745</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from offerings of common stock, net of issuance costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjYtMS0xLTEtMA_8679620e-5c29-4105-96b8-a7896d491f83">140,923</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjYtMy0xLTEtMA_8ca645fb-9322-43d3-ad2f-3f96bf98a34b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from issuance of common stock pursuant to option exercises</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjgtMS0xLTEtMA_841ab23c-eea6-4727-879d-1732fbaa0cae">9,650</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjgtMy0xLTEtMA_594f15fa-c4c6-4a57-970f-ca4b7e91218a">162</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes paid related to net share settlement of restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjktMS0xLTEtMA_a2ae7dd0-ed32-43ff-9deb-6565e1001fe8">1,922</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjktMy0xLTEtMA_0785cc55-2a3d-4a11-9b42-09629a63b8c5">504</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Repayment of loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzItMS0xLTEtMA_abcf19a2-ba62-4d9d-ba9f-9c6033272195">27</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:RepaymentsOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzItMy0xLTEtMA_d14efbd2-02e2-45c0-9419-247881fbb1b6">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:36pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzMtMS0xLTEtMA_f830435e-e213-4441-a3c3-72e2150d929d">148,624</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzMtMy0xLTEtMA_c5bfb45e-b994-4260-b715-83bf72d98122">370</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzQtMS0xLTEtMA_f722a0ff-7935-46e8-92a8-30b3d2660a0e">64,265</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzQtMy0xLTEtMA_1481bb70-ef16-4710-8464-9fdfed1887e9">10,842</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzUtMS0xLTEtMA_8b4755d6-71a5-4601-866f-8f1f9dfe36d2">66,896</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzUtMy0xLTEtMA_9d73d272-ff20-4104-9a85-bf0c57317057">155,948</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents and restricted cash at end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzYtMS0xLTEtMA_7ba9243f-7d3e-46e2-871a-2ed114e57171">131,161</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8ba61405a18e48f09259ca56e8354dab_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzYtMy0xLTEtMA_33aa7adc-0565-4b42-ace3-027e4243a289">145,106</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental schedule of noncash investing and financing information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fixed assets in accounts payable, accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzgtMS0xLTEtMA_3c464626-7a6a-4eb7-9a9c-84a6be385868">3,474</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzgtMy0xLTEtMA_a6a54522-9de2-4494-81d9-7ca9d5674306">413</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying notes to condensed consolidated financial statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_31"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Adverum Biotechnologies, Inc.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_34"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">1. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfMjcyMw_a1acbc94-b399-4108-b592-f38770252020" continuedAt="i9a237aab1f0f451db66ce75eab228175" escape="true">Organization and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i9a237aab1f0f451db66ce75eab228175"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or "Adverum") is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The Company&#8217;s core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;cGMP&#8221;) quality control. Since the Company&#8217;s inception, it has devoted its efforts to performing research and development activities, filing patent applications, hiring personnel and raising capital to support these activities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfOTgz_ef30d22d-cbc4-4343-aea1-d2389db994c9">407.9</ix:nonFraction> million as of March&#160;31, 2020. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. The Company believes that it has sufficient funds to continue operations into 2022.</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfNDk0NzgwMjMyNzczNQ_ae0187a4-b0e8-43bc-9569-9b7f6b2979a9" continuedAt="ia0baf50b7ec141debe5082f5fffd9e19" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2020, are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2019 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. </span></div></ix:nonNumeric><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ia0baf50b7ec141debe5082f5fffd9e19">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC</ix:continuation>.</span></div></ix:continuation><div id="i6cc84e466e2441dcb07b49b4c9803a6d_37"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">2. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfMzkxMA_f77bdbbc-d822-4f7c-9c72-9e0750b3b833" continuedAt="i812d7411e65840cea7d8b2cd605371b2" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i812d7411e65840cea7d8b2cd605371b2" continuedAt="i20ef4e95d2eb47b484843d3d2445b61a"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfMzkwNw_becc06c5-a719-4691-84d7-a960fb30ea8f" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfNDk0NzgwMjM0NDk2OA_cef5170f-7957-4909-9403-da601b8c5ded" continuedAt="i606d6ae614c64c8bb380b00353b2ac34" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Topic 326</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i20ef4e95d2eb47b484843d3d2445b61a"><ix:continuation id="i606d6ae614c64c8bb380b00353b2ac34">Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326.</ix:continuation></ix:continuation></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_43"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">3. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjg5Ng_9cfbff6b-5c09-4044-855b-9b0ffd70e579" continuedAt="i26e68b87f1a547e29b717106c09393fd" escape="true">Fair Value Measurements and Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i26e68b87f1a547e29b717106c09393fd" continuedAt="i59e6573df6354c97a853b98e4e9c6d1d"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy.</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjg5Nw_164e64ad-854e-4f5f-b48f-b1fe490c4d00" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC0xLTEtMS0w_f09fc678-6178-4def-b290-c6812c4c9d1d">18,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC0zLTEtMS0w_7b30689e-6f1f-4956-a785-fc09761bf4b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC01LTEtMS0w_2021cc17-2eb5-4a14-b6de-cc53939764b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC03LTEtMS0w_8d03da1f-94bc-4923-ba0c-c732400504cd">18,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi0xLTEtMS0w_2e003877-c86a-4757-87b5-d8f82ad3d9a5">86,930</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi0zLTEtMS0w_d5236f75-1b81-4cb6-b6ef-c6ffe845c4d3">78</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi01LTEtMS0w_e5123da4-3cc2-43f6-bb9e-ae13825325c9">3</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi03LTEtMS0w_29cf7043-029a-4f74-8824-1b0109e07221">87,005</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy0xLTEtMS0w_af186158-8e44-4963-b77c-84c7c8c4c35e">171,736</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy0zLTEtMS0w_4f7cb80e-b003-45d4-96c0-3bbf13fa531c">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy01LTEtMS0w_3195a25f-205d-475e-abf3-650acd5a67dc">121</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy03LTEtMS0w_77a3cd7d-1a08-4d6f-afba-34a7e2b5f896">171,624</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC0xLTEtMS0w_5d71f400-0004-44fb-8cc4-1fc350d254ae">9,499</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC0zLTEtMS0w_88d3451f-aafc-4b69-a99a-ac4029f7dad8">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC01LTEtMS0w_b2cbe766-bd9c-442f-998f-6be4ce3b62da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC03LTEtMS0w_5001f785-4de8-4cfe-b888-4e2293938274">9,500</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i833ac88809664274ab22787623b8d238_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS0xLTEtMS0w_beb3177f-b600-4b92-a147-fde4feaba435">286,480</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i833ac88809664274ab22787623b8d238_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS0zLTEtMS0w_b1912df5-3ece-4ae1-864d-05b22a473502">88</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i833ac88809664274ab22787623b8d238_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS01LTEtMS0w_dd21be42-f622-46a9-b9db-65813f2bf6a5">124</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i833ac88809664274ab22787623b8d238_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS03LTEtMS0w_bf777db7-c4a2-4c6d-addf-6a24483e110a">286,444</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:CashAndCashEquivalentAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtMS0xLTEtMA_285ccdb3-d66b-435a-a86f-99f4978e9b80">119,540</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtMy0xLTEtMA_76a71796-4639-44a2-8510-0eea4ba9b837">15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtNS0xLTEtMA_08d4575c-8ad9-47e0-94eb-3d3a684a9c58">15</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtNy0xLTEtMA_371928f3-8157-416c-9be7-4440625df636">119,540</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtMS0xLTEtMA_91211fbc-ad90-400f-9211-cec830bf9146">166,940</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtMy0xLTEtMA_dd2df514-00d8-4bb1-84df-9d77df269b29">103</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtNS0xLTEtMA_c2696613-2838-4315-bf8d-2e76a8038744">139</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtNy0xLTEtMA_54e0db15-cd2e-4c6c-8ca0-dde23de1e8bd">166,904</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC0xLTEtMS0w_1ff40325-6327-4422-98c3-f5ff37e1f38c">15,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC0zLTEtMS0w_3ce6b443-15da-4b73-b6b7-804d0c78098c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC01LTEtMS0w_c4044d3d-db39-476b-9576-04232d14f8ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC03LTEtMS0w_165ae7e2-314d-4ff7-a282-efefc96370ed">15,056</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi0xLTEtMS0w_399fe3c1-a552-455b-b5a7-1988207b9398">37,974</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi0zLTEtMS0w_646e93db-72b1-4b63-94e2-c176b3faf4d7">14</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi01LTEtMS0w_8ee2ee23-a9f1-4e47-a3f4-4b470e7768c7">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi03LTEtMS0w_a2eb3515-b759-4e29-acfe-5b59256fd2b5">37,986</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy0xLTEtMS0w_60b71511-1555-49c7-b4f9-5c2ad2b156a0">87,983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy0zLTEtMS0w_2c27f30d-9b7d-48be-a1ae-6e3606fb380e">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy01LTEtMS0w_0b2682cc-ef18-49ff-9888-bd9c76336036">8</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy03LTEtMS0w_5c819f10-24ef-42b3-b9d6-c87f3de170dd">87,983</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC0xLTEtMS0w_75a48627-1a6b-40fc-8fcb-af0575869f6f">10,495</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC0zLTEtMS0w_37e24632-ceab-4187-8774-5ee70ea8e639">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC01LTEtMS0w_776886e6-4e17-4fbb-a355-d5d60e5d6a21">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC03LTEtMS0w_025d2730-96bb-4dd1-8c82-713703906f33">10,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtMS0xLTEtMA_0ddd43b2-02f1-43e1-92f1-6e063c3a004b">151,508</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtMy0xLTEtMA_eed03e2a-bb54-4f81-a961-8932fed8891e">28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtNS0xLTEtMA_dc2d624d-3d46-486a-a9e0-e18c698fb339">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtNy0xLTEtMA_cac910ca-f50d-49ef-b292-7d2d37c417d5">151,526</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="advm:CashAndCashEquivalentAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtMS0xLTEtMA_6e0fab44-fd74-496f-a323-a10a3938534a">51,391</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:zerodash" name="advm:CashAndCashEquivalentGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtMy0xLTEtMA_6b689b01-3f12-4432-b1eb-06810f4c0d91">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="advm:CashAndCashEquivalentGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtNS0xLTEtMA_cf642fc0-b44e-4727-a1d7-3f78d32fdb19">3</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtNy0xLTEtMA_b46d0981-1934-44bb-b169-34d3983be0bf">51,388</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItMS0xLTEtMA_2056e580-13b2-425d-935f-6f7866964127">100,117</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItMy0xLTEtMA_1b4ff0ca-715e-4dd7-ad2a-ff3ea8006902">28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItNS0xLTEtMA_d0b5d309-2334-4b44-903d-1e3433bf8a7f">7</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItNy0xLTEtMA_a9af808f-39a7-4af2-8ea6-9204d61e71cc">100,138</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i59e6573df6354c97a853b98e4e9c6d1d">As of March&#160;31, 2020, $<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-5" format="ixt:numdotdecimal" name="advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMTA5OTUxMTYzNDEwNg_a911e08c-a326-490c-95e1-fd0c4aacdc18">20.3</ix:nonFraction> million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM0Nw_17c69df5-37f9-4e40-b044-a43f7f4fa76d">one</span> and <ix:nonNumeric contextRef="i342bf0ef26dc49da8828fe5944816454_I20200331" format="ixt-sec:durwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM2NQ_3da6e154-fc64-4bfe-b542-be482645242d">two years</ix:nonNumeric>. The remainder of the marketable securities have a remaining maturity of less than one year. As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company's consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of March&#160;31, 2020 were temporary in nature and none were in continuous loss position for 12 months or more. Therefore, <ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="INF" format="ixt-sec:numwordsen" name="advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjgwOQ_05fb28de-71ac-4586-b9d8-7450c2710a54">none</ix:nonFraction> of the Company&#8217;s marketable securities were other-than-temporarily impaired as of March&#160;31, 2020.</ix:continuation></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_61"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">4. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ3_d59ff891-04b6-4e48-a721-3916a7ac8e3b" continuedAt="i02ffba2131984432a9721337f5d845b2" escape="true">Balance Sheet Components</ix:nonNumeric></span></div><ix:continuation id="i02ffba2131984432a9721337f5d845b2"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ4_af76df42-7b75-4172-892d-df7c15a106d9" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consists of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iedc52aa3b04946a0a0eef67548681e3e_I20200331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMi0xLTEtMS0w_fa9ed5c6-dcee-4bf8-b6c6-09f4349c0df8">825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i707559898d544e9bb307731a2ae13d5f_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMi0zLTEtMS0w_b12efee4-52e8-4191-8e8c-32534dc747f4">752</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i70e71d13a2174d099753799db973fd83_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMy0xLTEtMS0w_d954dd4f-a0a0-4e3e-a543-5000e8e4c9f6">7,319</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i621486e661ba4c8b85b23a96dfe63109_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMy0zLTEtMS0w_51f0e725-830f-4c2e-9f6a-36a940143d37">6,291</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8729f4de91b34c2d919e7cf785fff591_I20200331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNC0xLTEtMS0w_0c0f090c-ec67-46ea-a37c-45e4d11d97b3">678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01f564a1a87d437f9d0b3f17d3bac012_I20191231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNC0zLTEtMS0w_333b0ede-5edd-46f2-9038-f81463ffa957">678</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i83fefcb42e1542bd867592dab7eee895_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNS0xLTEtMS0w_95c0f840-7b88-4a3a-bd91-d43548c7c18c">26,263</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="idce7caa83b044c50a6c225417896fd78_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNS0zLTEtMS0w_3be71d27-ec7c-4976-87ca-2584cc7c79ef">1,602</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie6384f75152d49f38ebf15724aca6383_I20200331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNi0xLTEtMS0w_6e83148e-738f-4a7f-912d-ed802c84f39d">233</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifa66768ec34c4f83b89a84a802763883_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNi0zLTEtMS0w_3f610091-30cd-4871-994e-b28358f07e63">23,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNy0xLTEtMS0w_b02ba02b-7135-47c9-a45c-723670356dfd">35,318</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNy0zLTEtMS0w_b6e5a01c-a85e-4ae7-99ae-1c809a7ccc71">32,876</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOC0xLTEtMS0w_d2627421-1160-48b0-a504-0c8412096ea4">8,591</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOC0zLTEtMS0w_eaca9fe9-aca9-4498-962d-e2e68f3a255d">7,992</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOS0xLTEtMS0w_a8fc28bb-0bd0-4f6e-993f-055049800458">26,727</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOS0zLTEtMS0w_124874ff-0c14-4d96-bc16-c64030b1cc9e">24,884</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense related to property and equipment for the three months ended March&#160;31, 2020 and 2019 was $<ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfMjMx_3a01fc7d-d79c-432f-9d98-5d2243d1d7e8">0.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfMjM5_05985cce-9d40-4a49-8cf8-3d5d510f256b">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses and Other Current Liabilities</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ2_c6aa7617-a851-47fb-922f-01ef5ce634e4" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.941%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfMy0xLTEtMS0w_3b37a692-7346-4a0c-ab00-2b702c8a3ac5">2,299</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfMy0zLTEtMS0w_acfa4429-f28e-46bd-8f4b-0e0cdd2e3cc1">4,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued preclinical, clinical and process development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNC0xLTEtMS0w_e6e7aa34-5c42-4b18-9f14-888f7dff2fa0">1,823</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNC0zLTEtMS0w_dd626568-9dd5-4a2c-8e8b-0f2e9490fb0f">1,973</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0xLTEtMS0xODY1_969db906-6504-4873-8672-61b11ea6a853">1,466</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0zLTEtMS0xODY1_8482ecc2-99fa-4251-9cbc-c381c786c822">2,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0xLTEtMS0w_bffb8a4d-8254-4024-b372-df62cceb54c6">2,491</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0zLTEtMS0w_242349e7-28de-4dae-812f-4401e8bc3f6c">2,636</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNi0xLTEtMS0w_6e2ec41d-4131-420f-85fd-b22d0751d003">8,079</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="advm:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNi0zLTEtMS0w_c755bcaa-8f73-4ddf-8feb-b6ff0c412aa4">11,271</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_67"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">5. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTAy_aee14956-4547-4913-a72d-bc7ff8142cf9" continuedAt="ida59bce684334ed6aad5da1b8eff6090" escape="true">Equity Incentive Awards</ix:nonNumeric></span></div><ix:continuation id="ida59bce684334ed6aad5da1b8eff6090" continuedAt="i6f88f9e2294046319657d2025fc099ec"><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTAz_42c4b4dd-4440-4d96-83ec-7f987f2606f2" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s option activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMS0xLTEtMS0w_60d266bd-c932-4314-9ca2-52f5cec8e92a">8,995</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i74e35996fd934b90add7c64de848251a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMS0zLTEtMS0w_d9f03879-4165-4261-b8f4-9d24669d027d">7.19</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMi0xLTEtMS0w_62c94bd5-9df3-49d8-920c-6b489114128b">1,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMi0zLTEtMS0w_119a5352-80d9-4b0f-973b-b5de6ca202d2">15.15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMy0xLTEtMS0w_7081984d-b162-4bb4-90b5-0e5ab8cf9fc6">1,310</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMy0zLTEtMS0w_8c23160b-863a-4fc5-8532-0fb8d2ba6b34">7.37</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNC0xLTEtMS0w_fac45a6f-9cad-4807-b4e9-0f4e217d8bce">207</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNC0zLTEtMS0w_0070c1a5-a52c-4272-b465-90f0dbdd74c7">14.05</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNS0xLTEtMS0w_834ee66b-3862-4446-aa79-3678d26017a6">9,072</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNS0zLTEtMS0w_1b24d7fd-4de0-4b84-a8bf-ea227cb88875">8.41</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNi0xLTEtMS0w_d9fc6faf-f50b-485c-ad77-b4048739c3d3">2,785</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNi0zLTEtMS0w_171cf4ca-5aee-486e-95a9-802acadab484">6.89</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><ix:continuation id="i6f88f9e2294046319657d2025fc099ec"><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTA0_081ec0ac-3874-41c8-9d9f-bd81607fb06b" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s RSUs activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i11acc5e392074f6aa619a7caf4b0e38b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMS0xLTEtMS0w_1e4ae5bd-63a4-4c25-bdaa-38e1d96b44bf">1,121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i11acc5e392074f6aa619a7caf4b0e38b_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMS0zLTEtMS0w_70fbcc7e-6ce3-48cc-8f9b-1a22e8fe9ab7">4.59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMi0xLTEtMS0w_155d3177-1046-4988-856d-c672ff6fc243">104</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMi0zLTEtMS0w_f3e3d744-cbfb-4e6f-928c-fdbc935c4158">15.75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMy0xLTEtMS0w_781dd3ec-c76f-4a11-9a27-1b1921ac46df">462</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMy0zLTEtMS0w_e4d36020-4b9d-4943-82c1-5c174f71ddd9">4.75</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNC0xLTEtMS0w_a41362f9-ad9f-45b6-b5fb-44a3f0d7bbef">28</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNC0zLTEtMS0w_e75d3da8-003b-4fc5-8620-326b46531e13">8.39</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNS0xLTEtMS0w_2b313ea8-d33c-4ab7-9e7d-dae2133a3db3">735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i747bceb18b5d4106adeb8f39000b9982_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNS0zLTEtMS0w_0e8b8117-9721-4b84-b5f8-6de58c71e362">5.94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTA1_bc2b50b6-ddd3-450b-bc5b-eac9fd690e9a" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0dff8015a05449eda49c8fb0645749d9_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfMy0xLTEtMS0w_2999b6d7-7da6-4b64-ba83-3e58721935d9">1,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ife518f866ce14a03be135a52d4f9429c_D20190101-20190331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfMy0zLTEtMS0w_4a5ab0b3-2947-4a91-9c92-4126d7126bb0">631</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5e6e4fe498c24ec5abb76f172e87c141_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNC0xLTEtMS0w_4e68154b-7014-499e-8545-a135b4aab90f">2,161</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i64910ab1df99412c876858849bf70e6f_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNC0zLTEtMS0w_c5467e6c-264c-4894-b46e-a25df94af9b0">1,131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNS0xLTEtMS0w_2aa3f82e-a1fb-4d89-9d07-7edf1271cb1c">3,409</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNS0zLTEtMS0w_da35dcab-f994-4204-90ff-81100c32d8ed">1,762</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;"><span><br/></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_70"></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">6. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RleHRyZWdpb246NjVlNTEzZDI0ZWI1NGQxNjgxNDkxMzkxMjM3ZDI5ODZfNDk0NzgwMjMyNjU2MQ_46a9e667-b110-4f4c-be52-7df523ad8172" continuedAt="if467c5e54ba649faa75b42dc419cfc35" escape="true">Net Loss per Share</ix:nonNumeric></span></div><ix:continuation id="if467c5e54ba649faa75b42dc419cfc35"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RleHRyZWdpb246NjVlNTEzZDI0ZWI1NGQxNjgxNDkxMzkxMjM3ZDI5ODZfNDk0NzgwMjMyNjU2Mg_ae8e3406-bb56-4c27-9ae7-f3c20a1004a3" escape="true"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.029%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.619%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.622%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ib286c4189e9142e595e64dd9e87b795b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNC0xLTEtMS0yOTQ2_a5338ec0-9e64-4ccb-9121-89b34859758d">9,072</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id78c5e96cfeb4a7ba9d2f8f09386b78f_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNC0zLTEtMS0yOTQ2_29a53143-4aca-4660-9846-165a8d98d7b3">7,969</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNS0xLTEtMS0yOTQ2_2b313ea8-d33c-4ab7-9e7d-dae2133a3db3">735</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i067845b9bbc441dca466c83c3266762f_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNS0zLTEtMS0yOTQ2_e07bc6e2-8f2d-4f69-a9c1-21b9708894f8">1,729</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2550dd60ce2c49f19a995e351a4d4e99_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNi0xLTEtMS0yOTQ2_1d0d0cf5-8b19-48a2-a5b5-c5e7e57056a6">45</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3ebb3283ddf14932b74fbf553fe5f243_D20190101-20190331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNi0zLTEtMS0yOTQ2_6d0a7414-e435-4670-b3af-24e7643ed8f3">132</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2be7ba555c8443369db8b32a5b5a90b0_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNy0xLTEtMS0yOTQ2_096f6af3-b799-4b4f-8d9a-119d2877dbc8">80</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i73b815ac0dad4ea7937de1d62295b3f1_D20190101-20190331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNy0zLTEtMS0yOTQ2_5244162f-2746-4e20-8ba8-1cd8c62d7010">90</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfOC0xLTEtMS0yOTQ2_f880c4ed-b89f-4c11-83e6-3b499fcedd75">9,932</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfOC0zLTEtMS0yOTQ2_1a88761d-2d11-4608-b203-9f7420b75326">9,920</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_73"></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">7. <ix:nonNumeric contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfNDEy_a4ee57ec-ad2e-403e-abec-24086486545b" continuedAt="ic6d6219d9c5a48a19a84c99e9c991a45" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ic6d6219d9c5a48a19a84c99e9c991a45">In February 2020, the Company entered into a common stock purchase agreement with James Scopa, a member of the Board, and Anne Kenner, as Trustees for the James P. Scopa and Anne E. Kenner Family Trust (the &#8220;Trust&#8221;), pursuant to which the Trust purchased an aggregate of <ix:nonFraction unitRef="shares" contextRef="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfMzAy_e5c368af-4eac-47df-8416-d4276ff626d1">10,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib89a5f94a6544269b3729160754cd23d_I20200229" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfMzU2_5c50eb0d-f3a0-4ecf-8dc2-ddd01ca212be">13.75</ix:nonFraction> per share, for an aggregate cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfNDEw_298b7d32-2a94-488d-a1b9-02835ee4b161">0.1</ix:nonFraction> million.</ix:continuation></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_76"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">The interim financial statements included in this Quarterly Report on Form 10-Q and this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the financial statements and notes thereto for the year ended December&#160;31, 2019, and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K, as filed with the U.S. Securities and Exchange Commission (SEC) on March&#160;12, 2020. In addition to historical information, this discussion and analysis contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (Securities Act), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). These forward-looking statements are subject to risks and uncertainties, including those discussed in the section titled &#8220;Risk Factors,&#8221; set forth in Part II &#8211; Other Information, Item&#160;1A below and elsewhere in this report that could cause actual results to differ materially from historical results or anticipated results. In particular, we encourage you to review the risk factor related to the impact of the coronavirus pandemic titled &#8220;The coronavirus (&#8220;COVID-19&#8221;) pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.&#8221;</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_79"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. We develop gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our core capabilities include novel vector discovery, preclinical and clinical development and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;cGMP&#8221;) quality control.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our lead product candidate ADVM-022 is a single intravitreal (&#8220;IVT&#8221;) injection gene therapy targeting the treatment of chronic retinal diseases that respond to anti-vascular endothelial growth factor (&#8220;anti-VEGF&#8221;) therapy, including wet age-related macular degeneration (&#8220;wet AMD&#8221;) and diabetic macular edema (&#8220;DME&#8221;). ADVM-022 utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. ADVM-022 is administered as a one-time IVT injection and is designed to deliver durable, long-term efficacy and reduce the burden of frequent anti-VEGF injections, and improve real-world vision outcomes for patients with wet AMD and DME.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Wet AMD is a leading cause of vision loss in patients over 60 years of age, with a prevalence of approximately 1.2 million individuals in the U.S. and 3 million worldwide. In recognition of the need for new treatment options for wet AMD, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted Fast Track designation for ADVM-022 for the treatment of wet AMD. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are conducting the OPTIC trial, designed as a multi-center, open-label, Phase 1, dose-ranging safety trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment-experienced, and previously required frequent anti-VEGF injections to control their wet AMD and to maintain functional vision.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patients in Cohort 1 (n=6) were treated with a higher dose of ADVM-022 (6 x 10&#94;11 vg). Patients in Cohort 2 (n=6) and Cohort 3 (n=9) were treated with a three-fold lower dose of ADVM-022 (2 x 10&#94;11 vg). Patients in Cohort 4 (n=9) are being dosed with the higher dose of 6 x 10&#94;11 vg used in Cohort 1.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In OPTIC, ADVM-022 continues to demonstrate robust efficacy. We have observed long-term durability beyond 1 year from a single IVT injection of ADVM-022 with zero rescue injections in Cohort 1. We have observed preliminary evidence of a dose response between the higher and lower doses. In addition, early evidence from Cohort 3 suggests that a 6-week prophylactic regimen of steroid eye drops results in fewer adverse events and less inflammation, as compared to a 13-day prophylactic regimen of oral steroids as used in Cohorts 1 and 2. ADVM-022 continues to be well tolerated with a favorable safety profile in all 3 cohorts. As we advance the OPTIC trial, we plan to present clinical data from 4 cohorts by the end of 2020.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Over 30 million people are impacted by diabetes in the United States. DME affects approximately 5% of people with diabetes and is the most common cause of vision loss in people with diabetic retinopathy ("DR"). Based on the safety and efficacy results from the OPTIC trial for ADVM-022 in patients with wet AMD, we are advancing our novel gene therapy for patients with DME. Our investigational new drug (&#8220;IND&#8221;) application was cleared by the FDA in May 2020. We recently initiated the INFINITY Phase 2 trial, a multi-center, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The INFINITY trial will enroll approximately 33 patients and is designed to demonstrate superior control of disease activity following a single IVT injection of ADVM-022 compared to a single aflibercept injection, as measured by time to worsening of DME disease activity. Additional objectives include assessments of treatment burden, visual acuity, retinal anatomy and safety outcomes. Participants in this double-masked trial will be randomized to one of three arms for their study eye treatment: Arm 1 will receive the higher dose of ADVM-022 at 6 x 10&#94;11 vg, Arm 2 will receive the lower dose of ADVM-022 at 2 x 10&#94;11 vg, and Arm 3 will receive aflibercept at a dose of 2 mg.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have licensed the right to use AAV.7m8 to GenSight Biologics S.A. (&#8220;GenSight&#8221;) to deliver certain therapeutic transgenes, including channelrhodopsin protein, which GenSight is using in their product candidate GS030 for retinitis pigmentosa, currently in clinical development.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In January 2020, we moved into our new facility in Redwood City, California. This new 81,000 square foot facility serves as our corporate headquarters and will include expanded laboratory space as well as space for expanded manufacturing process capabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Impact of COVID-19</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our results of operations and financial condition for the three months ended March 31, 2020 were not significantly impacted by the COVID-19 pandemic.  However, the full extent to which the COVID-19 pandemic will directly or indirectly impact these areas in the future is unknown at this time and will depend on future developments that are unpredictable.  We are actively monitoring and managing our response and assessing actual and potential impacts to these areas.  Please refer to the &#8220;Risk Factors&#8221; section for further discussion of the risks we face as a result of the COVID-19 pandemic.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impact on Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are continuously evaluating and addressing potential impacts of the COVID-19 pandemic on our operations.  Our offices, laboratories, clinical trial sites, contract research organizations, contract manufacturing organizations, and other collaborators and partners are located in jurisdictions where quarantines, executive orders, shelter-in-place orders, guidelines, and other similar orders and restrictions intended to control the spread of the disease have been put in place by governmental authorities. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are committed to the health and safety of our employees and their families and doing our part to slow the community spread of COVID-19. In mid-March, we implemented a number of actions, including implementing a work-from-home policy for employees whose jobs do not require them to be onsite, allowing for flexible work schedules, restricting in-person meetings, and limiting onsite activities to only the most time-critical or necessary operational activities. We have maintained certain essential in-person laboratory functions in order to advance key research and development initiatives, supported by the implementation of updated onsite procedures. We believe these measures and others have allowed us to mitigate, but not eliminate, the effects and risks on our on-site operations posed by the COVID-19 Pandemic.  </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impact on Clinical Trials</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The ultimate impact of the COVID-19 pandemic on our ongoing and planned clinical trials is uncertain and subject to change. We are working closely with our clinical trial sites to monitor and attempt to minimize the potential negative impacts of the evolving COVID-19 outbreak on patient safety, patient enrollment, continued participation of patients already enrolled in our clinical studies, protocol compliance, data quality, and overall study integrity.  Despite these efforts, we are unsure as to whether the COVID-19 pandemic will significantly impact trial enrollment or completion of our current or planned clinical studies.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Impact on Supply Chain and Manufacturing</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we have not yet experienced significant disruptions to our supply chain and manufacturing as a result of the COVID-19 pandemic, we cannot be certain that this trend will continue. Based on current information, we believe that our partners in our supply chain have been and will continue to serve us continuously during the COVID-19 pandemic.  However, certain of these partners have prioritized and allocated more resources and capacity to supply drug product or raw materials to other companies engaged in the study of potential treatments or vaccinations for COVID-19, which could result in supply interruptions. We have sufficient drug supply for our current clinical trials; however, to mitigate against future potential delays in product supply, we are currently implementing additional measures to address these risks, including securing additional supplies and manufacturing capacity reserve, which may result in additional expenses. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_82"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Overview </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Summary</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not generated positive cash flow or net income from operations since our inception and, as of March&#160;31, 2020, we had an accumulated deficit of $407.9 million. We expect to incur substantial expenses and increasing losses from operations in the foreseeable future as we continue our research and development efforts, advance our product candidates through preclinical and clinical development, manufacture clinical study materials, seek regulatory approval, and prepare for and, if approved, proceed to commercialization. We are at an early stage of development and may never be successful in developing or commercializing our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we may in the future generate revenue from a variety of sources, including license fees, milestone and research and development payments in connection with strategic partnerships, and potentially revenue from product sales if any of our product candidates are approved, to date we have not generated any revenue from product sales.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have no operational clinical or commercial manufacturing facilities, and all of our clinical manufacturing activities are currently contracted out to third parties. Additionally, we use third-party contract research organizations (&#8220;CROs&#8221;) to carry out our clinical development and we do not have a sales organization.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to incur substantial and increasing expenditures in the foreseeable future for the development and potential commercialization of our product candidates. We will need substantial additional funding in the future to support our operating activities as we advance our product candidates through preclinical and clinical development, seek regulatory approval and prepare for and, if approved, proceed to commercialization. Adequate funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital, or to do so on acceptable terms, when needed, or to form additional collaboration partnerships to support our efforts, we could be forced to delay, reduce or eliminate our research and development programs or potential commercialization efforts.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March&#160;31, 2020, we had $297.1 million in cash, cash equivalents and short-term investments. We believe that we have sufficient cash to fund operations into 2022.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">To date we have not generated any revenue from the sale of our products. We have generated revenue through research, collaboration and license arrangements with strategic partners. Our ability to generate product revenue and become profitable depends upon our ability to successfully develop and commercialize our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the amount or timing of product revenue. Even if we are able to generate revenue from the sale of our products, our sales may not be sufficient to generate cash from operations, in which case we may be unable to continue our operations at planned levels and be forced to reduce our operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Research and Development Expenses</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Conducting a significant amount of research and development is central to our business model. Research and development expenses primarily include personnel-related costs, stock-based compensation expenses, laboratory supplies, consulting costs, external contract research and development expenses, including expenses incurred under agreements with CROs, the cost of acquiring, developing and manufacturing clinical study materials, and overhead expenses, such as rent, equipment depreciation, insurance and utilities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expense research and development costs as incurred. We defer and expense advance payments for goods or services for future research and development activities as the goods are delivered or the related services are performed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We estimate preclinical study and clinical trial expenses based on the services performed pursuant to contracts with research institutions and CROs that conduct and manage preclinical studies and clinical trials on our behalf. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. We estimate the amounts incurred through communications with third party service providers and our estimates of accrued expenses as of each balance sheet date are based on information available at the time. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual accordingly.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At this time, we cannot reasonably estimate the nature, timing or aggregate costs of the efforts that will be necessary to complete the development of any of our product candidates. The successful development and commercialization of a product candidate is highly uncertain, and clinical development timelines, the probability of success, and development and commercialization costs can differ materially from expectations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">General and Administrative Expenses</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expenses primarily include personnel-related costs, stock-based compensation, professional fees for legal, consulting, audit and tax services, overhead expenses, such as rent, equipment depreciation, insurance and utilities, and other general operating expenses not otherwise included in research and development expenses. Our general and administrative expenses may increase in future periods if and to the extent we elect to increase our investment in infrastructure to support continued research and development activities and potential commercialization of our product candidates. We will continue to evaluate the need for such investment in conjunction with our ongoing consideration of our pipeline of product candidates. We anticipate increased expenses related to audit, legal and regulatory functions, as well as director and officer insurance premiums and investor relations costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Income, Net</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net primarily consists of interest income on our cash equivalents and short-term investments in marketable securities.</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_85"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our management&#8217;s discussion and analysis of financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. On an on-going basis, we evaluate our critical accounting policies and estimates. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions and conditions. There have been no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K (Annual Report) as filed with the SEC on March&#160;12, 2020.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact our business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. </span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_88"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Results of Operations</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Comparison of the Three Months Ended March 31, 2020 and 2019</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:64.520%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.676%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Change</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Operating expenses:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,751&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,620&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,040&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,576&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,464&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Total operating expenses</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,791&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,707&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,084&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(23,791)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15,707)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,084)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:11.25pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other income, net</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">885&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,218&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(333)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(22,906)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,489)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,417)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expense</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Research and development expense increased $4.6 million to $14.8 million for the three months ended March&#160;31, 2020 from $10.1 million for the three months ended March&#160;31, 2019. This overall increase was primarily due to $1.7 million increase in production costs related to product candidate ADVM-022 and earlier-stage research programs, $1.5 million increase in personnel associated costs including higher stock-based compensation expenses, as well as salaries and bonus as a result of increased headcount, $0.8&#160;million increase in facilities costs as we transitioned between our old and new facilities during the first quarter of 2020, and $0.8 million increase in laboratory expense, consultants and recruiting fees. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the periods presented, our research and development activities are attributable to our wet AMD and rare disease programs and earlier-stage research programs. We expect that research and development expenses will increase in future periods as we continue to invest in advancing our gene therapy product candidate ADVM-022 and earlier-stage research programs.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">General and Administrative Expense</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">General and administrative expense increased $3.5 million to $9.0 million for the three months ended March&#160;31, 2020 from $5.6 million for the three months ended March&#160;31, 2019. This reflects increases of $1.7 million in personnel associated costs including higher stock-based compensation expense, as well as salaries and bonus as a result of increased headcount, $0.8&#160;million in professional expenses including higher audit, tax and market research services, $0.6 million in consulting and contractor costs, and $0.4 million in facility costs and depreciation expense.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect that general and administrative expenses will increase in future periods as we continue to support advancing our gene therapy programs. We anticipate increased expenses related to audit, legal, finance and investor functions to support our organizational growth.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Other Income, Net</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The decrease of $0.3 million in other income, net for the three months ended March&#160;31, 2020 as compared to 2019 was primarily due to a lower yield from our investment portfolio.  </span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_91"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have not generated positive cash flow or net income from operations since our inception and as of March&#160;31, 2020, we had an accumulated deficit of $407.9 million. As of March&#160;31, 2020, we had $297.1 million in cash, cash equivalents and short-term investments compared to $166.0 million as of December 31, 2019. We believe that our existing cash and cash equivalents and short-term investments as of March&#160;31, 2020 will be sufficient to fund our operations into 2022.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2020, we sold an aggregate of 10,925,000 shares of our common stock for $140.9 million of net proceeds after deducting underwriting discounts and commissions and estimated offering expenses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to incur substantial expenditures in the foreseeable future for the development and potential commercialization of our product candidates and ongoing internal research and development programs, and expenses to build out our new facility. At this time, we cannot reasonably estimate the nature, timing or aggregate amount of costs for our development, potential commercialization, and internal research and development programs. However, in order to complete our planned preclinical trials and current and future clinical trials, and to complete the process of obtaining regulatory approval for our product candidates, as well as to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize our product candidates, if approved, we will require substantial additional funding in the future.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If and when we seek additional funding, we will do so through equity or debt financings, collaborative or other arrangements with corporate sources or through other sources of financing. Adequate additional funding may not be available to us on acceptable terms or at all. Our failure to raise capital in the future could have a negative impact on our financial condition and our ability to pursue our business strategies. To complete development and commercialization of any of our product candidates, we anticipate that we will need to raise substantial additional capital, the requirements of which will depend on many factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the initiation, progress, timing, costs and results of preclinical studies and any clinical trials for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the outcome, timing of and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities, including the potential for the FDA and other regulatory authorities to require that we perform more studies than those that we currently expect;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our product candidates to progress through clinical development activities successfully;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our need to expand our research and development activities;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the rate of progress and cost of our commercialization of our products;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of preparing to manufacture our products on a larger scale;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of commercialization activities including product sales, marketing, manufacturing and distribution;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the degree and rate of market acceptance of any products launched by us or future partners;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our need to implement additional infrastructure and internal systems;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to hire additional personnel;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to enter into additional collaboration, licensing, commercialization or other arrangements and the terms and timing of such arrangements;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the emergence of competing technologies or other adverse market developments; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the effects of the COVID-19 pandemic on our business, results of operations, and financial condition.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials. We may also be required to sell or license other technologies or clinical product candidates or programs that we would prefer to develop and commercialize ourselves.</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_94"></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Cash Flows</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(in thousands)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operating activities</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,616)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13,217)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash (used in) provided by investing activities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(70,743)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,745&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">148,624&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(370)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net increase (decrease) in cash and cash equivalents and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,265&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,842)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Used in Operating Activities</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March&#160;31, 2020, net cash used in operating activities was $13.6 million, primarily as a result of the net loss of $22.9 million, partially offset by $3.8 million of non-cash charges mainly related to stock-based compensation expense and depreciation and amortization expenses, and $5.5 million of net increase in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the three months ended March 31, 2019, net cash used in operating activities was $13.2 million, primarily as a result of the net loss of $14.5 million, partially offset by $2.1 million of non-cash charges mainly related to stock-based compensation expense and depreciation and amortization expense, and $0.8 million of net decrease in operating assets and liabilities, which fluctuate due to timing of expenses and payments.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Provided by (Used in) Investing Activities</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in investing activities for the three months ended March&#160;31, 2020 consisted of $66.5 million of net purchases of marketable securities and $4.2 million of purchases of property and equipment primarily related to the new facility. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities for the three months ended March 31, 2019 consisted of $4.9 million of net maturities of marketable securities and $2.2 million of purchases of property and equipment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Provided by (Used in) Financing Activities</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for three months ended March&#160;31, 2020 consisted primarily of $140.9&#160;million of net proceeds from the sale of our common stock and $9.7 million of net proceeds from the exercise of stock options, partially offset by $1.9 million in taxes paid relating to net share settlement of restricted stock units and repayment of loans.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in financing activities for three months ended March 31, 2019 consisted of $0.5 million in taxes paid relating to net share settlement of restricted stock units and repayment of loans, partially offset by $0.2 million of the net proceeds from the exercise of stock options.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have any off-balance sheet arrangements as defined in Regulation S-K, Item 303(a)(4)(ii).</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_97"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;3.&#160;Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under SEC rules and regulations, as a smaller reporting company, we are not required to provide the information required by this item.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_100"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;4.&#160;Controls and Procedures</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Evaluation of disclosure controls and procedures</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. Management, including our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of March&#160;31, 2020. The evaluation of our disclosure controls and procedures included a review of our processes and implementation and the effect on the information generated for use in this Quarterly Report on Form 10-Q. We conduct this type of evaluation quarterly so that our conclusions concerning the effectiveness of these controls can be reported in our periodic reports filed with the SEC. The overall goals of these evaluation activities are to monitor our disclosure controls and procedures and to make modifications as necessary. We intend to maintain these disclosure controls and procedures, modifying them as circumstances warrant.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of March&#160;31, 2020, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i)&#160;recorded, processed, summarized and reported as and when required and (ii)&#160;accumulated and communicated to our management, including the Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely discussion regarding required disclosure.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Changes in internal control over financial reporting. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There have been no changes in our internal control over financial reporting during the three months ended March&#160;31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">Limitations on the Effectiveness of Controls</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Adverum have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_103"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART II &#8211; OTHER INFORMATION</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_106"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item&#160;1.&#160;Legal Proceedings</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_109"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 1A.&#160;Risk Factors</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Quarterly Report on Form 10-Q. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and prospects. Further, the current </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">coronavirus (&#8220;COVID-19&#8221;) </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">pandemic and actions taken to address the pandemic may exacerbate the risks described below.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Financial Position and Need for Capital</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have incurred significant operating losses since inception, and we expect to incur significant losses for the foreseeable future. We may never become profitable or, if achieved, be able to sustain profitability.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred significant operating losses since we were founded in 2006 and expect to incur significant losses for the foreseeable future as we continue development of our product candidates. Losses have resulted principally from costs incurred in our research and development programs and from our general and administrative expenses. In the future, we intend to continue to conduct research and development, regulatory compliance activities and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the next several years.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently generate no revenue from sales, and we may never be able to commercialize any of our product candidates. We do not currently have the required approvals to market any of our product candidates, and we may never receive such approvals. We may not be profitable even if we or any of our future development partners succeed in commercializing any of our product candidates. Because of the numerous risks and uncertainties associated with developing and commercializing our product candidates, we are unable to predict the extent of any future losses or when we will become profitable, if at all.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We expect that our cash, cash equivalents, and short-term investments will be sufficient to fund our lead gene therapy programs into 2022. If this expectation proves to be wrong, we may be forced to delay, limit or terminate certain of our development efforts before then.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently expect our cash, cash equivalents and short-term investments to fund our planned operations into 2022. However, this estimate is based on a number of assumptions that may prove to be wrong, including our expectations about the timing of planned clinical trials and expected investments into our manufacturing capabilities, and changing circumstances beyond our control may cause capital to be consumed more rapidly than currently anticipated. As a result, our operating plan may change, and we may need to seek additional funds sooner than planned, through collaboration agreements and public or private financings. If we run low on capital before we are able to achieve meaningful clinical data for some or all of our product candidates, we may be unable to successfully raise additional funds, and, consequentially, may need to significantly curtail some or all of our development activities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will need to raise additional funding, which may not be available on acceptable terms, or at all. If we fail to obtain additional capital necessary to fund our operations, we will be unable to successfully develop and commercialize our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will require substantial future capital in order to complete the preclinical and clinical development for our product candidates and potentially to commercialize these product candidates. Any future clinical trials or expansion of ongoing clinical trials of our product candidates would cause an increase in our spending levels, as would other corporate activities. The amount and timing of any expenditure needed to implement our development and commercialization programs will depend on numerous factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the type, number, scope, progress, expansion costs, results of and timing of any future preclinical studies and clinical trials of any of our product candidates which we are pursuing or may choose to pursue in the future;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the need for, and the progress, costs and results of, any additional clinical trials or nonclinical studies of our product candidates we may initiate based on the results of any clinical trials that we may plan or discussions with the FDA, including any additional clinical trials or nonclinical studies the FDA or other regulatory agencies may require evaluating the safety of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs and timing of obtaining or maintaining manufacturing for our product candidates, including commercial manufacturing;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs and timing of establishing sales and marketing capabilities and enhanced internal controls over financial reporting;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the terms and timing of establishing collaborations, license agreements and other partnerships;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs associated with any new product candidates that we may develop, in-license or acquire;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effect of competing technological and market developments;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish and maintain partnering arrangements for development; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs associated with being a public company.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Some of these factors are outside of our control. We do not expect our existing capital resources to be sufficient to enable us to fund the completion of our clinical trials and remaining development programs through commercial introduction. We expect that we will need to raise additional funds in the future.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no product candidate approved by any regulatory authority, have not sold any products, and we do not expect to sell or derive revenue from any product sales for the foreseeable future. We may seek additional funding through collaboration agreements and public or private financings.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additional funding may not be available to us on acceptable terms or at all and the terms of any financing may adversely affect the holdings or the rights of our stockholders. In addition, the issuance of additional shares by us, or the possibility of such issuance, may cause the market price of our shares to decline.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to obtain funding on a timely basis, we will be unable to complete any future clinical trials for our product candidates and we may be required to significantly curtail some or all of our activities. We also could be required to seek funds through arrangements with collaborative partners or otherwise that may require us to relinquish rights to our product candidates or some of our technologies or otherwise agree to terms unfavorable to us.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are in the early stages of development and will require substantial preclinical and/or clinical development and testing, manufacturing process improvement and validation, bridging studies and regulatory approval prior to commercialization. It is critical to our business to successfully develop and ultimately obtain regulatory approval for one or more of these product candidates. Our ability to commercialize our product candidates effectively will depend on several factors, including the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">successful completion of preclinical studies and clinical trials, including the ability to demonstrate safety and efficacy of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">receipt of marketing approvals for any future products for which we complete clinical trials, including securing regulatory exclusivity to the extent available;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establishing commercial manufacturing capabilities, for example, by engaging third-party manufacturers that can provide products and services to support clinical development and the market demand for our product candidates, if approved;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">successful launch and commercial sales of the product, whether alone or in collaboration with potential partners;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">acceptance of the product as a viable treatment option by patients, the medical community and third-party payers;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">establishing market share while competing with other therapies;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a continued acceptable safety profile of our products following regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">maintaining compliance with post-approval regulations and other requirements; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">qualifying for, identifying, registering, maintaining, enforcing and defending intellectual property rights and claims covering our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our collaborators do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to commercialize our product candidates, which would materially and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the FDA placed our IND application for ADVM-022 for the treatment of wet age-related macular degeneration ("wet AMD") on clinical hold and requested certain information and requirements related to chemistry, manufacturing and controls (&#8220;CMC&#8221;). We subsequently responded to the FDA, and in May 2019, the FDA lifted the clinical hold, allowing dose escalation up to 2 x 10&#94;12 vg in the OPTIC trial. However, our IND remains on partial clinical hold for dosing patients with a dose of 6 x 10&#94;12 vg. Given the preliminary robust anatomical response we observed from patients in the first cohort, we dosed patients in the second cohort of the OPTIC trial with a lower dose of 2 x 10&#94;11 vg. We do not currently intend to dose patients at 6 x 10&#94;12 vg in any of our clinical trials involving ADVM-022, but should we need to, there is no guarantee that the FDA will lift the partial clinical hold promptly, if at all. In addition, if we are unable to respond to these CMC requirements and the requirements related to the partial clinical hold to the FDA&#8217;s satisfaction and within the timeframe we expect, the FDA will not remove the clinical hold, which may prevent us from beginning late-stage clinical trials involving ADVM-022, delay or prevent us from advancing our clinical programs and our business may be harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Of the large number of biologics and drugs in development in the pharmaceutical industry, only a small percentage result in the submission of a biologics license application (&#8220;BLA&#8221;) to the FDA and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval to market any of our product candidates, any such approval may be subject to limitations on the indicated uses for which we may market the product, or limitations related to its distribution. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, there can be no assurance that any of our product candidates will be successfully developed or commercialized. If we or any of our future development partners are unable to develop, or obtain regulatory approval, or, if approved, successfully commercialize, any of our product candidates, we may not be able to generate sufficient revenue to continue our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our gene therapy platform is based on a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have concentrated our research and development efforts on our gene therapy platform and our future success depends on the successful development of product candidates based on this platform. There can be no assurance that any development problems we have experienced or may experience in the future related to our platform will not cause significant delays or unanticipated costs, or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, the clinical trial requirements of the FDA, the European Medicines Agency (&#8220;EMA&#8221;) and other regulatory agencies and the criteria these regulators may use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel gene therapy products such as ours can be more expensive and take longer than for other product types, which are better known or more extensively studied to date. Regulatory approaches and requirements for gene therapy products continue to evolve, and any changes could create significant delay and unpredictability for product development and approval as compared to technologies with which regulatory agencies have more substantial experience. For example, the FDA issued a series of gene therapy guidance documents in January 2020 that we are evaluating and that may impact our future development efforts and clinical trial designs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Also, before a clinical study can begin, that clinical site&#8217;s institutional review board (&#8220;IRB&#8221;) and its Institutional Biosafety Committee will have to review the proposed clinical trial to assess appropriateness to conduct the clinical study at that site. In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for human research on or for approval of any of our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These regulatory review committees and advisory groups, and the guidelines they promulgate, may lengthen our regulatory review process, require us to perform additional studies, increase our development costs, increase or otherwise change CMC requirements, lead to changes in our regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will usually be required to consult with these, and potentially other, regulatory and advisory groups and comply with applicable guidelines or recommendations. If we fail to do so, we may be required to delay or discontinue development of our product candidates. Delay or failure to obtain, or unexpected costs incurred in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in our efforts to identify or discover additional product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The success of our business depends primarily upon our ability to identify, develop and commercialize products based on our platform technology. Our research programs may fail to identify other potential product candidates for clinical development for a number of reasons. For example, our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to lack efficacy, have harmful side effects, or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business, financial condition, results of operations, and prospects and could potentially cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human resources. We may focus our efforts and resources on potential programs or product candidates that may ultimately prove to be unsuccessful.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Few of our product candidates and proprietary viral vectors have been tested in clinical trials.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Drug development has inherent risk. Few of our product candidates and proprietary viral vectors have been evaluated in clinical trials in patients. Our lead product candidate, ADVM-022 for the treatment of wet AMD and DME, uses a proprietary vector, AAV.7m8, which has undergone limited human testing, and may experience unexpected results in clinical trials in the future. We, or any licensee or development partner, will be required to demonstrate through adequate and well-controlled clinical trials that our product candidate or another party&#8217;s product candidate containing one of our proprietary viral vectors are safe and effective for use in their target indications before seeking regulatory approvals for commercial sale. Drug development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials or any clinical trials using our proprietary viral vectors. Any such delay or failure could significantly harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our product candidates are not shown to be safe and effective, we may not realize the value of our investment in our technology. Promising preclinical results generated with a product candidate in animal models do not guarantee similar results when the candidate is tested in humans. For example, the levels of protein expression achieved from a vector in a preclinical model, including non-human primate (&#8220;NHP&#8221;) models, may be significantly higher than the level of protein expression achieved in humans. Similarly, human subjects administered our product candidates may develop side effects that were not observed in animal models and/or are more severe than those observed in animal models. In addition, even industry-accepted animal models may not accurately replicate human disease. For example, the laser-induced choroidal neovascularization model in NHPs is the industry accepted animal model for wet AMD, where efficacy is assessed by reduction of the number of clinically relevant neovascular lesions. Even so, this model does not replicate all aspects of wet AMD in humans, some of which may be relevant to the success of ADVM-022. Success in preclinical studies or in early clinical trials does not mean that later clinical trials will be successful, because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through preclinical and initial clinical testing. Further, safety and/or efficacy issues with a product candidate may only become apparent when the candidate is tested in human patients suffering the relevant disease. For example, while preclinical testing of our product candidate ADVM-043, including in animal models, showed promise, in the ADVANCE trial, A1AT protein levels did not reach a clinically meaningful levels of expression in humans, and we subsequently decided to discontinue development of ADVM-043. In addition, in clinical trials, such as our OPTIC and INFINITY trials, each cohort of patients may be treated with a different dose of the tested drug or different prophylactic steroid regimen, potentially resulting in different safety profiles or efficacy levels in each of the cohorts. Furthermore, the initiation of future trials for a product candidate will be dependent upon demonstrating sufficient safety and efficacy to the relevant regulatory authorities in preceding or other ongoing trials using the same product candidate. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising results. In addition, only a small percentage of products under development result in the submission of a marketing application and even fewer are approved for commercialization. Even if our clinical trials successfully meet their endpoints for safety and efficacy, FDA and/or other regulatory agencies may still conclude that the product candidate has not demonstrated a beneficial risk/benefit profile or otherwise does not meet the relevant standard for approval.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We cannot guarantee that results from any clinical trials that we plan will be successful, and any safety or efficacy concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Preliminary and interim data from our clinical trials that we may announce or publish from time to time may change as each clinical trial progresses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we may announce or publish preliminary or interim data from our clinical trials. Preliminary and interim results of a clinical trial are not necessarily predictive of final results. Preliminary and interim data are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues or further patient follow up occurs and more patient data become available. For example, although we have periodically announced interim data from patients in our OPTIC trial, which showed no drug- or treatment-related series adverse events (&#8220;SAEs&#8221;) or drug-limiting toxicities (&#8220;DLTs&#8221;), there is no guarantee that drug- or treatment-related SAEs or DLTs will not occur later in our OPTIC trial, either in these or other patients. In addition, in certain clinical trials, such as our OPTIC trial, individual cohorts of patients are enrolled with different dosages and other treatment conditions under our protocol. These different dosages and other treatment conditions may affect clinical outcomes, including safety profiles or efficacy, such as the number of rescue injections required, in each of the cohorts. As a result, preliminary and interim data should be viewed with caution and not relied upon until the final data from a locked database for the entire clinical trial are available. Material changes in the final data compared to preliminary or interim data could significantly harm our business prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our product candidates are subject to extensive regulation, compliance with which is costly and time consuming, and such regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preclinical and clinical development, manufacturing, analytical testing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of our product candidates are subject to extensive regulation by the FDA and by comparable regulatory authorities in foreign markets. In the U.S., we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years and can vary substantially based upon the type, complexity and novelty of the products involved, as well as the target indications and patient population. Approval policies or regulations may change, and the regulatory authorities have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="text-indent:-18pt;padding-left:45pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">such authorities may disagree with the design or implementation of our or any of our future development partners&#8217; clinical trials;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product candidate is safe and effective for any indication;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA or other regulatory authorities may not accept clinical data from trials which are conducted at multinational clinical facilities or in countries where the standard of care is potentially different from that of the U.S.;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval; we or any of our future development partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on distribution and use;</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">such authorities may find deficiencies in the manufacturing processes, analytical testing, or facilities of third-party manufacturers or testing laboratories with which we or any of our future development partners contract for clinical and commercial supplies; or</span></div><div style="text-indent:-18pt;padding-left:45pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#8217; clinical data insufficient for approval.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">With respect to foreign markets, approval procedures vary among countries and, in addition to the aforementioned risks, can involve additional product testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of related products, including those already on the market, may result in increased cautiousness by the FDA and comparable foreign regulatory authorities in reviewing our product candidates based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Identifying and qualifying patients to participate in the OPTIC trial for ADVM-022 for the treatment of wet AMD, the  INFINITY trial for ADVM-022 for the treatment of DME, and any future planned clinical trials will be critical to our success. The timing of current and future clinical trials will depend on the speed at which we can recruit patients to participate in future testing of these product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. We will be required to identify and enroll a sufficient number of patients with wet AMD for the OPTIC trial and/or DME patients for the INFINITY trial, and we will be required to identify and enroll a sufficient number of patients for any future clinical trials for our product candidates. Potential patients may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for our trials. Additionally, some patients may have neutralizing antibodies at titer levels that would prevent them from being enrolled in a clinical trial for any of our product candidates, or may meet other exclusion criteria. The incidence of neutralizing antibodies in the population of patients, particularly for rare diseases, is unknown, and may be higher than we expect. As a consequence, enrollment in our clinical trials may be limited or slowed. We also may encounter difficulties in identifying and enrolling patients with a stage of disease appropriate for such future clinical trials. We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics to achieve diversity in a trial.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Rare diseases impact a small number of individuals in the U.S. (fewer than 200,000) and therefore there is a limited patient pool from which to draw for clinical trials. Enrollment of eligible patients with rare or orphan diseases may be limited or slower than we anticipate in light of the small patient populations involved.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We plan to seek initial marketing approval of these product candidates in the U.S. and/or Europe and we may not be able to successfully conduct clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by the FDA or the EMA or other regulatory agencies. In addition, the process of finding and diagnosing patients may prove costly.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, if patients are unwilling to participate in our gene therapy studies because of negative publicity from adverse events in the biotechnology or gene therapy industries or inadequate results in our preclinical studies or clinical trials or for other reasons, including competitive clinical trials for similar patient populations or available approved therapies, our recruitment of patients, conduct of preclinical studies or clinical trials and ability to obtain regulatory approval of our product candidates may be hindered.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Our product candidates use an adeno-associated viral vector ("AAV") delivery system. Nonetheless, if patients negatively associate our product candidates with the adverse events caused by previous gene therapy products, they may not choose to enroll in our clinical trials, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we have difficulty enrolling a sufficient number of patients to conduct clinical trials on our product candidates as planned, we may need to delay, limit or terminate future clinical trials, any of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The occurrence of serious complications or side effects in connection with use of our product candidates, either in preclinical studies or clinical trials or post-approval, could lead to discontinuation of our clinical development program, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve new indications, which could severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the conduct of preclinical studies and clinical trials, animal models and patients may experience changes in their health, including illnesses, injuries and discomforts. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Various illnesses, injuries, and discomfort may be reported from time-to-time in clinical trials of our product candidates. It is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomfort and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by patients. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or later stage clinical trials, or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that one or more of our product candidates has side effects or causes serious or life-threatening side effects, the development of one or more of our product candidates may fail or be delayed, or, if one or more of our product candidates has received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">When a patient experiences a negative health event during a clinical trial, we must determine if it is related to our product candidate in order to understand the safety of our product candidates. The patients we enroll in our clinical trials for our current product candidates are less healthy than the general population, which increases the likelihood that a negative health event, unrelated to our product candidate, may occur. These health events may be misattributed to our product candidate, either by us, our investigators, or by regulators. Such misattribution could cause regulatory approval of our product candidates to be denied or delayed. For example, the patients enrolled in our OPTIC trial, and any future clinical trials for wet AMD, are often geriatric and have other health conditions unrelated to wet AMD. Similarly, patients enrolled in our INFINITY trial, and any future clinical trials for DME, suffer from diabetes, which has a number of comorbidities. We cannot assure you that we will be able to accurately determine whether or not a negative health event experienced by a patient in any of these or subsequent trials was related to ADVM-022, nor can we assure you that the FDA or other regulatory authority responsible for reviewing the safety of ADVM-022 will agree with our determination. If a patient in OPTIC, INFINITY, or another clinical trial experiences a negative health event, and that event is misattributed to ADVM-022, the trial may be placed on clinical hold, and regulatory approval of ADVM-022 may be delayed or denied.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, if a patient enrolled in one of our clinical trials experiences a negative health event, they may be forced to withdraw from our trial, or may become temporarily unavailable for follow-up visits, which may impact the amount or quality of data we obtain from our trial, which in turn may delay or prevent regulatory approval of our product candidate. Because patients we enroll in our clinical trials for any of our product candidates are likely to be less healthy than the general population, and particularly in trials like OPTIC that enroll a small number of patients, this risk is increased.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates built on AAV vectors have similar risks to other gene therapy vectors, including inflammation, cytotoxic T-cell responses, anti-AAV antibodies and immune response to the transgene product, such as T-cell responses and/or antibodies against the expressed protein. For example, based on our current clinical experience, ocular inflammation is a known side effect of ADVM-022 administration, but the duration of inflammation caused by ADVM-022, our ability to manage that inflammation using steroids or other anti-inflammatory treatments, and any potential clinical sequelae of that inflammation and treatments used to manage inflammation are not fully understood. If we are unable to manage this inflammation appropriately, the FDA or other regulatory authorities may not approve ADVM-022. Even if we achieve marketing approval, doctors may not prescribe, and patients may not use ADVM-022 or our other product candidates if they deem the levels or risk of inflammation to be unacceptable. Further, patients treated with ADVM-022 could develop antibodies against AAV.7m8 capsid and/or aflibercept protein. These antibodies could preclude these patients from receiving other AAV-based gene therapies and/or recombinant aflibercept protein in the future. Studies have also found that intravenous delivery of certain AAV vectors at very high doses may result in adverse events and have prompted the recommendation that studies involving high doses of AAV vectors should be monitored carefully for such adverse events. In addition, patients given infusions of any protein may develop severe hypersensitivity reactions, infusion reactions, or serious side effects including transaminitis. With respect to our product candidates that are being or may be studied in diseases of the eye, there are additional potential serious complications related to intravitreal injection, such as retinal detachment, endophthalmitis, ocular inflammation, cataract formation, glaucoma, hypotony, damage to the retina or cornea, and bleeding in the eye. Serious complications or serious, unexpected side effects in connection with the use of our product candidates could materially harm our business prospects, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, our lead product candidate, ADVM&#8209;022 is designed for long-term, sustained expression of an exogenous protein, aflibercept. Even though Eylea&#174; (aflibercept) has been approved by several regulatory authorities, including the FDA, for the treatment of wet AMD, there may be side effects associated with aflibercept being expressed as a gene therapy treatment modality. If such side effects are serious or life-threatening, the development of our product candidate and future product candidates may fail or be delayed, or, if such product candidate(s) have received regulatory approval, such approval may be revoked, which would severely harm our business prospects, financial condition and results of operation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We will rely on third parties to conduct some preclinical testing and all of our planned clinical trials. If these third parties do not meet our deadlines or otherwise fail to conduct the trials as required, our clinical development programs could be delayed or unsuccessful and we may not be able to obtain regulatory approval for or commercialize our product candidates when expected or at all.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not have the ability to conduct all aspects of our preclinical testing, clinical testing, or clinical trials ourselves. We are dependent on third parties to conduct preclinical studies and clinical trials for our product candidates, and, therefore, the timing of the initiation and completion of these studies or trials is controlled in part by these third parties and may occur at times substantially different from our estimates. Specifically, we use and rely on medical institutions, clinical investigators, contract research organizations (&#8220;CROs&#8221;) and consultants to conduct our trials in accordance with our clinical protocols and regulatory requirements. Our CROs, investigators and other third parties play a significant role in the conduct of these trials and subsequent collection and analysis of data.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There is no guarantee that any CROs, investigators or other third parties on which we rely for administration and conduct of our clinical trials will devote adequate time and resources to such trials or perform as contractually required. If any of these third parties fails to meet expected deadlines, fails to adhere to our clinical protocols, fails to meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be extended, delayed or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer those patients to another qualified clinical trial site.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the utility of certain data from the clinical trial may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any IND or BLA we submit to the FDA, or equivalent submissions to other regulatory authorities. Any such delay or rejection could prevent us from commercializing our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have relied, and expect to continue to rely, on third parties to conduct some or all aspects of our vector production, product manufacturing, product testing, protocol development, and research, and these third parties may not perform satisfactorily.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We do not expect to independently conduct all aspects of our vector production, product manufacturing, product testing, protocol development, protocol performance, and research. We currently rely, and expect to continue to rely, on third parties with respect to these items. We may not be able to enter into agreements with these third parties and if we do enter into agreements with these third parties, any of these third parties may not be successful at fulfilling their contractual obligations or may choose to terminate their engagements with us at any time. If we need to enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for vector production, product manufacturing, product testing, protocol development, protocol performance, and research activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations. If any of these third parties on which we rely do not perform satisfactorily, we will remain responsible for ensuring that:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">each of our preclinical studies and clinical trials are conducted in accordance with the study plan and protocols and applicable GLP requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">vector production, product manufacturing, and product testing are conducted in accordance with applicable cGMP requirements and other applicable regulatory requirements;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">other research is conducted in accordance with applicable industry and regulatory standards and norms;</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">any of which we may not be able to do.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These third parties may not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols. If third parties breach their contractual obligations to us, we may not be able to start or complete, or may be delayed in starting or completing, the preclinical studies and clinical trials required to support future IND submissions, development work, and approval of our product candidates.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reliance on third-party manufacturers entails risks to which we would not be subject to if we manufactured the product candidates ourselves, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to negotiate manufacturing agreements with third parties under commercially reasonable terms;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">reduced control as a result of using third-party manufacturers for some or all aspects of manufacturing activities;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">disruptions to the operations of our third-party manufacturers or suppliers caused by conditions unrelated to our business or operations, including the acquisition, change in control, or bankruptcy of the manufacturer or supplier.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval, or impact our ability to successfully commercialize future products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and our contractors are subject to significant regulation with respect to manufacturing and testing our product candidates. We have a limited number of vendors on which we rely, including, in some cases, single source vendors, and the contract vendors on which we rely may not continue to meet regulatory requirements, may have limited capacity, or may have other factors limiting their ability to comply with their contracts with us.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have relationships with a limited number of suppliers for the manufacturing and testing of our vector product candidates. Our suppliers may require licenses to manufacture or test such components if such processes are not owned by the suppliers or in the public domain and we may be unable to transfer or sublicense the intellectual property rights we may have with respect to such activities, and may be unable to acquire such rights, to the extent that we do not already have them.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract vendors for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured and tested in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s cGMP regulations enforced by the FDA through its facilities inspection program as well as other regulations enforced by other regulatory authorities. Our contract manufacturers have not produced a commercially-approved AAV product and therefore have not yet demonstrated compliance with cGMP regulations to the satisfaction of the FDA or other regulatory authority. Our facilities and quality systems and the facilities and quality systems of some or all of our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. If the facility does not pass a pre-approval plant inspection, FDA or other regulatory approval of the products will not be granted. In addition, the regulatory authorities may, at any time, audit or inspect our manufacturing facilities or those of our third-party contractors involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Should the FDA or other regulatory authority determine that the facility is not in compliance with applicable regulations, the manufacture and release of our product candidates may not be possible, and our business could be harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in laws and governmental policies may have an effect on regulations. For example, on January 31, 2020, the United Kingdom (UK) withdrew from the European Union (EU), commonly referred to as Brexit. Under the withdrawal agreement agreed between the UK and the EU, the UK will be subject to a transition period until December 31, 2020 (the &#8220;Transition Period&#8221;) during which EU rules will continue to apply. During the Transition Period, negotiations between the UK and the EU are expected to continue in relation to the future customs and trading relationship between the UK and the EU following the expiration of the Transition Period. Due to the current COVID-19 global pandemic, negotiations between the UK and the EU that have been scheduled since March have either been postponed or are occurring in a reduced forum via video conference. There is, therefore, an increased likelihood that the Transition Period may need to be extended beyond December 31, 2020 (although it remains the position of the UK government that it will not be extended). We and our contract vendors currently rely on other contractors based in the United Kingdom (UK). After the transition period, if the implementation of new governmental policies associated with Brexit occurs, these governmental policies may affect our UK-based contractors&#8217; ability to comply with applicable regulations, including existing EU regulations. If they are unable to return to compliance, or if an acceptable substitute vendor cannot be identified, it may negatively impact our business. Further, to the extent that our UK-based contractors have supply relationships with vendors in the EU, these contractors may experience difficulties, delay or increased costs in receiving materials from their vendors in the EU, which could have a material adverse effect on our UK-based contractors&#8217; ability to provide the services or materials to us.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if we become aware of a violation of our product specifications or applicable regulations, independent of an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third party to implement and which may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Such violations could also result in civil and/or criminal penalties. Any such remedial measures or other civil and/or criminal penalties imposed upon us or third parties with whom we contract could materially harm our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or our third-party contractors fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new biologic product, revocation of a pre-existing approval, injunction, seizure of product, or other civil or criminal penalties or closing one or more manufacturing or testing facilities. As a result, our business, financial condition and results of operations may be materially harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, if the service provided by an approved manufacturing or testing contractor is interrupted, there could be a significant disruption in commercial supply. An alternative contractor would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies showing comparability between approved product or testing, and product or testing provided after a contractor change, if a new manufacturing or testing contractor is relied upon for commercial production. Switching contractors may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of our product candidates, causing us to incur higher costs, and preventing us from commercializing our product candidates successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed, or we could lose potential revenue.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our reliance on third parties requires us to share our trade secrets and other confidential information, which increases the possibility that a competitor will discover them or that our confidential information, including trade secrets, will be misappropriated or disclosed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Because we rely on third parties to research and develop and to manufacture our product candidates, we must, at times, share confidential information, including trade secrets, with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements containing confidentiality provisions with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are purposefully or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Public disclosure of our confidential information also prevents us from seeking patent protection for that or related discoveries. Given that our proprietary position is based, in part, on our know-how and trade secrets, the unauthorized use or disclosure of our trade secrets would impair our competitive position and may have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our confidential information and trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future will usually expect to be granted rights to publish data arising out of such collaboration, provided that we are notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential information or trade secrets from any such publication. However, we may fail to recognize or identify to our collaborator such confidential information or trade secrets during the appropriate timeframe prior to publication, and they may be publicly disclosed without us filing for patent or other protection. In the future we may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development or similar agreements.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets could impair our competitive position and have an adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Any suspension of, or delays in the commencement or completion of, clinical trials for our product candidates could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Before we can initiate clinical trials in the U.S. for our product candidates, we need to submit the results of preclinical testing to the FDA, along with other information including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial protocol, as part of an IND. We may rely in part on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. If these third parties do not provide timely data for our product candidates, it will delay our plans for our IND submissions and clinical trials. If those third parties do not make this data available to us, we will likely have to develop all necessary preclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA may require us to conduct additional preclinical testing for any product candidate before it allows us to initiate clinical testing under any IND, which may lead to additional delays and increase the costs of our preclinical development. Delays with any regulatory authority or agency may significantly affect our product development timeline. Delays in the commencement or completion of any clinical trials that we plan for our product candidates could significantly affect our product development costs. We do not know whether any trials that we plan will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed or terminated for a number of reasons, including delays or terminations related to:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the FDA failing to grant permission to proceed or placing the clinical trial on hold;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patients failing to enroll or remain in our trial at the rate we expect;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patients choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">lack of adequate funding to continue the clinical trial;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patients experiencing severe or unexpected drug-related adverse effects;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or other government or regulatory authorities to temporarily or permanently shut down due to violations of cGMP or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any changes to our manufacturing process that may be necessary or desired;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, lacking the ability or resources to appropriately handle our product candidates, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, Good Clinical Practice or regulatory requirements, or other third parties not performing data collection or analysis in a timely and accurate manner;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">inspections of clinical trial sites by the FDA or the finding of regulatory violations by the FDA or an IRB that require us to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a clinical hold on the IND or that prohibit us from using some or all of the data in support of our marketing applications;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications; or</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">one or more IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional patients, or withdrawing its approval of the trial.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the FDA placed our IND application for ADVM-022 for the treatment of wet AMD on clinical hold and requested certain information and requirements related to CMC as described in &#8220;Our business will depend substantially on the success of one or more of our product candidates. If we are unable to develop, obtain regulatory approval for, or successfully commercialize, any or all of our product candidates, our business will be materially harmed.&#8221; above. If we are unable to respond to these CMC requirements and the requirements related to the partial clinical hold to the FDA&#8217;s satisfaction and within the timeframe we expect, the FDA will not remove the clinical hold, which may prevent us from advancing our clinical program and our business may be harmed.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Product development costs will increase if we have delays in testing or approval of any of our product candidates, such as the partial clinical hold on our IND for ADVM-022 for the treatment of wet AMD, or if we need to perform more or larger clinical trials than planned. Additionally, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to reflect these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for review and approval, which may impact the costs, timing or successful completion of a clinical trial. If we experience delays in completion of our clinical trials, or if we, the FDA or other regulatory authorities, the IRB, other reviewing entities, or any of our clinical trial sites suspend or terminate any of our clinical trials, the commercial prospects for our product candidate may be harmed and our ability to generate product revenue may be delayed. In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials, such as the partial clinical hold on our IND for ADVM-022 for the treatment of wet AMD, may also ultimately lead to the denial of regulatory approval of a product candidate. If we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Further, if one or more clinical trials are delayed, including as a result of the partial clinical hold on our IND for ADVM-022 for the treatment of wet AMD, or terminated, our competitors may be able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our product candidates, if approved, may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of, or the availability of data from, scientific studies and clinical trials and the submission of regulatory filings. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones will be based on a variety of assumptions. The actual timing of these milestones can vary dramatically compared to our estimates, in some cases for reasons beyond our control. If we do not meet these milestones as publicly announced, the commercialization of our products may be delayed and the credibility of our management team may be adversely affected and, as a result, our stock price may decline.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Final marketing approval for our product candidates by the FDA or other regulatory authorities for commercial use may be delayed, limited or denied, any of which would adversely affect our ability to generate operating revenue.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we are able to successfully complete our clinical trials and submit a BLA, we cannot predict whether or when we will obtain regulatory approval to commercialize our product candidates, and we cannot, therefore, predict the timing of any future revenue. We cannot commercialize our product candidates until the appropriate regulatory authorities have reviewed and approved the applicable applications. We cannot assure you that the regulatory agencies will complete their review processes in a timely manner or that we will obtain regulatory approval for our product candidates. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. If marketing approval for any product candidate is delayed, limited or denied, our ability to market the product candidate, and our ability to generate product sales, would be adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we obtain marketing approval for any of our product candidates, they could be subject to restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if U.S. regulatory approval is obtained, the FDA may still impose significant restrictions on a product&#8217;s indicated uses, marketing or distribution or impose ongoing requirements for potentially costly and time-consuming post-approval studies, post-market surveillance or clinical trials. Following approval, if at all, of any of our product candidates, such candidate will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other post-market information. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requesting recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or the manufacturing facilities for any product candidate that may receive regulatory approval fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">issue warning letters or untitled letters;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspend or withdraw regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspend any ongoing clinical trials;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">refuse to approve pending applications or supplements or applications filed by us;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">institute import holds;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">seize or detain products, refuse to permit the import or export of product or request us to initiate a product recall.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. The FDA has the authority to require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, if any of our product candidates is approved, our product labeling, advertising and promotion would be subject to regulatory requirements and ongoing regulatory review. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or be subject to permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Even if we receive regulatory approval, we still may not be able to successfully commercialize any of our product candidates, and the revenue that we generate from its sales, if any, could be limited.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if any of our product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payers or the medical community. Coverage and reimbursement of our product candidates by third-party payers, including government payers, is also generally necessary for commercial success. The degree of market acceptance of our product candidates will depend on a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">demonstration of clinical efficacy, including duration of efficacy, and safety compared to other more-established products;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">acceptance of new therapeutic options by health care providers and their patients;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prevalence and severity of any adverse effects;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">new procedures or methods of treatment that may be more effective in treating or may reduce the incidences of wet AMD, DME, or other conditions that our product candidates are intended to treat;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">pricing and cost-effectiveness;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the effectiveness of our or any future collaborators&#8217; sales and marketing strategies;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain and maintain sufficient third-party coverage and reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payers;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">unfavorable publicity relating to the product candidate; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the willingness of patients to pay out-of-pocket in the absence of third-party coverage and reimbursement.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payers or patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable. Our efforts to educate the medical community and third-party payers on the benefits of such a product candidate may require significant resources and may never be successful. In addition, our ability to successfully commercialize any of our product candidates will depend on our ability to manufacture our products, differentiate our products from competing products and defend and enforce our intellectual property rights relating to our products.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If the market for our product candidate, if approved, in the treatment of wet AMD, or any other indication we seek to treat is smaller than we believe it is, our future revenue may be adversely affected, and our business may suffer.</span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We are advancing the development of ADVM-022 for the treatment of wet AMD, a disease we believe to be the most common cause of vision loss in adults over the age of 50 in developed countries. If the size of the market for wet AMD or any other indication we seek to treat is smaller than we anticipate (including in our rare disease programs), we may not be able to achieve profitability and growth. Our projections of the number of people who have wet AMD and other indications, as well as the subset of people with the disease who have the potential to benefit from treatment with ADVM-022 or other future product candidates, are based on estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics, patient foundations and market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. The effort to identify patients with diseases we seek to treat is in early stages as we enroll patients in the OPTIC trial of ADVM-022 for the treatment of wet AMD and the INFINITY trial of ADVM-022 for the treatment of DME, and we cannot accurately predict the number of patients for whom treatment might be possible. For example, some patients with wet AMD have neutralizing antibodies at titer levels that may prevent them from benefiting from ADVM-022. If this patient population is larger than we estimate, the market for ADVM-022 may be smaller than we anticipate, and our future revenue may be adversely affected. In addition, we expect prophylactic steroid treatment will be required to manage inflammation associated with treatment with ADVM-022, and certain patients cannot be treated with prophylactic steroids. If this proportion of patient population is larger than we estimate, the market for ADVM-022 may be smaller than we anticipate. Additionally, the potentially addressable patient population may be limited or may not be amenable to treatment with our product candidates for other reasons, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our results of operations and our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Further, even if we obtain significant market share for any of our rare disease programs, because the potential target population is very small, we may never achieve profitability despite obtaining such significant market share.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, because the target patient population for any of our rare disease programs is relatively small, the pricing and reimbursement of these product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell any of our product candidates targeting such rare disease will be adversely affected. The manner and level at which reimbursement is provided for services related to this product candidate (e.g., for administration of such product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates targeting such rare disease.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payers for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payers, such as private health insurers and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Reimbursement by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product candidate is:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">a covered benefit under its health plan;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">safe, effective and medically necessary;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">appropriate for the specific patient; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">cost-effective.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Obtaining coverage and reimbursement approval for a product candidate from a government or other third-party payer is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of the applicable product candidate to the payer. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. While there is no uniform coverage and reimbursement policy among payers in the United States, private payers often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Further, reimbursement amounts may reduce the demand for, or the price of, our product candidates. If reimbursement is not available or is available only in limited levels, we may not be able to commercialize certain of our product candidates profitably, or at all, even if approved.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A number of cell and gene therapy products recently have been approved by the FDA. Although the U.S. Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) approved its first method of coverage and reimbursement for one such product, the methodology has been subject to challenge by members of Congress. CMS&#8217;s decision as to coverage and reimbursement for one product does not mean that all similar products will be eligible for analogous coverage and reimbursement. As there is no uniform policy for coverage and reimbursement amongst third-party payors in the United States, even if CMS approves coverage and reimbursement for any of our product candidates, it is unclear what affect, if any, such a decision will have on our ability to obtain and maintain coverage and adequate reimbursement from other private payors.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of legislative proposals and the trend toward managed health care in the U.S., third-party payers are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. By way of example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act was enacted with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The Affordable Care Act, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed care organizations and established annual fees and taxes on manufacturers of certain prescription drugs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There remain judicial and Congressional challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed Executive Orders and other directives designed to eliminate, circumvent or loosen the implementation of certain provisions of the Affordable Care Act or otherwise circumvent some of the requirements for health insurance mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#8217;s mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. Moreover, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the Affordable Care Act, effective January 1, 2019, to increase from 50 percent to 70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare Part D drug plans, commonly referred to as the &#8220;donut hole.&#8221; Further, in December 2018, CMS published a final rule permitting further collections and payments to and from certain Affordable Care Act-qualified health plans (&#8220;QHPs&#8221;) and health insurance issuers under the Affordable Care Act adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On April 27, 2020, the United States Supreme Court reversed a Federal Circuit decision that previously upheld Congress' denial of $12 billion in "risk corridor" funding. In December 2018, a federal district court judge in Texas found the Affordable Care Act&#8217;s individual mandate to be unconstitutional and therefore the entire law to be invalid. In December 2019, the Fifth Circuit affirmed the ruling regarding the individual mandate but remanded the case to the district court for additional analysis of the question of severability and whether other portions of the law remain valid. On March 2, 2020, the United States Supreme Court granted the petitions for writs of certiorari to review this case, and has allotted one hour for oral arguments, which are expected to occur in the fall. It is unclear how such litigation and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Other legislative changes have also been proposed and adopted in the U.S. since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This included aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and due to subsequent legislative changes to the statute, including the BBA, will stay in effect through 2030 unless additional Congressional action is taken. The Coronavirus Aid, Relief and Economic Security Act, or CARES Act, which was signed into law in March 2020 and is designed to provide financial support and resources to individuals and businesses affected by the COVID-19 pandemic, suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2020, and extended the sequester by one year, through 2030.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">These cost reduction initiatives could decrease the coverage and reimbursement that we receive for any approved products and could seriously harm our business. We expect that additional healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal, state and foreign governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressures.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Recently there has been heightened governmental scrutiny over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases.  Further, the Trump administration previously released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services solicited feedback on some of these measures and has implemented others under its existing authority. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of health care may adversely affect:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the demand for any product candidates for which we may obtain regulatory approval;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to set a price that we believe is fair for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the level of taxes that we are required to pay; and</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt;">the availability of capital.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">It is possible that additional governmental action is taken to address the COVID-19 pandemic. For example, on April 18, 2020, CMS announced that QHP issuers under the Affordable Care Act may suspend activities related to the collection and reporting of quality data that would have otherwise been reported between May and June 2020 given the challenges healthcare providers are facing responding to the COVID-19 virus.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Due to the novel nature of our technology and the potential for our product candidates to offer therapeutic benefit in a single administration, we face uncertainty related to pricing and reimbursement for these product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our product candidates are designed to provide potential therapeutic benefit after a single administration and, therefore, the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to many manufacturing and distribution risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The process of manufacturing our product candidates is complex, highly regulated and subject to several risks, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The manufacturing and distribution of biologics is extremely susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the manufacturing facility in which our product candidates are made, such manufacturing facility may need to be closed for an extended period of time to investigate and remedy the contamination.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, contaminants, raw materials shortages, natural disasters, power failures, and numerous other factors.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We and our contract manufacturers must comply with the FDA&#8217;s cGMP regulations and guidelines. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or any delay, interruption, or other issues that arise in the manufacture, fill-finish, packaging or storage of our product candidates as a result of a failure of our facilities, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates. This may lead to significant delays in the availability of sufficient supply of the product candidate substance for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions, and criminal prosecutions, any of which could be costly and damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates, if approved, and/or may be subject to product recalls, seizures, injunctions or criminal prosecution.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Our product candidates are biologics and require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as our product candidates generally cannot be adequately characterized prior to manufacturing the final product. As a result, an assay of the finished product is not sufficient to ensure that the product will perform in the intended manner. Accordingly, we expect to employ multiple steps to attempt to control our manufacturing process and assure that the product or product candidate is made strictly and consistently in compliance with the process.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">We have to develop the manufacturing process for late stage clinical product, and our current process has not been fully characterized and therefore is open to potential variations that could lead to defective product substance that does not meet specification.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Problems with the manufacturing, storage or distribution of our product candidates, including even minor deviations from our established parameters, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims and insufficient inventory.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Some of the raw materials required in our manufacturing process are derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt commercialization.</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">Any adverse developments affecting manufacturing operations for our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for product substance that fails to meet specifications, undertake costly remediation efforts, or seek more costly manufacturing alternatives. We may encounter problems manufacturing sufficient research-, clinical-, or commercial-grade materials that meet FDA, EMA or other applicable standards or specifications with consistent and acceptable production yields and costs.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in establishing and maintaining development or other strategic collaborations, which could adversely affect our ability to develop and commercialize product candidates and receive milestone and/or royalty payments.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have entered into development or other strategic collaborations with major biotechnology or pharmaceutical companies. Research activities under our collaboration agreements are subject to mutually agreed-on research plans and budgets, and if we and our strategic partners are unable to agree on the research plan or research budget in a timely fashion or at all, performance of research activities will be delayed. In addition, some of our strategic partners may terminate any agreements they enter into with us or allow such agreements to expire by their terms. If we fail to maintain our current or future strategic collaborations, we may not realize milestone and royalty payments or other revenues under the collaboration agreements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">34</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may form strategic alliances in the future, and we may not realize the benefits of such alliances.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may form strategic alliances, create joint ventures or collaborations, or enter into licensing arrangements with third parties that we believe will complement or augment our existing business, including for the continued development or commercialization of our product candidates. These relationships or those like them may require us to incur non-recurring and other charges, increase our near-and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because third parties may view the risk of failure in future clinical trials as too significant, or the commercial opportunity for our product candidate as too limited. We cannot be certain that, following a strategic transaction or license, we will achieve the revenue or specific net income that justifies such transaction. Even if we are successful in our efforts to establish development partnerships, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our competitors develop treatments for the target indications of our product candidates that are approved, marketed more successfully, or demonstrated to be safer or more effective or easier to administer than our product candidates, our commercial opportunity will be reduced or eliminated.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We operate in highly competitive segments of the biopharmaceutical markets. We face competition from many different sources, including larger and better-funded pharmaceutical, specialty pharmaceutical, biotechnology, and gene therapy companies, as well as from academic institutions, government agencies and private and public research institutions. Our product candidates, if successfully developed and approved, will compete with established therapies as well as with new treatments that may be introduced by our competitors. There are a variety of drug candidates and gene therapies in development or being commercialized by our competitors for the indications that we intend to test. Many of our competitors have significantly greater financial, product candidate development, manufacturing, and marketing resources than we do. Large pharmaceutical and biotechnology companies have extensive experience in clinical testing and obtaining regulatory approval for drugs. In addition, universities and private and public research institutes may be active in our target disease areas, and some could be in direct competition with us. We also may compete with these organizations to recruit management, scientists, and clinical development personnel. We will also face competition from these third parties in establishing clinical trial sites, registering patients for clinical trials, and in identifying and in-licensing new product candidates. For example, REGENXBIO is developing RGX-314, an AAV-based gene therapy delivering Lucentis (ranibizumab) for the treatment of wAMD, diabetic retinopathy, and diabetic macular edema, which competes for the same patients, study site resources, and personnel as ADVM-022. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">New developments, including the development of other biotechnology and vectorology technologies and methods of treating disease, occur in the pharmaceutical, biotechnology and gene therapy industries at a rapid pace. Developments by competitors may render our product candidates obsolete or noncompetitive. Competition in drug development is intense. In addition, we believe that duration of efficacy is an important consideration by physicians and patients when choosing a therapy. However, we do not know and may not know prior to any potential approval the duration of efficacy of our product candidates. We anticipate that we will face intense and increasing competition as new treatments enter the market and advanced technologies become available.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if we obtain regulatory approval for our product candidates, the availability and price of our competitors&#8217; products could limit the demand, and the price we are able to charge, for our product candidates. For example, Lucentis&#174; and EYLEA are currently available in the U.S. for treatment of wet AMD, diabetic macular edema, macular edema secondary to retinal vein occlusion and diabetic retinopathy. We will not achieve our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug products or choose to reserve our product candidates for use in limited circumstances. Our inability to compete with existing or subsequently introduced drug products or other therapies would have a material adverse impact on our business, prospects, financial condition and results of operations.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">35</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our potential competitors in these diseases may be developing novel therapies that may be safer or more effective or easier to administer than our product candidates. For example, if we continue clinical development of, and seek to commercialize, ADVM&#8209;022 for the treatment of wet AMD, it will compete with a variety of therapies currently marketed and in development for wet AMD, using therapeutic modalities such as biologics, small molecules, long acting delivery devices, and gene therapy. Lucentis and EYLEA are anti-VEGF therapies that are well established and widely accepted by physicians, patients and third-party payers as the standard of care for the treatment of wet AMD. There are several other companies with marketed products or products in development for the treatment of wet AMD, including Allergan, Bayer, Hoffmann-La Roche Ltd., Novartis, Regeneron and REGENXBIO.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have no sales, marketing or distribution capabilities, and we would have to invest significant resources to develop these capabilities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have no internal sales, marketing, or distribution capabilities. If any of our product candidates ultimately receive regulatory approval, we may not be able to effectively market and distribute the product candidate. We would have to invest significant amounts of financial and management resources to develop internal sales, distribution and marketing capabilities, some of which will be committed prior to any confirmation that any of our product candidates will be approved, if at all. We may not be able to hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms or at all. Even if we determine to perform sales, marketing and distribution functions ourselves, we could face a number of additional related risks, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may not be able to attract and build an effective marketing department or sales force;</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of establishing a marketing department or sales force may exceed our available financial resources and the revenue generated by any product candidates that we may develop, in-license or acquire; and</span></div><div style="text-indent:-18pt;padding-left:36pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our direct sales and marketing efforts may not be successful.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Governments may impose price controls, which may adversely affect our future profitability.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We intend to seek approval to market our product candidates in both the U.S. and in foreign jurisdictions. If we obtain approval in one or more jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to our product candidates. In some countries, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product candidate. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Business Operations</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain marketing approvals for our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in the treatment of those diseases that our product candidates target prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing symptomatic treatments they are already familiar with and for which greater clinical data may be available.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Trials using early versions of retroviral vectors, which integrate into, and thereby alter, the host cell&#8217;s DNA, have led to several well-publicized adverse events. Although none of our current product candidates utilize retroviruses and we believe AAVs used in our product candidates have low-integrating potential and are not known to cause disease in humans, our product candidates do use a viral vector delivery system. The risk of serious adverse events remains a concern for gene therapy and we cannot assure that it will not occur in any of our current or future clinical trials. In addition, there is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biological activity of the genetic material or other components of products used to carry the genetic material.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">36</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverse events in trials or studies conducted by us or other parties, in particular involving the same or similar AAV serotypes to the ones we are using, even if not ultimately attributable to our product candidates or to an AAV serotype that we employ, and resulting publicity, could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Similarly, our lead product candidate, ADVM&#8209;022 expresses the aflibercept protein, which is also the active ingredient in Eylea. If safety or efficacy issues occur relating to Eylea, even if not ultimately attributable to aflibercept, this may negatively impact our product candidate. If any such adverse events or issues occur, development and commercialization of our product candidates or advancement of any potential clinical trials could be halted or delayed, which would have a material adverse effect on our business and operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are dependent on the services of our key executives and clinical and scientific staff, and if we are not able to retain these members of our management or recruit additional management, clinical and scientific personnel, our business will suffer.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are dependent on the principal members of our management, clinical and scientific staff. The loss of service of any of our management or clinical or scientific staff could harm our business. In addition, we are dependent on our continued ability to attract, retain and motivate highly qualified additional management, clinical and scientific personnel. If we are not able to retain our management, and to attract, on acceptable terms, additional qualified personnel necessary for the continued development of our business, we may not be able to sustain our operations or grow. Although we have executed employment agreements with each member of our current executive management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may not be able to attract or retain qualified management, scientific and clinical personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the San Francisco Bay Area. Our industry has experienced a high rate of turnover of management and scientific personnel in recent years. If we are not able to attract, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, we do not currently maintain &#8220;key person&#8221; life insurance on the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%;">We may encounter difficulties in managing our growth and expanding our operations successfully.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to grow our organization, or certain functions within our organization, substantially to continue development and pursue the potential commercialization of our product candidates, as well as function as a public company. As we seek to advance our product candidates, we may need to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic partners, suppliers and other third parties. Future growth will impose significant added responsibilities on members of management and require us to retain or otherwise manage additional internal capabilities. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and clinical trials effectively and hire, train and integrate any additional management, clinical and regulatory, financial, administrative and sales and marketing personnel. We may not be able to accomplish these tasks, and our failure to accomplish them could prevent us from successfully growing our company.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with applicable state and federal healthcare laws, we may be subject to civil or criminal penalties and/or exclusion from federal and/or state healthcare programs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition to FDA restrictions on the marketing of pharmaceutical products, several other types of state and federal healthcare fraud and abuse laws restrict certain practices, including marketing, in the pharmaceutical industry. These laws include anti-kickback, false claims, physician payment transparency and privacy and security laws and regulations. Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of these laws.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">37</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced-price items and services. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formula managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Many states have similar laws that apply to their state health care programs as well as private payers.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payers; knowingly and willfully embezzling or stealing from a healthcare benefit program; willfully obstructing a criminal investigation of a healthcare offense; and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. The Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, federal false claims laws, including the False Claims Act, and the civil monetary penalty law prohibit knowingly presenting or causing the presentation of a false, fictitious, or fraudulent claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations of the False Claims Act can result in significant monetary penalties and treble damages. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the country, for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The Affordable Care Act, among other things, imposed new reporting requirements on drug manufacturers, under the federal Physician Payments Sunshine Act, for payments made by them to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure to submit required information may result in significant civil monetary penalties, for all payments, transfers of value or ownership or investment interests that are not timely, accurately and completely reported in an annual submission. Certain states also mandate implementation of commercial compliance programs, impose restrictions on drug manufacturer marketing practices and/ or require the tracking and reporting of gifts, compensation and other remuneration to physicians.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will need to build and maintain a robust compliance program with different compliance and/or reporting requirements. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, vendors, or other third parties that may violate such laws. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">38</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, &#8220;Trade Laws&#8221;). We can face serious consequences for violations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Among other matters, Trade Laws prohibit companies and their employees, agents, CROs, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, provide, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else or anything of value to or from recipients in the public or private sector. Violations of Trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax assessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We also expect our non-U.S. activities to increase in time. We engage third parties for clinical trials and/or obtain necessary permits, licenses, registrations, and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to comply with applicable U.S. and foreign privacy and data protection laws and regulation, we may be subject to liabilities that adversely affect our business, operations and financial performance.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, retention, and security of personal data, such as information that we collect about patients and healthcare providers in connection with clinical trials in the U.S. and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, result in liability or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For example, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), imposes, among other things, certain standards relating to the privacy, security, transmission and breach reporting of individually identifiable health information, upon health plans, healthcare clearinghouses and certain healthcare providers, and their respective business associates that perform services for them involving individually identifiable health information. In the event we are subject to HIPAA, and fail to properly maintain the privacy and security of certain individually identifiable health information, or we are responsible for an inadvertent disclosure or security breach of such individually identifiable health information, we could be subject to enforcement measures, including civil and criminal penalties and fines for violations of state and federal privacy or security standards, such as HIPAA and HITECH, and their respective implementing regulations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. HIPAA, HITECH and comparable state laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. Any liability from failure to comply with the requirements of these laws, to the extent such requirements are deemed to apply to our operations, could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results of operations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have established or are in the process of establishing privacy and data security legal frameworks with which we, our customers, or our vendors must comply. For example, the EU has adopted the General Data Protection Regulation, or GDPR, which went into effect in May 2018 and introduced strict requirements for processing personal data. The GDPR is likely to increase compliance burden on us, including by mandating potentially burdensome documentation requirements, granting certain rights to individuals to control how we collect, use, disclose, retain and leverage information about them. The processing of sensitive personal data, such as physical health condition, may impose heightened compliance burdens under the GDPR and is a topic of active interest among foreign regulators. In addition, the GDPR provides for breach reporting requirements, more robust regulatory enforcement and fines of up to 20 million euros or up to 4% of the annual global revenue. In the United States, California recently enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;), which took effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA also requires covered businesses to provide detailed privacy notices to California residents and respond to requests from California residents to exercise their rights under the CCPA without discrimination. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the U.S. In addition to a new ballot measure already introduced in California which </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">39</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">would amend the CCPA, the CCPA has prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, increase our compliance costs and adversely affect our business. Further, as we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and our development partners, third-party manufacturer and suppliers use biological materials and use or may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We and our development partners, third-party manufacturer and suppliers use or may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize our product candidates. For example, we may be sued if our product candidates allegedly caused or cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability, and a breach of warranties.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Claims could also be asserted under state consumer protection acts.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or cease the commercialization of our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">decreased demand for our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">injury to our reputation;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">withdrawal of clinical trial participants;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">costs to defend the related litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a diversion of management&#8217;s time and our resources;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">substantial monetary awards to trial participants or patients;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">loss of revenue;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the inability to commercialize our product candidates; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a decline in our stock price.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently hold $5.0 million in product liability insurance, which may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">40</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we and any of our future development partners or CROs are successful in commercializing our products, the FDA and foreign regulatory authorities would require that we and any of our future development partners report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We and any of our future development partners may fail to report adverse events we become aware of within the prescribed timeframe. We and any of our future development partners may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product candidates. If we and any of our future development partners fail to comply with our or their reporting obligations, the FDA or a foreign regulatory authority could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of the product and delay in approval or clearance of other products.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our internal computer systems, or those of our development partners, CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the ordinary course of our business, we, our CROs, and other third parties on which we rely, collect and store sensitive data, including legally protected patient health information, personally identifiable information about our employees, intellectual property, and proprietary business information. These applications and data encompass a wide variety of critical information including research and development information and business and financial information.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy. Despite the implementation of security measures to protect against unauthorized access or disclosure, our internal computer systems and those of our current and any future CROs and other contractors, consultants and collaborators are vulnerable to damage or attacks from computer viruses, unauthorized access, breaches, interruptions due to employee error, malfeasance or other disruptions, lapses in compliance with privacy and security mandates, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such material system failure, accident, or security breach to date, any such event could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to detect and respond to such security incidents and breaches of privacy and security mandates. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as HIPAA, government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business and damage our reputation, any of which could adversely affect our business. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to manufacture our product candidates and conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidate could be delayed.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have entered into a lease for a new corporate, process development, and research headquarters, which may be more costly to continue building out than we anticipate and may not provide all of the functionality we expect, which could cause us to incur unanticipated costs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2018, we entered into a lease for a building located in Redwood City, California, which we began occupying in January 2020. This facility serves as our new corporate headquarters and includes approximately 81,000 square feet of office, development, and research laboratory space. We believe this facility will enable us to increase our in-house process development capabilities to the 1000-liter scale. There can be no assurance that the continued cost of building out this space will not be significantly more than we expect, or that the functionality of this space will be as we expect.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, since we are not developing this space for clinical or commercial manufacturing production, we will continue to rely upon our limited number of suppliers to manufacture our gene therapy product candidates for clinical trials and if they are approved, for commercial sale.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">41</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, fires, disease epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. In addition, we rely on third-party research facilities, manufacturers and other service providers from other countries and from different parts of the U.S. to provide services and resources necessary to support our research and development plans, to produce our product candidates, and support our clinical trials. Our ability to obtain this necessary support or supplies could be disrupted if the operations of these suppliers or service providers, or national and international supply chains are affected by a man-made or natural disaster or other business interruption, including national or international health concerns. The occurrence of any of these business disruptions, including of our own operations, could seriously harm our operations and financial condition and increase our costs and expenses.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The coronavirus (&#8220;COVID-19 pandemic has impacted our business practices and the effects of its continued impact on our business, results of operations, and financial condition will depend on future developments, which cannot be predicted.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The COVID-19 pandemic has caused us to modify our business practices (including adhering to &#8220;shelter-in-place&#8221; orders, limiting employee travel, and cancelling physical participation in meetings, events and conferences), and we may take further actions that may be required by government authorities or that we determine are in the best interests of our employees, customers and business partners. We are uncertain that such measures will be sufficient to mitigate the risks posed by the virus or otherwise be satisfactory to government authorities and how long we will be required to continue these measures.</span></div><div style="margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Operating under the &#8220;shelter-in-place&#8221; orders has made it more challenging and time-consuming for us to conduct certain of our operations. The effects of operating under the &#8220;shelter-in-place&#8221; orders may continue to negatively impact productivity, disrupt our operations and negatively impact our business and financial condition, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. For example, restrictions on our financial functions&#8217; access to our facilities has led to a delay in our ability to prepare, complete and file our Quarterly Report on Form 10-Q for the first quarter of 2020. Separately, an increased reliance by us and the companies with which we do business on information technology systems may increase cyber security risk, create data accessibility issues, increase the risk for communication disruptions, or otherwise disrupt or delay normal business operations.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The COVID-19 pandemic may also affect our current and planned trials and development programs, possibly affecting our timelines for commercialization.  Shelter-in-place or equivalent orders and the current general reluctance of people to make in-person visits to healthcare providers for treatment of non-life-threatening ailments may make initiating clinical trial sites, identifying potential patients and enrolling them in our clinical trials, retaining any such patients, ensuring that such patients comply with treatment protocols, and collecting sufficient trial data to progress our clinical programs more difficult. For example, we believe that patient concerns related to COVID-19 caused some of our OPTIC trial patients to miss scheduled appointments for fear of contracting the virus which, if this were to be repeated over longer periods of time, could impact our ability to collect data we need.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In addition, due to the limited ability to access our facilities and our reliance on outside vendors who may be similarly affected, our development programs may not proceed along the timelines we previously anticipated. We rely on third-party research facilities, manufacturers, suppliers and other service providers from other countries and from different parts of the U.S. to provide services and resources necessary to support our research and development plans, to produce our product candidates, and support our clinical trials. Our ability to obtain this necessary support or supplies could be disrupted, or the cost of this support or these supplies could increase, if the operations of these suppliers or service providers, or national and international supply chains, including of transportation carriers and transportation hubs, are affected by the COVID-19 pandemic. In addition, if our relationships with our service providers, suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative service providers, suppliers or other vendors or do so on commercially reasonable terms or in a timely or cost-effective manner. Further, we may be subject to the inability or unwillingness of clinical investigators or patients to follow our research protocols as a result of the recent COVID-19 pandemic. As a result, delays could occur which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. The COVID-19 pandemic may also affect the operations of the FDA or other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Although we are taking steps to mitigate all of these effects, the occurrence of any of these disruptions, including of our own operations, could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">42</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The extent to which the COVID-19 pandemic continues to impact our business, results of operations and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. Even after the coronavirus outbreak has subsided, we may experience materially adverse impacts to our business as a result of its global human and economic impact, or as a result of our actions taken and not taken as mitigation measures during the COVID-19 pandemic. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct or other improper activities, including noncompliance with our code of conduct or regulatory standards and requirements.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in misconduct including code of conduct violations, fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct, or disclosure of unauthorized activities to us that violates: (1) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory authorities, (2) manufacturing standards, (3) federal and state health care fraud and abuse laws and regulations or (4) laws that require the reporting of financial information or data accurately. Specifically, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Relating to Our Intellectual Property</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our rights to develop and commercialize our product candidates are subject in part to the terms and conditions of licenses granted to us by other companies and universities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently are heavily reliant upon licenses of certain patent rights and proprietary technology from third parties that are important or necessary to the development of our technology and products, including technology related to our manufacturing process and our gene therapy product candidates. These and other licenses may not provide adequate rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future, or may contain other limitations on our ability to use such intellectual property or technology. As a result, our ability to develop or commercialize our processes and product candidates may be limited by the terms of such agreements. Further, the third parties from whom we license certain patent rights and proprietary technology may attempt to terminate their agreements with us. For example, we have received from Virovek a notice of intent to terminate our non-exclusive license to certain Virovek technology and know-how related to methods and materials for manufacturing adeno-associated virus. While we do not believe Virovek has the right to terminate the agreement, if it were terminated, we may be unable to obtain a new license to Virovek technology on commercially reasonable terms, if at all. If we need to develop or acquire alternative manufacturing technology, our product development activities may be significantly delayed, and if we were unable to develop or acquire alternative manufacturing technology, it could have a material adverse effect on our business. In addition, we may not be able to prevent competitors from developing and commercializing competitive products to the extent our licenses to patents are non-exclusive or limited with respect to fields of use or territories.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We anticipate that licenses to additional third-party technology will be required to advance our current development programs, as well as additional development programs we may initiate in the future. If these licenses are not available on commercially reasonable terms or at all, we may not be able to commercialize our current and future development programs, which will have a material adverse effect on our business and financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">43</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our success depends on our ability to protect our intellectual property and our proprietary technologies.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates, proprietary technologies, and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that any of our product candidates will have patent protection, that our patent applications or those of our licensors will result in patents being issued or that issued patents, if any, will afford sufficient protection against competitors with similar technology, nor is there any assurance that the patents issued will not be infringed, designed around or invalidated by third parties. Even issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to our product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own and license certain composition-of-matter patents and applications covering components of our product candidates. Composition-of-matter patents on the biological or chemical active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of any of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and courts in the U.S. or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be found invalid or unenforceable if challenged.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We own and license certain method-of-use patents and applications covering methods of treating certain diseases with our product candidates. Method-of-use patents protect the use of a product for the specified method or for treatment of a particular indication. However, methods of treating human diseases are considered unpatentable in many jurisdictions, and even where available this type of patent does not prevent a competitor from making and marketing a product that is identical to our product candidate for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patent applications may not result in any patents being issued;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">patents may expire before or soon after the product they cover is commercialized;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with, or eliminate our ability to make, use, and sell our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the U.S. for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">countries other than the U.S. may have patent laws less favorable to patentees than those upheld by the U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, we rely on the protection of our trade secrets and know-how. Although we have taken steps to protect our trade secrets and know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and third parties may still obtain this information or may come upon this or similar information independently.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">44</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Trade secrets do not provide any protection against the independent development of the trade secret by a competitor or other third party. If a competitor independently obtains or develops our trade secret, either by reverse engineering our product or other legal means, we would be unable to prevent them from using the trade secret, and our competitive position would be harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The biotechnology industry has been characterized by frequent litigation regarding patent and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology industry expands, especially in the field of gene therapy, and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents that may be infringed by commercialization of our product candidates. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Any claims of patent infringement asserted by third parties would be time consuming to defend against and could:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">result in costly litigation;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">divert the time and attention of our technical personnel and management;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">cause development delays;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">prevent us from commercializing our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; or</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities relating to our product candidate or processes could subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market our product candidates. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we cannot be sure that we could redesign our product candidate or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The patent protection and patent prosecution for some of our product candidates are dependent on third parties.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we normally seek to obtain the right to control the prosecution and maintenance of the patents relating to our product candidates, there may be times when the filing and prosecution activities for platform technology patents that relate to our product candidates are controlled by our licensors. For example, we do not have the right to prosecute and maintain the patent rights licensed to us under agreements with Regents of the University of California, Cornell University, and Virovek, and our ability to have input into such filing and prosecution activities is limited. If these licensors or any of our future licensors fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">45</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged administratively or in court.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we or any of our future development partners were to initiate or threaten legal proceedings against a third party to enforce a patent directed at one of our product candidates, or one of our future product candidates, the accused infringer could claim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, as are claims seeking declaratory judgment of invalidity. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a false or misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our defense of litigation or patent office proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research and development programs, license necessary technology from third parties, or enter into development or manufacturing partnerships that would help us bring our product candidates to market.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Even if resolved in our favor, litigation or other legal or patent office proceedings relating to our intellectual property rights may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We currently have rights to intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will depend in part on our ability to acquire, in-license, or use these proprietary rights. For example, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">46</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We sometimes collaborate with U.S. and foreign academic institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business, financial condition, results of operations and prospects could be materially and adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may fail to comply with any of our obligations under existing agreements pursuant to which we license or have otherwise acquired intellectual property rights or technology, which could result in the loss of rights or technology that are material to our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding our rights to intellectual property licensed to us from a third party, including but not limited to:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the sublicensing of patent and other rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ownership of inventions and know-how resulting from the creation or use of intellectual property by us, alone or with our licensors and collaborators;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope and duration of our payment obligations;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our rights upon termination of such agreement; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope and duration of exclusivity obligations of each party to the agreement.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If disputes over intellectual property and other rights that we have licensed or acquired from third parties prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is common in the biotechnology and pharmaceutical industry, in addition to our employees, we engage the services of consultants to assist us in the development of our product candidates. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology or pharmaceutical companies including our competitors or potential competitors. We may become subject to claims that our company, our employees or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. We require all employees to sign proprietary information and invention assignment agreements, but they may fail to do so, or our agreements may be found invalid or unenforceable. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">47</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we do not obtain patent term extensions for patents covering our product candidates, our business may be materially harmed.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we are able to secure FDA marketing approval for one of our product candidates that is covered by an issued U.S. patent, that patent may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984 (&#8220;Hatch-Waxman Act&#8221;). The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial conditions and results of operations may be materially and adversely affected.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could materially and adversely impact our business, financial condition, results of operations, or prospects.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain. In addition, Congress may pass patent reform legislation that is unfavorable to us. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We may not be able to obtain intellectual property rights or protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Filing, prosecuting, obtaining and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">48</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">others may be able to make gene therapies that are similar to our product candidates but that are not covered by the claims of any patents that we own or have exclusively licensed;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors or future collaborators might not have been the first to make the inventions covered by the issued patent or pending patent application that we own or have exclusively licensed;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we or our licensors or future collaborators might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any patent applications that we have filed or may file in the future may not lead to issued patents;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any of the issued patents that we own or have exclusively licensed may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any of the issued patents that we have filed or may file in the future may expire before or shortly after commercialization of the covered product;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our competitors might conduct research and development activities in countries where, or for products for which, we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Third party patent rights could delay or otherwise adversely affect our planned development and sale of product candidates of our programs.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are aware of patent rights held by third parties that could be construed to cover certain aspects of our product candidates. In addition, changes to our product candidates or their uses or manufacture may cause them to infringe patents held by third parties. A patent holder has the right to prevent others from making, using, or selling a drug that incorporates the patented compositions while the patent remains in force. While we believe that third party patent rights will not affect our planned development, regulatory clearance, and eventual marketing, commercial production, and sale of our product candidates, there can be no assurance that this will be the case. In addition, the Hatch-Waxman exemption provided by U.S. patent law permits uses of compounds and biologics in clinical trials and for other purposes reasonably related to obtaining FDA approval of drugs and biologics that will be sold only after patent expiration, so our use of our product candidates in those FDA-related activities does not infringe any patent holder&#8217;s rights. However, were a patent holder to assert its rights against us before expiration of such patent holder&#8217;s patent for activities unrelated to seeking FDA approval, the development and ultimate sale of our product candidates could be significantly delayed, and we could incur the expense of defending a patent infringement suit and potential liability for damages for periods prior to the patent&#8217;s expiration.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to prepare accurate and timely consolidated financial statements being prepared in accordance with U.S. GAAP could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (&#8220;Sarbanes-Oxley&#8221;), our management is required to report upon the effectiveness of our internal control over financial reporting. Our independent registered public accounting firm is also required to attest to the effectiveness of our internal control over financial reporting, and the related report is required to be included in our annual reports filed with the SEC. Sarbanes-Oxley Section 404 compliance requirements are complex and require significant documentation, testing, and possible remediation. If we or our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting, and the trading price of our common stock may decline.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">49</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Although we have determined that our internal control over financial reporting was effective as of December 31, 2019, we cannot assure that there will not be material weaknesses in our internal control over financial reporting for this period, following completion of our independent registered public accounting firm&#8217;s review of our internal control over financial reporting, or in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations, or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by The Nasdaq Stock Market, the SEC or other regulatory authorities. Failure to implement and maintain effective internal control over financial reporting, including failure to remediate any material weaknesses we or our auditors identify, could also restrict our future access to the capital markets.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">The trading price of the shares of our common stock has been and could continue to be highly volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including those discussed above and others such as:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to enroll and dose patients in any clinical trials that are on-going, or that we plan to conduct in the future;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain regulatory approvals for our product candidates and delays or failure to obtain such approvals;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our plans to conduct additional preclinical studies to determine the best gene therapy candidates to advance in development;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">results of any clinical trials, and the results of trials of our competitors or those of other companies in our market sector;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">investor perception and analysis of the results of our clinical trials, which may be different than our own;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments in the U.S. and foreign countries;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">failure to maintain our existing third-party license and collaboration agreements;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">delays in manufacturing adequate supply of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">adverse publicity relating to the gene therapy market generally, including with respect to other products and potential products in such markets;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">market conditions in the pharmaceutical and biotechnology sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">sales of our stock by insiders and stockholders;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">trading volume of our common stock;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the outbreak of COVID-19;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">general economic, industry and market conditions other events or factors, many of which are beyond our control;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">additions or departures of key personnel; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">intellectual property, product liability or other litigation against us.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, in the past, stockholders have initiated class action lawsuits against biotechnology and pharmaceutical companies following periods of volatility in the market prices of these companies&#8217; stock, and similar litigation has been instituted against us. Such litigation could cause us to incur substantial costs and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">50</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We have been subject to securities class action lawsuits in the past, and could be subject to additional such lawsuits in the future, which could result in substantial losses and may divert management&#8217;s time and attention from our business.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the past, we and certain of our former officers were involved in purported securities class action lawsuits, which have since been settled. The purported securities class action lawsuits asserted that the defendants violated the Exchange Act and the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and alleged that the defendants who are no longer at Adverum made materially false and misleading statements and omitted allegedly material information related to, among other things, the Phase 2a clinical trial for AVA&#8209;101, a program which was discontinued in 2015, and the prospects of AVA-101. We settled these lawsuits for $13.0 million, of which $1.0 million we contributed to cover our indemnification obligations to the underwriters, and the remainder was contributed by our insurers. Any future litigation of this type could result in payment of damages or settlement fees and diversion of management&#8217;s attention and resources, any of which could adversely impact our business. Monitoring and defending against legal actions are time-consuming for our management and detracts from our ability to focus fully on our business activities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">variations in the level of expenses related to our clinical trial and development programs;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">addition or termination of clinical trials or addition of cohorts to clinical trials;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any intellectual property infringement lawsuit or other litigation in which we may become involved;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">regulatory developments affecting our product candidates;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our execution of any collaborative, licensing or similar arrangements and the timing of payments we may make or receive under these arrangements;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">nature and terms of stock-based compensation grants; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">derivative instruments recorded at fair value.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">If we sell shares of our common stock or securities convertible into or exercisable for shares of our common stock in future financings, licensing or collaboration arrangements, or acquisitions, stockholders may experience immediate dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, licensing, collaboration or similar arrangements, grants and debt financings. We do not have any committed external source of funds. As a result, we may from time to time issue additional shares of common stock or securities convertible into or exercisable for shares of our common stock. On August 8, 2019, we filed a universal shelf registration statement on Form S-3 with the SEC that automatically became effective, pursuant to which we registered for sale an undetermined amount of any combination of our common stock, preferred stock, debt securities, warrants, and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a &#8220;well-known seasoned issuer&#8221; under SEC rules. In February 2020 we sold an aggregate of 10,925,000 shares of our common stock for $140.9 million of net proceeds after deducting underwriting discounts and commissions and estimated offering expenses. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends or other distributions. Furthermore, we may issue common stock as consideration in acquisitions. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If we raise additional funds through licensing, collaboration or similar arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research and development programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">51</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. These provisions include:</span></div><div style="text-indent:-18pt;padding-left:54pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the authorization of the issuance of &#8220;blank check&#8221; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the limitation of the removal of directors by the stockholders;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">a staggered board of directors;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the prohibition of stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the elimination of the ability of stockholders to call a special meeting of stockholders;</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the ability of our board of directors to accelerate the vesting of outstanding option grants, restricted stock units or other equity awards upon certain transactions that result in a change of control; and</span></div><div style="text-indent:-18pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the establishment of advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We do not intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have never declared or paid any cash dividend on our common stock and do not currently intend to do so for the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">We are a smaller reporting company, and the reduced reporting requirements applicable to smaller reporting companies may make our common stock less attractive to investors.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a smaller reporting company. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not smaller reporting companies, including reduced disclosure obligations regarding executive compensation. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business and financial condition.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Legislation enacted on December 22, 2017, known as the Tax Cuts &amp; Jobs Act (&#8220;TCJA&#8221;), significantly revises the Internal Revenue Code of 1986, as amended. Many aspects of the TCJA are unclear and may not be clarified for some time. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Future guidance from the Internal Revenue Service and other tax authorities with respect to the TCJA may affect us, and certain aspects of the TCJA could be repealed or modified in future legislation. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (&#8220;CARES Act&#8221;) was enacted and signed into law. The CARES Act includes changes to the tax provisions that benefits business entities, and makes certain technical corrections to the TCJA. According to U.S. GAAP, companies are required to recognize the tax effects of new legislation during the reporting period that includes the enactment date. U.S. states and localities are at various stages of conforming to federal income tax changes as well as proposing limitations of net operating losses. In foreign jurisdictions in which we operate, relief measures include deadline extensions and acceleration of credit refunds. We have evaluated and determined that the impact of these provisions is immaterial. </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">52</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Changes in corporate tax rates, the realization of net deferred tax assets relating to our U.S. operations, the taxation of foreign earnings, and the deductibility of expenses under the TCJA, the CARES Act, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, cash flow, financial condition, or results of operations. In addition, it is uncertain if and to what extent various states will conform to the TCJA, the CARES Act, or any newly enacted federal tax legislation.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Our ability to use net operating loss carryforwards and other tax attributes may be limited by the Code.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have incurred substantial losses during our history and do not expect to become profitable in the near future and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire, except as described below.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Under the TCJA, as amended by the CARES Act, federal net operating losses (&#8220;NOLs&#8221;) incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating NOLs arising after 2020 is limited. In addition, under Section 382 of the Code, our ability to utilize NOL carryforwards or other tax attributes, such as research tax credits, in any taxable year may be limited if we experience an &#8220;ownership change.&#8221; Generally, a Section 382 ownership change occurs if there is a cumulative increase of more than 50 percentage points in the stock ownership of one or more stockholders or groups of stockholders who owns at least 5% of a corporation&#8217;s stock within a specified testing period. Similar rules may apply under state tax laws. In connection with our acquisition of Annapurna in May 2016, we determined that certain NOLs and research and developments tax credits for both federal and state purposes were severely limited and therefore we removed a significant amount of NOLs and research and development tax credits from our deferred tax assets. In addition, we may have experienced an ownership change as a result of the February 2018 underwritten public offering of our common stock, and may in the future experience ownership changes from future offerings or other changes in the ownership of our stock, including as a result of our February 2020 offering of our common stock. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From the state legislative aspect, Governor Newsom&#8217;s proposed budget which was submitted on May 14, 2020, could have an adverse impact to the utilization of California NOLs deductions and research credits. Specifically, his budget would suspend utilization of California NOLs and limit the utilization of credits to $5 million per year for 3 years. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result, the amount of the NOLs and research credits carryforwards presented in our financial statements could be limited and may expire unutilized.</span></div><div><span><br/></span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_112"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 2.&#160;Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_115"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 3.&#160;Defaults Upon Senior Securities</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_118"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 4.&#160;Mine Safety Disclosures</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable.</span></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_121"></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:10pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 5.&#160;Other Information</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Not applicable</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">53</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_124"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-108pt;padding-left:108pt;margin-top:10pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Item 6.&#160;Exhibits</span></div><div style="padding-left:9pt;text-align:center;margin-top:6pt;"><span><br/></span></div><div style="padding-left:9pt;text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">EXHIBIT INDEX</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:34.988%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.672%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.456%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.865%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.389%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">INCORPORATED BY REFERENCE</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXHIBIT DESCRIPTION</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FILE NUMBER</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">FORM</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">DATE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">EXHIBIT<br/>NUMBER</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">PROVIDED<br/>HEREWITH</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-36579</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 9, 2017</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312516588027/d130217dex32.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">001-36579</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8-K</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 12, 2016</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Reference is made to Exhibits </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1501756/000156459017003759/advm-ex31_910.htm">3.1</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;"> through </span><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312516588027/d130217dex32.htm">3.2</a></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">.</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1501756/000119312514280644/d729335dex41.htm">Form of Common Stock Certificate.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">333-197133</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">S-1/A</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">July 25, 2014</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex101.htm">Form of Indemnification Agreement for Directors and Executive Officers</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">Employment Agreement, dated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">July</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm"> 2</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">6</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">, 20</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">19</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">, </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">between</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm"> Adverum Biotechnologies, Inc. and </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">Angela Thedinga</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex102.htm">.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex103.htm">Promotion Letter, dated February 21, 2020, between Adverum Biotechnologies, Inc. and Angela Thedinga</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex311.htm">Certification of Principal Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex312.htm">Certification of Principal Financial </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex312.htm">Officer, as required by Rule 13a-14(a) or Rule 15d-14(a).</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.2*</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex322.htm">Certification of Principal Financial </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="advm-20200331xex322.htm">Officer pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">X</span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, formatted in Inline XBRL.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-indent:-54pt;padding-left:54pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">54</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-indent:-54pt;padding-left:54pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">*&#160;The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Adverum Biotechnologies, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">55</span></div></div></div><div id="i6cc84e466e2441dcb07b49b4c9803a6d_127"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;" href="#i6cc84e466e2441dcb07b49b4c9803a6d_7">Table of Contents</a></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:54pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.440%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.022%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 28, 2020</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ADVERUM BIOTECHNOLOGIES, INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Leone Patterson</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leone Patterson</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">President and Chief Executive Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Executive Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:51.440%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.022%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 28, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Thomas Leung</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas Leung</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Chief Financial Officer</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%;">(Principal Financial and Accounting Officer)</span></div></td></tr></table></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-top:12pt;"><span><br/></span></div><div style="text-align:center;margin-top:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">56</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>advm-20200331xex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i097364045219451985d2f0c6acb737f1_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit 10.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration: underline;">INDEMNIFICATION AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Indemnification Agreement (&#8220;Agreement&#8221;) is made as of &#91;&#9679;&#93;, 20__ by and between Adverum Biotechnologies, Inc., a Delaware corporation (the &#8220;Company&#8221;), and &#91;&#9679;&#93; (&#8220;Indemnitee&#8221;).</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as directors or officers or in other capacities unless they are provided with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Board of Directors of the Company (the &#8220;Board&#8221;) has determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain liabilities. Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends, such insurance may be available to it in the future only at higher premiums and with more exclusions. At the same time, directors, officers and other persons in service to corporations or business enterprises are being increasingly subjected to expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself. The Bylaws (the &#8220;Bylaws&#8221;) and the Certificate of Incorporation of the Company (the &#8220;Certificate of Incorporation&#8221;) require indemnification of the officers and directors of the Company. Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;). The Bylaws, the Certificate of Incorporation and the DGCL expressly provide that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such persons&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of the Company and its stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, this Agreement is a supplement to and in furtherance of the Bylaws, the Certificate of Incorporation and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder&#59;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Indemnitee does not regard the protection available under the Bylaws, the Certificate of Incorporation and insurance as adequate in the present circumstances, and may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity. Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf of the Company on the condition that he or she be so indemnified&#59; and</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 1.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Services to the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Indemnitee agrees to serve as a director, officer, employee or agent of the Company, as applicable, or, at the request of the Company, as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise, as applicable. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee. Indemnitee specifically acknowledges that Indemnitee&#8217;s employment with the Company (or any of its subsidiaries or any Enterprise), if any, is at will, and the Indemnitee may be discharged at any time for any reason, with or without cause, except as may be otherwise provided in any written employment contract between Indemnitee and the Company (or any of its subsidiaries or any Enterprise), other applicable formal severance policies duly adopted by the Board, or, with respect to service as a director or officer of the Company, by the Certificate of Incorporation, the Bylaws and the DGCL. The foregoing notwithstanding, this Agreement shall continue in force after Indemnitee has ceased to serve as a director, officer, employee or agent of the Company, as applicable, or, at the request of the Company, as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise, as applicable, as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Definitions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  As used in this Agreement&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;References to &#8220;agent&#8221; shall mean any person who is or was a director, officer or employee of the Company or a subsidiary of the Company or other person authorized by the Company to act for the Company, to include such person serving in such capacity as a director, officer, employee, fiduciary or other official of another corporation, partnership, limited liability company, joint venture, trust or other enterprise at the request of, for the convenience of, or to represent the interests of the Company or a subsidiary of the Company.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;A &#8220;Change in Control&#8221; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events&#58;</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.&#160;Acquisition of Stock by Third Party.  Any Person (as defined below) is or becomes the Beneficial Owner (as defined below), directly or indirectly, of securities of the Company representing fifteen percent (15%) or more of the combined voting power of the Company&#8217;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#8217;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors&#59;</font></div><div style="text-indent:108pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.&#160;Change in Board of Directors.  During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 2(b)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">2(b)(iii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">2(b)(iv)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) whose election by the Board or nomination for election by the Company&#8217;s stockholders was approved by a vote of at least two-thirds (2&#47;3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board&#59;</font></div><div style="text-indent:108pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii. &#160;Corporate Transactions.  The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty-one percent (51%) of the combined voting power of the voting securities of the surviving entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving entity&#59;</font></div><div style="text-indent:108pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iv.&#160;Liquidation.  The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale or disposition by the Company of all or substantially all of the Company&#8217;s assets&#59; and</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">v.&#160;Other Events.  There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act (as defined below), whether or not the Company is then subject to such reporting requirement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the following terms shall have the following meanings&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(A)&#160;&#8220;Exchange Act&#8221; shall mean the Securities Exchange</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Act of 1934, as amended from time to time. (B) &#8220;Person&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;3</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same</font></div><div style="padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">proportions as their ownership of stock of the Company.</font></div><div style="padding-left:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(B)&#160;&#8220;Person&#8221; shall have the meaning as set forth in Sections 13(d) and 14(d) of the Exchange Act&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Person shall exclude (i) the Company, (ii) any trustee or other fiduciary holding securities under an employee benefit plan of the Company, and (iii) any corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.</font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(C)&#160;&#8220;Beneficial Owner&#8221; shall have the meaning given to such term in Rule 13d-3 under the Exchange Act&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Beneficial Owner shall exclude any Person otherwise becoming a Beneficial Owner by reason of the stockholders of the Company approving a merger of the Company with another entity.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#8220;Corporate Status&#8221; describes the status of a person who is or was a director, trustee, partner, managing member, officer, employee, agent or fiduciary of the Company or of any other corporation, limited liability company, partnership or joint venture, trust or other enterprise which such person is or was serving at the request of the Company.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#8220;Disinterested Director&#8221; shall mean a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#8220;Enterprise&#8221; shall mean the Company and any other corporation, limited liability company, partnership, joint venture, trust or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, employee, agent or fiduciary.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#8220;Expenses&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts and other professionals, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax transmission charges, secretarial services, any federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties, and all other disbursements, obligations or expenses of the types customarily incurred in connection with, or as a result of, prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a deponent or witness in, or otherwise participating in, a Proceeding. Expenses also shall include (i) Expenses incurred in connection with any appeal resulting from any Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond or other appeal bond or its equivalent, and (ii) expenses incurred in connection with recovery under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;4</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">whether the Indemnitee is ultimately determined to be entitled to such indemnification, advancement or Expenses or insurance recovery, as the case may be, and (iii) for purposes of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> only, Expenses incurred by or on behalf of Indemnitee in connection with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement, by litigation or otherwise. The parties agree that for the purposes of any advancement of Expenses for which Indemnitee has made written demand to the Company in accordance with this Agreement, all Expenses included in such demand that are certified by affidavit of Indemnitee&#8217;s counsel as being reasonable shall be presumed conclusively to be reasonable. Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#8220;Independent Counsel&#8221; shall mean a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has been, retained to represent&#58; (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning the Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;The term &#8220;Proceeding&#8221; shall include any threatened, pending or completed action, suit, claim, counterclaim, cross claim, arbitration, mediation, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory, legislative or investigative (formal or informal) nature, including any appeal therefrom, in which Indemnitee was, is or will be involved as a party, potential party, non-party witness or otherwise by reason of the fact that Indemnitee is or was a director or officer of the Company, by reason of any action taken by him or her (or a failure to take action by him or her) or of any action (or failure to act) on his or her part while acting pursuant to his or her Corporate Status, in each case whether or not serving in such capacity at the time any liability or Expense is incurred for which indemnification, reimbursement or advancement of Expenses can be provided under this Agreement. If the Indemnitee believes in good faith that a given situation may lead to or culminate in the institution of a Proceeding, this shall be considered a Proceeding under this paragraph.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;References to &#8220;other enterprise&#8221; shall include employee benefit plans&#59; references to &#8220;fines&#8221; shall include any excise tax assessed with respect to any employee benefit plan&#59; references to &#8220;serving at the request of the Company&#8221; shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;5</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">its participants or beneficiaries&#59; and a person who acted in good faith and in a manner he or she reasonably believed to be in the best interests of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in manner &#8220;not opposed to the best interests of the Company&#8221; as referred to in this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnity in Third-Party Proceedings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall indemnify Indemnitee in accordance with the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal Proceeding had no reasonable cause to believe that his or her conduct was unlawful. The parties hereto intend that this Agreement shall provide to the fullest extent permitted by law for indemnification in excess of that expressly permitted by statute, including, without limitation, any indemnification provided by the Certificate of Incorporation, the Bylaws, vote of its stockholders or disinterested directors or applicable law.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnity in Proceedings by or in the Right of the Company</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Company shall indemnify Indemnitee in accordance with the provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Indemnitee shall be indemnified to the fullest extent permitted by applicable law against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery or any court in which the Proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provisions of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is a party to (or a participant in) and is successful, on the merits or otherwise, in any Proceeding or in defense of any claim, issue or matter therein, in whole or in part, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;6</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with or related to each successfully resolved claim, issue or matter to the fullest extent permitted by law. For purposes of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Indemnification For Expenses of a Witness</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any other provision of this Agreement, to the fullest extent permitted by applicable law and to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness or otherwise asked to participate in any aspect of a Proceeding to which Indemnitee is not a party, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her on his or her behalf in connection therewith.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Partial Indemnification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of Expenses, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which Indemnitee is entitled.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Additional Indemnification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Notwithstanding any limitation in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Company shall indemnify Indemnitee to the fullest extent permitted by applicable law if Indemnitee is a party to or threatened to be made a party to or a participant in any Proceeding (including a Proceeding by or in the right of the Company to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement (including all interest, assessments and other charges paid or payable in connection with or in respect of such Expenses, judgments, fines and amounts paid in settlement) actually and reasonably incurred by or on behalf of Indemnitee in connection with the Proceeding.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;For purposes of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 8(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the meaning of the phrase &#8220;to the fullest extent permitted by applicable law&#8221; shall include, but not be limited to&#58;</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.&#160;to the fullest extent permitted by the provision of the DGCL that authorizes or contemplates additional indemnification by agreement, or the corresponding provision of any amendment to or replacement of the DGCL, and</font></div><div style="text-indent:108pt;text-align:justify;"><font><br></font></div><div style="text-indent:108pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.&#160;to the fullest extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its officers and directors.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 9.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exclusions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnification payment in connection with any claim made against Indemnitee&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;7</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;for which payment has actually been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision&#59; or</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;for (i) an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act (as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof) or similar provisions of state statutory law or common law, or (ii) any reimbursement of the Company by the Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by the Indemnitee from the sale of securities of the Company, as required in each case under the Exchange Act (including any such reimbursements that arise from an accounting restatement of the Company pursuant to Section 304 of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), or the payment to the Company of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 306 of the Sarbanes-Oxley Act)&#59;</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;except as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, (ii) such payment arises in connection with any mandatory counterclaim or cross-claim or affirmative defense brought or raised by Indemnitee in any Proceeding (or any part of any Proceeding), or (iii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law&#59; or</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;if a court of competent jurisdiction determines that such indemnification payment is prohibited by applicable law.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Advances of Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Notwithstanding any provision of this Agreement to the contrary (other than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">), the Company shall advance, to the extent not prohibited by law, the Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding (or any part of any Proceeding) not initiated by Indemnitee, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances from time to time (which shall include invoices received by the Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be so included), whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#8217;s ability to repay the Expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement. In accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, advances shall include any and all reasonable Expenses incurred pursuing an action to enforce this right of advancement, including Expenses incurred preparing and forwarding statements to the Company to support the advances claimed. The Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement, which shall constitute an undertaking providing that the Indemnitee </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;8</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">undertakes to repay the amounts advanced (without interest) to the extent that it is ultimately determined that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required other than the execution of this Agreement. This </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to S</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">ection 9</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 11.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Procedure for Notification and Defense of Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;Indemnitee shall notify the Company in writing of any matter with respect to which Indemnitee intends to seek indemnification or advancement of Expenses hereunder as soon as reasonably practicable following the receipt by Indemnitee of written notice thereof or Indemnitee&#8217;s becoming aware thereof. The written notification to the Company shall include a description of the nature of the Proceeding and the facts underlying the Proceeding, in each case to the extent known to Indemnitee. To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification following the final disposition of such Proceeding. The failure by Indemnitee to notify the Company hereunder will not relieve the Company from any liability which it may have to Indemnitee hereunder or otherwise than under this Agreement, and any delay in so notifying the Company shall not constitute a waiver by Indemnitee of any rights under this Agreement, except to the extent (solely with respect to the indemnity hereunder) that such failure or delay materially prejudices the Company. The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board in writing that Indemnitee has requested indemnification.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;The Company will be entitled to participate in the Proceeding at its own expense and, except as otherwise provided below, to the extent the Company so wishes, it may assume the defense thereof with counsel reasonably satisfactory to Indemnitee. After notice from the Company to Indemnitee of its election to assume the defense of any such Proceeding, the Company shall not be liable to Indemnitee under this Agreement or otherwise for any Expenses subsequently directly incurred by Indemnitee in connection with Indemnitee's defense of such Proceeding other than reasonable costs of investigation or as otherwise provided below. Indemnitee shall have the right to employ its own legal counsel in such Proceeding, but all Expenses related to such counsel incurred after notice from the Company of its assumption of the defense shall be at Indemnitee's own expense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if (i) Indemnitee's employment of its own legal counsel has been authorized by the Company, (ii) Indemnitee has reasonably determined that there may be a conflict of interest between Indemnitee and the Company in the defense of such Proceeding, (iii) after a Change in Control, Indemnitee's employment of its own counsel has been approved by the Independent Counsel or (iv) the Company shall not in fact have employed counsel to assume the defense of such Proceeding, then Indemnitee shall be entitled to retain its own separate counsel (but not more than one law firm plus, if applicable, local counsel in respect of any such Proceeding) and all Expenses related to such separate counsel shall be borne by the Company.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;9</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;The Company shall not settle any Proceeding (in whole or in part) if such settlement would impose any Expense, judgment, liability, fine, penalty or limitation on Indemnitee which Indemnitee is not entitled to be indemnified hereunder without the Indemnitee&#8217;s prior written consent.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;The Company shall not be liable to Indemnitee under this Agreement for any amounts paid in settlement of any threatened or pending Proceeding effected without the Company's prior written consent, which shall not be unreasonably withheld.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 12.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Procedure Upon Application for Indemnification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;Upon written request by Indemnitee for indemnification pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, a determination, if required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (i) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee&#59; or (ii) if a Change in Control shall not have occurred, (A) by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (B) by a committee of Disinterested Directors designated by a majority vote of the Disinterested Directors, even though less than a quorum of the Board, (C) if there are no such Disinterested Directors or, if such Disinterested Directors so direct, by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (D) if so directed by the Board, by the stockholders of the Company&#59; and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or Expenses (including attorneys&#8217; fees and disbursements) incurred by or on behalf of Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. The Company promptly will advise Indemnitee in writing with respect to any determination that Indemnitee is or is not entitled to indemnification, including a description of any reason or basis for which indemnification has been denied.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;In the event the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof, the Independent Counsel shall be selected as provided in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. If a Change in Control shall not have occurred, the Independent Counsel shall be selected by the Board, and the Company shall give written notice to Indemnitee advising him or her of the identity of the Independent Counsel so selected. If a Change in Control shall have occurred, the Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that such selection be made by the Board, in which event the preceding sentence shall apply), and Indemnitee shall give written notice to the Company advising it of the identity of the Independent Counsel so selected. In either event, Indemnitee or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;10</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Company, as the case may be, may, within ten (10) days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee, as the case may be, a written objection to such selection&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 2</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of submission by Indemnitee of a written request for indemnification pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof and the final disposition of the Proceeding, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Delaware Court for resolution of any objection which shall have been made by the Company or Indemnitee to the other&#8217;s selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by such court or by such other person as such court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(c)&#160;If the Company disputes a portion of the amounts for which indemnification is requested, the undisputed portion shall be paid and only the disputed portion withheld pending resolution of any such dispute.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 13.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Presumptions and Effect of Certain Proceedings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;In making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall, to the fullest extent not prohibited by law, presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 11(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, and the Company shall, to the fullest extent not prohibited by law, have the burden of proof to overcome that presumption in connection with the making by any person, persons or entity of any determination contrary to that presumption. Neither the failure of the Company (including by its directors or Independent Counsel) to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or Independent Counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, if the person, persons or entity empowered or selected under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;11</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Company of the request therefor, the requisite determination of entitlement to indemnification shall, to the fullest extent not prohibited by law, be deemed to have been made and Indemnitee shall be entitled to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such sixty (60)-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement to indemnification in good faith requires such additional time for the obtaining or evaluating of documentation and&#47;or information relating thereto&#59; and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the foregoing provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not apply (i) if the determination of entitlement to indemnification is to be made by the stockholders pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement and if (A) within fifteen (15) days after receipt by the Company of the request for such determination the Board has resolved to submit such determination to the stockholders for their consideration at an annual meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;For purposes of any determination of good faith, Indemnitee shall be deemed to have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the directors or officers of the Enterprise in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Enterprise. The provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. Whether or not the foregoing provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 13(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the Company.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;The knowledge and&#47;or actions, or failure to act, of any director, officer, trustee, partner, managing member, fiduciary, agent or employee of the Enterprise shall not be </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;12</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;It shall be a defense to any action brought by Indemnitee against the Company to enforce this Agreement that it is not permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed. In connection with any such action or any related determination of entitlement to indemnification, the burden of proving such a defense or that Indemnitee did not satisfy the applicable standard of conduct shall be on the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 14.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Remedies of Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;Subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in the event that (i) a determination is made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement within ninety (90) days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">6</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">7</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or the last sentence of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement within ten (10) days after receipt by the Company of a written request therefor, (v) payment of indemnification pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Sections 3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">8</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, or (vi) in the event that the Company or any other person takes or threatens to take any action to declare this Agreement void or unenforceable, or institutes any litigation or other action or Proceeding designed to deny, or to recover from, the Indemnitee the benefits provided or intended to be provided to the Indemnitee hereunder, Indemnitee shall be entitled to an adjudication by a court of his or her entitlement to such indemnification or advancement of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred eighty(180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the foregoing clause shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 5</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;In the event that a determination shall have been made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement of Expenses, as the case may be.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;13</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;If a determination shall have been made pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 12(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement. It is the intent of the Company that, to the fullest extent permitted by law, the Indemnitee not be required to incur legal fees or other Expenses associated with the interpretation, enforcement or defense of Indemnitee&#8217;s rights under this Agreement by litigation or otherwise because the cost and expense thereof would substantially detract from the benefits intended to be extended to the Indemnitee hereunder. The Company shall, to the fullest extent permitted by law, indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Expenses to Indemnitee, which are incurred by or on behalf of Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement of Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company if, in the case of indemnification, Indemnitee is wholly successful on the underlying claims&#59; if Indemnitee is not wholly successful on the underlying claims, then such indemnification shall be only to the extent Indemnitee is successful on such underlying claims or otherwise as permitted by law, whichever is greater.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement of Indemnitee to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 15.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Non-exclusivity&#59; Survival of Rights&#59; Insurance&#59; Subrogation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;The rights of indemnification and to receive advancement of Expenses as provided by this Agreement (i) shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of directors or otherwise, and (ii) shall be interpreted independently of, and without reference to, any other such rights to which Indemnitee may at any time be entitled. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement of Expenses than would be afforded currently under the Bylaws, the Certificate of Incorporation and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;14</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees or agents of the Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim or of the commencement of a Proceeding, as the case may be, to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable (or for which advancement is provided hereunder) hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font></div><div style="text-indent:72pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;The Company&#8217;s obligation to indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, trustee, partner, managing member, fiduciary, employee or agent of any other corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of Expenses from such other corporation, limited liability company, partnership, joint venture, trust or other enterprise.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 16.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Duration of Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement shall continue until and terminate upon the later of&#58; (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director, officer, employee or agent of the Company, as applicable, or, at the request of the Company, as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise, as applicable, or (b) one (1) year after the final termination of any Proceeding then pending in respect of which Indemnitee is granted rights of indemnification or advancement of Expenses hereunder and of any proceeding commenced (including any appeal thereof) by Indemnitee pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement relating </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;15</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">thereto. The indemnification and advancement of expenses rights provided by or granted pursuant to this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or of any other Enterprise, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives. The Company shall require and shall cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company to, by written agreement, expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 17.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law&#59; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 18.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Enforcement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director or officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director or officer of the Company.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that this Agreement is a supplement to and in furtherance of the Certificate of Incorporation, the Bylaws, any directors&#8217; and officers&#8217; insurance maintained by the Company and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the provisions of this Agreement shall apply retroactively as of the date such Indemnitee began service as a director, officer, employee or agent of the Company, as applicable, or, at the request of the Company, as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other enterprise, as applicable.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;16</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 19.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Modification and Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 20.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notice by Indemnitee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement of Expenses covered hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to the Indemnitee under this Agreement or otherwise.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 21.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed, or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(a)&#160;If to Indemnitee, at the address indicated on the signature page of this Agreement, or such other address as Indemnitee shall provide to the Company.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)&#160;If to the Company to&#58;</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Chief Financial Officer</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Adverum Biotechnologies, Inc. </font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">800 Saginaw Drive</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Redwood City, CA 94063</font></div><div style="text-indent:36pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(650) 656-9323</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or to any other address as may have been furnished to Indemnitee by the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 22.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Contribution</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by or on behalf of Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and&#47;or transaction(s) giving cause to such Proceeding&#59; and&#47;or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and&#47;or transaction(s).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;17</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 23.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Applicable Law and Consent to Jurisdiction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Section 14(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court of the State of Delaware (the &#8220;Delaware Court&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) appoint, to the extent such party is not otherwise subject to service of process in the State of Delaware, irrevocably The Corporation Trust Company c&#47;o Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801 as its agent in the State of Delaware for acceptance of legal process in connection with any such action or proceeding against such party with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 24.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Identical Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 25.&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The headings of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="text-indent:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ADVERUM BIOTECHNOLOGIES, INC.&#160;INDEMNITEE</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name&#58;&#160;&#160;Name&#58;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title&#58;&#160;&#160;Address&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">31484755.1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> &#160;18</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">151093448 v1</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;"> </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>advm-20200331xex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2f52fa9c4ae2424792a02ebdd75d8786_1"></div><div style="height:118.8pt;width:100%;"><div style="text-align:right;margin-top:2pt;"><img alt="image11.jpg" src="image11.jpg" style="height:56px;width:250px;"></div><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#595959;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverum Biotechnologies, Inc.</font><font style="background-color:rgb(255,255,255, 0.0);color:#595959;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </font></div><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#595959;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1035 O&#8217;Brien Drive,</font></div><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#595959;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Menlo Park, CA 94025</font></div><div style="margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#595959;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">O&#58; 650.272.6269</font></div><div style="margin-top:2pt;"><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 10.2</font></div><div style="text-align:justify;margin-top:0.02pt;margin-bottom:0.08pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%;">July 26, 2019</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Angela Thedinga</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Re&#58; Employment Terms for Vice President, Program Management&#47;Strategy</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Dear Angela,</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This letter agreement (the &#8220;Agreement&#8221;) memorializes the employment terms for your anticipated hire by Adverum Biotechnologies, Inc. (the &#8220;Company&#8221;) in the position of Vice President, Program Management&#47;Strategy, reporting to Leone Patterson, Chief Executive Officer. These terms will become effective on or before August 1, 2019 or at a later date determined by mutual agreement (as applicable, the &#8220;Hire Date&#8221;).</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Effective as of the Hire Date, your employment terms will be as follows&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">Compensation and Benefits.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Your base salary will be $340,000.00 annually ($14,166.67 per pay period), subject to payroll deductions and all required withholdings, representing full-time employment with the Company.  Your salary will be paid in accordance with the Company&#8217;s standard payroll schedule.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In addition, for each calendar year starting with 2019 you will be eligible to earn an annual performance bonus with a target bonus amount equal to thirty percent (30%) of your base salary during the bonus year, subject to the applicable Company annual bonus plan. Your annual bonus for the 2019 calendar year may be prorated based on your Hire Date. Your annual bonus will be calculated based on attainment of individual goals (including corporate and personal objectives) to be determined by the Company&#8217;s management each year. Bonus payments will be in the form of cash, and will be granted entirely at the discretion of the Company&#8217;s CEO and Board of Directors. Any cash bonus payments will be less payroll deductions and all required withholdings. For each calendar year starting with 2019, in addition to a cash bonus, you may be eligible for an annual equity grant, provided that you are actively employed with the Company through and including the date of such annual equity grant. Your annual equity grant for the calendar year may be prorated based on your Hire Date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">A one-time signing bonus of $100,000 will be paid within the first thirty (30) days of your employment and will be subject to payroll deductions and all required withholdings. If you terminate your employment with the Company within eighteen (18) months of your hire date for any reason other than death, disability, or &#8220;Covered Termination&#8221; (as defined in the Change of Control and Severance Agreement) you will be responsible for repaying the signing bonus&#59; or if&#160;the Company terminates your employment within eighteen (18) months of your hire date for Cause (as defined in the Change in Control and Severance Agreement) you will be responsible for repaying the signing bonus. You will be reimbursed for your travel, accommodations and transportation pursuant to the Adverum Travel and Entertainment policy for the first 3 months of your employment as you transition from Chicago to the bay area.</font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:0.02pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;vertical-align:text-bottom;width:91.071%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #b1c0cd;border-left:1pt solid #ffffff;padding-left:1pt;padding-right:1pt;"></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="height:118.8pt;width:100%;"><div style="margin-top:2pt;"><font><br></font></div></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">You will be eligible to participate in the Company&#8217;s general employee benefits in accordance with the terms, conditions and limitations of the benefit plans to the extent such plans have been established by the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">New Hire Equity Grant.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In addition to the compensation and benefits described above, the Company will grant you 100,000 stock options, representing the option to purchase shares of the Company&#8217;s common stock at a price equal to the closing price of the common stock on the Hire Date. The foregoing stock option award will be granted outside of the Company&#8217;s 2014 Equity Incentive Plan as an inducement grant and standard form of stock option agreement, and shall provide that 25% of the shares of common stock subject to the award of the option shall vest on the first anniversary of the vesting commencement date and 1&#47;36th of the remainder of the award will vest monthly thereafter such that the entire award shall be vested and exercisable on the fourth (4th) anniversary of the vesting commencement date.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">Confidentiality and Proprietary Information Obligations.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.8pt;">Company Policies and Proprietary Information Agreement. You will be required to sign the Employee Proprietary Information and Inventions Assignment Agreement attached hereto as Exhibit A (the &#8220;Proprietary Information Agreement&#8221;).</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:5.18pt;">Adverse or Outside Business Activities. Throughout your employment with the Company, you may engage in civic, academic teaching and lectures, and not-for profit activities so long as such activities do not interfere with the performance of your duties hereunder or present a conflict of interest with the Company. You may not engage in other employment or undertake any other commercial business activities unless you obtain the prior written consent of the Company&#8217;s CEO. The Company may rescind its consent to your service as a director of all other corporations or participation in other business or public activities, if the Company, in its sole discretion, determines that such activities compromise or threaten to compromise the Company&#8217;s reputational or business interests or conflict with your duties to the Company. In addition, throughout the term of your employment with the Company, you agree not to, directly or indirectly, without the prior written consent of the Company, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, executive, partner, employee, principal, agent, representative, consultant, licensor, licensee or otherwise with, any business or enterprise engaged in any business which is competitive with or which is reasonably anticipated to be competitive with the Company&#8217;s business&#59; provided, however, that you may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (but without participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange. You hereby represent and warrant that you have disclosed previously to the Board all other employment or other commercial business activities that you already undertake, or intend to undertake (to the extent currently known by you), during your period of employment with the Company.</font></div><div style="padding-left:36pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:0.02pt;margin-bottom:0.08pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:118.8pt;width:100%;"><div style="margin-top:2pt;"><font><br></font></div></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">No Conflicts.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">By signing this Agreement you hereby represent to the Company that, except as previously disclosed to the Company&#58; (a) your employment with the Company is not prohibited under any employment agreement or other contractual arrangement&#59; and (b) you do not know of any conflicts which would restrict your employment with the Company. You hereby represent that you have disclosed to the Company any contract you have signed that may restrict your activities on behalf of the Company, and that you are presently in compliance with such contracts, if any.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">At Will Employment.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Your employment relationship with the Company will be an &#8220;at-will&#8221; arrangement. This means that either you or the Company may terminate your employment at any time, with or without cause, and with or without advance notice. This &#8220;at-will&#8221; employment relationship cannot be changed except in a written agreement approved by the Company and signed by you and by a duly authorized officer of the Company.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:-18pt;padding-left:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:9.75pt;">Miscellaneous.</font></div><div style="padding-left:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.1.  Conditions of employment. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">As required by law, your employment is contingent upon satisfactory proof of your identity and legal authorization to work in the United States. Additionally, this offer is contingent upon your completion of the employment application, verification of your references, satisfactory completion of a pre-employment background check and execution of the Proprietary Information Agreement and the Acknowledgment of Business Ethics and Conduct Guide and Company Policies by or on your first day of employment.</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.2.  Entire agreement. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Agreement, together with your Proprietary Information Agreement (Exhibit A) and Change in Control and Severance Agreement, forms the complete and exclusive statement of your employment agreement with the Company. The employment terms in this Agreement supersede any other agreements or promises made to you by anyone, whether oral or written, concerning your employment terms.</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.3.  Succession and assignment. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Agreement is personal to you and shall not be assigned by you. Any purported assignment by you shall be null and void from the initial date of the purported assignment. The Company may assign this Agreement to any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company. This Agreement shall inure to the benefit of the Company and permitted successors and assigns.</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.4.  Enforceability. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.5.  Governing law and jurisdiction. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Agreement shall be construed and enforced in accordance with the laws of the State of California without regard to conflicts of law principles any action or proceeding by either of the parties to enforce this Agreement shall be brought only in a state or federal court located in the state of California, county of San Mateo. The parties hereby irrevocably submit to the exclusive jurisdiction of such courts and waive the defense of inconvenient forum to the maintenance of any such action or proceeding in such venue.</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:0.02pt;margin-bottom:0.08pt;"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:118.8pt;width:100%;"><div style="margin-top:2pt;"><font><br></font></div></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.6.  Headings and captions. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit or affect the scope or substance of any section of this Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.7.  No construction against drafter. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Any ambiguity in this Agreement shall not be construed against either party as the drafter.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.8.  Waiver. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any successive breach or rights hereunder.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">6.9. Counterparts. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">This Agreement may be executed in counterparts, which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures.</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">7.  Acknowledgement of Full Understanding. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE FULLY READ, UNDERSTAND AND VOLUNTARILY ENTER INTO THIS AGREEMENT. YOU ACKNOWLEDGE AND AGREE THAT YOU HAVE HAD AN OPPORTUNITY TO ASK QUESTIONS AND CONSULT WITH AN ATTORNEY OF YOUR CHOICE BEFORE SIGNING THIS AGREEMENT.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration: underline;">Please sign and date this letter and return it to me by the close of business on July 29, 2019 in order to confirm your anticipated employment terms as set forth above.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">We look forward to a productive and enjoyable work relationship with you.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Sincerely,</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Adverum Biotechnologies Inc.&#58;</font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:justify;"><font><br></font></div><div style="text-align:justify;margin-top:0.02pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:504.00pt;"><tr><td style="width:1.0pt;"></td><td style="width:153.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:114.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:114.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:114.25pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Leone Patterson</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">Leone Patterson</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">Understood and Accepted&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Angela Thedinga</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">Name&#58; Angela Thedinga</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#595959;background-color:rgb(255,255,255, 0.0);">Date&#58; July 29, 2019</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:54pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="margin-top:0.02pt;margin-bottom:0.08pt;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>advm-20200331xex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1c0e1548a3c245ed97e74f85f64e2aab_1"></div><div style="height:36pt;width:100%;"><div style="text-align:right;"><img alt="image01.jpg" src="image01.jpg" style="height:50px;width:237px;"></div><div><font><br></font></div></div><div style="padding-left:295.5pt;"><font><br></font></div><div style="text-align:right;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit 10.3</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">February 21, 2020</font></div><div style="padding-left:6pt;padding-right:398.75pt;margin-top:23.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Angela Thedinga</font></div><div style="padding-left:4.5pt;padding-right:398.75pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Re&#58; Promotion</font></div><div style="padding-left:6pt;padding-right:378.95pt;margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">Dear Angela,</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">Congratulations on a successful year at Adverum! This year has been eventful and challenging for all of us here at Adverum. We have met the huge challenge of scaling our business all while keeping our lab running efficiently and with integrity. We sincerely could not have done it without you.</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">As we review your performance in 2019 and look forward to continued growth and success in 2020 we are pleased to inform you that you have been selected for a promotion. Effective February 21, 2020, your new job title is Chief Technical Officer. This promotion comes with a salary increase resulting in a new base salary of $374,000. In addition to the increase in your salary, your target bonus percentage for 2020 has increased from 30% to 40%.</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">We are also excited to reward your performance with a bonus in the amount of&#160;$51,000.00.</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">In addition, Adverum&#8217;s Board of Directors has awarded you additional equity options as Incentive Stock Options (&#8220;ISO&#8217;s&#8221;) in recognition of your 2019 Performance Review and contributions to the success and growth of Adverum. Specifically, you have been awarded 150,000 ISO&#8217;s.</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">The ISO&#8217;s will vest and become exercisable as follows&#58; subject to you continuing employment with the Company through each vesting date, 25% of the shares of common stock subject to the award of the Option shall vest on the first anniversary of the vesting commencement date (the date of the equity award) and 1&#47;48</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">th </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">of the total shares granted shall vest and become exercisable monthly following such anniversary such that the entire award shall be vested and exercisable on the fourth anniversary of the vesting commencement date. The Option shall be subject to the other terms and conditions set forth in the Company&#8217;s 2017 Inducement Plan and the Company&#8217;s standard form of Nonstatutory Stock Option Agreement. You should consult with your own tax advisor concerning the risks associated with accepting the Option.</font></div><div style="text-indent:36pt;padding-left:9pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">We look forward to another great year with you at Adverum.</font></div><div style="padding-left:4.5pt;margin-top:8.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%;">Sincerely,</font></div><div style="padding-left:4.5pt;margin-top:8.95pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:458.25pt;"><tr><td style="width:1.0pt;"></td><td style="width:153.25pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:73.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:73.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:73.75pt;"></td><td style="width:1.0pt;"></td><td style="width:1.0pt;"></td><td style="width:73.75pt;"></td><td style="width:1.0pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Leone Patterson</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leone Patterson</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Calibri',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="padding-left:4.3pt;"><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="padding-left:171pt;padding-right:171pt;text-align:center;margin-top:2.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">Adverum Biotechnologies, Inc.</font></div><div style="text-indent:-0.05pt;padding-left:183.7pt;padding-right:183.55pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">800 Saginaw Drive Redwood City, CA, 94063</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>advm-20200331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia2ea1584232245f890bd59bd9ba8a657_1"></div><div style="height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.1</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Leone Patterson, certify that&#58;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;28, 2020 </font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:2.093%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.578%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:52.385%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.944%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;Leone Patterson</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leone Patterson</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>advm-20200331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i1b40c670b4ee4d7bac73ade9447afb80_1"></div><div style="height:36pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 31.2</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF THE PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</font></div><div style="text-align:center;margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO SECTION 302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:6pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Thomas Leung, certify that&#58;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.&#160;I have reviewed this Form 10-Q of Adverum Biotechnologies, Inc.&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">c.&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">d.&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-72pt;padding-left:72pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">a.&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:-36pt;padding-left:108pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">b.&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Date&#58; May&#160;28, 2020</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:4.588%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:52.319%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.994%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;Thomas Leung</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas Leung</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:36pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>advm-20200331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="iae68c87cd35e403b8dd96b1fce846740_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.1</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended March&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Leone Patterson, in her capacity as Chief Executive Officer of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of her knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.437%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.608%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 28, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;Leone Patterson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leone Patterson</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>advm-20200331xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i561762a1eb914e85807932e2e384168b_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit 32.2</font></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:54pt;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the Quarterly Report on Form 10-Q of Adverum Biotechnologies, Inc. for the fiscal quarter ended March&#160;31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Thomas Leung, in his capacity as Chief Financial Officer, of Adverum Biotechnologies, Inc., hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge, the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Adverum Biotechnologies, Inc.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:3.856%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:45.437%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.099%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:40.608%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 28, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47;Thomas Leung</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas Leung</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>advm-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:advm="http://www.adverum.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.adverum.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="advm-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.adverum.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Stockholders Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationAdditionalInformationDetail" roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstruments" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments">
        <link:definition>2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsTables" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
        <link:definition>2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponents" roleURI="http://www.adverum.com/role/BalanceSheetComponents">
        <link:definition>2109104 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsTables" roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables">
        <link:definition>2310302 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
        <link:definition>2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail">
        <link:definition>2412405 - Disclosure - Balance Sheet Components - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail">
        <link:definition>2413406 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwards" roleURI="http://www.adverum.com/role/EquityIncentiveAwards">
        <link:definition>2114105 - Disclosure - Equity Incentive Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsTables" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables">
        <link:definition>2315303 - Disclosure - Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail">
        <link:definition>2416407 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail">
        <link:definition>2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentiveAwardsStockBasedCompensationExpenseDetail" roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail">
        <link:definition>2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShare" roleURI="http://www.adverum.com/role/NetLossperShare">
        <link:definition>2119106 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareTables" roleURI="http://www.adverum.com/role/NetLossperShareTables">
        <link:definition>2320304 - Disclosure - Net Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossperShareAdditionalInformationDetail" roleURI="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail">
        <link:definition>2421410 - Disclosure - Net Loss per Share - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.adverum.com/role/RelatedPartyTransactions">
        <link:definition>2122107 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
        <link:definition>2423411 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentAmortizedCost" abstract="false" name="CashAndCashEquivalentAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" abstract="false" name="StockPaidValueForTaxWithholdingForShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedGain" abstract="false" name="CashAndCashEquivalentGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_TrustMember" abstract="true" name="TrustMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" abstract="false" name="OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedExpensesAndOtherCurrentLiabilities" abstract="false" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashAndCashEquivalentGrossUnrealizedLoss" abstract="false" name="CashAndCashEquivalentGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" abstract="false" name="AccruedPreclinicalClinicalAndDevelopmentProcessCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_CashEquivalentsAndShortTermInvestmentsMember" abstract="true" name="CashEquivalentsAndShortTermInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="advm_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" abstract="false" name="DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>advm-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42ff95d0-5392-47df-b119-2322dedc4cf2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_243fec80-1763-4d61-a8a1-7c0bee712392" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_42ff95d0-5392-47df-b119-2322dedc4cf2" xlink:to="loc_us-gaap_Liabilities_243fec80-1763-4d61-a8a1-7c0bee712392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6a651165-aa3f-46c5-8fbb-0e287f3ac4cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_42ff95d0-5392-47df-b119-2322dedc4cf2" xlink:to="loc_us-gaap_StockholdersEquity_6a651165-aa3f-46c5-8fbb-0e287f3ac4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5a32b82e-4761-4d29-a907-734b5249d023" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_171e66b3-049f-4428-b126-000e5c9be3f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a32b82e-4761-4d29-a907-734b5249d023" xlink:to="loc_us-gaap_LiabilitiesCurrent_171e66b3-049f-4428-b126-000e5c9be3f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e33481ff-7c88-4390-8ae9-cdbcfe4f0210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a32b82e-4761-4d29-a907-734b5249d023" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e33481ff-7c88-4390-8ae9-cdbcfe4f0210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ae5d2fec-b2ce-4f75-96e7-8faa13d5e9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5a32b82e-4761-4d29-a907-734b5249d023" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ae5d2fec-b2ce-4f75-96e7-8faa13d5e9a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_15667fa7-7f14-468a-8307-3f0387f0b71e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:to="loc_us-gaap_AssetsCurrent_15667fa7-7f14-468a-8307-3f0387f0b71e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0f920b73-4fc9-448a-91be-7c73419f5598" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0f920b73-4fc9-448a-91be-7c73419f5598" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf0c8fda-9d3d-4017-9950-f7b8f41da2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_bf0c8fda-9d3d-4017-9950-f7b8f41da2cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_ae780423-6006-46e6-be37-ea7a891e19d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_ae780423-6006-46e6-be37-ea7a891e19d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_75774887-275f-4416-8d60-bd1b5e47ac66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dddab899-a0b2-4f9e-8aca-c6644ebc5f25" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_75774887-275f-4416-8d60-bd1b5e47ac66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9f08c86b-9fdc-46dd-b052-44dc214ba1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0e08a943-be29-4a10-8f92-642ce4093a39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f08c86b-9fdc-46dd-b052-44dc214ba1b5" xlink:to="loc_us-gaap_AccountsPayableCurrent_0e08a943-be29-4a10-8f92-642ce4093a39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_0a42ec92-572c-4dbe-b4b9-c181d6c91f1e" xlink:href="advm-20200331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f08c86b-9fdc-46dd-b052-44dc214ba1b5" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_0a42ec92-572c-4dbe-b4b9-c181d6c91f1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9673c286-8535-4029-b837-6451db37c017" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9f08c86b-9fdc-46dd-b052-44dc214ba1b5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9673c286-8535-4029-b837-6451db37c017" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cc821205-cba8-4a5b-a488-f7220139ac5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4095baea-573b-4768-a99c-5176052649de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc821205-cba8-4a5b-a488-f7220139ac5b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4095baea-573b-4768-a99c-5176052649de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_ffb5131e-a3f7-4db3-8c74-baaef6d0a2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc821205-cba8-4a5b-a488-f7220139ac5b" xlink:to="loc_us-gaap_ShortTermInvestments_ffb5131e-a3f7-4db3-8c74-baaef6d0a2ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9c715e-0748-41d3-9dd1-71ff9f3ade47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cc821205-cba8-4a5b-a488-f7220139ac5b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a9c715e-0748-41d3-9dd1-71ff9f3ade47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a76fd8c4-3938-4510-9aa1-01b2cd8d906b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:to="loc_us-gaap_PreferredStockValue_a76fd8c4-3938-4510-9aa1-01b2cd8d906b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_149fd2ec-78bd-4c8e-9012-0a873944db07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:to="loc_us-gaap_CommonStockValue_149fd2ec-78bd-4c8e-9012-0a873944db07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_84d3470e-d2e8-4c30-a2d8-8408fcd3b821" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_84d3470e-d2e8-4c30-a2d8-8408fcd3b821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21bda0a9-35ea-4522-b19c-2f42744bad5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_21bda0a9-35ea-4522-b19c-2f42744bad5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_985ee5fe-fff8-4db3-8ae1-76d0da8b4028" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bd7ee8d-eb1d-4599-9c9a-aae5a6128b62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_985ee5fe-fff8-4db3-8ae1-76d0da8b4028" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_95d772d0-2cf1-45ce-a6a4-06c885b654eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ed37e054-f27a-4706-a838-189ac8f47a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_95d772d0-2cf1-45ce-a6a4-06c885b654eb" xlink:to="loc_us-gaap_OperatingExpenses_ed37e054-f27a-4706-a838-189ac8f47a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_59fb206b-c73d-4e52-b3c8-2954c89b1046" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bd6840e8-fab0-4bfd-942c-7c6c8a1b7722" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_59fb206b-c73d-4e52-b3c8-2954c89b1046" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bd6840e8-fab0-4bfd-942c-7c6c8a1b7722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ce76dcf-2baa-4666-9a35-70ec1049465a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_59fb206b-c73d-4e52-b3c8-2954c89b1046" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ce76dcf-2baa-4666-9a35-70ec1049465a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_03823da7-66dc-4288-b750-30e50a737d75" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6473d13b-c59c-4f28-b298-afe8112961dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_03823da7-66dc-4288-b750-30e50a737d75" xlink:to="loc_us-gaap_NetIncomeLoss_6473d13b-c59c-4f28-b298-afe8112961dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_a291ca2c-b233-428f-a5a1-6f5e6780d2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_03823da7-66dc-4288-b750-30e50a737d75" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_a291ca2c-b233-428f-a5a1-6f5e6780d2ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bd42532f-864d-42da-a311-8fba2e3fc15e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_03823da7-66dc-4288-b750-30e50a737d75" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bd42532f-864d-42da-a311-8fba2e3fc15e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4184121d-a887-46b8-b794-d58f829f8995" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8dd168f4-dd93-472b-a51d-4c10245f5dcd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4184121d-a887-46b8-b794-d58f829f8995" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8dd168f4-dd93-472b-a51d-4c10245f5dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9fe93a1e-6d1c-4378-b67b-da64ba8c222c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_4184121d-a887-46b8-b794-d58f829f8995" xlink:to="loc_us-gaap_OperatingIncomeLoss_9fe93a1e-6d1c-4378-b67b-da64ba8c222c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d4d319-786c-4b0c-a267-50d0e9dfe152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad09c411-1d35-4dd7-beaa-e24063ef259b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d4d319-786c-4b0c-a267-50d0e9dfe152" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_ad09c411-1d35-4dd7-beaa-e24063ef259b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_644830f7-29c7-43dc-a7e1-68bda118e3fb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d4d319-786c-4b0c-a267-50d0e9dfe152" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_644830f7-29c7-43dc-a7e1-68bda118e3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1f0cda5b-e78a-4f5d-a23e-19511e711578" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87d4d319-786c-4b0c-a267-50d0e9dfe152" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1f0cda5b-e78a-4f5d-a23e-19511e711578" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a036959f-b0d9-4539-bde0-6d289945a00c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a036959f-b0d9-4539-bde0-6d289945a00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilities_149c8d39-3d62-4a72-8399-ad5273a48837" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilities_149c8d39-3d62-4a72-8399-ad5273a48837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9af31ae8-af16-4b7d-96f7-caba613d0e60" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_NetIncomeLoss_9af31ae8-af16-4b7d-96f7-caba613d0e60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4a053b7e-2955-455b-a78c-d35b1ceeaf85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4a053b7e-2955-455b-a78c-d35b1ceeaf85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8c026aa5-dd92-4b76-adfe-0d1cf11e15ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_ShareBasedCompensation_8c026aa5-dd92-4b76-adfe-0d1cf11e15ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_e796e737-ad3f-44cb-b383-a1ebcaf83e8f" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_e796e737-ad3f-44cb-b383-a1ebcaf83e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d7f7fcdd-0118-4320-8644-65e2d27dfca5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_DepreciationAndAmortization_d7f7fcdd-0118-4320-8644-65e2d27dfca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9b3fa95-87ad-4dd6-b18d-e2d4fddc838d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_b9b3fa95-87ad-4dd6-b18d-e2d4fddc838d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_05e48829-4153-4c3a-a679-7ae7ec21657c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_05e48829-4153-4c3a-a679-7ae7ec21657c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f1f0884b-9cc6-4690-9d2f-c11f00e23602" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f1f0884b-9cc6-4690-9d2f-c11f00e23602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32415d66-c552-4b69-bcca-82c74e72c822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_84653e89-d6c7-4f00-adc2-80cb5af0e514" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_32415d66-c552-4b69-bcca-82c74e72c822" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_03c86d7b-f0d3-461c-91e9-382c293095e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9670bc3c-61d9-48c0-88a2-839b054c48e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_03c86d7b-f0d3-461c-91e9-382c293095e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9670bc3c-61d9-48c0-88a2-839b054c48e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50f6a631-1bf8-4d63-b9d1-7d252e27c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_03c86d7b-f0d3-461c-91e9-382c293095e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_50f6a631-1bf8-4d63-b9d1-7d252e27c1dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45abbb19-5074-4525-9f42-17ee77706a14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_03c86d7b-f0d3-461c-91e9-382c293095e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_45abbb19-5074-4525-9f42-17ee77706a14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16cbeb88-05c9-4667-8432-65fec05ef74b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_717ff4df-a706-4b37-a5e8-57add1ae37e5" xlink:href="advm-20200331.xsd#advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16cbeb88-05c9-4667-8432-65fec05ef74b" xlink:to="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_717ff4df-a706-4b37-a5e8-57add1ae37e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d5734262-89e9-4e31-a162-80fc3a254397" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16cbeb88-05c9-4667-8432-65fec05ef74b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d5734262-89e9-4e31-a162-80fc3a254397" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cdefb32a-a9e5-40a7-b028-21954cd0f1b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16cbeb88-05c9-4667-8432-65fec05ef74b" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_cdefb32a-a9e5-40a7-b028-21954cd0f1b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_3a65a07c-6ad5-48c3-83c1-fe6b9c764e2c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_16cbeb88-05c9-4667-8432-65fec05ef74b" xlink:to="loc_us-gaap_RepaymentsOfDebt_3a65a07c-6ad5-48c3-83c1-fe6b9c764e2c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4203639a-69af-4906-9334-2276385cd7f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60008a74-3816-47e8-8bca-26e69b7f07f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4203639a-69af-4906-9334-2276385cd7f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_60008a74-3816-47e8-8bca-26e69b7f07f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_05f3dd82-999b-470d-8414-00ea2ef13474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4203639a-69af-4906-9334-2276385cd7f9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_05f3dd82-999b-470d-8414-00ea2ef13474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_76371556-737f-4bd1-be92-8b4e90aad5d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4203639a-69af-4906-9334-2276385cd7f9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_76371556-737f-4bd1-be92-8b4e90aad5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_1938c5e5-e7e4-4d85-92e4-d94b802b0bfd" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_666e35d9-cd54-4fbc-921d-791e3e3b3e38" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_1938c5e5-e7e4-4d85-92e4-d94b802b0bfd" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_666e35d9-cd54-4fbc-921d-791e3e3b3e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2460dba8-6cb4-491b-8d02-e73d35e39481" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_1938c5e5-e7e4-4d85-92e4-d94b802b0bfd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_2460dba8-6cb4-491b-8d02-e73d35e39481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_18ee92e3-83a2-41b0-aada-a5d7c3e1f0be" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost_1938c5e5-e7e4-4d85-92e4-d94b802b0bfd" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_18ee92e3-83a2-41b0-aada-a5d7c3e1f0be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponents"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_45fccfec-d8c9-470d-86f6-8ea855a3f85d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6a8e32f4-6955-4f7c-9b0c-38d041435441" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_45fccfec-d8c9-470d-86f6-8ea855a3f85d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6a8e32f4-6955-4f7c-9b0c-38d041435441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_916aa96e-9d02-476f-806a-6aff3759dd35" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_45fccfec-d8c9-470d-86f6-8ea855a3f85d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_916aa96e-9d02-476f-806a-6aff3759dd35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6233c388-8837-4c30-8f9d-76a9ee4fc799" xlink:href="advm-20200331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_526672b1-7b01-485a-98ac-c296f5083d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6233c388-8837-4c30-8f9d-76a9ee4fc799" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_526672b1-7b01-485a-98ac-c296f5083d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_d999e5ae-9897-425b-b5fd-3ed08f6f0108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6233c388-8837-4c30-8f9d-76a9ee4fc799" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_d999e5ae-9897-425b-b5fd-3ed08f6f0108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_5f630ddf-9fc8-4d7c-80bc-20c46a6150a9" xlink:href="advm-20200331.xsd#advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6233c388-8837-4c30-8f9d-76a9ee4fc799" xlink:to="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_5f630ddf-9fc8-4d7c-80bc-20c46a6150a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b2d609c-b8a4-471a-a8de-da150f5899eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_6233c388-8837-4c30-8f9d-76a9ee4fc799" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3b2d609c-b8a4-471a-a8de-da150f5899eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwards"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsTables"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShare"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareTables"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>advm-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended" id="i3ccc524f4ee14ec59259e7441f3e93ae_CoverPage"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ia7e2969e682e4136bbe39f87f0ba2667_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="if105d237906e4041ac94344d5c3e18a7_CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ic08a0550032c4b749ee8241fe0cf42d0_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a61fef55-b0cc-4996-88fc-28a445e80705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_SharesOutstanding_a61fef55-b0cc-4996-88fc-28a445e80705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cce2c40-6c28-4b3a-99f1-f600ab32c32f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockholdersEquity_2cce2c40-6c28-4b3a-99f1-f600ab32c32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c3611bb-3566-4f75-9367-5ddf62d92e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c3611bb-3566-4f75-9367-5ddf62d92e1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce878155-8869-496a-abca-69d17eed9948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce878155-8869-496a-abca-69d17eed9948" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4cd9930-ce04-4c92-8af0-c8a924101a25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4cd9930-ce04-4c92-8af0-c8a924101a25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4cd9ff1f-e3c4-4af8-b5ee-57d595c8d837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4cd9ff1f-e3c4-4af8-b5ee-57d595c8d837" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad8b4c08-b870-42d5-9494-54698fc17011" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad8b4c08-b870-42d5-9494-54698fc17011" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_9839c4f8-a252-4b58-bab1-d076f67fd057" xlink:href="advm-20200331.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_9839c4f8-a252-4b58-bab1-d076f67fd057" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_15f1e8c2-930c-4f08-9d9a-e0bef0379572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_15f1e8c2-930c-4f08-9d9a-e0bef0379572" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6986730f-e2f0-42c2-a70d-4cfe95efca93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6986730f-e2f0-42c2-a70d-4cfe95efca93" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_0194ddbd-14d6-46a4-9d9c-213210c0d964" xlink:href="advm-20200331.xsd#advm_StockPaidValueForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_0194ddbd-14d6-46a4-9d9c-213210c0d964" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_72a344e9-bfbd-4683-b483-44fa4eb621a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_72a344e9-bfbd-4683-b483-44fa4eb621a0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bb331e71-f704-49bf-bb00-644d9731e1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bb331e71-f704-49bf-bb00-644d9731e1dd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1a71c95e-8d01-4229-98d3-a1684cc07f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1a71c95e-8d01-4229-98d3-a1684cc07f6b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7339bc5-bd93-4bb7-9582-8e4ed9f8f0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_NetIncomeLoss_d7339bc5-bd93-4bb7-9582-8e4ed9f8f0b8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fee68eab-e23a-45df-b4bb-b2f5bfb1ed8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7fba8fa-e71a-44e1-92f9-47d36762af8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d3410dbe-d11f-431b-ba81-4c057df1667d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:to="loc_us-gaap_EquityComponentDomain_d3410dbe-d11f-431b-ba81-4c057df1667d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:to="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f7982cd-5e65-47c0-af50-4f4998fbf40c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_CommonStockMember_6f7982cd-5e65-47c0-af50-4f4998fbf40c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_08ed5b60-0fa4-4a96-9362-6c485157fa23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_08ed5b60-0fa4-4a96-9362-6c485157fa23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da937f2e-90ef-40d7-817c-2931153d49f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da937f2e-90ef-40d7-817c-2931153d49f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_33b8a895-d742-4e76-b9d1-f4fdcd6c81ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_RetainedEarningsMember_33b8a895-d742-4e76-b9d1-f4fdcd6c81ae" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended" id="i0820f4be422d4bd091ebb0f384fb1240_CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="ia4ac55028f694f3098e2594ffd3f7b4d_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="ide5eb18dac3b46e09c459f0586db0c31_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="extended" id="icafc62d687a24fe59ca6b24520b93a80_OrganizationandBasisofPresentationAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i253265d6c33e4923be1d04e94b5f61e1_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic41b2424707746179e592a3ed4e9c8c8_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended" id="i3f4e1904e4c8483a89e7972e314b8062_FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended" id="if155ff4170404d19a899eff0cebdf93f_FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended" id="i0a896f54e6244a19b0fa99e46aaf0ecd_FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b0a83bb-b09e-475d-80cf-053540b22aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b0a83bb-b09e-475d-80cf-053540b22aa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cdeb3ad-7f02-40fc-9eb1-acf9a0506b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cdeb3ad-7f02-40fc-9eb1-acf9a0506b54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34e9997d-fd72-4a5d-b29b-096155bbf69e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34e9997d-fd72-4a5d-b29b-096155bbf69e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dceb3a65-a2ff-41a2-be68-c265307a2e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dceb3a65-a2ff-41a2-be68-c265307a2e14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_f652a25a-46e7-4243-a000-1b25f1ed8dda" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_f652a25a-46e7-4243-a000-1b25f1ed8dda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_8b800897-ba2a-45cd-bc70-30c620d7fbe9" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_8b800897-ba2a-45cd-bc70-30c620d7fbe9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_bada5399-db5e-4f05-8b1f-3cba32b74ac1" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_bada5399-db5e-4f05-8b1f-3cba32b74ac1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_74dde5d9-a02d-4643-a579-efa47afb6223" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_74dde5d9-a02d-4643-a579-efa47afb6223" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_52c3187f-7e24-4584-86b5-ddb4e931d6c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_52c3187f-7e24-4584-86b5-ddb4e931d6c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_f669f3d3-f64a-4f9a-96b3-8048e35cff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:to="loc_us-gaap_BondsMember_f669f3d3-f64a-4f9a-96b3-8048e35cff61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_e611d367-b2dc-4054-956a-4f5d3577604e" xlink:href="advm-20200331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_e611d367-b2dc-4054-956a-4f5d3577604e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6579c1e3-4092-4418-9f34-1f496f73a0ff_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6579c1e3-4092-4418-9f34-1f496f73a0ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b1971a51-cf3b-40d7-861d-1bcfe6cc5f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b1971a51-cf3b-40d7-861d-1bcfe6cc5f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4710838-2074-4d0b-9010-d1203d24d7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4710838-2074-4d0b-9010-d1203d24d7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0fa315cb-4d05-48a0-8427-a4064d8bbbdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_CommercialPaperMember_0fa315cb-4d05-48a0-8427-a4064d8bbbdd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f689c11f-c35a-48c7-9a99-29caeb2fd55a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f689c11f-c35a-48c7-9a99-29caeb2fd55a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ce33eeec-39b8-4eae-9fe5-107ac6fbfcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ce33eeec-39b8-4eae-9fe5-107ac6fbfcf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c5592c0c-f705-4461-90c3-53ad5ad708e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c5592c0c-f705-4461-90c3-53ad5ad708e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended" id="ie61c84da984643cebccb9fc986e1d356_FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_c86c94df-2f18-469c-a389-73af7dcea5cb" xlink:href="advm-20200331.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_c86c94df-2f18-469c-a389-73af7dcea5cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3262b0ab-77a1-4c0a-925b-da2189780f00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3262b0ab-77a1-4c0a-925b-da2189780f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_8e8f2cd6-b28e-4f09-ae2f-3d351a22bbdb" xlink:href="advm-20200331.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_8e8f2cd6-b28e-4f09-ae2f-3d351a22bbdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:to="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_249f8732-f1e0-43d0-a819-7197638fde67_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:to="loc_srt_RangeMember_249f8732-f1e0-43d0-a819-7197638fde67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:to="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19543cde-80aa-44e3-bef3-7c6bca899cc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:to="loc_srt_MinimumMember_19543cde-80aa-44e3-bef3-7c6bca899cc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_225b1994-1152-4a3e-bd50-0065627f43f1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:to="loc_srt_MaximumMember_225b1994-1152-4a3e-bd50-0065627f43f1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponents"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended" id="i3e89fae0256f4aea845103786b13d731_BalanceSheetComponents"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended" id="i0c49ef9e7ae7443a85718d73716a7bbf_BalanceSheetComponentsTables"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended" id="i4620fa25a3bb435385ca7a8790ab75b0_BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2ae7f99e-1f10-401c-88eb-7228957b4003" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2ae7f99e-1f10-401c-88eb-7228957b4003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e89084aa-3179-4445-b2f7-0735b9d37d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e89084aa-3179-4445-b2f7-0735b9d37d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a5c43fbb-3ece-4311-b134-8e632bbb6716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a5c43fbb-3ece-4311-b134-8e632bbb6716" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0dbe1d07-daee-41ab-9633-f8036a81c62b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0dbe1d07-daee-41ab-9633-f8036a81c62b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_be8028d2-333b-488d-8b65-0cef4e7cd2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_ComputerEquipmentMember_be8028d2-333b-488d-8b65-0cef4e7cd2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b7887f33-a56a-4ecc-8aaa-b421d8fe14d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_EquipmentMember_b7887f33-a56a-4ecc-8aaa-b421d8fe14d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_25a17325-8383-4f21-88ca-b135d0fa0a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_25a17325-8383-4f21-88ca-b135d0fa0a83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bc5f4950-69aa-441d-bc7d-42bba6875cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bc5f4950-69aa-441d-bc7d-42bba6875cd4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e357eb2b-ba3b-4086-bc4c-fb8ac1d0f111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_ConstructionInProgressMember_e357eb2b-ba3b-4086-bc4c-fb8ac1d0f111" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended" id="i242875aa04d44bea88f551b344509b73_BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended" id="i9615605080b5412789bc46e90f0abf79_BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwards"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended" id="i686f8923eeb44f9e8d033a7e60717813_EquityIncentiveAwards"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsTables"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended" id="i2dc665982ad7494cbb16134eb0026f64_EquityIncentiveAwardsTables"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="extended" id="ie0b490d267094300ad819865f7b132db_EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"/>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended" id="ib9b439c45800473d843bfbcdb9c549e2_EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9afa88c4-d8e7-4337-ad8f-80ad741c9822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9afa88c4-d8e7-4337-ad8f-80ad741c9822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1579c5a8-de73-4f26-8c59-69662865092c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1579c5a8-de73-4f26-8c59-69662865092c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7e8af4a8-82c2-4e3c-a899-a88c0aca9e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7e8af4a8-82c2-4e3c-a899-a88c0aca9e74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b9f37d62-b473-493e-a827-f01fcb032823" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b9f37d62-b473-493e-a827-f01fcb032823" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f164eed7-8c9a-41ca-9edc-918415663d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7025b23c-aa3d-4ed5-9458-9b767cb99354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7025b23c-aa3d-4ed5-9458-9b767cb99354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e73ada2-dc76-40fc-910c-7fe3db216667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e73ada2-dc76-40fc-910c-7fe3db216667" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c814f574-7a9e-4d7a-82fc-46ad2e630e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c814f574-7a9e-4d7a-82fc-46ad2e630e8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_259a7674-af11-45fe-9342-812343fdbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_259a7674-af11-45fe-9342-812343fdbe34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f091f9a-a9d5-44ae-93f2-ed40597f53d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:to="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e45f2b-1d61-412b-abee-30f48acab812_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62e45f2b-1d61-412b-abee-30f48acab812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a68bb165-f6d1-4f35-a939-723cefbb5b16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a68bb165-f6d1-4f35-a939-723cefbb5b16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="extended" id="i5ef63030e00b4565995ce77f2bf3fe83_EquityIncentiveAwardsStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a6385f9-e382-401a-9208-888ec1cabb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a6385f9-e382-401a-9208-888ec1cabb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f1869925-705b-4d1c-98ed-ff9ab286c53c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f1869925-705b-4d1c-98ed-ff9ab286c53c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_346bb94a-d20a-4822-9a50-d9d45e30183b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_346bb94a-d20a-4822-9a50-d9d45e30183b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_624dfd2c-5a87-4668-ae7c-4f91aab205f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_624dfd2c-5a87-4668-ae7c-4f91aab205f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShare"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended" id="i8352b48707634995b6d859df4d96dfc8_NetLossperShare"/>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareTables"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended" id="ibc8dc00532a94d77afb4c1fce0b37bf7_NetLossperShareTables"/>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended" id="i5fbd1654d83f4c9cbb39d0abd1de3f6f_NetLossperShareAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ee777412-dec9-4328-87f3-c75c23eb5bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ee777412-dec9-4328-87f3-c75c23eb5bad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_390d0acd-efb0-4dc8-a41c-1a4eda0462e9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_390d0acd-efb0-4dc8-a41c-1a4eda0462e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46940476-32a4-45ff-a73c-1e909dabd340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46940476-32a4-45ff-a73c-1e909dabd340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4ab65bf-10e1-417e-9d71-c6d27feea30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4ab65bf-10e1-417e-9d71-c6d27feea30f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_66d9485e-e121-48ca-92f8-3d263a1f12df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_EmployeeStockMember_66d9485e-e121-48ca-92f8-3d263a1f12df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dc582ad2-2724-432a-8985-b2ec512d14d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_WarrantMember_dc582ad2-2724-432a-8985-b2ec512d14d9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="extended" id="i4c57099dd4f9433a97e988abfbf03ac5_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended" id="i3d3686d2a075415a864edeb5697e7d00_RelatedPartyTransactionsAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0dc478-2f5e-4c18-ae49-db5f8bd49e11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0dc478-2f5e-4c18-ae49-db5f8bd49e11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d1f20d5d-0e3c-4aa6-b64e-5b14234d21d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d1f20d5d-0e3c-4aa6-b64e-5b14234d21d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6eab8390-9616-4b58-a5e8-8ba3f5643f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6eab8390-9616-4b58-a5e8-8ba3f5643f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:to="loc_us-gaap_EquityComponentDomain_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:to="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3c86630f-5646-4fe0-9939-2ff70e0a5e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:to="loc_us-gaap_CommonStockMember_3c86630f-5646-4fe0-9939-2ff70e0a5e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f843d8ce-f2cc-4b42-bf99-02398e50ce47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:to="loc_us-gaap_RelatedPartyDomain_f843d8ce-f2cc-4b42-bf99-02398e50ce47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:to="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TrustMember_f8f77920-0bd3-4f04-bb71-536f5df8d545" xlink:href="advm-20200331.xsd#advm_TrustMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:to="loc_advm_TrustMember_f8f77920-0bd3-4f04-bb71-536f5df8d545" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>advm-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_91f12e32-9f15-4104-bd9d-9fabf749c10a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_62f7977c-8b45-414f-b326-cc0b609efc93_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0e775df9-4a44-4c95-a897-ad682d7cf255_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_fe702bc1-7ff9-4011-a57b-dd724747d6ea_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0517a88a-b521-4a28-bf10-356802977174_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a140ea50-1de1-4f16-a388-8098468b86a2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_bb19bd11-d182-4785-963f-549a6096a356_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3fc3fed5-01c3-4ef2-8f74-c2a473e6f65c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_0db1d782-603f-4b22-98d2-461d0309490e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e658a356-321d-42ea-bbc9-1828cf84c10c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0eaeff3d-c535-46b6-b289-fea3248be1de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c62ebdd6-4667-4302-9d18-46438a3e0ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_a90343bf-f1e0-4c07-b2df-b23859e60b49_negatedLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, unrealized losses</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Loss</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_597aeb73-d5d5-402f-a5ca-4318c38f1c80_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_76a39249-00c8-4e3a-bbab-8717a3c568e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_52205ebd-d85f-43da-863e-4b6c745eca34_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_2d6d3a7d-a397-475e-b91a-5de05b2bbb89_terseLabel_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_label_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:label id="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_documentation_en-US" xlink:label="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:href="advm-20200331.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:to="lab_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_9206cc36-ac74-4482-a1c5-d0be92cefcaf_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f7bf1564-7dd1-4f5d-875b-72eaf87a37bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_27322d8f-af1b-4b21-8aae-181a1ca3c231_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cd9462e7-2f96-49e1-91bc-093e8361e2f8_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_03a7c275-d654-4114-a60f-7b488c23687a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_d853c762-d3d4-4c87-943c-e826b637b326_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b8156581-047d-4576-a35a-c1db552a9c5b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_39f2d886-625e-449f-9e38-df53c6bf91ea_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash purchase price</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_262c11ba-00be-4090-9fc3-e545beae0c12_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_afc534e0-5c8e-45e2-a417-da7dee656486_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_a6b4077e-f5c7-4096-9ab3-1ec2f277622d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8980f8cc-d73d-4548-9348-8aa0ed461b59_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9415a41a-5576-408a-b15b-8304de44d376_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon release of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_167b7b93-9d88-4cb5-8418-949f642b82e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40012044-2a29-41be-b363-b3343461a24d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_d6aefc11-4e57-46c7-b7c1-6428680dce9a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs of $332</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8608ca0-8938-4f21-92e7-870b1ce1143a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_fd141635-c229-4b44-bdb2-f701690a9b55_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ebcdb413-2e88-4b05-8e3b-24fbe015afa1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a8221088-7349-4f0a-9eed-3f581b223ef9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_42a8d0ec-68b9-4770-b5ae-8988f1fb2383_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss)/Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d0eace7e-390d-4a62-ab9a-f8021a20a983_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0eb1f865-2e3b-4aa2-9061-85e1175ba212_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_f4536319-66c1-4944-98ca-d31f55b252ff_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e9252200-5524-44f9-b689-62e2ff154a37_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_995abfcd-eeba-477d-98a2-da08a0594fc7_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7e5c6de0-f3ca-4a48-999a-a8ef97a98044_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BondsMember_19b17ba3-1460-43ed-bd6e-6d2348709a5e_terseLabel_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bonds</link:label>
    <link:label id="lab_us-gaap_BondsMember_label_en-US" xlink:label="lab_us-gaap_BondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BondsMember" xlink:to="lab_us-gaap_BondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_9ea5227c-63c2-4843-9568-0e9beea773c7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ec2c4e27-570e-4ac8-b7c3-354ff51e8caf_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_810caf75-f951-449e-a456-b470d0d5d919_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of noncash investing and financing information</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_9c3abe54-0d18-470a-8d55-8b3a8ddbec0a_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b8f755e9-0655-4902-9379-198c38b59aa2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_f22f37ea-6b85-4820-aaad-f925a3d3b4b6_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share &#8212; basic and diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_72dba46d-9975-418c-9299-21499cf67b58_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_3a7e324b-6a2b-415e-aa3c-79445c16480e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_9a233dca-7a78-4b60-996e-e9194424fb6e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f8a9bd91-dd32-4059-b96b-ee012c42d63a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1b502a78-9164-4f72-966b-7b2ab3dc266a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a5f7b93c-4975-4749-89a1-36f8ff28cfcf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d3320bfb-aa26-4480-9767-4da772e5d015_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7550e492-a4d7-49ef-97e5-dd792dde2338_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_32e146e4-8174-4bc1-9eae-e84d4e0aa594_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_61cee7ec-bb71-403e-b335-8b637353d75f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_f5ee24ae-7bf3-42fd-9141-260504614769_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities term</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ff5670d5-8ed7-439a-8e69-82bd84646176_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Options Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_f70eafe7-a761-43cd-ae8a-3239f22499f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_37e8956c-a71a-4fc2-aeae-e4930eaaeec9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_41e896db-cca1-44f0-affe-04353de519c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_0f0a88ff-ec78-4bbe-afab-62b4f0887287_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3b227b3f-5bf2-48c1-b05e-e489fc304853_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d7184eb-ffab-4cdf-acfd-c61a55af67b8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_599d8c7a-0395-46c3-80c1-61d0bcce6055_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_278066d5-5c17-4ad4-a6c3-5cf3b1bc32c9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares used to compute net loss per share - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7af1cefe-351e-4a5a-b8de-f669081bc3fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_a5beffb0-d373-48fe-941f-5bbf69caf582_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_d48db863-238c-49f0-8c71-e998f739073c_negatedLabel_en-US" xlink:label="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes</link:label>
    <link:label id="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Paid Value For Tax Withholding For Share Based Compensation</link:label>
    <link:label id="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_documentation_en-US" xlink:label="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock paid value for tax withholding for share based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:href="advm-20200331.xsd#advm_StockPaidValueForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:to="lab_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_1edb0dba-807e-4fc3-a815-ed263f3db90b_terseLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_f5e1ff5b-d12f-447a-a626-52924b3f633d_totalLabel_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_label_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses And Other Current Liabilities</link:label>
    <link:label id="lab_advm_AccruedExpensesAndOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:href="advm-20200331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="lab_advm_AccruedExpensesAndOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_14647fea-92b0-42ae-b79f-fcd973c85745_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_b203947c-82c2-40a2-b459-5fc495a3c5fe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7dcadbb5-2cad-414d-95dd-1ba8cb7cd11e_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_acb25123-923a-4802-ba5a-a7594e708ab4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_800bdcb5-e67c-491d-a5cd-d46d6a79e2da_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c6737ea9-cd20-4bfa-b5b2-173dcc8c33bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_86fff10f-9d36-409d-aaa9-ed5143bb304f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_76387963-e992-46aa-9693-a48177da693a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6766ae97-9bb0-42c6-aec0-3918870aa636_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1e7a0d6f-0035-41c8-a18f-55d2f6717375_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_554a6eea-e1e6-41ba-8748-66f5663928b1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_3baa38b5-1a6f-46f1-8986-b39221455cd7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_6fca6e6c-2fc3-4871-bafc-4d8552e8d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9f020b84-0575-48db-b1ed-12fc4398ebff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_339a75f3-fd82-42db-94dd-b54f02ca6609_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2d41655e-4529-4200-9fd3-aeebfd267152_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_707bf69d-0612-4f41-8b6b-9f702eff4fb2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_66af4518-ea43-43c1-9c0f-c7facb83cbf3_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bd37852d-c2a2-420f-ac23-a95bb30ea9f0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_63ebd414-41e8-42e3-885a-d16cdcb51be2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilities_7857a95f-d21b-42b3-8783-807ec6b8b143_terseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Lease Liabilities</link:label>
    <link:label id="lab_advm_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilities" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_advm_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f3277f6b-b676-4176-a952-b1da6c377451_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_ffe29e32-dda2-476a-a5ac-00fadc2fd0ad_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_bdb43215-1772-4eb3-934b-f152bd85ba83_negatedTotalLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash Equivalents, Amortized Cost Basis</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Amortized Cost</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentAmortizedCost_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent amortized cost.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentAmortizedCost" xlink:to="lab_advm_CashAndCashEquivalentAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_607cb7b4-9954-4b88-b452-5d5a73a3db08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_950bc836-0afd-45c5-9c99-419ccdce1c8f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposit and other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5cebe017-4efe-45f7-9818-f10dae6dda27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_58afa9f0-0e40-4ca2-98ac-212672755288_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92e047bc-92ff-4f5f-b598-a1b2396903e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_270e8f3c-d092-4a7f-95ba-b4efdb3f5522_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_45aa28de-e334-4671-9f0d-5f6a733813cd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0bd30d59-8d16-4d34-958d-ed75642f6312_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4ce052c2-a470-4bed-b51f-0f1a7652141f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_4c12e675-de64-4f12-9a27-12d00a1958fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c81f08f8-e8a9-421e-b411-3862e1973974_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cf80be64-e66d-41c3-8cf8-e237d3a22fc4_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_e1523d15-34e0-4c20-941a-f80b61cc0397_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_078a2668-ca4e-437d-93f3-3608ce53520f_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on marketable securities, net</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc1deb1b-aea4-4858-ae9f-d9c66fb2dc3c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_f2a79cf5-b2ca-4e8d-8051-66a843ad4fa5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47544085-686b-432f-a404-0008137c9f82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55d11a5e-c69a-4db2-8d8b-23c165878cc1_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_83bb8df2-eec8-4f6f-8009-5b9592b683bf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d184d17e-8be8-4e48-bf67-99ce224b03cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_23ece262-ebc4-472d-aa28-83c2d70ee153_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b5fd71d7-fbc3-4d9d-8fbe-939c9f64f211_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_6bed9854-d5f2-421e-b78d-fd09ed5a81dd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_e0263a7d-6412-44db-a0c6-cfeb6ad60dc6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2f8641bc-25e6-4bd3-8826-3afca01a9106_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c37930b4-bb12-4818-a370-9fab18e62429_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_470974de-5f31-46ec-91bd-a269a214e034_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_a532b551-a1a5-4d98-a665-efe2fc8fd51a_terseLabel_en-US" xlink:label="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical, clinical and process development costs</link:label>
    <link:label id="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_label_en-US" xlink:label="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preclinical Clinical And Development Process Costs</link:label>
    <link:label id="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_documentation_en-US" xlink:label="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued preclinical clinical and development process costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:href="advm-20200331.xsd#advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:to="lab_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_35af8d01-60e5-46b5-931b-5d5cdd53c13b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_06fd5e6b-7a7c-4d08-acb0-00d1e92f379f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_15a2a592-4b0d-4272-ae31-e969cdd46b4c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8c09bcdd-88fe-4ec5-8051-23c65381121d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_96cd42eb-38cb-4d54-a61a-a29ec6598db8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Awards</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_bd342792-59dc-4e39-b057-6a91f35c5996_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_85dd56c2-b199-4e5c-bd28-d69f67e69d87_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_e9f07ede-e78b-4f56-ba41-d9005901a405_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_55d47617-5e66-423c-b60b-8a174805b5f5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2106e53d-9145-4b0a-9e52-1cb3c9cb77f8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5469d375-48a2-46ab-9841-9cd8df469abe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_90f48659-0341-4ecf-b544-777d4a8b02e6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_bb0170c8-f7c3-4cf2-94f8-cc2c7599e3f4_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b88bd6ed-918c-45b2-bc55-8acb967ce348_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_669b2cb5-9da0-492f-89ad-18a0ea8c1ced_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_79f5c26a-91af-4918-8477-85beff473058_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a6026050-3cc4-4bf7-a957-2e21f35a30c8_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b1ba820f-7395-4b68-8c88-3221137bd6ee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f80216ee-b4f5-4116-89e5-8a5122258ffd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_f2ea35d0-2a90-43f0-89ba-6b0310ebf913_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a55583ba-6df0-4ece-9142-fea82f4c1200_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0bc38dbe-c5c9-443f-bb9a-707168bc74dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3b62f80e-5d8f-47a4-a1fa-56ab344544f9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock pursuant to option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7ae4095a-c876-4fd8-91ab-fa56b8f08cd6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_eebe3e45-17f9-420a-a0ee-5f2a9854d237_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_dbf307d6-a0b4-4f41-bc5a-4dce95abd68f_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b55e52a3-00eb-4391-a9cd-d5f94bb61ed3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_502e0efd-cd48-4465-9417-907492bf7f98_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_6eda562c-7881-4901-97cd-ffc89ab2df6e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_830b574e-6ac9-45f8-b902-c8ad29a08df5_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_7d90d5c8-c4e2-4a66-9785-d926e5ffc296_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_bf191c71-ec1e-491e-9257-e798ad088402_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3a5f58ce-966c-4ce3-ad68-00cf9bea18db_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_16993f1e-2c2a-4a0c-979d-b8c9203c5df6_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_92f0597e-8c1e-4f8d-817f-fd5e37f9cd68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_28f40002-a91d-41f3-90a7-89748c34b00d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_47abe9c5-ca00-4e53-b4dd-350e20d54dac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_37079232-646f-4517-a74c-812c05cbf0cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_39629442-daa2-4fcf-8c9d-967d6cd39ea6_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_483899be-b762-4749-88f2-73ed377714a6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of restricted stock units</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ce07e8e0-5d42-4857-9ed4-e7057fa7536c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fab380b3-dcb5-4040-9ac8-84fc17a627e1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_67e6290b-a250-4d79-b66e-6f88db7febbf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_3a0e937b-1cb8-44b2-85ee-f801f721c24a_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Components</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_c2f0b535-69c7-4f8d-a6ce-6eff18756ddb_terseLabel_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_label_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporary Impaired Investments Available For Sale Securities</link:label>
    <link:label id="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporary impaired investments available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:href="advm-20200331.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:to="lab_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d85fe306-1c83-49c8-930d-098e0061ddac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_569a0372-329b-4780-8cdd-f24d505e059c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_46a29235-b34c-40e9-b7bd-2dc7b60b1e22_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21d3321f-c2fb-4543-8b16-34082771ba8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ddb5ad2e-9b84-41dd-a33d-f163e8dd9672_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_7e4ca593-963b-4823-9313-cc5b990a8c12_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fd2a6f9b-77c3-4078-80a3-06e7adf2591c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_06faacdb-aae3-41a2-a07d-dbe81613656c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3f29fb9f-4ebe-4d97-97e3-92f8a92397ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs of $332 (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0fc4f21c-e5af-43c7-8d7f-fd907168f9a6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_676d5c87-b95e-4808-9b02-627feb4cdf5f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_46eeaab8-52d5-44af-b75a-e86b21fad6f0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_af92735d-5e2f-424c-8a74-d217d0073ba8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_6a101270-e167-4936-8e61-c7371173a047_terseLabel_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_label_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period</link:label>
    <link:label id="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_documentation_en-US" xlink:label="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:href="advm-20200331.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="lab_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_88ba536b-b3ad-47f9-a809-22d2d22327c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_87d24405-1193-4514-b6b9-780fd7722747_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e1ab5b38-e718-4e99-8320-9ae0abd26005_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_TrustMember_9a3ff485-2680-4dd9-a6fe-8d1d4fb16c03_terseLabel_en-US" xlink:label="lab_advm_TrustMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust</link:label>
    <link:label id="lab_advm_TrustMember_label_en-US" xlink:label="lab_advm_TrustMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust [Member]</link:label>
    <link:label id="lab_advm_TrustMember_documentation_en-US" xlink:label="lab_advm_TrustMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trust.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TrustMember" xlink:href="advm-20200331.xsd#advm_TrustMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_TrustMember" xlink:to="lab_advm_TrustMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_bdec6847-ac09-40b8-9fb0-c2db1117ebb0_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_9aa0bf50-8115-4800-8c74-4daff44cc446_negatedLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock surrendered for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bd53aee5-8989-4431-ac7a-1bb0e51e4495_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_89941a14-3496-4c54-92b3-d0cf76b53dbf_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3157a31c-8e15-4d76-b5c3-dde65adf4cb5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_be8d0938-6466-47be-b550-c6c2e3956f13_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_97ff92a2-7e09-460a-9f56-da327b627528_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_72d75d24-e921-4370-81f7-9735da9984df_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c995c958-de03-4945-986d-867814f6e7b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ca4e2d3c-81c6-4a6c-87b8-1253333aa6ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c5ab3c04-a69a-4cff-ac8e-0de98649af25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_95e1e366-40c6-4b09-aa1f-a349f3040f03_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_be28908d-490f-437e-ba84-c85bb985862e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_bafc61fa-2eb0-4def-9fef-ed2bfc649286_negatedTerseLabel_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:label id="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Operating Lease Right-of-use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:to="lab_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_96346160-3391-44b8-a57b-ad455bf09d1f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets in accounts payable, accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_e8cadf32-dc49-4a32-b229-4d9f01e285eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_4d605967-83a5-46ed-ad37-bb05306add87_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f74bef8b-034d-496b-bb4b-2edbf9d2b21c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_95b8aa99-c175-4870-bcfc-78784faa989a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1822a7e2-1657-4af4-b10e-77b75a7c05e0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_747e7c12-e3a8-400f-b4e3-b1be93610c2d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a24d84a3-9620-4ced-ba47-8b716ac16191_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9441e222-1e9f-4e2b-a157-b7c59c56d2a2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2a95283b-7689-48ca-add8-2fa01e0abfb8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1aaa9250-27dc-4719-85e8-3c211bf9b11f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ab9dc7f9-3562-40e4-8768-753e2ffd6972_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_dc456423-87f2-42f5-80cc-956daa41c6b4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_98cbbbc4-d76f-41d7-9023-8b74423eebba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premium and accrued interest on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b1e29cbf-9bd5-4d0d-8e3d-d00d070460eb_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_991049d1-d493-4d9b-b736-2a83f07dd586_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d8736196-d8e8-430a-8757-db42e88697b0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_bce89a2b-bd70-47d7-9936-c9fcb7afc96c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_4417af79-774f-49b9-947d-e38ee616fdd8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cc49532c-0007-4b5a-a7da-68035ace0eef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b430c6ff-bc01-493a-9ed2-ba33d5dfeda0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_815c12e1-107e-45bf-950c-9c5fde328574_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a82e87d1-f684-4a3a-ab91-d5c354140a5d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_95741d40-739f-491b-a4d5-c93b0f489871_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fdddc68d-0142-45f6-9a7c-6f55304d3786_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9d552b72-9a4d-4aa2-bf13-7ba14d084e4a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_12e642ec-30f9-4880-875d-cac3976d25be_negatedLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash Equivalents, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_9b211baf-5fb9-4f46-a37a-c98b9f1d4177_terseLabel_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash Equivalents and Short-term Investments</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_label_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Short Term Investments [Member]</link:label>
    <link:label id="lab_advm_CashEquivalentsAndShortTermInvestmentsMember_documentation_en-US" xlink:label="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and short term investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:href="advm-20200331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:to="lab_advm_CashEquivalentsAndShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f1416638-2740-48cc-a92b-6ba454296051_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_9edecd94-8e40-4cc4-b1ae-3f44202cc621_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_3819e5d5-f6fd-4fa0-9331-00b6d17ff76e_terseLabel_en-US" xlink:label="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offerings of common stock, net of issuance costs</link:label>
    <link:label id="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Offerings Of Common Stock Net Of Issuance Costs</link:label>
    <link:label id="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from offerings of common stock, net of issuance costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:href="advm-20200331.xsd#advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:to="lab_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_e73cafdc-58af-48a8-8c52-2d047e85d3ad_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e8aaee28-c54b-4839-b597-9eeecf3ba821_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_881d647a-4c41-4d03-b493-abc67b5b32fa_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_14525d13-2709-434d-a0f5-9c1a85305a28_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eadbf1bb-03ae-418b-a641-87e4b317624d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_973fe531-40f9-483b-aa5c-58c9031d6d26_negatedLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c8c36d1e-fe80-47be-9322-6691280ef7fa_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2c2de04b-0b1f-4cae-926d-3435b9604841_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_cf19088b-370d-4802-9e04-b7b87a2e68ee_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_28b2346c-109c-46e8-866a-c309acd7698b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_f1afa472-56f1-46e5-bc66-54a8142fbd94_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_447f542b-352d-494a-9dd8-822a69f0c3d6_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_fc66aad1-bbe8-49d0-af45-e142f02e7553_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6d953094-7921-4413-a962-436c1645eb0d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_03ef7096-117f-451e-8a58-7b977d6f2596_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1b555c27-0374-4031-9af4-80d25c0ac284_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_539a06b3-70ef-47e4-a1b5-e02af21c6ffa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_d4c55d30-c784-49ca-bcd4-afa184d0e491_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_908bf5b5-fd9d-4bff-9fe0-a06d8f90fc3a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_57ec50a8-e73f-4840-bdb0-04011d535acf_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_e7b1bdcc-bcd1-4c2f-bb6b-e0527401b381_terseLabel_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Cash equivalents, unrealized gains</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_label_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalent Gross Unrealized Gain</link:label>
    <link:label id="lab_advm_CashAndCashEquivalentGrossUnrealizedGain_documentation_en-US" xlink:label="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalent gross unrealized gain.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:to="lab_advm_CashAndCashEquivalentGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_d7f3940c-9195-491b-8f83-259d5b7f3f95_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>advm-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:1cfaf5bb-bec3-40d2-be84-8ab55712c51c,g:ede5412c-7c4c-479f-8605-94fc260da43a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.adverum.com/role/CoverPage" xlink:type="simple" xlink:href="advm-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_18591670-d867-4851-8283-2f6834e54919" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentType_18591670-d867-4851-8283-2f6834e54919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_0edce2f5-5cb4-42c1-a2fc-a2f043fe314d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentQuarterlyReport_0edce2f5-5cb4-42c1-a2fc-a2f043fe314d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_d1b435a5-849b-43aa-afc0-92347931c63f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentPeriodEndDate_d1b435a5-849b-43aa-afc0-92347931c63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f4122a84-4cf3-450b-8e3e-45b483fd02e9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentTransitionReport_f4122a84-4cf3-450b-8e3e-45b483fd02e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_623c8988-5838-4e9d-a5b9-e872530a661e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityFileNumber_623c8988-5838-4e9d-a5b9-e872530a661e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d105d87c-d29c-4c51-9985-fedb99225d7c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityRegistrantName_d105d87c-d29c-4c51-9985-fedb99225d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3e65d914-9625-4a6a-9df7-4ed50fceea5c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3e65d914-9625-4a6a-9df7-4ed50fceea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c9379f64-6301-46ed-a49f-e4aaac00e1e7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityTaxIdentificationNumber_c9379f64-6301-46ed-a49f-e4aaac00e1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a87c0950-dac8-47b9-bf58-c8dbb44dc2e5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityAddressAddressLine1_a87c0950-dac8-47b9-bf58-c8dbb44dc2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_26a85aa7-53b0-4eeb-94ed-558cde319c34" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityAddressCityOrTown_26a85aa7-53b0-4eeb-94ed-558cde319c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6ede8420-f78a-4133-83d3-8441e875d06d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityAddressStateOrProvince_6ede8420-f78a-4133-83d3-8441e875d06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b1c20ae7-67d0-42ba-8f29-ecd58acef026" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityAddressPostalZipCode_b1c20ae7-67d0-42ba-8f29-ecd58acef026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_080fe0ee-e9c2-494a-9cdd-9097fcd81640" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_CityAreaCode_080fe0ee-e9c2-494a-9cdd-9097fcd81640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2728e2cd-0ac0-4f3c-b03b-4363692c754c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_LocalPhoneNumber_2728e2cd-0ac0-4f3c-b03b-4363692c754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f056df51-e421-4110-839c-9ea07bea9231" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_Security12bTitle_f056df51-e421-4110-839c-9ea07bea9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_3a839eb2-cef9-4ba9-b785-538a8fd9d823" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_TradingSymbol_3a839eb2-cef9-4ba9-b785-538a8fd9d823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_df34b4d0-751d-49e3-9d8e-eb1f460d18d1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_SecurityExchangeName_df34b4d0-751d-49e3-9d8e-eb1f460d18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ca99e648-8a8f-4def-ab84-65a601d45542" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityCurrentReportingStatus_ca99e648-8a8f-4def-ab84-65a601d45542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_12cd45f1-d885-4f4f-8d84-f3bdc8dd894c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityInteractiveDataCurrent_12cd45f1-d885-4f4f-8d84-f3bdc8dd894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fcc685f7-3279-498c-b735-0cfd57551efe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityFilerCategory_fcc685f7-3279-498c-b735-0cfd57551efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_0999c8bf-b757-4d0a-a34f-7d9a3e1084fc" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntitySmallBusiness_0999c8bf-b757-4d0a-a34f-7d9a3e1084fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_9dd2bbba-6da3-45f2-be98-00febbe80f59" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityEmergingGrowthCompany_9dd2bbba-6da3-45f2-be98-00febbe80f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_aad92824-1a70-4acf-92ce-2072f6e8a1ac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityShellCompany_aad92824-1a70-4acf-92ce-2072f6e8a1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6838d7b0-35a6-413f-a8c4-7de3cd6e040d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6838d7b0-35a6-413f-a8c4-7de3cd6e040d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_927d8760-a1da-4079-b3f2-458007311d43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_EntityCentralIndexKey_927d8760-a1da-4079-b3f2-458007311d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_76cfbcd6-f053-4853-8631-c855751645c0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_CurrentFiscalYearEndDate_76cfbcd6-f053-4853-8631-c855751645c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1a691a45-3398-4ff9-9b90-1e8ba2d8dd45" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_AmendmentFlag_1a691a45-3398-4ff9-9b90-1e8ba2d8dd45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2fc92d60-af43-4c0f-afcb-a68bb0c07900" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentFiscalYearFocus_2fc92d60-af43-4c0f-afcb-a68bb0c07900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_67ad906b-b304-4b20-8e36-0e5b14c4904a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2a934584-ccaa-4e2e-bb84-60f0faeb27fb" xlink:to="loc_dei_DocumentFiscalPeriodFocus_67ad906b-b304-4b20-8e36-0e5b14c4904a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f0148de6-58ba-4ccd-8bb9-32cfd4e8eddd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0148de6-58ba-4ccd-8bb9-32cfd4e8eddd" xlink:to="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0a36115-db4f-4162-b999-f8e53cf9fea0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0a36115-db4f-4162-b999-f8e53cf9fea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c70ff144-57ba-4180-b877-e4cb59950043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:to="loc_us-gaap_ShortTermInvestments_c70ff144-57ba-4180-b877-e4cb59950043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e95ffacc-c6e4-408f-9a72-a0ed368b2cfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e95ffacc-c6e4-408f-9a72-a0ed368b2cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_754ce4f5-8a48-4c06-a81e-246784b57691" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_04e3a2d5-bf0c-49ce-883a-d419c01656d2" xlink:to="loc_us-gaap_AssetsCurrent_754ce4f5-8a48-4c06-a81e-246784b57691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_249a3762-8a29-4103-a110-7937f67d4407" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_249a3762-8a29-4103-a110-7937f67d4407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c012626c-b203-496a-8f90-db6d26cd79d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c012626c-b203-496a-8f90-db6d26cd79d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3723e862-3d32-43a9-ac29-adb4928f3405" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3723e862-3d32-43a9-ac29-adb4928f3405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7a817fa2-34b7-42bc-9f7e-75f546b9ec28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7a817fa2-34b7-42bc-9f7e-75f546b9ec28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b73157b0-7812-4ab5-adea-0e0394b32094" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_ba91a69c-26c9-4522-af83-7ebbad003817" xlink:to="loc_us-gaap_Assets_b73157b0-7812-4ab5-adea-0e0394b32094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f0148de6-58ba-4ccd-8bb9-32cfd4e8eddd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5075436a-0f0a-4b43-baca-dd8a94f9e6d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_5075436a-0f0a-4b43-baca-dd8a94f9e6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_08b9406e-77d3-47ac-95e1-efaee36c5c2e" xlink:href="advm-20200331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_08b9406e-77d3-47ac-95e1-efaee36c5c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14d04b6b-5ce2-429b-852b-98d773775571" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14d04b6b-5ce2-429b-852b-98d773775571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ae8c8e19-3cb6-44da-8fa1-82d72979fecd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_688d7391-f025-4f10-944b-77fa143e98ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_ae8c8e19-3cb6-44da-8fa1-82d72979fecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0da66659-6b09-4813-9872-7e215f55f3f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0da66659-6b09-4813-9872-7e215f55f3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9bab1952-d818-4139-8a60-861c01b82879" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_9bab1952-d818-4139-8a60-861c01b82879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1009829d-3ecb-4ae0-92b6-f6f0a792b2aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_Liabilities_1009829d-3ecb-4ae0-92b6-f6f0a792b2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_664293a2-bf7c-4f4b-bef6-a48781544b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_PreferredStockValue_664293a2-bf7c-4f4b-bef6-a48781544b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_722df4ef-1625-4d78-996f-cf42d55a7b73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_CommonStockValue_722df4ef-1625-4d78-996f-cf42d55a7b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4f0dd937-bc5c-44fd-a84c-18e69367369f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_4f0dd937-bc5c-44fd-a84c-18e69367369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b9c25ee-54e6-4a69-a02a-f8731895e9e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6b9c25ee-54e6-4a69-a02a-f8731895e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8335e458-40c3-4f93-bd97-cac86e16745c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8335e458-40c3-4f93-bd97-cac86e16745c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_73cdbcc8-8f2e-47d9-98f2-c3e0a75b51b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_af5f37f4-4d48-4f61-b8ad-6b73042ac1d1" xlink:to="loc_us-gaap_StockholdersEquity_73cdbcc8-8f2e-47d9-98f2-c3e0a75b51b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_439d257f-287d-4f64-b6a9-4d96d2c24432" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0a989b32-f80c-4d1b-b639-aee60b86c3dd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_439d257f-287d-4f64-b6a9-4d96d2c24432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_da04ebe7-ef8d-44f5-99cf-3a72b7202ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_da04ebe7-ef8d-44f5-99cf-3a72b7202ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8da388e2-fedf-450f-89bd-31615e33a376" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_da04ebe7-ef8d-44f5-99cf-3a72b7202ad3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8da388e2-fedf-450f-89bd-31615e33a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9aeeeb1f-5064-4c7b-80dd-8ba17034ab20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_da04ebe7-ef8d-44f5-99cf-3a72b7202ad3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9aeeeb1f-5064-4c7b-80dd-8ba17034ab20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_283dc092-d2dd-4fd7-ac32-4192b8ccf3d6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_da04ebe7-ef8d-44f5-99cf-3a72b7202ad3" xlink:to="loc_us-gaap_OperatingExpenses_283dc092-d2dd-4fd7-ac32-4192b8ccf3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ae5af4b2-5fa1-4323-8f67-858791925e0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_OperatingIncomeLoss_ae5af4b2-5fa1-4323-8f67-858791925e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fa275502-3f7b-4796-a58c-130af6e004aa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fa275502-3f7b-4796-a58c-130af6e004aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_76c5a260-9bda-4150-bf90-4e4766420ff0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_NetIncomeLoss_76c5a260-9bda-4150-bf90-4e4766420ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_baf7f8a7-6aef-4f8c-9532-81e1289676f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_baf7f8a7-6aef-4f8c-9532-81e1289676f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_85ef7684-fd43-4ada-9fba-9cd15bc62da9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_baf7f8a7-6aef-4f8c-9532-81e1289676f5" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_85ef7684-fd43-4ada-9fba-9cd15bc62da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0a148766-77ee-4ac3-81af-954a6e7f7fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_baf7f8a7-6aef-4f8c-9532-81e1289676f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_0a148766-77ee-4ac3-81af-954a6e7f7fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e099f99d-e86d-4ac9-8e86-fa675490d453" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_baf7f8a7-6aef-4f8c-9532-81e1289676f5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_e099f99d-e86d-4ac9-8e86-fa675490d453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_4c14ab1f-18f0-4197-be07-cf2d82ae02f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_4c14ab1f-18f0-4197-be07-cf2d82ae02f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4f2dcce7-3a0b-4c37-aea8-71b2c49b1a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_e64d7d98-2d20-4a00-bcd0-ad06848c2d3c" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_4f2dcce7-3a0b-4c37-aea8-71b2c49b1a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ec18aea-4d40-44fb-8047-1c95cf2b97b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ec18aea-4d40-44fb-8047-1c95cf2b97b8" xlink:to="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d3410dbe-d11f-431b-ba81-4c057df1667d" xlink:to="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6f7982cd-5e65-47c0-af50-4f4998fbf40c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_CommonStockMember_6f7982cd-5e65-47c0-af50-4f4998fbf40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_08ed5b60-0fa4-4a96-9362-6c485157fa23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_08ed5b60-0fa4-4a96-9362-6c485157fa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da937f2e-90ef-40d7-817c-2931153d49f6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_da937f2e-90ef-40d7-817c-2931153d49f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_33b8a895-d742-4e76-b9d1-f4fdcd6c81ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7296489d-adbb-4824-bc4e-b4ff9765a3bd" xlink:to="loc_us-gaap_RetainedEarningsMember_33b8a895-d742-4e76-b9d1-f4fdcd6c81ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6c57566f-51d9-42ab-b39a-42551d5b01f3" xlink:to="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a61fef55-b0cc-4996-88fc-28a445e80705" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_SharesOutstanding_a61fef55-b0cc-4996-88fc-28a445e80705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2cce2c40-6c28-4b3a-99f1-f600ab32c32f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockholdersEquity_2cce2c40-6c28-4b3a-99f1-f600ab32c32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c3611bb-3566-4f75-9367-5ddf62d92e1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0c3611bb-3566-4f75-9367-5ddf62d92e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce878155-8869-496a-abca-69d17eed9948" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ce878155-8869-496a-abca-69d17eed9948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4cd9930-ce04-4c92-8af0-c8a924101a25" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c4cd9930-ce04-4c92-8af0-c8a924101a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4cd9ff1f-e3c4-4af8-b5ee-57d595c8d837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4cd9ff1f-e3c4-4af8-b5ee-57d595c8d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad8b4c08-b870-42d5-9494-54698fc17011" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ad8b4c08-b870-42d5-9494-54698fc17011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_9839c4f8-a252-4b58-bab1-d076f67fd057" xlink:href="advm-20200331.xsd#advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_9839c4f8-a252-4b58-bab1-d076f67fd057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_15f1e8c2-930c-4f08-9d9a-e0bef0379572" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_15f1e8c2-930c-4f08-9d9a-e0bef0379572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6986730f-e2f0-42c2-a70d-4cfe95efca93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_6986730f-e2f0-42c2-a70d-4cfe95efca93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_0194ddbd-14d6-46a4-9d9c-213210c0d964" xlink:href="advm-20200331.xsd#advm_StockPaidValueForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation_0194ddbd-14d6-46a4-9d9c-213210c0d964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_72a344e9-bfbd-4683-b483-44fa4eb621a0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_72a344e9-bfbd-4683-b483-44fa4eb621a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bb331e71-f704-49bf-bb00-644d9731e1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_bb331e71-f704-49bf-bb00-644d9731e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1a71c95e-8d01-4229-98d3-a1684cc07f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_1a71c95e-8d01-4229-98d3-a1684cc07f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d7339bc5-bd93-4bb7-9582-8e4ed9f8f0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_NetIncomeLoss_d7339bc5-bd93-4bb7-9582-8e4ed9f8f0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_fee68eab-e23a-45df-b4bb-b2f5bfb1ed8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_SharesOutstanding_fee68eab-e23a-45df-b4bb-b2f5bfb1ed8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7fba8fa-e71a-44e1-92f9-47d36762af8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5752e56f-9bb2-4088-bf72-8ebd1302b769" xlink:to="loc_us-gaap_StockholdersEquity_d7fba8fa-e71a-44e1-92f9-47d36762af8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8c9880ef-8fa8-4789-9f7e-facc6969e428" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e92e7b99-d3ba-427c-80ba-b931c471a5df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8c9880ef-8fa8-4789-9f7e-facc6969e428" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e92e7b99-d3ba-427c-80ba-b931c471a5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="advm-20200331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ced25994-d282-4d7b-bc50-0abdac21b613" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:to="loc_us-gaap_NetIncomeLoss_ced25994-d282-4d7b-bc50-0abdac21b613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_160fac16-55c2-42e9-b7c6-d0bac6e4e25c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:to="loc_us-gaap_DepreciationAndAmortization_160fac16-55c2-42e9-b7c6-d0bac6e4e25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_070c4cbf-d557-417e-95fc-e0ef27a4efdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:to="loc_us-gaap_ShareBasedCompensation_070c4cbf-d557-417e-95fc-e0ef27a4efdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_db84765e-066a-41ba-8cbb-98da195a1e65" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_db84765e-066a-41ba-8cbb-98da195a1e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_62ddc978-dd4a-43f7-8b53-7e6b4ad1c430" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_965aa3cf-ba20-450d-aeaa-7664c3b5ec10" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_62ddc978-dd4a-43f7-8b53-7e6b4ad1c430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8b688761-f6cb-412e-95d3-a21da48dbacf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8b688761-f6cb-412e-95d3-a21da48dbacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_edd16395-55ab-4106-837e-fe40029622ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_edd16395-55ab-4106-837e-fe40029622ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_d5a5065f-bf2c-4300-aa97-6c258202bc7b" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset_d5a5065f-bf2c-4300-aa97-6c258202bc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_83760006-1f32-4322-9390-f6c642ced3c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_83760006-1f32-4322-9390-f6c642ced3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9aa3ed2d-4acd-4665-9e9b-9b44a504b0fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9aa3ed2d-4acd-4665-9e9b-9b44a504b0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_IncreaseDecreaseInLeaseLiabilities_3ab5b6f5-e52a-4278-90db-52f03091054b" xlink:href="advm-20200331.xsd#advm_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e28cedea-fdcc-45db-ab60-db6111995a09" xlink:to="loc_advm_IncreaseDecreaseInLeaseLiabilities_3ab5b6f5-e52a-4278-90db-52f03091054b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2eff95f-c8b4-4a07-95bb-d5ee0d02099e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3bcc4d9b-897f-45ee-a2f7-bd8e6cb8f3e6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a2eff95f-c8b4-4a07-95bb-d5ee0d02099e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d7ade72c-0238-4633-9495-3846f935ef41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_d7ade72c-0238-4633-9495-3846f935ef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d8c79e7f-4648-40b1-b640-d09cfe8813b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_d8c79e7f-4648-40b1-b640-d09cfe8813b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5bb76635-b8f2-4a7d-8c66-dfe46107694b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5bb76635-b8f2-4a7d-8c66-dfe46107694b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bea93943-5297-46dc-a7f8-7c8fd4598dfb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c098a11d-d9ed-4660-b59a-54b541bcdb9d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bea93943-5297-46dc-a7f8-7c8fd4598dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_8792b820-1052-4fac-bbc8-d2540a34177e" xlink:href="advm-20200331.xsd#advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:to="loc_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts_8792b820-1052-4fac-bbc8-d2540a34177e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e15bf853-97fc-42d7-9a75-ecf33d5def2e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e15bf853-97fc-42d7-9a75-ecf33d5def2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_45bd643d-03f2-4be4-b3d6-1d91931a26dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_45bd643d-03f2-4be4-b3d6-1d91931a26dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_f5399a0f-b404-49d8-b55a-7ada4a274db9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:to="loc_us-gaap_RepaymentsOfDebt_f5399a0f-b404-49d8-b55a-7ada4a274db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30466d16-0ed1-4835-b543-d9ca5ace2f66" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8264428e-ec22-41c6-ab52-f89eeb07d0fa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30466d16-0ed1-4835-b543-d9ca5ace2f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_235d7778-dcb4-45d2-82d0-83acc2089160" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_235d7778-dcb4-45d2-82d0-83acc2089160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5db2f06f-5904-4d03-9773-a078335a2d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5db2f06f-5904-4d03-9773-a078335a2d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194917c-0424-43d9-8b38-a092ce30e9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e194917c-0424-43d9-8b38-a092ce30e9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b97392f5-729f-4aa9-87c5-0fb329787f23" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6bb03df8-cf26-405f-bab3-955e35cf9a28" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b97392f5-729f-4aa9-87c5-0fb329787f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7e39de80-8a6a-4616-846a-851638f1492e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b97392f5-729f-4aa9-87c5-0fb329787f23" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7e39de80-8a6a-4616-846a-851638f1492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62edc809-589d-4e5f-a557-2c89baca04df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bc50fc0a-3a27-4178-98b1-16d8ad5f7a76" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62edc809-589d-4e5f-a557-2c89baca04df" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_bc50fc0a-3a27-4178-98b1-16d8ad5f7a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#OrganizationandBasisofPresentationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c414a283-5a5e-4089-ac89-25f6f0b1cd71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f0b8f24-60f2-408f-be2d-8314e3b762cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c414a283-5a5e-4089-ac89-25f6f0b1cd71" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3f0b8f24-60f2-408f-be2d-8314e3b762cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_758ba5b0-5511-4d29-9f24-8e3f642d837b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_469526ae-743e-44dc-8916-801f2dd8c5c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_758ba5b0-5511-4d29-9f24-8e3f642d837b" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_469526ae-743e-44dc-8916-801f2dd8c5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="advm-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c1775485-af9e-47e9-be63-1418dee6829c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9a36841f-2aa6-4f6e-b2ca-71a3f0118681" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1775485-af9e-47e9-be63-1418dee6829c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9a36841f-2aa6-4f6e-b2ca-71a3f0118681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5c9e5587-e0c1-486e-8bbc-38edc4f2b73f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1775485-af9e-47e9-be63-1418dee6829c" xlink:to="loc_us-gaap_UseOfEstimates_5c9e5587-e0c1-486e-8bbc-38edc4f2b73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2ae1836a-2ab9-49b1-bc73-2c198649cd8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c1775485-af9e-47e9-be63-1418dee6829c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2ae1836a-2ab9-49b1-bc73-2c198649cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f91ef791-849b-495a-8f9d-dd1fe3a67fc3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f54597d5-e2ec-4b7e-96ac-b621f24aeb5b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f91ef791-849b-495a-8f9d-dd1fe3a67fc3" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f54597d5-e2ec-4b7e-96ac-b621f24aeb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22bb6042-14ce-44f9-9f94-695073ae87b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_55079da1-f8d1-474e-85ed-1c9e939c8706" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22bb6042-14ce-44f9-9f94-695073ae87b5" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_55079da1-f8d1-474e-85ed-1c9e939c8706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3b5d89f7-4201-4c20-a2b7-13dc39b434d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3b5d89f7-4201-4c20-a2b7-13dc39b434d5" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_52c3187f-7e24-4584-86b5-ddb4e931d6c7" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BondsMember_f669f3d3-f64a-4f9a-96b3-8048e35cff61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:to="loc_us-gaap_BondsMember_f669f3d3-f64a-4f9a-96b3-8048e35cff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_e611d367-b2dc-4054-956a-4f5d3577604e" xlink:href="advm-20200331.xsd#advm_CashEquivalentsAndShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_97c306b7-5599-49c9-ba64-b64520f75410" xlink:to="loc_advm_CashEquivalentsAndShortTermInvestmentsMember_e611d367-b2dc-4054-956a-4f5d3577604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_6579c1e3-4092-4418-9f34-1f496f73a0ff" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_b1971a51-cf3b-40d7-861d-1bcfe6cc5f2a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_MoneyMarketFundsMember_b1971a51-cf3b-40d7-861d-1bcfe6cc5f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4710838-2074-4d0b-9010-d1203d24d7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d4710838-2074-4d0b-9010-d1203d24d7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_0fa315cb-4d05-48a0-8427-a4064d8bbbdd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a8e42955-93d8-4c6b-b799-a6d966866c16" xlink:to="loc_us-gaap_CommercialPaperMember_0fa315cb-4d05-48a0-8427-a4064d8bbbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f689c11f-c35a-48c7-9a99-29caeb2fd55a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ce33eeec-39b8-4eae-9fe5-107ac6fbfcf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ce33eeec-39b8-4eae-9fe5-107ac6fbfcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c5592c0c-f705-4461-90c3-53ad5ad708e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_99674f99-3151-4142-a62f-0407205ac710" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c5592c0c-f705-4461-90c3-53ad5ad708e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_680503f4-cb43-4b88-97bf-d36867a2d93a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b0a83bb-b09e-475d-80cf-053540b22aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b0a83bb-b09e-475d-80cf-053540b22aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cdeb3ad-7f02-40fc-9eb1-acf9a0506b54" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9cdeb3ad-7f02-40fc-9eb1-acf9a0506b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34e9997d-fd72-4a5d-b29b-096155bbf69e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34e9997d-fd72-4a5d-b29b-096155bbf69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dceb3a65-a2ff-41a2-be68-c265307a2e14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dceb3a65-a2ff-41a2-be68-c265307a2e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentAmortizedCost_f652a25a-46e7-4243-a000-1b25f1ed8dda" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentAmortizedCost_f652a25a-46e7-4243-a000-1b25f1ed8dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_8b800897-ba2a-45cd-bc70-30c620d7fbe9" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedGain"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedGain_8b800897-ba2a-45cd-bc70-30c620d7fbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_bada5399-db5e-4f05-8b1f-3cba32b74ac1" xlink:href="advm-20200331.xsd#advm_CashAndCashEquivalentGrossUnrealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_advm_CashAndCashEquivalentGrossUnrealizedLoss_bada5399-db5e-4f05-8b1f-3cba32b74ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_74dde5d9-a02d-4643-a579-efa47afb6223" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_11d1e5d2-e9bf-4dba-af52-961b947d01d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_74dde5d9-a02d-4643-a579-efa47afb6223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a814ec00-59e9-4cc0-a952-485402aa9be8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_a814ec00-59e9-4cc0-a952-485402aa9be8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:to="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_249f8732-f1e0-43d0-a819-7197638fde67" xlink:to="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_19543cde-80aa-44e3-bef3-7c6bca899cc9" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:to="loc_srt_MinimumMember_19543cde-80aa-44e3-bef3-7c6bca899cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_225b1994-1152-4a3e-bd50-0065627f43f1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ba9dfe89-8fec-462c-8097-d0d2fd499c86" xlink:to="loc_srt_MaximumMember_225b1994-1152-4a3e-bd50-0065627f43f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_1713693d-174a-4198-aa68-086efe2580ae" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_c86c94df-2f18-469c-a389-73af7dcea5cb" xlink:href="advm-20200331.xsd#advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears_c86c94df-2f18-469c-a389-73af7dcea5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3262b0ab-77a1-4c0a-925b-da2189780f00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTerm_3262b0ab-77a1-4c0a-925b-da2189780f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_8e8f2cd6-b28e-4f09-ae2f-3d351a22bbdb" xlink:href="advm-20200331.xsd#advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_96a95145-d865-4add-ba30-9b4250fdbc5e" xlink:to="loc_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities_8e8f2cd6-b28e-4f09-ae2f-3d351a22bbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponents"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e9070344-677e-49dd-8851-8ade1cb20c95" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_72ba5d58-8cdd-4c54-88ad-83a4e71ee2b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_e9070344-677e-49dd-8851-8ade1cb20c95" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_72ba5d58-8cdd-4c54-88ad-83a4e71ee2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b9148212-d42a-4c1c-a685-c6202fe7f7d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2bd214b1-4800-44d7-b357-0275864ac2b0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b9148212-d42a-4c1c-a685-c6202fe7f7d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_2bd214b1-4800-44d7-b357-0275864ac2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_35cfd58e-a611-4c64-a062-1a3fbc8f26e1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b9148212-d42a-4c1c-a685-c6202fe7f7d2" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_35cfd58e-a611-4c64-a062-1a3fbc8f26e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cbb1d66d-673f-4ba4-ac0b-049682b2d159" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cbb1d66d-673f-4ba4-ac0b-049682b2d159" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0dbe1d07-daee-41ab-9633-f8036a81c62b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_be8028d2-333b-488d-8b65-0cef4e7cd2df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_ComputerEquipmentMember_be8028d2-333b-488d-8b65-0cef4e7cd2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b7887f33-a56a-4ecc-8aaa-b421d8fe14d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_EquipmentMember_b7887f33-a56a-4ecc-8aaa-b421d8fe14d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_25a17325-8383-4f21-88ca-b135d0fa0a83" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_25a17325-8383-4f21-88ca-b135d0fa0a83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bc5f4950-69aa-441d-bc7d-42bba6875cd4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bc5f4950-69aa-441d-bc7d-42bba6875cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_e357eb2b-ba3b-4086-bc4c-fb8ac1d0f111" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_72ec1bcc-683c-4425-9df5-d0868d7e57d7" xlink:to="loc_us-gaap_ConstructionInProgressMember_e357eb2b-ba3b-4086-bc4c-fb8ac1d0f111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14aa0faa-9f36-47dc-9b65-38469628d76c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2ae7f99e-1f10-401c-88eb-7228957b4003" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2ae7f99e-1f10-401c-88eb-7228957b4003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e89084aa-3179-4445-b2f7-0735b9d37d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e89084aa-3179-4445-b2f7-0735b9d37d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a5c43fbb-3ece-4311-b134-8e632bbb6716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4ea181b8-7a86-4ef1-8908-c508088a18d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a5c43fbb-3ece-4311-b134-8e632bbb6716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_880c36d8-39ef-497a-a9bd-76bb3f758c3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_2c267e1b-30c9-4b6f-be7c-2eff015c0b49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_880c36d8-39ef-497a-a9bd-76bb3f758c3a" xlink:to="loc_us-gaap_DepreciationAndAmortization_2c267e1b-30c9-4b6f-be7c-2eff015c0b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_f3c85133-a16a-47c5-9cb0-23c2501fa326" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_f3c85133-a16a-47c5-9cb0-23c2501fa326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c226735f-5511-47c7-b009-339f7114739a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_c226735f-5511-47c7-b009-339f7114739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_92347187-09b6-4d8b-9509-3640220b8572" xlink:href="advm-20200331.xsd#advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:to="loc_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts_92347187-09b6-4d8b-9509-3640220b8572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ede8637d-3c4e-48c6-a501-32053866c429" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ede8637d-3c4e-48c6-a501-32053866c429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_87d8ffe1-08ae-4249-9bf5-b382114d4d6e" xlink:href="advm-20200331.xsd#advm_AccruedExpensesAndOtherCurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_042e4b78-67b6-46d4-85a9-c1eff5a9a9ac" xlink:to="loc_advm_AccruedExpensesAndOtherCurrentLiabilities_87d8ffe1-08ae-4249-9bf5-b382114d4d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwards"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc73f776-2523-4563-be93-e77f0b8ef1d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_98280694-1fdc-430e-b65f-7500464b041a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fc73f776-2523-4563-be93-e77f0b8ef1d3" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_98280694-1fdc-430e-b65f-7500464b041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0db4581d-9dc2-445c-a7e6-c0c204c6fd8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0d1406c8-2ae7-4841-9ce8-4a5ecdb4960a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0db4581d-9dc2-445c-a7e6-c0c204c6fd8c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0d1406c8-2ae7-4841-9ce8-4a5ecdb4960a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1e9d3805-a90a-4b8c-af19-13264838f2eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0db4581d-9dc2-445c-a7e6-c0c204c6fd8c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1e9d3805-a90a-4b8c-af19-13264838f2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_74a09728-d72a-4835-8baa-d75985ee8cea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0db4581d-9dc2-445c-a7e6-c0c204c6fd8c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_74a09728-d72a-4835-8baa-d75985ee8cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f31c68e8-8b37-462d-bf74-3f44e6af535e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f31c68e8-8b37-462d-bf74-3f44e6af535e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17548f6f-8d87-4f5c-94b6-61abc3d30f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_17548f6f-8d87-4f5c-94b6-61abc3d30f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_db86a5e2-b315-43c9-85bc-3e05913d85c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_db86a5e2-b315-43c9-85bc-3e05913d85c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4994dbc7-24b1-4aa7-a6d3-a7ce89b94116" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4994dbc7-24b1-4aa7-a6d3-a7ce89b94116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a1246ccc-14f0-4522-89bd-86edb0f8fc1b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a1246ccc-14f0-4522-89bd-86edb0f8fc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4dabced0-e464-4ad2-8204-c0cafd6ec985" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4dabced0-e464-4ad2-8204-c0cafd6ec985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54e70fe5-9a42-4905-a2c7-e39ff19df511" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5ccf2b04-a4e6-4aee-a2ff-21f21ba64643" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_54e70fe5-9a42-4905-a2c7-e39ff19df511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f31c68e8-8b37-462d-bf74-3f44e6af535e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_036d21fa-05ce-4b8f-9f23-b431b622111e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_036d21fa-05ce-4b8f-9f23-b431b622111e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c14f3082-faed-474c-a211-2cad226ec152" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c14f3082-faed-474c-a211-2cad226ec152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3f7f7072-cf26-4579-94fc-1e484463f84f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3f7f7072-cf26-4579-94fc-1e484463f84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_82bb6fdb-9b7d-4ecc-b209-c460a6e136a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_82bb6fdb-9b7d-4ecc-b209-c460a6e136a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_760c6c60-155a-49a6-b6f9-e9f161d3fe1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_760c6c60-155a-49a6-b6f9-e9f161d3fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_81cd7973-5b6f-4530-bcea-29ca60c3d3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ce74441c-c31c-41f4-adea-5dcb5889fdd0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_81cd7973-5b6f-4530-bcea-29ca60c3d3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ffb24055-be3b-4b85-a36e-25e9d87aabca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ffb24055-be3b-4b85-a36e-25e9d87aabca" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:to="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_62e45f2b-1d61-412b-abee-30f48acab812" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a68bb165-f6d1-4f35-a939-723cefbb5b16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1efdcafb-5f8d-41ef-96e5-2b4b479fd3c8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a68bb165-f6d1-4f35-a939-723cefbb5b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8903ca41-49ee-4eb5-a20b-cf15e15bd65e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9afa88c4-d8e7-4337-ad8f-80ad741c9822" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9afa88c4-d8e7-4337-ad8f-80ad741c9822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1579c5a8-de73-4f26-8c59-69662865092c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1579c5a8-de73-4f26-8c59-69662865092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7e8af4a8-82c2-4e3c-a899-a88c0aca9e74" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7e8af4a8-82c2-4e3c-a899-a88c0aca9e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b9f37d62-b473-493e-a827-f01fcb032823" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b9f37d62-b473-493e-a827-f01fcb032823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f164eed7-8c9a-41ca-9edc-918415663d02" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f164eed7-8c9a-41ca-9edc-918415663d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_009f18d5-25c7-4e8b-9d4c-de6061132bd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7025b23c-aa3d-4ed5-9458-9b767cb99354" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7025b23c-aa3d-4ed5-9458-9b767cb99354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e73ada2-dc76-40fc-910c-7fe3db216667" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5e73ada2-dc76-40fc-910c-7fe3db216667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c814f574-7a9e-4d7a-82fc-46ad2e630e8d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c814f574-7a9e-4d7a-82fc-46ad2e630e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_259a7674-af11-45fe-9342-812343fdbe34" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_259a7674-af11-45fe-9342-812343fdbe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f091f9a-a9d5-44ae-93f2-ed40597f53d3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a7c4327d-a7b6-4ed7-a18f-fed443401dbd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f091f9a-a9d5-44ae-93f2-ed40597f53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#EquityIncentiveAwardsStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_dc6f666d-f4ff-4596-89f7-90b6dff05dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_dc6f666d-f4ff-4596-89f7-90b6dff05dc6" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f1869925-705b-4d1c-98ed-ff9ab286c53c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_346bb94a-d20a-4822-9a50-d9d45e30183b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_346bb94a-d20a-4822-9a50-d9d45e30183b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_624dfd2c-5a87-4668-ae7c-4f91aab205f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_4d20abe8-2472-4110-a748-59887f609552" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_624dfd2c-5a87-4668-ae7c-4f91aab205f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bb6ca6d0-d77a-4bf7-9273-8d3dbdb14ca9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a6385f9-e382-401a-9208-888ec1cabb8c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_2f27f4d5-e0ad-474c-b129-281684210f90" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7a6385f9-e382-401a-9208-888ec1cabb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShare" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShare"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0a782999-359d-4fda-974e-9d72e7ea410d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4cb8f2be-56c0-47d5-9bfe-f7a6ea0288ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0a782999-359d-4fda-974e-9d72e7ea410d" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4cb8f2be-56c0-47d5-9bfe-f7a6ea0288ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareTables" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareTables"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_80f1859c-5875-4379-a5fb-a8de5e2f0419" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_45499e6c-fc4a-4abc-91fb-1bd100c3f19f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80f1859c-5875-4379-a5fb-a8de5e2f0419" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_45499e6c-fc4a-4abc-91fb-1bd100c3f19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#NetLossperShareAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f9509525-eacd-415b-be3e-5f37976386e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9509525-eacd-415b-be3e-5f37976386e8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_390d0acd-efb0-4dc8-a41c-1a4eda0462e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_46940476-32a4-45ff-a73c-1e909dabd340" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_46940476-32a4-45ff-a73c-1e909dabd340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e4ab65bf-10e1-417e-9d71-c6d27feea30f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e4ab65bf-10e1-417e-9d71-c6d27feea30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_66d9485e-e121-48ca-92f8-3d263a1f12df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_EmployeeStockMember_66d9485e-e121-48ca-92f8-3d263a1f12df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_dc582ad2-2724-432a-8985-b2ec512d14d9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4c4fb4e4-ca71-456a-b19e-be134958a10d" xlink:to="loc_us-gaap_WarrantMember_dc582ad2-2724-432a-8985-b2ec512d14d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_31280c46-ddab-46e8-8b02-8a7c26382f6f" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ee777412-dec9-4328-87f3-c75c23eb5bad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ae9d8397-d51b-4101-a672-6cc7e80cd6b4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ee777412-dec9-4328-87f3-c75c23eb5bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_fe1a7f77-ed49-4c04-b6fd-c5a065229b63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_07d3efe1-cbb4-4270-8bae-f71ddd65bfe8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_fe1a7f77-ed49-4c04-b6fd-c5a065229b63" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_07d3efe1-cbb4-4270-8bae-f71ddd65bfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="simple" xlink:href="advm-20200331.xsd#RelatedPartyTransactionsAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d48a0971-17de-4181-a8f2-cad1572852bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d48a0971-17de-4181-a8f2-cad1572852bd" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dd1a0b4-b747-4e2a-9e7c-d8f2f70e5fef" xlink:to="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3c86630f-5646-4fe0-9939-2ff70e0a5e4f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aa4397f4-5b14-4946-a75b-ef3b4be6badc" xlink:to="loc_us-gaap_CommonStockMember_3c86630f-5646-4fe0-9939-2ff70e0a5e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f843d8ce-f2cc-4b42-bf99-02398e50ce47" xlink:to="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_advm_TrustMember_f8f77920-0bd3-4f04-bb71-536f5df8d545" xlink:href="advm-20200331.xsd#advm_TrustMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_5570eb01-dfec-4a2a-8985-8f4f88fb5b5f" xlink:to="loc_advm_TrustMember_f8f77920-0bd3-4f04-bb71-536f5df8d545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_35a05440-6399-4638-ab46-16bdc409692e" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0dc478-2f5e-4c18-ae49-db5f8bd49e11" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fb0dc478-2f5e-4c18-ae49-db5f8bd49e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d1f20d5d-0e3c-4aa6-b64e-5b14234d21d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d1f20d5d-0e3c-4aa6-b64e-5b14234d21d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6eab8390-9616-4b58-a5e8-8ba3f5643f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f1b742b8-9e81-470f-9019-45e1026a1119" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6eab8390-9616-4b58-a5e8-8ba3f5643f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image01.jpg
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MI[^_G[6D1IZEU.MUUHJ<ZW/7F;HYQ4<GCR.5H.215> M*<V[)%$-$00HK3%
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M=NV@573X\NU;/+/_(".5*N_[Q2KCN\>-Y"/;3H6F-)J6#+CS>IMO+=QAN3%
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MPHCY^7GN:=/S4P9(HIISKWT(":VW-*N+-[AH7;ITR6'VQI!F*4%:6J(  "
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MW<]8-D>2I/SYRB;J:\_P1ST+NL$9E?&GKY_C/SCX$ "CSE"6)8NI(R6E[6*
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M(/4(@#L1%\AEXEU$PS,6Q!II>-?>A GTZ,:G=!>V(DT\S:UP@SHKA5(H*>@
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M\'<J15Z0-KTM8&T@3@Q_>^C0PQP^_#)T.F33T^1Y"7E.H]%DW[Y]M'4(]PA
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MINL/+!*/IAG&L<HA$[\V[P*:9$IZS;ROHHJQ7#<9UE2BK[S.KHPHBD#Z]:8
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MQJ?"0Z\"_;[FK_.(S3Y<)J"3P+H.O/+*,NI*PK_\W2_39R!N:\)2%0PL:X_
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MK+A6B1V[D=8$( 2SL[,?$/3ZT*%M@4 .I$E"EF6]65.PG"3XRN]&KY[G410
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M>?*))S@]_1Y@BVH+G_'LNQE//ODDDVLGN?.N*92T&W*N\YLGKA#=.@JP,#'
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CA:UZCN.8(/KX>?5)C_\#$M)K<_<8)((     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image11.jpg
MB5!.1PT*&@H    -24A$4@  !1<   $E" 8   !^N-7P    "7!(67,  $SE
M  !,Y0%USO"5  #_EDE$051XG.R=!YAE596V!R0U01@01! D(XID 1D0!!04
M%1!,@R)!1!%%,: $%9&@2! 0!#J'JNK*N;IR#ETYY]"50U?.U=7=:_:WJBZ#
MV.&>?=,)Z_V?_<\\CMU]SSD[K/7M%?Z+!$$0!$$0!$$0!$$0!$$0-/BO0/\
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MG@W/S]&BFD."( B"L#]F%A>I=W:&2D>V4[XZ2S!PKG1.3]&T^K^)Q6$/8#?
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MM2$6#0]R2@!N0X?4YHB;/E=J@*3I&H-3\W?O8F,.8M#>1,4]"4C_HQQXI&M
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M01A"6TS>T$7$17L/B#\0Z)!29*5L$!$7K3%<3>8^%K&!.WH_N#67!;#.Z:E
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M&!8#T6D3T8[E:H-]?WI8@3+R4*\-2K3128#?@)2S+$ZAL$>4E"!X SCU*!>
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M.3PI&GV3.H?01=7*30A$7!3,B(B+UF!2O5L(C,\J.^(*#T4"9#(A8^I6Y1O
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M6J^^@1&F%P:H?2290JMNI7_DG>26N(A4ZO5EUU!ISQLTOSBN'-A%'[U-P5?
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MTL0(.D3CAA311->GQ7-M&%^"R,@2-8DWJP,#3BV:R2 "$&'9$%L.UX@X]>>
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M(D+AQ*+)#C8N,T<IHN#VR>H01'CXC]1B0QU(A#JC;D[#Q!@+B]@ K#M#!#.
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MP)F'L^_LF&"ZKS"+ZV\YH=.JB(O.0,1%]S"3N A0<N0.99=_/-+X=T-Y&%R
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M[_NMW%3MWWRE>M[G:LK]TOC$'9"E^J@Z6T[7*%F%["$TJLD8Z/5K)*:(BVZ
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M_U9NMH6YU"^L[3U=MKA2U3^+WET_W;S!O3!PJ X9CS1JIB^D&!N)B[E'HS_
M)NVJ<Z\,-*;/FGR?>]J,">XK):NMUU0N#DTZ<?)1<XZ9K$QI]+D!V=5D"+Z'
MGI5[]U@V>*K *<9H_N&FDN!SCSZ-Z_9WN -'M!?$ XF+(AV1N'AF6KUS.]G;
M5&]9DA^4!3[\PF'D=WQG8[&59)+9(N)+RZ$^LX')O ]]3@QHH^PV%VVA3 "Q
M95I3O;LP(%&%ZXK\J>[/55O<UAQH 93IXB+GRM;N3AM,2$_TD QR?*.?E6_P
M>_FAI'YV*EXY6\E\C_8S(X#3IW&MM^53%>20N#@&I+-W'SMJ*:6A$:SG^8?[
MO=*U9H#%.LJ\H:_7&OY?LS@O)N-D/->%,Q]V[_/.X>TUVZP<.UTF?;8=/NSF
M[VZRTI"0P3HH_U?.FV:-L3GTY6@]$8F+N0="$OM42+_ R+IZ4?XTZTN;Z] J
M@@S.:$L8(M<ELQ]Q$QIJK:0J57#VW5-7;0)AR'=@P!>E@/L'!I2Y$2<D+HIT
M1.+B^""KG6F?M XY;VKTO;]&7[3X85@6%5%J\Q-?J%9;XQWB:P///R[6 WWH
MU1LS/6'Z+BU\GC[CH:#GRSE,'[OZ@[VI_BH))]/%1>S90\>/6S;R"[R/$S(0
M]VDS!GLOEG<=2(H>@I7&D$T2N] L0J9=TZ.7ZJ-4MJF2N#@&O(P(:S3##)D
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M$QMK$YZMGLM(7!3IB,3%V(A,)N;[<RYSKL9JAQ.4NC)_JKN[;KMEL&C-AX$
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MAWZN7]^PQO:X9+Q'G'TO\F?F+RM*4_W5Q1C$*BZRG_]D\WK;YU*]U^;ZA=-
MZ1_M>Q#4CI]\-&/M!XF+F0'O',,!WKHT/V["#?V<'ZBO<:W^G58&V!,A0%?3
MVVU5) B 3PFH1(CVXN]\O&B957I15DG?3?8:6O;00_GHHZDIG:;D&1&:OM_T
MZR1@OZ7K@'NXH=9ZZ[]Q2?S>R[%L9%H%4=%S0_E&AP]Y-(NJS1(-9Y;$Q<<I
M[&AWWRU=&U09>R8;G+ZBWRXM=NT#AVU*>J:35>+BM*9ZRR@+F>B#2$5&'!L>
M&Y!(+S@2$1C;^@^YDOT=-B3CHZN76@E@(@_L4UT(T1SFO'.41F=#%"P6<9%^
M;31))D+^[8W%&74QO9D^+$29B6[24_-U?A]YQ8*9EJ;^8G\_F+J,V$-S]*?/
M>,@,EEA[&,5Z\3D^MF:9N[VFTFWT#AI.1#8<2KD.(A!#55Z1X.;1D8M,6Z;3
MY6?X=+IL)59Q\9DS)UA&"('35.^UN7[A3/]\RP8KS5O8VFRM7S*UMY+$Q<R
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MDX8"-4PPWY5%,QRR0EQD\,(OMI1:7X70+\&(\5*_H?8<TR"$3(*7CL5>ZE]
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M*9&/%]DH+N+(,NF8S)71ZX@+AY96 ]@ZB!SC6:/<)X:$T;N-8-T]ZU\V1J7
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M+KF./IJ%G <0#D[VW_R<Z\W^QN^*+1Y-MG*RD=/R8VF"X^BA+LC]3=&*12I
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MY$B0V<E*IKD#>YKR;4HFO:Q?C*]")UNG(0555FCB4?V4+) IJ>1BZJ#D8O*
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M74K'+R>W<W4BH.2BDHMNL/=8#^C3N.<'@I&F1C@H[(UD9$?Y!4HN1H]XDXL
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A*!0*A4*A4"@4,>'_ W]G)03(.)3N     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633636320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 599<span></span>
</td>
<td class="nump">$ 426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>70</ContextCount>
  <ElementCount>219</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>26</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Stockholders Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Equity Incentive Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwards</Role>
      <ShortName>Equity Incentive Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adverum.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/BalanceSheetComponents</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsTables</Role>
      <ShortName>Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/EquityIncentiveAwards</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adverum.com/role/NetLossperShare</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail</Role>
      <ShortName>Organization and Basis of Presentation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Balance Sheet Components - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail</Role>
      <ShortName>Balance Sheet Components - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail</Role>
      <ShortName>Equity Incentive Awards - Summary of Stock Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail</Role>
      <ShortName>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail</Role>
      <ShortName>Equity Incentive Awards - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Net Loss per Share - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail</Role>
      <ShortName>Net Loss per Share - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="advm-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="advm-20200331.htm">advm-20200331.htm</File>
    <File>advm-20200331.xsd</File>
    <File>advm-20200331_cal.xml</File>
    <File>advm-20200331_def.xml</File>
    <File>advm-20200331_lab.xml</File>
    <File>advm-20200331_pre.xml</File>
    <File>advm-20200331xex101.htm</File>
    <File>advm-20200331xex102.htm</File>
    <File>advm-20200331xex103.htm</File>
    <File>advm-20200331xex311.htm</File>
    <File>advm-20200331xex312.htm</File>
    <File>advm-20200331xex321.htm</File>
    <File>advm-20200331xex322.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782763744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 14,751<span></span>
</td>
<td class="nump">$ 10,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,040<span></span>
</td>
<td class="nump">5,576<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,791<span></span>
</td>
<td class="nump">15,707<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(23,791)<span></span>
</td>
<td class="num">(15,707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">1,218<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,906)<span></span>
</td>
<td class="num">(14,489)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Net unrealized (loss) gain on marketable securities</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(54)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (23,014)<span></span>
</td>
<td class="num">$ (14,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share &#8212; basic and diluted (in USD per share)</a></td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares used to compute net loss per share - basic and diluted (in shares)</a></td>
<td class="nump">73,797<span></span>
</td>
<td class="nump">63,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634671584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Adverum Biotechnologies, Inc. (the &#8220;Company&#8221; or "Adverum") is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The Company&#8217;s core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#8220;cGMP&#8221;) quality control. Since the Company&#8217;s inception, it has devoted its efforts to performing research and development activities, filing patent applications, hiring personnel and raising capital to support these activities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $407.9 million as of March&#160;31, 2020. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. The Company believes that it has sufficient funds to continue operations into 2022.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2020, are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2019 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6765317760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,409<span></span>
</td>
<td class="nump">$ 1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="nump">$ 1,131<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606781200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Equity Incentive Awards</a></td>
<td class="text">Equity Incentive Awards<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s option activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Stock Units (&#8220;RSUs&#8221;)</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s RSUs activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(462)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615637824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Summary of Cash Equivalents and Short-term Investments</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(121)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171,624&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,480&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,540)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,540)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,391)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,388)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6652954848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Basis of Presentation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 407,935<span></span>
</td>
<td class="nump">$ 385,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772369600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,932</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634710384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text">Balance Sheet Components<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Property and Equipment, Net</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consists of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,263&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,591)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="margin-top:9pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Depreciation and amortization expense related to property and equipment for the three months ended March&#160;31, 2020 and 2019 was $0.6 million, and $0.4 million, respectively.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,299&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued preclinical, clinical and process development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767072528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Basis of Presentation</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8212;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2020, are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2019 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. </span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. </span></div>The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Topic 326</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the </span></div>Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6761572048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 35,318<span></span>
</td>
<td class="nump">$ 32,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,591)<span></span>
</td>
<td class="num">(7,992)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">26,727<span></span>
</td>
<td class="nump">24,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">825<span></span>
</td>
<td class="nump">752<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,319<span></span>
</td>
<td class="nump">6,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">678<span></span>
</td>
<td class="nump">678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">26,263<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 23,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782204480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 130,162<span></span>
</td>
<td class="nump">$ 65,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">166,904<span></span>
</td>
<td class="nump">100,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">9,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">300,448<span></span>
</td>
<td class="nump">175,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">20,406<span></span>
</td>
<td class="nump">20,963<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">26,727<span></span>
</td>
<td class="nump">24,884<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">999<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposit and other long-term assets</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">348,599<span></span>
</td>
<td class="nump">222,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,663<span></span>
</td>
<td class="nump">4,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,079<span></span>
</td>
<td class="nump">11,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability, current portion</a></td>
<td class="nump">4,025<span></span>
</td>
<td class="nump">4,034<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,767<span></span>
</td>
<td class="nump">19,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">27,753<span></span>
</td>
<td class="nump">28,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">44,646<span></span>
</td>
<td class="nump">47,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">712,713<span></span>
</td>
<td class="nump">560,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(833)<span></span>
</td>
<td class="num">(725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(407,935)<span></span>
</td>
<td class="num">(385,029)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">303,953<span></span>
</td>
<td class="nump">174,957<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 348,599<span></span>
</td>
<td class="nump">$ 222,727<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782400592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (22,906)<span></span>
</td>
<td class="num">$ (14,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">599<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,409<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium and accrued interest on marketable securities</a></td>
<td class="num">(179)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(48)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,345<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">557<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,514<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(2,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_IncreaseDecreaseInLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(470)<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(13,616)<span></span>
</td>
<td class="num">(13,217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(127,733)<span></span>
</td>
<td class="num">(22,454)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">61,200<span></span>
</td>
<td class="nump">27,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(4,210)<span></span>
</td>
<td class="num">(2,186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(70,743)<span></span>
</td>
<td class="nump">2,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts', window );">Proceeds from offerings of common stock, net of issuance costs</a></td>
<td class="nump">140,923<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock pursuant to option exercises</a></td>
<td class="nump">9,650<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of restricted stock units</a></td>
<td class="num">(1,922)<span></span>
</td>
<td class="num">(504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of loan</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">148,624<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="nump">64,265<span></span>
</td>
<td class="num">(10,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">66,896<span></span>
</td>
<td class="nump">155,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash at end of period</a></td>
<td class="nump">131,161<span></span>
</td>
<td class="nump">145,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of noncash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Fixed assets in accounts payable, accrued expenses and other current liabilities</a></td>
<td class="nump">$ 3,474<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Operating Lease Right-of-use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from offerings of common stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771428368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">1,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(462)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in USD per share)</a></td>
<td class="nump">$ 4.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">15.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested and released (in USD per share)</a></td>
<td class="nump">4.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">8.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in USD per share)</a></td>
<td class="nump">$ 5.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615726576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text">Net Loss per Share<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#8220;ESPP&#8221;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock options</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,969&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,729&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ESPP</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">132&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants to purchase common stock</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">90&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,932</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,920&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649995984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment, net consists of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Computer equipment and software</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">752&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Laboratory equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,319&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,291&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">678&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,263&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,602&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Construction in progress</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">233&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,553&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total property and equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,318&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,876&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less accumulated depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,591)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7,992)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,727&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,884&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued expenses and other current liabilities consist of the following:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.941%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employee compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,299&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued preclinical, clinical and process development costs</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,823&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,973&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,466&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,607&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,491&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,636&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total accrued expenses and other current liabilities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,079&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,271&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>35
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "advm-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 10,
   "contextCount": 70,
   "dts": {
    "calculationLink": {
     "local": [
      "advm-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "advm-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "advm-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "advm-20200331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "advm-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "advm-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 241,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 6
   },
   "keyCustom": 12,
   "keyStandard": 207,
   "memberCustom": 2,
   "memberStandard": 23,
   "nsprefix": "advm",
   "nsuri": "http://www.adverum.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.adverum.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Balance Sheet Components",
     "role": "http://www.adverum.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Equity Incentive Awards",
     "role": "http://www.adverum.com/role/EquityIncentiveAwards",
     "shortName": "Equity Incentive Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Net Loss per Share",
     "role": "http://www.adverum.com/role/NetLossperShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Related Party Transactions",
     "role": "http://www.adverum.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Equity Incentive Awards (Tables)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsTables",
     "shortName": "Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.adverum.com/role/NetLossperShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail",
     "shortName": "Organization and Basis of Presentation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Balance Sheet Components - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail",
     "shortName": "Balance Sheet Components - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "role": "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ib7f03b30ae4e49ffbf09b800ef895809_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i74e35996fd934b90add7c64de848251a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Equity Incentive Awards - Summary of Stock Options Activity (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail",
     "shortName": "Equity Incentive Awards - Summary of Stock Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i74e35996fd934b90add7c64de848251a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i11acc5e392074f6aa619a7caf4b0e38b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
     "shortName": "Equity Incentive Awards - Summary of Restricted Stock Units Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i11acc5e392074f6aa619a7caf4b0e38b_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Equity Incentive Awards - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail",
     "shortName": "Equity Incentive Awards - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Net Loss per Share - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail",
     "shortName": "Net Loss per Share - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "if3cc70262de5431e9151b30abf240ea9_D20200201-20200229",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Stockholders Equity",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.adverum.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - Fair Value Measurements and Fair Value of Financial Instruments",
     "role": "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments",
     "shortName": "Fair Value Measurements and Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "advm-20200331.htm",
      "contextRef": "ia1c289aae9114e718b061d97eb326203_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 26,
   "tag": {
    "advm_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued preclinical clinical and development process costs.",
        "label": "Accrued Preclinical Clinical And Development Process Costs",
        "terseLabel": "Accrued preclinical, clinical and process development costs"
       }
      }
     },
     "localname": "AccruedPreclinicalClinicalAndDevelopmentProcessCosts",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalent amortized cost.",
        "label": "Cash And Cash Equivalent Amortized Cost",
        "negatedTotalLabel": "Less: Cash Equivalents, Amortized Cost Basis"
       }
      }
     },
     "localname": "CashAndCashEquivalentAmortizedCost",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 1.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized gain.",
        "label": "Cash And Cash Equivalent Gross Unrealized Gain",
        "terseLabel": "Less: Cash equivalents, unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedGain",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashAndCashEquivalentGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 3.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalent gross unrealized loss.",
        "label": "Cash And Cash Equivalent Gross Unrealized Loss",
        "negatedLabel": "Less: Cash equivalents, unrealized losses"
       }
      }
     },
     "localname": "CashAndCashEquivalentGrossUnrealizedLoss",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_CashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash equivalents and short term investments.",
        "label": "Cash Equivalents And Short Term Investments [Member]",
        "terseLabel": "Total Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "CashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "label": "Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in lease liabilities.",
        "label": "Increase Decrease In Lease Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_IncreaseDecreaseOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "label": "Increase (Decrease) Operating Lease Right-of-use Asset",
        "negatedTerseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other than temporary impaired investments available for sale securities.",
        "label": "Other Than Temporary Impaired Investments Available For Sale Securities",
        "terseLabel": "Other than temporary impaired investments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds from offerings of common stock, net of issuance costs.",
        "label": "Proceeds From Offerings Of Common Stock Net Of Issuance Costs",
        "terseLabel": "Proceeds from offerings of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period",
        "terseLabel": "Common stock issued upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "advm_StockPaidValueForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock paid value for tax withholding for share based compensation.",
        "label": "Stock Paid Value For Tax Withholding For Share Based Compensation",
        "negatedLabel": "Restricted stock surrendered for taxes"
       }
      }
     },
     "localname": "StockPaidValueForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "advm_TrustMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trust.",
        "label": "Trust [Member]",
        "terseLabel": "Trust"
       }
      }
     },
     "localname": "TrustMember",
     "nsuri": "http://www.adverum.com/20200331",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premium and accrued interest on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r27"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r27"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r23",
      "r96"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r33",
      "r36",
      "r37",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss)/Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedLabel": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r107",
      "r109",
      "r129",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r109",
      "r125",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r165",
      "r175"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r2",
      "r3",
      "r31"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r83",
      "r93"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r81",
      "r84",
      "r93"
     ],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r110",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BondsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security, in which the authorized issuer owes the holder a debt and is obliged to repay the principal and interest (the coupon).",
        "label": "Bonds [Member]",
        "terseLabel": "Corporate Bonds"
       }
      }
     },
     "localname": "BondsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r62",
      "r63",
      "r64"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Fixed assets in accounts payable, accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r21",
      "r61"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail": {
       "order": 2.0,
       "parentTag": "advm_CashAndCashEquivalentAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "negatedLabel": "Less: Cash Equivalents, Estimated Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r61",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r141"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of noncash investing and financing information"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r39",
      "r41",
      "r42"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-sale, Term",
        "terseLabel": "Marketable securities term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r59",
      "r94"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsAdditionalInformationDetail",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "Net loss per share \u2014 basic and diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r138",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r138",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r138",
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r18",
      "r166",
      "r177"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Net unrealized (loss) gain on marketable securities",
        "verboseLabel": "Unrealized gain (loss) on marketable securities, net"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r57",
      "r60"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r38",
      "r40",
      "r43",
      "r60",
      "r70",
      "r171",
      "r179"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liability, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r143"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r137"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r27"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "advm_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Deposit and other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r133",
      "r134",
      "r135"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of restricted stock units"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r48",
      "r50",
      "r82"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r2",
      "r19",
      "r20"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Cash purchase price"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r48",
      "r49",
      "r82"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r52",
      "r127"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock pursuant to option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r23",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r22",
      "r95"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r97",
      "r178"
     ],
     "calculation": {
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail",
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r8",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r8",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r105",
      "r144",
      "r145",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r132",
      "r185"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r4",
      "r10",
      "r65",
      "r184"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r101",
      "r176"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/OrganizationandBasisofPresentationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsAdditionalInformationDetail",
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of Cash Equivalents and Short-term Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r109",
      "r124",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r109",
      "r124",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r23",
      "r97"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponentsScheduleofPropertyandEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r66",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r110",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r112",
      "r121",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r114",
      "r126"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Options Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in USD per share)",
        "periodStartLabel": "Beginning balance (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r108",
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in USD per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofRestrictedStockUnitsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r102",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Equity Incentive Awards"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/EquityIncentiveAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "negatedLabel": "Restricted stock surrendered for taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r11",
      "r167",
      "r168",
      "r169",
      "r174"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r30",
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs of $332 (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Common stock issued upon release of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r101",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Common stock issued upon exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.adverum.com/role/EquityIncentiveAwardsSummaryofStockOptionsActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs of $332"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r16",
      "r17",
      "r80"
     ],
     "calculation": {
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/FairValueMeasurementsandFairValueofFinancialInstrumentsSummaryofCashEquivalentsandShorttermInvestmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/NetLossperShareAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted-average common shares used to compute net loss per share - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.adverum.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62557-112803"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r186": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r187": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r188": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r189": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r191": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27340-111563"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>36
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V'?6K=W_]CX*JAJ^'47Z@M02P,$%     @ !(*\4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M ^>*:4IPI_E.^MHV31IV4&9(]%@,=Y=AHG@_WLN2Z7*X^0M02P,$%     @
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M6(<X-,=EE0=!YIF5]Z#;XE1$778%W T\E$]']@(0S "!TN%NT'@^#OL.RJ:
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M[(JB=LV@X9>FJ7N7;J\WF=O5[:5MKLO+D=SEIBY._7%C<#WSG/\'4$L#!!0
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M"8,E^]_LNZV<?'3BVMBW53_]#?9O_=#62Q1GI2Z_S[^79OJ]+?$_JLD5<*F
M]PJN[?^KH)8*ZD<%/24_.YM2_:D<RNVZ:V]!-X_6M1PG!3PIUYG[L7#JN^E_
M+MO>E;YO0<7KZ'T,M&AVLP8?-7=%Y*+?FT"IB1VRZOBY@8(KLD1N08E)J*F^
M^I2$QZ(6 ^@I@'X(D"O2";,DF23-)%DAYG%"4A%DH'66RVZ,Z,8(Z: <(!$#
M)"P=4#2?66,>C)H\)\EPC4;/P*2BD90;B3-B)&6-*!U3)UP$:>+IDTRTD@E]
MHHF5C+6R@I1:D43H&=]<M)(+5@RQDO-6-.FY@FMT+/N 6%[\L3#3/ ,,'GX
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MVW:PSF/\Q?7XV9:'^TMEC\/XF+KG;KZKF5^&]KK<0T7WR[#M?U!+ P04
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MX=E.8S89WO3S#V++-R[_ %!+ P04    "  $@KQ0R87^&;,!  #2 P  &0
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M!"VV/2LV;0O5Q97DN/O[4K+K>9NQ%TFD> X/*2H;C'UU+8 G[TIJE]/6^^[
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M]3>IDM* 326ZLP4W]JE8# Z5<=N#W:MI8";#R'Y^"\CR(.5_ %!+ P04
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ML:D0T+HPO?-S,]ZTL7"Z3X^(3"^Y>@=02P,$%     @ !(*\4!/?BW$8!
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M4E!("E@Q08!"N'/#^6:@B>9',^QH07>Y$I0.3X Q*L+IQ,M%\"F ,& *F:"
MSP%$WF$*W+T(:-^Q*>/.C.+A4?(?T+T8N'O1N'TQF>@Y!#<=BMYA"=QV*)YC
M20P<(S@B0U/&,!2%4Z4/=S$"VIC0"0JX_U ZWQ4,-R .9[C2@OK?DWY--YZ
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M$,2I3R'H4H@MO:+3CP%VUXC[9#E"M%A$%/C1/,'D/P+QHD <!.(/7;B[Z,*
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M:X1D60$C\H&WT.@W1RX84?HH3DBV LC!DAA%. @2Q$C=^'EF;3N19_RL:-W
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M/55L[Q\Y5Z"##![T;57Z=S >*!R5V2[U7O0SL3\HW@[S'HT_G?P?4$L#!!0
M   (  2"O% [WD2Q;@(  *4(   9    >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;)56[8Z;,!!\%<0#')AO3@0I256U4BM%5[7][1 GH#.8VDZXOGUM0S@"
MFRKW)]AF=G9FP[)D'>.OHB1$6F\U;<3*+J5LGQU'%"6IL7AB+6G4G2/C-99J
MRT^.:#G!!Q-44\=SW<BI<=78>6;.=CS/V%G2JB$[;HES76/^=T,HZU8VLJ\'
M+]6IE/K R;,6G\@/(G^V.ZYVSLARJ&K2B(HU%B?'E;U&SUL4Z0"#^%613DS6
MEK:R9^Q5;[X>5K:K%1%*"JDIL+I<R)90JIF4CC\#J3WFU('3]97]LS&OS.RQ
M(%M&?U<'6:[LQ+8.Y(C/5+ZP[@L9#(6V-;C_1BZ$*KA6HG(4C KS:Q5G(5D]
ML"@I-7[KKU5CKMW ?PV# [PAP!L#5.[_!?A#@/\>$!CSO3)C]1.6.,\XZRS>
M_ULMU@\%>O95,0M]:&IG[BFW0IU><B_V,N>BB0;,IL=X$PP:$8YB'U-X4(J-
MMPB?)=@N$4D$9_!!$[Z)]V],^#!! !($AB"X(0AF5>@QH<$T!I.F_MP)!/)<
M6$H(2@D!*2%,$($$T>/%B$&"^(%BQ$N?[ORYV2Y!<1JEL)0$E)( 4NX\&2E(
MD#Y>#.3"#>(^4(X!=&/5#V?E $ H]N[4 ]UI5P2HB>]0@.VX1MX':@+W&_(?
MJ8F_L!LL2K+$H$E/W6J!6Q=!O9O<H8!;#H4?J C<="AZI"+1PFWBSBNRQ*3S
M]X<S>;G7A)_,'!16P<Z-U*_1R>DX:]>>'@ZS\XV>P69HO-/T _P[YJ>J$=:>
M235ZS( X,B:)DN@^*7&E^F88-Y0<I5[&:LW[P=EO)&N'CP)G_#+)_P%02P,$
M%     @ !(*\4$<A[5P2 @  !08  !D   !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&ULC53;CILP$/T5Q ?$7$(($2!M4E6MU$K15FV?'3():&U,;1.V?U]?
M""74V_8%>X8SY\PQ>/*!\1=1 TCOE9)6%'XM9;=#2%0U4"Q6K(-6O;DP3K%4
M(;\BT7' 9U-$"8J"8(,H;EJ_S$WNR,N<]9(T+1RY)WI*,?^Y!\*&P@_]>^*Y
MN=92)U"9=_@*7T!^[8Y<16AB.3<46M&PUN-P*?RG<'?(--X OC4PB-G>TTY.
MC+WHX..Y\ /=$!"HI&; :KG! 0C11*J-'R.G/TGJPOG^SO[>>%=>3EC @9'O
MS5G6A;_UO3-<<$_D,QL^P.@G\;W1_">X 5%PW8G2J!@1YNE5O9",CBRJ%8I?
M[=JT9AU&_GN9NR :"Z*I0&G_K2 >"^)% ;*=&:OOL,1ESMG@<?NQ.JS_B7 7
MJ\.L=-*<G7FGW J5O951FN7HIHE&S-YBHCEF&SQB#G]BP@F!5 =3&Y&KC7WD
MD @7$@Z,6R)V.HU->?P@\0;!VDFP-@3K!X)XT:/%) ;3VF,(LB@)@L"ME#B5
M$H?2VDVP<1)L_M]KZB1(_^UUGSJ\OFETZY39.F22A8S%I'.9>)4F;IG,*9,Y
M9#8+&8O)9C+!:OD+H]FMHL"O9@ )KV)]:X;?+#O-N*?(W,K?<#L@/V-^;5KA
MG9A4=]O<P MC$E0KP4J=::UF\A00N$B]3=6>V\ED \FZ<>BB:?*7OP!02P,$
M%     @ !(*\4.1E0'F.&P  *H,  !0   !X;"]S:&%R9613=')I;F=S+GAM
M;.U=6W/;R)5^SOZ*+J]K(U6!-"_BS3.9*MF27$KLL<:R)Y5-[0,(M$AD0("#
MBV2E\N/W.Z>[P09Q(2A/*MDM/8Q'!/IZ+M^Y]&GR^S3-Q-=-&*5_>+'.LNWK
M5Z]2;RTW;MJ/MS+"F[LXV;@9/B:K5^DVD:Z?KJ7,-N&KT6 P?;5Q@^B%R*/@
MUUR^C?,H^\.+T7SVXH?OT^"'[[,?WL;W,A$W[DJ*GDC7;B+3[U]E/WS_BEZK
M)F/Q(8ZR=2HN(U_Z^V\_N$E?C(>.& U&@^K+1S$:U;]3,__U?)EFB>ME_[/_
M_B+V\HV,,O'Y<2OW7PX'O9\:._R4NTDFD_!1?)+;.,GV&V9)7AFPZ'PCDR#V
M::_BPLTJ[<QV_^-WOZO;U&[1B1NE01;$4<,B[MPPK8Q^&65!]BBN@E"*'_/-
M4B;[+0:#86\\G<P6#5T_R55 !,42?G0WE0G.?1 ]WX@W09Q);QW%8;P*9.J(
MZ\CK-PR)5W&"+;BT&T?<9B"+B!/!TI0\XO]^E9R7#8-]=K^*:Q\4"NX"CT=L
MV.AHT)N,)O/Q:-8PTKGO0UBQ=/V'>!]$4GR,*FN9#P;BUET%D?L@+I+@7CJ'
M1GQ+G[##S_%#M-_VD_0?8@@(M3DT3D&JFR2^#R*OLK2WYX>&N(G3S W%?P?;
M6CHOS@;3<654'@%(4-ME.JE([?O8PQPWZSAJ$KOI9-I;C$>5J3X'&40UOA/#
MT<GR5-Q*+T]J"/,VWFS Z=LL]GYQQ,M!?P Y%ELW$?=N6%5&*(\?1"MQ^[A9
MQF%%AB]^_K#_S$PL+K]Z:S<"FM5)_X_GMQ?G%=S0)'^;)PEIKE)7GA[LRRMP
M^)<J0A:* M0!E$'$"#M<,V2+ED.+("*K.*F0[-SS)-[CK:]:-HQRNW'#4+S)
M4TA_VK2RRXU,5K2E=TG\D*TA%YNM&S7)[^U:8LCV-F6.WK+A$!_S#-(:$>^:
MNH$<"63M&J;DJ_B3K Q/@C$9#&>3:46&-'^N@I2D]2\2TM.$TKW><-0;#RLT
M!33[#,]7H5M98H'=]@Q7>%BA:BORZ][:CM3V_ZFRLK<Q"!*EX#7^2N,P\)GQ
M;]S0!6P01V26PD)_N;T0)R]/Q4L11.+S.LY3D+LR_H7TC$T>5@R%H:.;IACS
M=>6UFZX%!A4>_2%_S0.H*-I7)KE=0TUZD/@-UG(OTVQ3U^HFD5LW\(7\NJ7]
MI3QTG*TA^5YI(14,B GWVMM\W)*"D%R'TDVE2(+5.NO%=[T<'^J[ (G1"9)(
MZZ#=;6G9CHAD14T_84])X!$?B!95(F]C6'AK0V$<K11!VK94_\YP)0S<91#"
M<9!5U@ 2R.2F ,Y'=QE6C;OGP;-II;4U?,4(, E-@T>GZ,-P&%<,89E!QPP,
M6I/).##^1UYX%$>]#G.HQ;0T8*!:QZ$OD_2__G,^&LZ^8_9GCQ4R0V3O)&;T
M14J=&FQ9[3N8;?;YL!:2^AZ4U'.W =96PZM\DX>LY9I%P-M$KL$YLA]A7 5S
MNX\OX3\%%9E5=$@;-WN0;BPS=O_?-_1L0"QV>1@)B,5:0=& QWU;VN)[;-&"
M-!5\E'#-.8!S5NQ1Q;D=.!A]J' :&@Z,]Q3>^?)>AC'#P7Z[=S*29+6HF>MO
M@HA=;++S]?2,*U.W(%<-HY7HPV&,-[(6FGZ$!C5WK$I29><T0![!10R#OX-K
M)]3H5*P0*PK(]L9-?I$908Q(E6-5HU%7<2*#5:35V'L4%'6DH?+I7?]ON;((
M->IS0,S-Y@1HI*1"L!"/OA-+-PT\Q:T@S$G>3K!BDJ"B[>G^<'^69!6DWW,1
M^E"<ZVD%5O*6DPAG,1,-(S(X[<W>:YA7C5"9L)-FV'@D+EG#.IMW%K(V%[L%
MEFX(EJXCN)T'84D)4YE?)Z2TIZ^N633;.E_4X],;A*=11'*_U*Z-14CA9L)V
M7>:'>Q_JP>3H@7UDQ+$3;$,)J%;,-G 709J2.<VWW%XF7I!RK*/>QEL%;*V2
M<.QHG4=(I')Y,$"R\U-4NSP*LM9U?=KOD;(.0Q;QY [Q:N9^E;_!"%67$8-I
M;MRXC^PNGR<)Q6O*"P,O$]X6#4&I@C\'V9JTA'C^<1D&*[?.5>@(197U?-DA
M($.?AL$F!*R%XDL.=YK$N=5"[74]U/PHW>G0^U"/:X@;-R1?S9+#PH$+3 ,O
M3A6JO1R/1VUB\\0AGZ17#RY)5KLB=&9>-=YK95Y=MO.)1N'DQB7G=RVS &'E
M(=-06H.V)E5,U'/N3_E[,V=S4O:V(/F.2T_:*H>95V'\T#VJY2YWW.4NB3>6
ME\4YEX:8::?]9.43Z<611^G5PL[C*?W-X2X[ ^0#=1D: 2"&"S3*D&NXH4CF
M[[40=6Z]H_VCZR;(-ZJ?CML"RA\!6#N[8&RA*V3B_%>ZMPT..GFVM@A3F?RG
M!ML' K\Z/^\@U0\)@4H]'.#430XGWZ6(&)3O1-D/;J;?=.Y2FF1;FV9HI,")
M)L$I=;P/?'Q8/M;N[1 ][H((FGF('DGL2>D;/;I#N(L>:4=4;A\M:(!XL<T3
M>I.1PBEOIX#KJH?+_@<GCN#H,'QH-54>.80M"PL,JW> JB[+5KL<Z!+&;D5%
M"V[8/-AQIHZR=4,@;%,^S(FOO9E3P7F AKP:/TS:<TV-2;FZSF2+EH6U)V'D
M5.0WCRDIF]0TVFV^W2J.4/[!6TL_5P<#$?"6!K"$&>/LB!E$Z@"SSJT+OF)Z
M#5T@H;N7_W(*Y'Q:QNMCLG(C@\G4\PW"/-:"&VR?ME*+Y&H5M/8;&#>/,*+9
M8':;0[2>RXD3[(ACX-'@.YV6YT_#[^APZ87N_ )R!@H(+PPB\A5Z:4;A[DI&
M4A!)W.TCQT#H#?<\64G>0QYM(+0;Z5,7J!@I,F&QAT N4:) &N=#30G<^K#/
MTIP-F)Q)6IX$^N/G'BD3?"0R_BD:IG#0E1IK]1)^GC"DRCLZ"H37SI"'GK2L
M%%8;+KGB+1V%:;OIZEED#G^(ALID$)46I1->*?:*=7ON=I?;@FJ&.68V%+)S
M/@"[&!_$O?0R$!7[]>B ^M%A&@11C]P2"5,0Y7=@=)Z8] [,>@I13+?P!6@C
M84C;$'0(P-O;$CRF:7DN"+7[N/>(5%$+[3LZ8?Q0FNJ&3Y8\"LNT)'CO/MQH
M,3@5O^8NV5AL.LJ2..R+6SIO)&)5Z$(OMNHL-\@$3!:M(R9-I[ 1W("GPFX1
M]D:Z2;,G#9DR"PL=*'5(;;?@.+T!(.@C7KQ;![P+#)G&421#+5E!2D]UCI3F
M3($CF)\63FY%,7I9[FC149RQV*DC,GJ:8%U1+I4=HIVGKL(@+9"I2)DH0681
MH3HP,S5 '(EAC9<H:_OR)M8NS4Y0M)^<Y?#E;##K+\0F"$/NP*K_@4EIW/3R
M"FAV3]$?\^2)F5Y-=4^.ZXI3CSNO]8!/3),&!-\K5_N%=WG"&-F!J^7%+648
MH!E6MX9!T-*3YJ3  ?6[R^&WJVP:(21X$>\RP'!O8]KPJ-\ @CK+1Q,2U/.4
M"J+<W _8%!6AA6>'%MJ:<.:["#*86$LI(_*UMVZB?$P:./'907D(LK7XTK_M
M:S$BQ<5KL%;ZQM:PS$)RO0#6;:=ZW.O=^?E._]BHQ2$XP9*7D#U-=N$./;LM
M7$=N79Q44S0;*( SX]]>OBU&IE0(1P;!!L/JL^F^..<,Y2;(:+4Y95XP24Q^
M.0PO%,X#,%%.XRZ.,Z@*N:6)-HT[<EG&5[&4H#ZB1T0,O0GV@XH=$ZJ#K!8K
M:%RU#A86+.$W8Q@OB_1X(SD'R[)<AVEN%.5T&G5P$E#>(3F@0>(MS( R*X!U
MUR2A$GD70@4%G:M;R2.'1P^4#Q-'H ][-T0K"BN!W*QV=H>'=4#*13259 /<
MY)'9Z8H[-TAVRS(24K5@M=NQN*;4$TJ4ATK0+'WC--R:;$ B8;A4#1?EZ/P]
M '(TV[-BF0';,)_A^UZ:Y9EIH,80  54)MV'UW<Y"/9(A^:T1:"%EK8<%DQJ
MMU&MUR1-N%!-8^(%IJ;*DR(=1<X,I!KS^SM$M^3J$*,S)='41"QS_!%+932,
M%T#\U3NS]:!>ZFF3!$FAS.3AV=4VF2#R*UM#T$Q) TVG/ T 41RY]T&2I\:]
M$B<OWG[\^?JB-US FX,L^'(#-^<!U@--(&59R(5)Q!O]*8#(>%FM^"QU48C3
M(""6(ZYT1YT2.)I"]OD5MRWY/L[.BT*@X(9%V%!O43AR=/1.Y)9CB<C(AM4P
MW>'0.EBML<$\,E#&+(549,%&*@K_!F9"K3IL5C%(:9R'/HD\%5=R+!='?\.R
M^"U;D2-%$U,J?5+3*G@F99'*ZI-X^@:E]KEZKJ!.E2D1$:^P4C$<]/Y4:"(K
MH=+TJEK!2\/S8MDP-97"O]M\LR&LHOP@W'9V:RE57XU\]GI2I>KK% (I__""
MO':9W,L71PPGOJC<[250=L.!0X7+_R07@)1<R91J6B3JB$;'S*G$@_UFN./E
M"0RVI):](638N+\ 3XL]<TXP3?.-/F%2&G%W)[6>*R] <L(QUPY&?8+/X3@&
M'B1I&2=DF-Y[<;$ED-6!"P30XGBL;F7[#&1I[XN/Y#U#?%>Q2J/#LCHV6215
M!C(Y."HQQ+'!2?L[NP11&9%4=@#(Y"ASRZ6&;;12!^[JZ,K9%4+4'!_V*3@S
M*UURTJ^T2E)+(!4"25[.+J)0"8H(:X$U!.XK$ZGRBST30AI, @E4Z5-9$BPB
M[?SQ6.,3HBN..HU'"(8%"2(3JLOSB.[GP&_V6)1%\!C;_(!R@,;,$E6+K?2!
M-)[<4U<8KIAP6;'Y.A)_S!'_ UZF#L]Y54B#U>N62@/=! '"FQC_@ZV[.K]]
MPUD+/L&I;?IERP;\Y,7Y[1<TI2EZP[%CS7 =I5F2JY4P2 Z_$V^AZHA.WG/H
M]%I\ %WRI'"U2F\906L',\ZX^ Q'T1/CT524W'U(5FS6GN;+%+K-L9,I,F2N
M*.\" H;!5WG L/-:8#-\7 T[[Y@/B][@S/XP42)8/!@.%3ZEFC8[,&&IV"F@
M%N^-VK1/9E.?3+ 4IR0V8JL"+_6:?1*9:;7?>79*JCR$-?Q9S;\I$[-H["FJ
MZG 59EJI39,F[.K+"L=#*YTEQ:R#*B/ GP&K$B%O5L9$O4!]S-"W^,4L@HYL
M0!QM8VDZBO%H[9K!K(0]C!CU@%Q4Z9X4^35RKX*$-_NPAB'1L,2N_KT;<(JG
MAV7U.-?@RV5F'1'HU%&:D=]P1Y6@2MY\256" >=G,:HZ=(D>[<DXDZ>45*6]
M+/):D9Q+R2K2:JQ,5=BRAT7'7#"T?Y><F:"HE,T=.[$E-E%*XO V8 W7C":N
M NT:>MEK9]Y@FMPK2)YF.GXK'&Y3,6JSB]>^E(S"DGE+T8?Q:BKI80+UGQG4
M+0571+?>8<9:_6X9[J(PFFVIW6^<7[DV.> 65%9QE@$($_=:9FL=P&V'8ZT"
MR+)5MYIM[(6H<%EE)8""[\G+%D/Q6OR4<[IOFW ^D5TBGE_9(14Y!GQ)P]OA
M"9Y9UK*OAQMAN(]+<O1808-HFV?&K+&\F%G59 [4F:*#5/Q:6@/-F$)-.>=<
M-Y^SUR&(BM5:B0N=N0*X%"JB5U0TBG>+)6TPR8PDB9>Q2B4B[K,:J5DHC'35
M*H'T0& "= 0G1=S+9;]:N%L)-@;!OD1QA63% C7>J86@;Z96&L5F*3HY]ZC=
M*]/-\JRUW2E[/2TK^UQI;+AF@0"'XPJW*./$B=L*3SH(4K]N<)U:H:EUV!<&
ML&X^I2WDH]DYIQ?[ECK5>W),#QY1U2,9264 !QF"Q-JM:EW968O8:$=8KVDG
M1"99H?.%+!\J*9MT%3"C'$106H6M%G8=4L(N64C98CQE4TT53ZZGS6B1%@;]
M?(G8G..0QT"&?,9P;_S;)2SQFA9@C=XG?\[U32[ $,^.C7<81J1A,AJZL:.?
M!"E[JS&X\HOL_1)$?E-_2BNH)3*I\U1%V92 :J"1R@""?6Q0^CJ#2V<UD<I=
MDVNVXC(PFV1T%DVGS5R:#2>$GJA;;0@18^I#YR]TFL,7T]0QOF]J_'?;!&LV
M*D&F-JR7IE5 '7I3_+A?.K8,_%=N^HM2&0XV=+$'KX!9H\C!\:<ZJ-;7.=66
M$EE*#6B^,+=,@L2C2(32CAA9Y1-(:\G]42EMC1ND_G0BQ3)#83'1RDW@^_F%
MW,=".SHD [9'0ZH50N] )CZ<+6"-1$RK1M%U9[8TR+ M8OTB_R;=)09JTY]U
M!]-I[;63UWLI37%>>+QOR?E0!PY6O=\[T*OTP*0<2K;[Y)HVI.N13@UPO:8+
ML7NH)%Z*X=P9#R?XPU0KVW_IEYIKK[M)K9A/G<5X(&9S<3(^%?.9,QA,^+S
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MZ=+^M^2@Q2ZGR(G /U;7/R[-#[NPS]42"]3SLOP+8=C/3C:[L/4)W<L<?L(
M968?,4 -WX_IO2<"QW3M C('<G,V=C?$Q1U@Z)OELM7[>'>$PM>FY#KTNSI*
MU;L(?=LNVELV[:&]UU6+_!XMLD>(VJ$KA$<[!P=_M$R/K"BD?U>/HE&.AO-.
MKNRA]&"';& 73TZK3@<-^HWRANW)#'L.*\8IY_IJ$GHM/^A5RK)5"_ZZ_$X,
M9=OVGQW,NAUQY>DXE_N5Q2V&2OV;J!_459O*ZH>E)'=%*>6R+T:+^I\H:UQS
M*Q>;?M*M+BMA?I\20,8WF6I53=TIJG2O7CO:-7F5IMD/_PM02P,$%     @
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M'@:GU:U2EUAWKV\-=)^;PAS;3W;GOP!02P,$%     @ !(*\4"+"7(-F 0
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M+GAM;%!+ 0(4 Q0    (  2"O%#,JLUA[P   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  2"O%"97)PC$ 8
M )PG   3              "  ;<"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ !(*\4(F.OKPV P  .0\  !@              ( !^ @  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  2"O%!E;,LJK0,
M (@0   8              "  60,  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  $@KQ09 &'"\\"   H"@  &               @ %'
M$   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ !(*\4 I'
M]&Q@!   _Q0  !@              ( !3!,  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    (  2"O%#U+J_)NP$  -0#   8
M  "  >(7  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  $
M@KQ0U??ST"L$   8$P  &               @ '3&0  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ !(*\4$K=3'ZU 0  T@,  !@
M         ( !-!X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   (  2"O%"X9&.KLP$  -(#   8              "  1\@  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  $@KQ0)-)?4+,!  #2 P
M&               @ $((@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ !(*\4*^80#ZU 0  T@,  !D              ( !\2,  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  $@KQ0:PO5![8!
M  #2 P  &0              @ '=)0  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    (  2"O%#)A?X9LP$  -(#   9              "
M <HG  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ !(*\
M4'66)22U 0  T@,  !D              ( !M"D  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  $@KQ0E6HPV]4!  "<!   &0
M        @ &@*P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   (  2"O%#4,O4>MP$  -(#   9              "  :PM  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ !(*\4$%(DX?& 0  -P0
M !D              ( !FB\  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  $@KQ0T3<^#M,!  "<!   &0              @ &7,0
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  2"O% W_4^3
ML@$  -(#   9              "  :$S  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ !(*\4"7R9HZU 0  U0,  !D
M ( !BC4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  $
M@KQ0$]^+<1@$  !>%0  &0              @ %V-P  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  2"O% [NTN%Z0$  )0%   9
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M970R-2YX;6Q02P$"% ,4    "  $@KQ0:$P_,E8"  !?!P  &0
M    @ ':1P  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M  2"O%"'8U2'+0(  ( &   9              "  6=*  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ !(*\4#O>1+%N @  I0@  !D
M             ( !RTP  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  $@KQ01R'M7!("   %!@  &0              @ %P3P  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  2"O%#D94!YCAL
M "J#   4              "  ;E1  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    (  2"O%#TZ$+>/0(  'P*   -              "  7EM  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ !(*\4*US24S_ @  -A0   \
M         ( !X6\  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (  2"O% B
MPER#9@$  (P2   :              "  0US  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    (  2"O%#8%3G%A0$  $L3   3
M      "  :MT  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     F "8 / H
' &%V      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781830832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Summary of Cash Equivalents and Short-term Investments (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">$ 166,940<span></span>
</td>
<td class="nump">$ 100,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(139)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">166,904<span></span>
</td>
<td class="nump">100,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentAmortizedCost', window );">Less: Cash Equivalents, Amortized Cost Basis</a></td>
<td class="num">(119,540)<span></span>
</td>
<td class="num">(51,391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedGain', window );">Less: Cash equivalents, unrealized gains</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_CashAndCashEquivalentGrossUnrealizedLoss', window );">Less: Cash equivalents, unrealized losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Less: Cash Equivalents, Estimated Fair Value</a></td>
<td class="num">(119,540)<span></span>
</td>
<td class="num">(51,388)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">18,315<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">18,315<span></span>
</td>
<td class="nump">15,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government and agency securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">86,930<span></span>
</td>
<td class="nump">37,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">87,005<span></span>
</td>
<td class="nump">37,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">171,736<span></span>
</td>
<td class="nump">87,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">171,624<span></span>
</td>
<td class="nump">87,983<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_BondsMember', window );">Corporate Bonds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">9,499<span></span>
</td>
<td class="nump">10,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">10,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=advm_CashEquivalentsAndShortTermInvestmentsMember', window );">Total Cash Equivalents and Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="nump">286,480<span></span>
</td>
<td class="nump">151,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 286,444<span></span>
</td>
<td class="nump">$ 151,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized gain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_CashAndCashEquivalentGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalent gross unrealized loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_CashAndCashEquivalentGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_BondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_BondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=advm_CashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=advm_CashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782199184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)/Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 201,167<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 522,503<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
<td class="num">$ (320,543)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</a></td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(504)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,489)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,489)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">188,143<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">523,923<span></span>
</td>
<td class="num">(754)<span></span>
</td>
<td class="num">(335,032)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">174,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">560,704<span></span>
</td>
<td class="num">(725)<span></span>
</td>
<td class="num">(385,029)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs of $332 (in shares)</a></td>
<td class="nump">10,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs of $332</a></td>
<td class="nump">$ 140,873<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">140,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued upon exercise of stock options (in shares)</a></td>
<td class="nump">1,310,000<span></span>
</td>
<td class="nump">1,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued upon exercise of stock options</a></td>
<td class="nump">$ 9,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Common stock issued upon exercise of warrants (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued upon release of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation', window );">Restricted stock surrendered for taxes</a></td>
<td class="num">$ (1,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,922)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities, net</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(22,906)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,906)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">$ 303,953<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 712,713<span></span>
</td>
<td class="num">$ (833)<span></span>
</td>
<td class="num">$ (407,935)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_StockPaidValueForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock paid value for tax withholding for share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_StockPaidValueForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6771533456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">$ 1,466<span></span>
</td>
<td class="nump">$ 2,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation</a></td>
<td class="nump">2,299<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts', window );">Accrued preclinical, clinical and process development costs</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="nump">2,636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_AccruedExpensesAndOtherCurrentLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,079<span></span>
</td>
<td class="nump">$ 11,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical clinical and development process costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_AccruedPreclinicalClinicalAndDevelopmentProcessCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782857824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Detail) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">9,932<span></span>
</td>
<td class="nump">9,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">9,072<span></span>
</td>
<td class="nump">7,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,729<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from net loss per share (in shares)</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615906800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments &#8211; Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (&#8220;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Topic 326</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8221;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#8220;other-than-temporary&#8221; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the </span></div>Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>42
<FILENAME>0001628280-20-008534-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-008534-xbrl.zip
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MT^WXV(#\=+DXT?=&'W/G?*?\&(_7(U#T<CMZ_NE@RX=_+N0:62R5UEXA1+U
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M?10"GTJ$>K0!?%I;.V+UQOII_; 6T6N'[F/+.9,2 ^&< Q%R$)"66N!H($%
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ML_[2G0N@7WKZ]..PUXO-&M4E*3A\H ?#_E2"RK.E+>!]2JSAEDE *33Q3\#
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M\DY94JM,LRSR'G!\QSM:5QY&[R].^^T)=[;MXKS"%1B?>T<S+\[,.R/>0M@
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MH_AL\=)./N[V"LU-2\.FW5*^O;3D!2F<I=#(8YAA]YJ%#(W"46Z !N<!59X
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MG&[F--4: 0^M!U0P#K32!B@I8' ..>6*;?'D(D8I<E_1E);97IA=YK%E4>U
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MKY'/^ZBQ555L>LI:DN</D28<G &[/.'@L^+@A&4>+(GHAX&5C!;;O J@+'4
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M\0GF7C7>GA#PV1#PJ@8K-CYPB3$(9?5P@CW0Q5YXW 6()'2,*!9M\$6,9,+
M9&I7OM'3=&KJX"ET%F=[=JCN!VE>Z.UCFV\R+Q1EGZ*:C[2I:M=V9 DXH*B,
MP ;#BCDA!;1R 6"/?! D:$-T4==^4<&?T[_3G%":$TJX.4US0@DWGX2;5[ZH
MQ=P*9"@0Q!E O=(@RDP K S4TLEX-)1E/:)H$VXF)[6"\T%38.*/YH+LM6KV
MA<G_N+IR#^JKB8%RG_V^GEZ[[35"R=/2._,S?I]@STW)?&[AI@\[/1_?Y-R[
M[(]B_/Z9'>B\DT4#J:U[1WZ\#X&WPUZY>]D;>_13.A7R5D[[=0NS=BG0[4MY
M[ER*_W,4>S(]'VQZ[DRZ[ $):3G5P$KIH^DI Y!4$>"1<$P&Q!GB"RN,5L+L
MG+7ICUGVR*<4]U[7YTYH]QIH=^5H!XJ48 $"ZA %E$$.I&8$*,25DXP1Y5"Y
M55Y5MMR<-<2;'UM\]G,K/W5[\6&=+$)5SW?L63;HQ7NVRIWC,NT.A_U!JNL\
MW?9W&3*YMO_?*. [%OW'L>0;A>!'[5SMN,:5&JQ>:D%TW#9#0Y]^[?;* X-!
M+S?#DNP:W:\ZWF:0B.U!Q+8[:<9387'@@0 LM %4>0A,P %0B*S!7C-55$1]
M:3-^3K.84B9GY>#S+<WX!)J5!LTK;P!:K9$0#BC-/:"$8* <44!#8Q#Q&H4@
M%E8H3OF?R1U(V7._$OC'GR;57M97?K:-B*K5C?\Y%5/YE2/[RB<8WF(,7%![
MXN\'\;>]MHB-6<*P]""H8ADULA(81!6 D'&L@L16L+($!435F+^8J[295YW<
M2/22Z*4*]/(F>9B)7IZ17B8FBS3R%$H'M$"17A1'0&O- 5,<4D@T))".LC)I
MHI?D.E9Q)FD*7,>+A5?9L>]E_:;N^>R__B$QPN\SH_NY'6T3FK>& ^]>-N+R
M?!F*U>KA9Z7]1U<(_46_32/O?_6][4)9G]>]Q'?.Q*WK7B?V5?_BN1^*L5%L
M*S@:&9<\#Q//WX/G#R;=2".\-\$+$(R&@%),@<08@L"TL!HCHRA<6(%+M^PE
M^!:S9X\86M7#I&K.K24^27Q2+3YYHC^9^.35^.3*;]16F$@:&B@H(I\HQ8 Q
M0@,7!*4,"B-<*/@$_YQGF/@DN8T5GG%T^8^+)I6WS3O.=P;+0$U<4-Y!_:P@
M]Q3E=?G?6VU^HWZMO.-!<_0=P9(9OI??O ,Z]H@^\,7"P'8$Y=(%[6?#OG?9
MH%LN%XR 6)2.O.FF@E\XJ+&G*K06_I8!/3XZ?M[#E]U5CEWO)->10-]PCZD+
M35L=*5I]V#:^MQE*VMT<#OJ#J$"Q8^]BX!2YO0\#'TUZ=$Q'(PD;"QPKMJ+B
M+G(QEPI(;;%1BDK'Z,***&K3O\:N*F\R;J>>J6=Y<52"Z-]#]&M6V$P0_3H0
M?>4D>2JI#]$U0LIP0)TCP(@(T<AP0[SBEC*\L,+)(L*O48,X0?2,.5/ORBSI
M"TO\IN,RDJ:-SHOOO6_KWD'>&<V7XBHX+N6#E_-!;*7]M2N#2XS?]C[3MO!4
M=.<L*E;6Z0[B TOOI?#0"E<F?BHG@G7$K2SD'=VQN6[%=XP_%*GF_>NNRT2'
M'7?[>3'JEGN^56Z2_OXD=X/FR(\:-X3B)<%^\A$OK]0F/CLBYOOQF("3M[C%
MK[R/>%;^,KUW*W>V^I?W(560\J]E2F^XDA-_B[<LZ89;&T&4<NXQI<A9 X6A
MRE"K)"2:NWW,%BXN:O:N\/'  ]/S^@CH$#MF6;=.]%E_X=VU_KLAV)_D]=3>
M"^'E>J^4?63Z;J]<3[$<#8T(R,5I1>/U]#4Z:_8*D^@?OY>X6%AIE/5/NB'[
M6%A3Y<C6*[=ITR]'2U6&A[A]>*RZR,S#=O8ACU!GFYWXW(/<]Q>SC8Y=>@ H
M5/PU/U[B]\=)_-Z^1.U"SMN#KCUJ=EM17?IEZH1XGZW_>Y@/SJ:I(QY*>G]L
M=+)!LSN,MW7]/V?Z37<Z>NCR*/B[7W-,;F-^Y2-^&U="NG9&Z2OJX:![P8<C
M([3\96RXQE=MZ>.^7[[X\)/'/1G\+5[KP@S+.V7SR^=>4<82'-/&., ];M#X
M^-+HV TC?G00RR5)Q=W'?WGQ+P_*)2[P(Z^%2^A7!QEY[+6IQ6_<8A0O)72J
MFCQ]G1Q;+.][[6_FQ>Z)W2\:,%1/"AC^ML%CTGK^9$]YBP7R"LL$BRFVTF!Y
M_?!"KWMR,\9;!06ZO65)F7ZG3*NQ=86GI%O95YT[L-$I(P(?]7%A6OU*O9(B
MS)8B6#ML#UNE9U367ACIP>2BF/*7/XKJ:7^^&RV02?HQC_I1ZL&:#[G-[ZY+
ME31@UC2@T8V,<"U.\M^E)MR(DDR)Q?FTO+"G2?XI&VQ43BW*Z=V[ZT._D-2?
MH0N32KP85[3C2;^DADI/?4[3J5.2\UH=W?R@6[IC?:8'V9JWODA1R0A:S(KL
ME]G>MNYF;U<O64D:39R!P0MK*41":F*E,IH+X1UV:G^CD!+"UW.4-NJ?'I"D
M-**KB72DJN0?G=4O\H\./^1[G_?B]7OY7J/>K#6V\EI\SFY\ZEZ\;N]PK[E[
M7H-UO'N5?W2X<[;9V#FO?]X[VON\<UH_W&KMMN.QQB[=;6PUZ]__/JR=?R/U
MM8/SF_E']<8&JS=J<*^]=;376,?USW_'YW]JU@^;S?KG=;3WO79>7[-P<ZT>
M:ODX]V@;GNP+@CE$!@.N*0/4,@LT]@YP 7%4>4T0=PLK7"P2_/.&2Q7*/GK2
M^OZW&%75S/Y\-<IYINHQ;R&YZ2\>4RD6^;ETS.,HY.?RHY-N[LC!33SQ,)XX
MO^0)C!!E3@;@B5" ZL@3*@@&#,3.<\JB'I.%E4JO(4@4D2@B4<1L4(2V 6MC
MK4624&N0<5H;!)UT'B.KX=T4<7\G([''$]D#7;('A#18SS@@FAM I?5 48F!
MBY+3$D'$C5I881PN"OAS!;'$(8E#$H=44^&KQB$/JH L$0\$8@9YH$H@$P*Q
M#&*HI CA5R1R1RF11!E/I0QR21E."\ET<,#HZ&90SSDPF$I A!5(($TP,]'A
MN&5-W P4G$Q,D9@B,45UF((+[ZSG'F+)J=94&FVH0Q9Q+X5 [!Y,D?R.5R,1
M=D4B A+)! 0>4@6*\B9 "84 TRA(([AP."RLQ%,6X2W3&XE($I$D(JF<PE>-
M2![ (X)ZPI3BP2E"C8+QO83EU'E))69(I[!5!>CC=*)^$D)62>0EP$1;0)GF
M0,KXB3OA@J%$!D865I"@BXJER8\79I&*E91_^.;$;]&/)1Y$)WI4^J)][#O]
MT;[$_K3X?'?Z_^OLJGD_+J\:Y(_K\K_9[H<W>JVBJE?-TM9)P9.")P6?=P5_
MB-%., I:0L^XIMPIR8N8#^1!!4H%E<]9(?5JQ^-^HWNUKK-8UKG1&2_H++-?
M2T+_.,'G6SX:^_U\X+=][T=N_=?8.UVWY6WWH%/>Y6_=&OKD"SS$%SB;F,*.
M#IK'UEL M=8@"MX#):P  5G!.2/".[.P0A8I?(T\V02C"4:K(;ID)R0%3PJ>
M%#PI^'0J^.ON&)X,X2DUA">#XMQ8YIC50"AM $7. 8T@!!1S&Y##$"&63.$J
M1[U?=D><ZQ>\82'IVR1XRP8X&_W^L%Q/W V7>]\44?/%<J^;^&-^<8+M]D>5
M1O_S=6'S.C9^U6<E,&Z&,KA_T?R/1>,2KCT U^H?X<G8P8_/V#V)]VKY?VV=
M[7UWQP93OGMNBSXYVEO;.=\]/,#UM8VSS;7F8?U\]Z2^5CNI?:^Q>CL^X_NG
M4%\[@O7S^/Z'M;-Z8Q755_>AIH%1&8!D# &JD022%'MJ*J89%MQ!I"-.$OP3
M2E9I]Z19L6=>8O>C!RY;OQBMWJT->[$+1Z;):#5[[(3R4!K!#QS!IU<CV+)]
M3#5S"DM@??Q#C:- 4Q8 MUXPBY@@"BVL(+BH*KB;QO09)X]/['H"Y%2N8ZK4
ME OI5*$*RJQ0Q\\VG;5:F4 YQ,10C)@)4/,(+S!0+#EW#[;I[N"&TE=-U/!(
M:CB_1@V"*4H4%\!#Z:(Y)A'0#B-@F*0&>Z,9MY$:$BLD5DBLD%BAXID"B3!>
M@##0=5_"&@$=$H $1$'T(C@P$C,@$);!,(,"IY$P*%R4XF<?/M%&HHU$&W-+
M&R\V<9Q0(*% 0H&$ @D%$@HD%)@*%*AHCDUR(5]B.NHR4::Q2S:_[4<74DA"
M-;"&:4"]"=&)I#Q^=0(S19$1Z,*)),F)K&2ZS OD*-[<F'6\ARA0$Q>4=\!P
MM,RTVBDT'R?29LIT&>^RX7&YRM3W;-XO<VM&1[O'A6;W7S;%83Y3-F]-<7CB
M5-4SICB4!S='XE\?ZX5+_/*X=(>3?>)D%!87  OL(K- "11V GAD#<0>$0>+
M\.0B03"E8:9\]CD!Q[1@(RGX3"OX%,Y')N)_QKG)DWW+J6*&"B"I"H :HX%Q
ME@(<K3NFG-0JD(45M<A9(OZ$B_."BXGXDX(G!4\*GA1\6A5\"J=)DF7[K%,F
MJ_M>.LF+LO^$80^HI0Y(A3A 6 02*$*2\V3;5GFRY&77%L_-9,F)[O5T9_#"
M\R2O-NV.8)4(Y<76@HZ80[L?[=$FQ1]N5J=8+:1ZX(OUVQ_.KDX9+^E>C5)W
MHZK-&YW^H#<<K?,>-'VOT=2=FT2ST1E142*<AQ#.U?;'9_%]SO9#D=Y-, *,
MR:*RF^% :17_6$XH(B%X8:JXM>4#Z.9-1M]O+''\6EE=U8.EVU5FUO5AZE/'
MWF@435L&:0*;*G5, IL$-@EL$M@DL$E@4ZU>2V"3P":!30*;!#95ZJ8J[MTX
M=2H^4^D!:<506C'TBI-@/=_R>C0'UO/]02^W ^_&YQ43.&GET#2M''K \J"M
M2VF7IY5S874_V R?NKW@\\&PEU:C/FRF:_OZ:B&J".1 6ZH!Y1@!J8D @EJ/
MM?,,>;:P$G]/:14IX6Q.X#!E5"8%3PJ>%#PI>%+PI.!)P9.")P5/"IX4?"H4
MO&*Y^V@4=*QX/V[=C"CVA[V>[SC?B[^$;B\;Z%/?G_HIMK?HVC_>/+A8/J;8
M(?)3M]?0I]_S0;/9;15=%G^X/1T_Q1,?ESE_LJ\$#LA+ 5#PQ4(M(8 F1@)B
M#)>0\2"]6EA![.==EOY,DU-I]G76T"_-OB8%GVD%OYO>WZ;NT&B-76'#%8Q?
M+L9.M/]2M']5>\A!:96"#BAK2*1]K8'"'@(D/3=6(DVH*XH.*OSS1&(B_H2+
M,X>+B?B3@B<%3PJ>%'Q:%?PAENUKU!U*ENUK!K0F:@]![HD5H2BIZ8N"VH$
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M&<2]5\A))9&)7$EB/0XB%5IOHG-YX_.H#^.H\BJ7%.DF*2B;'@<J0?0BX$7
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M]XN*O@05_>U<78:D))6*>:2)3*"@IX2,"!(1%67D)')!W=:NP'RY8<,"@ 4
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MG+<7G+,Y;_^/=ST[!O4ZAG]>?ZD[8C7?NJ$G&J><?+\?R$YK8NP<CKMP#_\
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MEBAOO2G>T(9C_]F<-]0FHB41&NG(.>)&,N24\DASKSR0NV<B;NW"2&\K)E<
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ML=WO/6M!N^(@GU85G/D:.RWR['%4R7MS?6E-:4UIS<^VIF'+W9J/K[=4[3H
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MR!A&4PQ:&Q*W=FD!SP*>!3P?*E7XL=&S>,+O@YZ',_TS>!HDY0&QP"7B6EI
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MA;B,%EFF<@YOY('D3#7' +?5*E8@;[P3H@$>Y@)P#PQPF"0AN256J\#S*JR
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MIGFVCQ(N]X(P];GO)2SPXIRQT$\\)TL].T[SU/47\TF/^=SX=UG7QHQ7!AW
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MC[/4],(L-R//#LS,<\(@SP,GR.QG+VUK!#=S2?/0BN-J]P$IR@Y?U/V+P.9
MYC/@)40U/UW58D IEHOU4$#@^-AH#7B?YP1QXH9.#  ^]+TT<]SL[\-5).,L
M407#$JQ$&^]P.MW;?E@Z^-/YVT]]BR=69N8NLX 84@P'2!TSRS++3IEC.PG'
MF+6]<#F:MZL$.B*VU&,1*:O/M$K!-R* ^V4:IG\+GO&N*D'YS6JT>B!_8-,4
MJ.4543+13$LFP0]&)H!*+OYVXB@),]<Q'88M(J(H,YF=Q*;E1*[/N9?8 ; +
M:V^Y Z(!0F@,/^RM -[KP,6LK M\XI<*@4IQKA5@_:\74K)[#I"D0!ZKOLF2
MNL2ZM2^DP</2A^A_9[E*W!K,ODX]N,DX[N:#)-OJ+TW_]RVTH*#5@LZJSAIU
MRLVDXNR+R7+8F5_8^()=UL_^V=O A9-=.K#OW;X\?[CMH\,'WE)61-N_B.KI
M^!A.GFW?I(VS"IGP/VYPXL]>GE!U9F#OKY!_3[%X!'NYBIH6KXLLO&S:5J39
M((11@OZT9>KSX9Q/#&=/&!B/V!3H'K%_"XU0R6WJ&@6?0.QL?%D7A*3>%%,0
M.EC^'S8Q(RY&S[SG=3.>TR-O0>"R?B&^3=?+Z,6_%'/@B^G5!&G[JM1Y@<RS
MF!AYNR/U'"#%A(J<]SL"P-;]#MH9/ ^:SGL^*ZNY ?OV!L2^85OF[[2#]-@#
M'@9@(*IKGG #6!S-#.3<YV8J$ [I?8B35ZX'1YV6<]A4>*3BH(,I#>^2LPH+
MN,-:#WA*BJ*@*U6.=B17AZ\5"OT#+G)$V(S!B=$"RZ9"?;.!+R]O^_^1RIH7
M8RPRKU;_Y]X?H*RV;B9ZT^NO  ^GIZ1"3 HQR^=_O'[U,XY&M7?%BFU'5&#>
M,T C1R9!<X6]@I.=EQ5:/F%2 NS!)R-QY%E_Z4PM72Z$=.D+T+C-<5E^*:@;
M1GLL.&W9<V+"&?J]<#M@^CB^F)03[BL-2%O6?CK'O]JQZ](N ,JD(WS>?^9G
M<7C] >W7*P9L]Z@;V>N/K!IP: \J[7[/@ M5\ZM6BH7\ZR;Y+#N15$7]11P.
MT"^O<*-P&J->*?\2AI2[V_7FJ,5:C'DQQX.7LWH/XQEO  R653V2TX)'YS@E
MH SX+EJAC,-#^H(-'[[%BP 'K1TGLE5)"?MPS<;E!<V0CVM^@;>F90:5H,7Y
M&:B=*5U*T8< WH^D6DG*AG5F19[#:^ -P&O8&-@'-4#0"$H]3)K-O$B+&=TQ
M^6<BQ1E#LWLS9M7(N,!N"_!.ZB-S63:TF?R\ %9)5Q3W(:=]:*\K/($?%: ^
MB[.E]@ME54[9>5$U-8P/)SPITH4]/5EX3%' J[=_'1Z8=MRV86F_#TJ8? V,
M@G<WP38Q'+LY$%!/Y86DGA'4A(&N?S&O.U-C.\]I;X11MU&Y46K\ L?K6%[:
MLI@+4 A 39M1;XJID3?S!DXPX^=PKC.BR9&T0Z5L"JP1^>JLXAE5J-J3:[NS
MD3Z^SD@?;8+8O!IEO#WG%1+6UJ" JQ6/_0S6TTRP00\S4GB /%G HN BG?(I
M)\G(9I?40@D-KW-8'I\C*VJF$V E$R0.H+$I:O DG>A.$@56R-^ 5W%6<[BT
M'UI*ZP\]J\JL >).L7]*QE >9[P&74Y<4_CXO,C@NW"]$>K"'8$WII?8S DP
M;),24VUJ*2#Y5^RR4LL.*DR^A3=PT7"H.2^FV(>IPEN,II(92XJQ8/<2WP F
M@%D:YYP8!O):^+VZ'.%-4%M$ZVM_T2X0?0#GCU7 07ZQ:8.,ATRAU%T=F%;-
M1T8]XVF!ZQA3IR4R<-#J9F@,J6M]2)0X-;M<^!.^OZDJ?.5O94GX0WO5NY:U
M* :5_G;4]8CZ#W#D8GY)#*8JQWL[0LUXK&.$@4LD9>P?_'5D6HXC*!W[=(T)
M[5; Q[%9U[C=J,._3MI]*J:?I63M46QW"52OKSF=/78L.P/9 *16X>?43TR0
MOY"+0)FS<DID3=UWSEDMK@LPY!+&&B.[AAV] /$L!9::%CW_U^O?WK23D[/1
MX<$%W$C4]Y64FS Q?,9Q_D(\M"/BP_M'![W&85G!$HY717V3@Q!C[5<.CEYW
M\*;=4KA;8SBFFJS-Y:PJ^!R]-O("P16KBVQD[.__M1=.(@"SK*HN<;9HM,S'
M!8#KE,\0-(B^:/P_#4ASKC5!DV0J+K3^"NVRIW!)^'S.]_I'G4W@CM;"683
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M.V(Y!TE)8^$&=MQENN9J7IR5HL\:L$XX>CQ.H;O,L!'C.2?LKR0 <8;VA/9
M(Y-#PO!B%;B\]@&3,$2!5"V]U4CF!8 -H&ID.45%_>2N8#[X:L5019-&G:?
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M@/^4TQ>E^.*, $I)=(H*.3E/@>%VUGNT ]:U<+"B;::U?@CCW BE.#HD6=K
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M1B>Y%3& ;3B'BL?8$1I%[6QEK,?:4(_6^D\R!X3^_*R6(6UZ9W7'$D9(#/9
ME$!.:7'K-66;4DWDCK:1+7N&\;\@2\Y1-:,8NP8QR5?$8/U\IJ5ORCB4 N0)
MOJFLR DC?Y.A+G,*GH*[PUH57X:K('.;?IF6%U,4/B2)"3RT%^;* !=IJZK0
MORA#6Q! PF*D*T&HDC 1V+," Y+(4TG7B)TJO;HUJ%%T&R$.>D[$.I%=OL2-
MP#,1"ZIER)%:%+SPW9B #6!=]'.*@*05H5M=Y%;:GFS>5!2JI<7923^4""(#
M%I9+SL DX;0I0TOGN#VW?VU(ZS7\8+J-\;LW=7RAG5(X@'03!])EEE62,)>I
M<1TUJ!BSCL4 I2+[*=%8A7BD%3\4F]@B X%_ZV+.9< JAJ @[7%B-V5URJ;%
M-SVBE1[H2Z>%IW 5)1$Z[&O[7L'T, !P2H*R0E";DCD).,5G&*G&:TWL4<0H
MHE!%7QCA*?Z5IU1XQ: <??A+?<;'('--./W9&*^-^N"T*1"ET=>ZN=0%'"BK
MY%,R!D#T<92F^KE@M'U/&\AFBE&6.Z_T&@*9"1KE9\V<[$XT!>"ZI^C?GB+7
M0I[2S,]*$9>Z>\[;R:28:U&9@(/&:%_7-+&<B))/9N/RDG<1DX!L:6HJJCDK
M%8=&\L#Q:HQ8%4$DDPEFO%UJYZ"HGYP>DR(S2302 H1[,J8P770<&]-&)0LS
M%<+1P?+V4:$E@P;[Q41+KGD&RB-</6!6PNS:3?^"XG@_EPEJD21\I?,6ISJ1
M/@=T%\_Y"#T)0@,GSC_F7PNT>.!KC#H]XUDSYB(45) @P7X3KF\-5WG"*5!)
MTB_ZB.@!,;32J0OAYBBGX\O.^(TRU4R1XO!V4V # D>$R2UO(#5:#=&YI90'
M&;9.*3?P3<6 VKEI.%:YFD4(894)@:B\)5_X9<=(Z)BU@#MI2T8;P A-&AB%
MW*&6]FR8,E8TLXQ8A=P"PL,9H 0Q_P2N.Q>:<LV5@:+N+G\M5DA' H,TM'&X
MJ9AY.3(2N,)XFM(;AW_2XWJ)59" 5EQV:M(L-$ W(R?M(NAZUX&N'T%<OU)2
MY02ERJ[(;#3DH4<#374+H>?KY?#TM%0"'3V$=*EZ,K<6B%C=-.*:75*!2$S8
M4^@6N0:9$L9 9G#=R;=!6N@*.4ZT+5"P !3 I">SN2#Y:8'F+9I\ARZFF(&,
MHG4!9O#S<GR.[VW7639S,LKC.J7!4C+[4?N[,'"*@-<N%GZF;''J1G?VSC$R
M]DOYO2Y;IET;VMH(M:#AI(1S)XOEN$ N,Q)^5AD:*^4]"&#TXPH;'<KUTXI,
MD,8!* !X<06?@/N-7MG6"==,D6T@^B9%B!-LN$(56J5YR8/H]L @2RWR,[5P
M6IL, D:OWB)YR.7^$ #_#^#\L'>OSM0=Z 5$[P@#^7"&P0474LRBH+GD<T.+
M"=,I"1%FU<S:H"^DEEKL4MKN4A]^WT1=)"+OTD,ZZV6KC%=<:>+JTFHN<$6O
MO9RQ"UWPPC@*P!&^EY>X-_4.-+/%=Q'H0P,;"N>>>I2)15YKS%!+$CN )134
M5.BU,_29@,3_QD7L)F(!H7U,,*4 M@^FJ[)ZT,R6(NC$68D5D$==V6/1_,HN
MVEPH<5!2X\&,"X1F?'K*3K5D+V)&R/=:MMMZ#BAEZIRE:3%E7>"I6FV;W$/I
M6?*<,?M 3(R2/Q7%=&BN;E#S(X9,4Y=/X\ Z UH02B^,L]8XU"$D@YUB^M]<
M66:Z)8">Q2Y%6(7<&O&>EJ=J]N@>WNZ<02U:(^A(NJ\\0,)<.F2O*<FO_W5Z
MGU(D^O>B/45$H4!::B,G[%+;1FTLO)+3^DI5;8@9>)*8 ><^*BU$SE!I80@T
MN%V@P39D-W9IZ2K/<7M,3;>%CG\T$UC"Y=:L[V;>:D1E,M<+5262%.>R)%2.
MIC RY*"XPL@&$7"H&1_J@@*'*180W?LR-8JB-8#RM;H RGTT$G!45*E+TV;2
MB-2SC"-H(!CYDV>%>W%;C0B!!<I'H9_">PC<)?6<"22@9*=,I4S16X)"&,,N
M>;TT9>4<*E$V<[JC$ER06[3#A=)OL]J*U&IPRN9$$'0Y,W5^!H=^>G:C7-"1
MAB)X7RN[[!#?", (_X+ARKAS: RC@)YSBH 4"1XSX4*NQ%$4,IOI' ,?9Z)X
MEC U3R:\PMLK#>BMTH\.KZD,Y1:YO1CILY"TBEAFBH -47W=I&CLRQNTUZE'
MA8&^]Y[6VKJT4[L2'="J7+@_?4>DNF=8:X CA<DX_W.&^8D$T:4JH$-/&4]B
MY!S_#E/F]1SC@Z0;835YSMBEJL&"!#WE6GT3$<UUBOG-4D\Y*V;2X-OB:TH/
MTF;9@FPVQM@I(*EI:V5?0?9$12W18? *KOMB)=/!D=:_:V?H0M=(Y"[T#./M
M?>]=F07%0H:$%,K!A,8F9=A1WU]0T3N3?5\K4AXUJC(Q%ZZ4HI+F,M1$NK Y
MJ55A#!,]8\ZH&NTU3KNNUL7[M[4>R$0)O?32WKP7&0R\4?HZA E=TI[^CATB
MCJLDW()@(X$'9T.ZZWIQIB(Z%O>UTZ&7),#Z&TVR@>PFE+C:FUVGQN:PHUT8
MF9J(-&50Y:'.4[Q F[UTEWL1INO$Y'=+R?V,_Z=!?J:62Z)0F+?8.2M$908*
M^D,+%J <0$;B;[R:P,W%=\[Q[NX9AWEG U9?JUA14ZD)!*?T-#)0V,1R]7 7
M9WQ*QX)3%T^CK4P_F,X=3BDR&M]?/!W=-)VJ6EGPI[1-<F<4!$LY[.BC5)ZK
MJ_$2[.AIQ29D;[J* .7K=^5B[U\+@W]RXG#/UK++"7N/! )''R\EI4M?8(W)
M7")Y4.3>D)!?<$0":5TLF^)H/*2,!OT4.AR&/\*,G!VV^K\7Z&)':.KD=FA*
MY) )2X3&5S6#;?=E]47%:-5U'BTP$!$;(' IM?\^U6JQK0"8(EU,);L"P;50
M6'%Y]68<.>&D:U)NI&!T(D*O-IJ9]')J0W6JQ[BM>2.D@L9<UHF4/>-7WJ;K
M45D&K*9? N->4UP-@_?*M.B2.M68/=&SQ-)EY""]@E$S)F+4R#HI<6%A&_:,
MU_!?E$DJ2T^.LUJ%6'?$(^$((=BDR2B-*^A#"IV_KRVC(M)6^*I;O2;1U]93
MF/5(TWGK81SCYM3R<#5IHL1(/WYLEQF1)AX/-/'X6MHP=H1%O>K*:[">BU'1
M?GY%?$YMH*< 4["E$[(M@#<I 7[L&>_7&F64)6A6%;!A!?FH1#"\""&:\G%;
MZR@M:[PA5/K>3,C=B"XT&$ B$3G8J!<_+WT^%%^ ?ASR]HB1,)2Y$F!K42]:
M-U%=SV\G3_@?LYQ$0:.V*X7DKJA-C62$6CT7(688"@9CC'3+RPJOU%J+DHI=
MP(0";7+ 6L\0F5?$U!",B.D#.P8$7DAG;('!"P3;B5O.;Y,DL 6T+'6SJ2B+
ML/H\B0(,UIV=K%Z7RWH):@"EW[3F&50_3LLR(UR,KD*JP28BMDEW6OO*ONZ$
MY"#&H1IZ(E,(-?NJ5W2V?0,^!5<"U028[ Z=5"VCI70549![3U&4L3+JRB6]
MA'NU2>T&]?JNJ-LMKV-[0.BF!IV\R[+ BZK*FQ([[-("EN>G_,B+H5JJ@B<_
M8^-<U-I(TZH1/FF:IS0,7FB+ISP.3'&@?$UQM:44;Q>G$@^[1:JBHB2LD:\(
M74P&EPJC@X@JX Q&$F,+Z[S^8L'B-3:FP*0,J$TE/)!E993)Z;)=CRS@*".E
M22>5XXN:7;A^GFEF?_HSS2EA8[I?]1GG<X&2J9J-.EXMB$33U-F\W3%2R&D5
M(C.C0V@4MR;VBLEB*>U>RENVN'%DU]6*-*AET&'1_K/L,U:+$2^$95%\;%I6
M*!#&E[MR+_>UK!L]&@CM627"R,L^!4T9LKY1N_F5WJN$.*V*$A3& JGS2H+N
MPHZ%]0;CW_B2(:R\QH)-U9AUM\:B%6VE[8RMR)N$A6,:+BRR521&Z\N!XA[)
M! *BN*I,E*Z#%"?F,UJ6!BMG)#8+IK*NA+(P.EX'NX?(DR>)/'&':A5#$,GW
M!I%LI9K\&YDDA*%>+W)YSG=-4=97ROHKO4]EECP:N:A\BVX:U9UP#$)UK.NR
M(%D BPIY,F=?6X@SNG?U4$^0.Y6[T'F&VL4C3J"'+M GHG<4N5:Y%D;'TQOL
ML'#5DW^-2K&I8%-"N-+;W2:;R8QEQ-OCSF,GOENV1;%DJA$BSHK!&YMTT176
M)2C<2,?[?L>='O L,S]YOQ0M'6A__DO=4?0<$Z0;1.K]*10S0C"Z67-A.EV/
MAG;K-#ROM5P@8AP),I4!#ZT[KTT!&^GU#$1:N,P_$2FHE4:"0)B3HIFH6"%<
MJ6KR0$H)W:,=-D"JAAUH8!_!>^8[PD?%N@JY+@Q8Z[@F4:G4&BAD'0Y=Q;-)
M]?H6SC:\%##P%RX\$W7;_64%U=PP.-C?@3X7KU3BYS[HKXT(M7^'F:R*>?VA
M68'_U62G74NEUTJ[WQ5:;"IIY>EU=UK7X@B+OZ^HQR'#NU95\&@M&JT[K)D2
MIR2ICVW:A/R?@LY5B.355?VL5%*"EE N@B)(O H[!#%-XOM4?_RW_?UW0C,6
MC[:,7Z1-W.+E*G^Y5BFQ[ O7[#RX^L\ME8@2')03*\V9,FE7V9I0]<9R_FBL
M+]HR-2/E):MU(RSB MQ>S*458@PVLY 6-"46B2DHDF8=2<]TDFZG*QSP"@!H
MUJJIWJ2H2[L2PFE*!B+T-0H4!"MH)BK]2GKQ6Z]^*5N6"8,)5Q$V:5&E(,[F
M>$[29* 1C3A?B@6A;@.X3A+TL-NXFFZ'64(Q8#BBZK: 6\&UK95.WZ[]25L8
M1=IR,F2V;(84!'=<.!)%_0,1U+B'W:[TUDX(NZ1A0MG(:IT(A/]#/$%P2-L@
M8?"0ET58:RJ]-L*T;(T=,J6US6F[\ESE1*AK%J_AT>0F3=2,Y[W/?E[14^V/
MUZ_6=4K;$;YW<E5-'U%85N^$I>I9/'^FTLV>_7RKBC\WZ&RUKMK12K_;DL-L
ML5A)6[KC"B?0Z%8EA18-@[T"1:MRP6Z(**(=0!0[VDQS'7ZB2IA%W15F.J%"
M7$<E%>)ZO:H0%Q(@-I>\;E.DS57NB\2MO2>HBRMKYJ6RD5+=0O&7A,IKF!0
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M 9[C)8:CK7G:B!N=\9P+PQX9_Z>@F:7B-Z !ABH?('16R(!?Y:2?\S%&-S4
MVV$T4.@ ]E.6SD -&S'5ZR%Z@29/ <0[V^."=Z#G5*DOZSF?#.>[$5-=?[Z:
MY?L,C2[:Z;;!AL,9;L)4;W2&%)XOHAAT'T'G 4)S\;A(^;26=N(E56RE?XA<
MDV?*24._M=;%ND%U77MZH)=-F.IZ"0^G!,J8!&\4&DS.WSE/SZ8P-_1S:620
MG0,?X KY:2:9^@42PFZ>M>UOS5GC5*\XZSRGL'(X:?SUU=N_#@],.S;0X,8G
M1:J\H\K7.=(=1EU@E A.6.%"'7*=-H4.9*Z3/^0Z#;E.WYGKM 4>_,.<(B<
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M, GC+E7ION?,[V$#MX<@^F7"=H%@[+A',%O +1Y8_CPLJ5]I#7@B-+N*\%:
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MJ32,JYY15O@SV:AV#*33JIBRP@=Z-O#=5!%&9#X*XPM^F9Z0K0W@04#H0"2
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M>_0&S4^=-LBEEDL&1AXO*.G-",-;H%O-^52LX:H;RRW-B!:BLP,(!Y+*]DD
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M_)'$.4S+=];%Y0G%XLTU4OK/IZP[DP%-4C879&2!J$-A:,E%#QX$+1,QC\=
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MS-67ECU_("#Q-Z0 %L]X/+C,R<'\B$EJ6#=1-Y ^%3^2@/*J_V""#(UY?]H
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MUJFV&7$4?V66U\L?XMCX::A*[N2E'^:2B):[=$=N7WN@7'R?:&6VCDYR,OD
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MKF">T'SF]!5HK]9AW[>(-#C9WE>7#?.RQD%@%W)XZ&"[JK5"9%:TN>60$7L
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MC$$AR:,7PI:&&\(NLW\MM[LOK ME\59SWDH>]\)QQ]GW('Q>5VW72R\E#?M
M-@_^3QVR_+S4<.GC<9:O[HC\AU['J^!<HY +E$=\M6W %'6R$:Y:XO60\4GZ
M9LF@I[([[$?8B$P%3J'GVU!*X@<B*EV\BS:E0QWK=1NB2:W2;5O&%X 8[B'/
MY:*;=%O$AV#:DGF?$ZY+UP_]QV;6D=&++4Z/+MNAX3U$#(UP?G'<RTTH ?#
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M6F?!($\H9YXZB1_YB@\9CT!<(I>$)H:-H+8#5*H]D.8\K?;'M=I&VJ_,B52
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MC;(0AX)!9C;VE(@"(T&1CHIM\;NV&9?47GG!XB/KICYK091MK0U9E.BXP3"
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M<HR)<5N075AS&,4Z$9R%!BCGB/,ZK]<2D?-,0 +8RL&X@9-AHKU.(AW*+:A
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M8?_ZOY[^X3/BZER\^I\_O[J@IYIL?%K=3#B3;J/LEH,:=G;1#:ZS[#^1_&P
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M19&%O[52F)JK=6BWU*#)>0ZAREYG '\QW!!JK')R)6LC5GA(!RN['W% 0J!
MZ)',]2.8SE0F[2TO+'6ZQJ$2??'H[T9XI'@EMZS52%':>E-=\FSALWVH:G,0
M1=R7@SEIYXIAQDI88A>OXL$J*4V%F+ G!]BU&I V#3LA/B](GWKP+G/C@S<B
M BSJKCMZSJFU,F@"(YWR$]>TV1B+W^JP2XN QIQYF\.0+L$ZWJ[A:J_8X2=?
M2F?_,$1X)DRA=K\'X'X?71KN5ZH><T* 9EQH,55;6I;J/1C,?B8MBAL)'FPI
M",+'W8 @?>CZ<KW.&-\&0APQ#"D-N+@-@ [8]SBT"'-X4M^A0Q7X%L2Y$5C#
M6I&O*GGT(+$,[;'$[W/KMVNCP:]VF+"Y"9Z?/UI!CK%(.Y=CK!MI.G%14+Y:
M]CC<E8.GR4%%?2%;DW'SU>AU5*R,R7M<:E)P"(5N*$HB-#UWUTH'?5)!^[5[
M:$Y.1KYT.*<E5Z5L;#E4AP ZA1_+A$Q;M,I(U:&GY1[RHO6@L6$:KZ&E!?RM
MEQ&+P7#;W+ITPJU24M)!CU_&7H8TWALS"+=O@(:#]]8P)C8[X?=''\IM(6=^
MP"HIO(DD)"=A-WV%2! U>T@M]15KWDDHC7+=W/LF^U*UR9"5G8AV'!5GQ %X
M#ME/FHFTQR8:N+'9,W.>]F%&BJ8)!I-'Z08=W/'[IC9SN07R>4 *,=&G+TVK
MLI?GJIEOXVI\!0%$:%(#X+NX:.$[<:\1-9K>D;)%ZN>'5PAKL* <'1(@^Q:8
M^%8TZ#WUU90!8/5MY  6=Z%LNSF#<- <I2.=GDL%0)9HZ:X':5(JNE8*MAOH
M/"Z9B:6R3#I?;$.MOK *XG-2E=&;C,R*N.\:%'_B=^"X)FNU+'=5KPN6_VV5
MV-G\FPB9U-%@#RYL,D0)2)IU?4^!L$01/.?)%W"=>-'I!T^_6,0S$D@J@I4\
MY<K>D&<E"^1\+8E>]!=DDH/)*&[B_.!WZ7';4-8Y3 KC8P=8A)CXX%*=6DYN
M[^[ZH?_'1AND(#?5:H_<YC'ZPT^>.Y,Z+]-*!H-BW#W?GU) BL<348S\PEVS
MGE_F6 Z!M<T&S@IC'OB]'7,(T\$+RUR"$>-*5V<D^VLAPD>8M]'2,S</#0/*
MW;X%[V&>2O^ *#,G'I*1L42KY#VX3^6.=,=N@S4H26@Z^U@];S(MO"<8:I*X
M;S*FFY1*&;'>Y*!L1LAY!#QS5XJ([Q2)9J-H\XFV"VG?I1<<;%@>=:9RY@D!
M].7XYAP!OHT5DT:$]BN49L:LBP4K+U3*!ZF=O>X-SA=?L><AQXR^7M!P6>O!
M:D78B6X'Z%":GMK'/H.+/B?G5%]>TH*WN/7&[V>="GG7QG<)291*FYYO?.*R
M?(A.KH82VM'FVS=<%=]REX4&2^Y[]"4@H)S-I7M8O$@:7N(@RTYBV!GO8:TR
MF_XH*D S\QXE+^,'B]^C.:)8D-,BF!<MFA)7^@-B,W]2W&G2YD2EB+&CDH-)
M<R*B*:\Y>6)"0U12VX(=X*0_G?_I5D);$0/&CJ*^_8Q7#+.N=X/:EF.\1(VX
MT)'4>V7J7.9#2+#6845E[^M0QDB4N@LWY6T&F?,B2*2+VWB55-7(5<F(\+,R
M/]!*Z//EM_S%[LOBT8M;<7LTZ*37&3R&]-J]Y*[ZFZ[A;ST,R))L;]Z_R24/
MY(,.K=ZZ+?>2C[]$,1^K:4,PEV"'BZL:\ ^Z7KE)MB$+\I2*F9[-GY?NV/?5
M\CV6!(K)&UQ[A,(J$M!)10V8?S::SNCM&;'*32G_%E;E._Z& 6[W?/&ED/XJ
M&R. 1<A9J+MLGR*BX[*-!H CN[4D)M D(5)$;+36R+ZTEX0LJ8B@*-YT\3[;
M2-7'*U"D1'72K[!4N#\LU^#HJJ^"*GPXU'(VU%/U_G&=X>=_.%7O3]7[XZ_>
MH\:@-\@%K/=_B_5>O(TW#'J2XU5$=$KPQ2B5:)%"?15_!J 9R3(+V<%FPQY7
M@RH/W2/1VK,H:4.U<:E/<_\TUYRW^UJIVZBY&>1#"C2-H<&>H6,%XLYH4+FX
MOPGRCZ9=,94C\C1$4.A5!^0C@3] QI<^H(44=VM6??0E&\M86\L"[0$VW]\0
MU!>>-/^K6B4H@\PBY(_(.XXAT92/L_C>ORXRI:3_>]DVY8H(<..G.<!+E^H=
M33:&?%-N]L'?U\NRNRX0E)%<.'!^E#@1QWE-"DZM,C>?<0\37E0N/<DR22ZK
MDR6W45'$%1UK:1HH2:H/__!$D)>AO\4?C]B03:2R-9\']]\U.29TVS,VF:)1
M72@)1Q&\Q<M>PA'W ,RU*YGT(Z(+?@E@(P8WO ?WN\N>T0),#**N$<)#*AS9
MY4Z.+'BK*"VH?3P'? BNH[7E;2W>QT;0(N9VY2#L[!28_+D=!P_D]@=!CA+"
MV5H<N*'#;IT,2N$N&5,N%MP)/".]"W>4VIL(U3 YG$8OS$ <\K$8"*([0XH^
MSL5?9/O?9WZ4B)>93H[%^_<6]4\\ Z\M-_P&?)6.21"R]O&XZH\NEE0A>/KY
MY_^^^$32UW]Z_>;B0C+7GXKTRXJXX_1;+!"3\RMKHH8[,]NE-LG-V6U)? M9
M1ME'6[%3Q(O4)0MH5"QCY"T*Z1IN9-949'ITX;W-TG4?L]U\,3^L[67XY9>-
M\M7U$ 2"F2?6\@/?^X6_DBYCX++GDUZF66,RC>K*DI;9\W"/U1WW,L^.#H$.
MDQD7#'8N=:3+1HB&]SL/?UE+@7!;LEY+?6>_D\>! !(!8T_Y.\"<,<O[#?'&
MXWAM!;RT1%IEF?BE&;(O<&V$*ZW%6SCIXZFB<"<P;X6_$,+B @FF%=U_+_"!
M"Y*SGW "RJV8*ZU-]AY)IC':83^#LEAJ?T<[FD%SF*MAG OU9<XNB=P1#E+=
M$.$3D2R&%>48N0"SA&HBK>,FK*XL?-2;SXNGR(O$C]Y4S8;Z"_HQJGQJDC3O
MN^*#2&CMU-9!+<-=G&E)[)8<(;L#,EH.!S&4'<]#D@U[_^12Q5*(S4N)R_,]
MQ6,@8=Q]BQ2OE:*^HK]^P;U4\>V.Q5#GE42=/Y^SD#18SO4\G([$YLJ9L7@\
M0L^%YIKT&>)#DBU.%@07>JC5'48R0[]!?N/LT<@@%/.KI[F5)K58I\UWCA&3
MOY+4(X<OI"[$)5& ]R*!N;CHH^M41_?A:R*)H!0@E6SB.5_TY5:N%F*.,!.?
MBI::3JK+I/?NQ_47W="S^XY:E)U4M:M #.9<*;7[-N!8<F.FV#1=9W<@JR[1
MRQU87DX[1U/-?XJ+F#)Q;AR;2FYRRIY5!(?VEPO[?^9$3B3^R@.*"4+*#CP.
M8Y+0[WTWT#J:N1'BMP(+(=^I7254A*H-P6M]2:)[.Y7'5^^59]/-(H(&;DH%
MS@76ZBR>VHUUE]%/+N4G*_#*P[[U_4;"B ,;,N\W])O*+HKXSC=5MK5=JGMT
MG9POOH:N$9M^MWX=58/6>DW0<EF!TPU6$X0*:)JT\T*'*#549MQJ^N#KK#DC
ME]LK^3UGI%5*,"V\7BF^TE]P881<S6&^?RHI?"RF?*+5RV+84L%#/<CL&:JA
M4'Q7F9"8)>68Z:"H^NX62NHHZ.:T\GQ.IE;J QTHKJJR6]\&L-J/T/B-D.AG
MZUZX8Z,O\\;R[&]T^&_W* K7,@!W3<B;L8G?YF](57K-1UP*]CSN&K&( "#2
M/FTZPB3E57UDVT72C*J-V-GBL4)NNXO??!TVJPFJ?HX@JRW:JK$BO&.TE'P>
MK8,5 N-) K.Z3!.^AFJ^UA ^?5E,7M/4A$*1<!R_3D[!%8JUE+ I^4()GUNG
M6SCY;M8=@4";5;$+7"#0!="2+&LJ"ID@EIQ[/R$S5]<P/_1Z74?J?"_$,Y8P
M7-1C:M:K4^27[5LGY.4L@L;@NMU&5:G1_IHR_%3&X[0#E_"Y2SU:!(5*I T,
M[H1JC8G, $_IZ QS?VDO'(MI&D)UE+!ME7!JT4(UERCYC]>*K7A2#'-_(=74
M:6OAM29#G=IJM?XMSTAL1CM*SII"4K,,*Q*5340Z@&%5XEE*RFQ1@B2A W5_
MGY!S"I K($V[:D3O= )?LC F9 VPU,0PQG. BV'6VWVM\G=QYK(H2$!Z]@P#
M[M$WSW1=#?-7^[FRM[<@SF18;% 85IHX:P13E:,C"K$]=/I'U?-"'57"5ZCX
M1#09<9-L4D<&YS#VK9RO?)**8>V=,;S0%1$AEO&5-Y&EYHQR%6/J!*K/@$:3
M-Q0=:^K91]C O2>B+.(F$NW@,<#4AOUP145>@Z3[1K_T0Y9#H$0I"JI7*5*
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M()H)G@F>8TV@H=IM,,5E2I_-""C?T$+GS<BZ-\FUI#'ZPS[T&C//T>8X>6&
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MJO% 5"^D!R15DK*K7J"^0\ $]I2C%V(C8A_5T& "R/LYU'+8-2&B)N@-;JZ
MQ6^B2<W'F$F5K^N\T>/DYZ$S1R^)YZ8QK@E,X?SY0&WQI?G+J#>61IJI1^\H
M3^(]<019=)N:-5)CTOC*X>MJPK DEY67SCMJ0M=CC.R:K8V:^!3<A6*I HSH
MW<?PJ,[V/LN6J$T/QHA7OK.&A>%@2@CS>MUO?3W#<*&1^N- 8YQT6Y+&>\1[
ML47PPB@]F,9^C9SVL #<#<L1>GJ<_)!_,-#H,Q'?C";;!V.Q*MW9NJO7252B
M]Y;,4,U3E#@$[Y&UYO7VS::T\VZ,>'ZW!B8P,@%^64$_"Y>")!+'7!]1,&"#
M!YLD-AXZ!-BRRLBS ':M**P;&' 4DKTK-[L?8'^?,GLZ_&#EPFN 5;BMR!-
M!:OJP-F<4/4,E<3:&4@R:$N'O9\+<H<I M4>[3#7*?6JJ$XXOD86Q/ 0GG3J
M![]C;5+UBH.V'W1CIUR&6"DRS'YAMQ?/*=+7(JV'&T'F+:5:7V'D8CMKHY[L
MGYT]G.BO;).0$@."$-<A_09.^2,;SM2DF*'A46S&-8F"PR(,7%#+EV'>'667
M4]2$&\,L5&'T3*GM3N9@=#C*U_U$1A;I4*(0:U_^LRL-DB'BH=FQP6[Q@5:
M2[AO379355GR'/L*/4^5)U\$!BW[_M5\WJTW1./L^..$/"Z'W-F<SB<2=&'N
MC[P_I52!QC!U([9:-G2M?,Q7!.)X.IW8=4L:^"P,<#78](J#5X#I<%0C7:P
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M=3+F'PIN_H#U1:XQ7&Y.A#OO#*\75VERZ]0@$AN6%C@T:)0'F!J.UCUZ0%X
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M@F,@56W#^[QB^OO(,3;QE&0#; >*=XR'\TX\*1E.Y)UXY71<QK3V6WC)'Y%
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M8V)E!,R2$RLE0S2"6?:^/;_81*CF?AW%\_,(U8Q0S4-F9^+24&#\N6"H;>@
M (U*<IY;I->QARU4&EN(PZA4'=5UHGOSNJ&^<?VIP#RRQ2566/JY9NORFB0F
M)Y*##8[!0RP2( L-W5PZWG(R$._(RB!G,O3."'.Q[Y_QW?QF145@@#1=;;WH
MQ*%3@R85Z2-W3P98R^&@&,)ALDS3S(X&.AT8_3(2=<#?P*J@O8S!"1!(G.O
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MY9XA:%J1-?JIMU9$64\%6N!J@!PW]"334!"99C$G\@%JNN9N\57EH3>8.Q"
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MM%7A:FDUFV8_TMQ9-444V0QLN*;7J0I:*QJ92 1.$8TMMO^2%INF92)N(.F
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M ^[J!'+"FI"#MFMD#4M(-ZBY#%4PL<&U8.K"JAL79WT)+*WPHX)M.. P<3@
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M"S=6]>S%Z,*U@4;YALX%\[F/(\H)26@E<)->E.N=588 M.YPJ,05Z7]OFE[
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M:Q(KH 7&=V&"'P^E.A2'YLW6O@F\DA%L+;6C@!>)N#U#B4Z9 ND8\8:^-=M
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M/8E:2PDAJLQ5"^7/EJ_#Q+7Y55J;[%$?F4ET(ZPG5J!Z1*8"_0@:T#RWX^4
MM[HM='P;MMM+N-$&][[([5W^<PQ3TGHT.X[K8A"1H\,]%TER+  :5[PKF<M*
MN29.SH-4'=+&5@$$]310#10GW0B)FER>#/QP@D%*B23.2Q+S#Z0H9!IM3DA'
M$HE(R@QQ3E&23;!9LN1YFZCN(:(.:4^K (EJ\J^&B/<PGG3].('TTH]/E[97
M8ZGD@FA*-1HMT 0]<4/ &V\= X94MD##?02M@P3Y[2"ABMSK^KDSKA9(,<H8
M::TAW*@2F#%-;-*4A,2" FD\,MK,Q;U-S3KZ5]^._G>7>(N4SI7'XC*UT>I
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M]PIF/]\,YQVDBZVBG@KME,LDT.2(5,*1D(!B),HQBI7*4]HDWE^'N -+ K5
MUNT;K+K.ZK1[WR5KJ:FT$,6DBS8A*2)I3J0WR+ HTQR2XD:4)AQA'@N=UESK
M&]CT:^&BA?0;I<B=SX)Y**>>3..^8A)Q&AV,Z(/73.#FHIM,>-SX['E?AR][
M,AG;:Z$:$.X"='I =,/I;,*+]%2)8* 4EV"0I$ISGK&18,@4&/JT/MLFARCK
MD;=A$?Z3^'/MMYN=%5>Q2=IW\,)/4UMGY91D*K>>C91K[U4Y*>$%X!K9S4!H
M8C&C9\D4-*GR6DW.(17?[PDS%?32QBEY>$(@F#+/5!BDJLSWEC&0(*P@GD&(
M"& 41][*/]EY"*/^3HQ*8Z54,RROX+R#V/?SLH3G9Z7TX#\S%">338XIH0%@
M92XRIZ7H0!*M@"=N4HZ^R1;U $WK0,A\7R:FEH8:.CBW)G'U@@LB>Z>(-3Z5
M!+ F@96N)YYD3BE:89M44#Q*V3KPL=\7?.IJJVZM71E/B")8KOZ@"C!"*Z/;
MF!*EE]83KXTCQH.!R)E6IDW1Q7T4K0,:]YUL6W75T]#DS.>3O)I/;5@YIZ27
M6:;6RD!<C&7@J:/$)9Y)9/@&!2XT;7+*NAVY:V7XZ'<&M#UHMF;#?0=3A2SL
MP>_RJ_YX9E"11B3^K']Q-EX<JB0XWBI):Q)5F587M",A1D\LCT:"X=&V:=;:
MCMRU4/C4)]RU4;@'S=;KZ4%YW)KCMCSQ&8E=?F'ADR?0]4?I[DT7!Q=IV@D5
M3_WP$[SW$_@M9XB3'A71ZF0"R32AO=<L$L? $8%,<B>H4] DD[E?-O=XUN:T
MH2&*2#0K!Q8VHL]N_31%':B245IH,L]GV[.V)^Y9.ERTK\@]M\! Z_/@5<?B
MBF;MM6"$A>D@"2U(<&6R6^** S>Q7>O<5N5I3]PK]<UC=%<,M,;HZ_[0#^,R
M?5+Y$ +"2%$CRW <15R6G# #8(RAVN^U9F$%B8=T_O;M8W17##P%1IF. 8*U
MA*KR)!ZM#;%2<*(52@DCZ6QDDW+";3&ZX:'#8O7=.U1\5^82O<L+D]&F'6UO
MQN.+\NSDEZ,Q.LV&F9QERL27(2$RE(2W DN4\2DQ#\+ K:SR/6</VZQ^2*Y-
M(QPMG4 TUU"3^MTI8>_.IZ.2?OL*7>RC9'I)&2&Y1B_)H261@%N39^5/FJ/P
M7$GA&LT ?H2R0_)%&H.JC;:JU]2^A^E<M(^CC_[K7_W):>FF0>9+Y>_J ]N8
M( ?!/?$.R@, O"&!<DLX*Z,_$LTL-*VPW93@;Z'>MCKF]J'<BF,4KTK0W^5I
M5X3P6GEJ,.;S29683V"X%QG)H(.+1DMHTTQZFY!OH;2G-G1V4D;+)M-WW2<_
MG.<;_3 A=OOC43[I8(S$SN[T)2K6Z[I;XZH5NNTVI7WG5L7'%[P9U?MFF$?=
M#(*ORN#,K=I%=UMP+R)>F^.=I?^AW-+=Y2A_Z'\:]G,_EB:'V5$RWJ@GHT$_
MEGAB"S&O>>4*\MR&AST)KKT ]R_(1@)][?O==$[[[^#'%]VLN1=OC^O71WF^
M@92[8CS!+T]/MK:0[+9+51!Q%2Z?2M8?2V7)/B4^7_#IY+Z*XZ>2_O7=>2N/
MA]^</O9GLOS8G^TWR+W2]W2ZK2#/2B,&;C>Q%F?VII%U?GI=PI_Q9.HL]"2G
M0@OGB78^$^FH)DX(23@W6E@5D\EMGD:Z(:$[UV8\O-[-K/1_=:/QPL2YTB?R
M M!S@C(&3%-*K3>2"%L:1@Q88D/TA&O0+IA,\;\GD-9ZU!]2;K,I3N]4;^Q=
M]_5*BAZ<I+#0HDY5%BE93IQSY=%\-&'TRR2A%,I#V9B0ILEIU[H$'E(.]$G!
M5T6#S?"U[JU1!G'>W!HH!<.4TL0(@_()B9$ CN/](<%1[Y-*!V46EZ@_J%3I
M-V$7MU=^G5ZFE0\K79)-CSEAHP)%P( D,EE%',??DI/!4AYHR.DQYW7-M>JS
MLD+</:TU")4<B4DA0SE$9(@E8AP# 2+@_W9[AE:L>!"#C%JH>^G\LXG\JY9R
MWGTJ[W4P4LI/!Z,2I_2XU#25IWCJ&) \QP*QB7*4ATA"@7#2-GGPV]H4'L+^
MWQ)-;576T&ZN\'E[S ):<"AG'IX3R0(E:,<]\2J9*(!E&AX-_3=:\1 JH0["
MUFPL_I:'3UMF0RH?LC2@XNDR1?L[CGGA!Z5BY\,IP*2<=H^&V^:X[[E2!2&N
M0V,C06R?@'[P>LV$TB1]O'JI#_$4TL4 RD'B;&"97YA5]@=,MK^7=UNPF7"W
MXKA2QO;>H7"X;$^J'&.&2)(M-0W3G(#.FECP5BDOLE5-&J4?(JI"(=_J:T^W
MPI[V%@3/$@/:,CXE&W2TR]@]@<Z19%(H*9MXL@^3=4BYTVJ(65&T5TLS+1YB
MO#CH '\?P(J)!_>/6'1,>^\T$%><;&ET)I9J3[3/61CE$CK=37)4E1C8,(!J
MFZ9J!L$G47=+'WKUAE/91=Y\D69;Z5,[N#=;^7P6Y-7#^_R\07SVN)W)PCS
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MB:,RN+99IJ$0MX+;/) H_P0T^+_^\/]02P,$%     @ !(*\4#C97<=6(
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MD[\I7?X],<O%0_*WQ?+OTV\<@'^K7GJ]>'Q>3K_>KQ*8PG3_K\L_9])P@X4
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M;.*D!>_GZUO+0,8X"[$G:<0"KF_>V,-L.M_>]$:_8O$")2I_G.UP6 KQT?V
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MP\LQQC1W;*(LKR MM8LM@<!H3J%!,K.:!YY%;%L?HS$\.^=1ZP%8*F1.E=!
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MV:5YO]HU:F"=%LG%*[WF*_UUL6SBX]?\0Q1$*,4@RUCN:NXA( K! *&I481
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M9L2Q]%Y.14(\Y#HKM(F3+L BX7N^,HO5S=@DAVO2&?_Z?O))=;-%$C,7I+0
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M=Y>\W6Z?5, : 3TH!"WFU='-M 6[KOMY492KY]&A.H5=8A4=N12+-%,%RI0
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M+C_2)OCWY>*/]:?GBY//8?YMXG,6,<8 )H>:151J.KQWP%C!&-&QHH?(SGJ
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M7+4K3%C:>VT)Q(2*MM:J)O#%(EA=M#+18[J\4!IT [N+FG':8+78N Z6=0>
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M/>T@F7< FROE]F?T6R%R45B ;X9?9.O >U,@%26RUL&27)JD7M\@9.P+E":
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M((M<7<=L(:1:"\:]B"ZE(G,3"W6+DG&/4MN@YS!Q=Q 57C!P>? V":A#45&
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M@*?OE]QM&<NA#B80")[5\SV6+3AN$P@O.=<R*U_&*HQ\!,Z:'9,VP%D3U72
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MT7H,?FX:K8&UTT'$><5O36EY2L^?ACB=79Y,77)6FS>2#4825QT9F8R"P(R
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MB5$6JUUJ,]/].)?N5TWX#<L]$4D8BSS63EQDH*,I$-$F$%@*XSJQJ)JD&SQ
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M9?5O.C=!N^3"L:0,Y!PB*+.9A<<$N&"3(.F(8CHWFQW<]PZ!O78F\]%Z[N%
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M'F..UL ;%OU[H*#3>Z)W.*O)1&_#<OWM ^UOJY V593[W K=^UU#W 'M1NA
M-S[W/>SR]!UYL,7:6BI*FD],U:&I&9(.S&@A?#1-ZIR_1]CAH>[=W_]BNDJS
MQ>KTZBTILUD2D"FVBI%<(&$9[3ZA9HCPG',-PMK<?CV"QG$MW: HNAT&M]'4
M$[-3 U]L[_.8EM;MV%?=WX5L5BXP3\$3MQEITW6TZ;HB**#*7%OAM&C3NK2U
MX;OTS.][TL_?KKUSYH#30M5*,3#2TP(FEQM")'^<FYB38MYXT7AXZ".H[=P8
M/@99]U]HM])>!Y'+15W060UX=5 7\]H!XVR&8,X\,#+OT:K:J%;4SLLV0289
M%LM0%VR3;/$05;W<'3=#Q4T<#J:B#O!V@X?M$5H(BF*NHD!'3KZ$)\D$JR-@
MD5%%-!3R-*D3N9.:D?$UG+9O'DX?+/H.\$/DGRSF5\_797+&2%9 &Z)=%63@
MZQQ'4:I 6-"HFMBH6Y3TT,/C(.TNAA1U!UC9S4"?E?8[);-+%+V(E$!%)2 6
MLM1,2.]0LX2J20??W4GLY8SY6+M>(^5U!LOM,M6:UD\D>.2"Q$$XO_AQ117G
M2M11-[KNOTE*G_[\H4I_ %M[:&!$#-7#A<F'Y>GJ_,JPN&*M%PQ8S'467CWM
MB13O:&F*SL5EK?1UY-P^G[CYI?U@8!_E+ :05&=6XLI2N+RI*)Q\0!$=.8 4
MU2I+V[*OJUQIY$R8P'F;$JOO$39R>^E>-JK]%-4!\#8.W\O5ZA3SB]/E=/[Q
MK-K\;*[@:_QC\Q9Q%1F)QCIR_C2"2KRV]5 >,JU%%[/RR'D+^.U&7C\F['!(
MW#H.&%P_733Z>1\V$]8K=YNFL.?7HI/,BV!99V!UBJ4*P4 T"C<AC9 J"YZ;
MI-?>1]"XGGA;; VA@PYLV-OE(B'F5;USK^LAS!/Q=26@G1@,T4E/ :SA%,I&
M3<M#;U)=@BP4WLK"FUPY?)>R<;?/IN@:5BO':#"R?:/^4P<\_-N__']02P,$
M%     @ !(*\4.*+-ZW[20  M$ " !<   !A9'9M+3(P,C P,S,Q>&5X,3 Q
M+FAT;>U]:Y/;1K+E]_T5N':,ISL":G7K+<O7$6VI/:,-CSPA:=:QGVZ 0)$L
M"P0X*( M[J_??%6A"@#9I"QK2 H;=\=JDBC4,RL?)T_^\%^O?GWY_O_^\R::
MUXL\^N>_?OKE]<OHFWOW[__V\.7]^Z_>OXK^_OX?OT2/+BZOHO=54AA=Z[)(
M\OOW;]Y\$WTSK^OE]_?OW][>7MP^O"BKV?WW;^]C4X_NYV5IU$569]_\^ -^
M O^KDNS'__7#?]V[%[TJTV:ABCI**Y74*HL:HXM9]%NFS(?HWCWYU<MRN:[T
M;%Y'#RX?7$:_E=4'O4KX^UK7N?K1MO/#??[[A_OTDA\F9;;^\8=,KR*=_?<W
M^O+YTX=/'ET^>OS@ZOFCQU?/GSW.'DPOTR=).GGZ\.GTZG^NH)/WX>?\C*G7
MN?KO;^8*W_W]TP?+^L6MSNKY]U>7EW]Y\0W]Z,<?IF51PYLJ>)+_R0WTFJG5
MQ_I>DNM9\3T-!AO !^SWDR3],*O*ILCNI65>5M]7L\G9@\>/8_O_H\N+R_,7
M_-VWE_3_7F #]Z;)0N?K[__Z7B^4B=ZHV^AMN4B*O\8&%NJ>496>\@^-_G_J
M^RL<!_UY*P.#=G)=J'LRT*L'-+J;CW,]T75T=7EQ%0YM>% IS+^J#GM4U-U,
MI665X/[]/H)^J0I_!OU^_>;5S3_>O/[Y]<OK]Z]_?1-=_^WMS<T_;MZ\WSYZ
M#4T4]?</GT 'O.GXO3&UGJ[M? SLD$]KZ#\^L8^&M\O[N3;1:QC"HM!3G=+\
M1M>S2BDZX&????OLP8/+%^X3^OOJQ7D$CRV23$6)B<II]-VWSZ]>P/\\>?H<
M__/P10R'_G_^)YJLHZ3(HHFJ;Y6"AK.5JII%]),N:Y7."QCE3"L30P_2BSA*
MHE<J3VZ32D6PUDM9[NBLGJM(.O*R7"R38FV[$5/SO;>[?LO(:J7L$Q=?:%L<
MS^GZYL>W-R]?O[_^Y=UX8G8X,;_]_>;MS?6[.)K#I_D:=NIBJ6H\+$M5F;(P
MT3Q9*=CR\(6*%B5LYDKE35HG\).ZC."]\/6RF>0ZS=?0>)[YN]W@B<ITI=*Z
MK.!L57"\X& J_K<NHA).0Q6ER3))X3:'@35%KHR)X&,X;/"V956N= :W\JVN
MYQ&<T7\W<$GCQW#FZ$#5<YC/V1Q:,PUH!:G"IMT/=4<:)+,$?EC#YV65Z0)_
M4FGS@<Y]FB=Z8>@0)JET7WX._5E ?S2I!F53X\_A,UW1#,"(<#+L@RL>"KQM
MHN9)/I4?^Q/SW;>/G[\8=^@^.Q1G\*<RJ3*<SE?MGN*Y%5$:B%?ZM9/Q<]R*
ML+>K!;PD@X>2.J8M6,'U2\M7UQ4L'RUCI6I8^ CV4 Y[!WX.DPCKFL'?)@Y>
M>*OS'!]5BR6=B 4\1\_B9L/_G96X9R:)T?!D CNO-I$I<Q6ICTM5&!5'N4XF
M.M?UVMO#T)+L<7<2::=!4_[;L:_48#,Q.M.P0V'JIU6YB."043=LX_#%172=
MUW,Z+-C&M*D*;>:THZ?00NJ?(9RM"=YR293"1H&%K/AMH'TJLP15.8,.XFZ'
M'R<+&&;T+[R:LNA=#8?*W(,!JZXL@,?YP$]0Q\9S3C?*$LZ5ZDSK1.5:K921
M=9KI%?0E;:H*91-TYH,"A;V$16F;KN&[#)KIC&218&M1LDITGDQRFEJ- D F
MH6Y S)0%"#]8'!2#T#\8WT(W(@M(\I#H4Q_3''H.+X2I)*$0F03D8@T[/F[E
M7-Q*N7;(=A7AO9[(".:G')X8DH,3A>ND"S124 A!=V'-?X<7XEXN93/!+/%4
M0(?@^,(<+/ Q7/X9RS^0WO /W$5E+.O&_:MQ(T#7%[B7*YYWF-(D$RL+7GA;
M-B#>Y4* Y9B0X*UE\EI)Z19Q>$"X854^O8C>XXE>@XYDPF-+'[ES2^/!1F%#
MLQQ7N%]!R?*TJBU28-MS[B457!>P?+WK0MH-UC/;('LNHE9!HUT'LJ+$K0=#
M1XN0UJG[@F53F48N4VSK;ZI059)#F^W@?DEN[:OH<)$ M+JE/]17?WOYBU,-
MO>F-[YY .\O8!&ZF"M8,5E6N7]X-L*%(0AI[IFA-23C6I5.+N^)IH183U4[6
MQ(KPW8X+'3[HS!(E87_^QGOTD^[1II#K@1053R9TA2=MB_ZN)1D@PDCQQLDT
M+F*3PRT&BRMW*3;:7J?X%[4OBSLNWA]0@@;4&?JV715O1>#2V6E%T!"&1BN-
MUC%((1%*$T4:,QYV4_=4+J>#U&7Z85[FF3W)KD_VEV9.-TC"1SDQ!J_>X/WV
M$?B<%*N)/R"[9]=.7_',@. ^'W?6WCL+52(4!0FL ZI),4QN@R.CI2Q4"A<"
MZH#3L@K6U%X*#:D(L*PEV((S,KWHFO?%QSJV B7)5B1?1 <.C:6XLR=*6=D\
MQWT(4RSVZ4+7J/V@6V:Y! .4M#NX[T"]=AM)%'2V4Z'KV%U=-*HU7OW!3"NX
MNDE]A@5JT&)#05ET6RO*&G>F\02CRK;ON67)[NKO6=BNE._&];V[WPP_EDS
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MZ:Q&>+*BX S^!'W!:&@./;'M7;%]4Q5-==:D&LUE](45$N5L+S PKI.J+L#
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MQN&KPC@<_UVT593.RUL$X!_VUFAU0;#<)++,=R,Q@V4J.M/G(=[O3.MSSIY
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M<CZ4Y*WK+37E^Q18J&?YM'2=9.M0%28:2-8P4"5$">S+5:<GN>B+9^>%<GU
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M'B^LP()4P"!4B%)YOC7W:PLFJ:?"4U5J6XN'"F[W,"B<8W"2>\)$CP]_("<
MSWUR^/W'8W?T6;1/#[__/,],]6GJMJP!R)[#[_S7<L\,D:-OOF3Z=*QMUM_9
M]NOE%*^4AX<_D!.X4AX=?O]/XDIY=OC]'Y1DON*Z1:IU_1NN3IP@N?<K:HF
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M9\U&<^O$/OMI_PC_.\$%M@<\D?'T^)\]F0C#+L6$7:N$I_\,#'#!MA%:#NQ
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M$"$-17@T? VX"];)AW#^K&7M#S[@&>,LYDCG"/YFD<#%X$ BI$F29SF/JR?
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MU4576HS%$%U'IU^X;WZ8*/W))TC>I>22WF38BMM@'9=(Q&M,@?6E02>!1EH
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M5DX>[*])1GFH]36LI6$EH5GP*Y"^0O?#JM[MV.FK: K_C+(D/OU_4$L#!!0
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M.:J:6[^GG7_;]\7-F^NG_P=02P,$%     @ !(*\4,Y2*6B="   (2\  !<
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MM"0IN 41A4B+HC5D<F^I>U,#*GU3K%91(HM  ' BP)EF.F7T\:@*21")A2I
M)-F,*PV5KB84'UJ]0<MJ"0NJ4.:!MJ\.#IT<#M,[MGNW=]1J'O95[O \%6&
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M&^8! &%D=FTM,C R,# S,S$N>'-D4$L! A0#%     @ !(*\4#])<%6?%
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M=FTM,C R,# S,S%?<')E+GAM;%!+ 0(4 Q0    (  2"O%#BBS>M^TD  +1
M @ 7              "  ;#0 @!A9'9M+3(P,C P,S,Q>&5X,3 Q+FAT;5!+
M 0(4 Q0    (  2"O%!%B=-6&A8  +B*   7              "  > : P!A
M9'9M+3(P,C P,S,Q>&5X,3 R+FAT;5!+ 0(4 Q0    (  2"O% 4O5JH!P@
M *@O   7              "  2\Q P!A9'9M+3(P,C P,S,Q>&5X,3 S+FAT
M;5!+ 0(4 Q0    (  2"O%#-5/42A@@  !0O   7              "  6LY
M P!A9'9M+3(P,C P,S,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    (  2"O%#.4BEH
MG0@  "$O   7              "  29" P!A9'9M+3(P,C P,S,Q>&5X,S$R
M+FAT;5!+ 0(4 Q0    (  2"O% Y:1?/#@4   $<   7              "
M ?A* P!A9'9M+3(P,C P,S,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    (  2"O% \
M>N0&&04   @<   7              "  3M0 P!A9'9M+3(P,C P,S,Q>&5X
=,S(R+FAT;5!+!08     #0 - &T#  ")50,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>advm-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:advm="http://www.adverum.com/20200331"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="advm-20200331.xsd" xlink:type="simple"/>
    <context id="ia1c289aae9114e718b061d97eb326203_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib3b5cb04ce03418782a7afb3b064fa24_I20200522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-05-22</instant>
        </period>
    </context>
    <context id="ib7f03b30ae4e49ffbf09b800ef895809_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i74e35996fd934b90add7c64de848251a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iacf2abccc1834cb1bdaab10d8de21ca0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia816f302506f4971bff3c5020987ffa0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67edce6e02864aa48bab4d1c16e87715_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7321fa80e56a46d986877106f9f44748_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4c01bdf8459643d8a68ef8c51b769185_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i093bc26ce2354e49aecd7233bb878cbd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i24e8cce64cab4c6e9d91184e4d15997c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a23c9af1b9940d09d585b851026690a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idaf6e1fd67294be9a4ce6f1605da8ebf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i05a0800f62f84a1f83badb8e82cff328_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ieecaee0157b64ef9ba48e56e97f43459_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie3969f7d77a94b91b93ebc11fb4d9a86_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie296a832075d46d2b88ab3bca1eecd12_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="idefba8ae62c94026a09f3f5f81761591_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ib67d336e80f142c7ad1f135676f4b5f4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0984d4527bd849dea64c0968d781c858_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i6e2950d05d944066bb3c8f6b9541befb_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8ba61405a18e48f09259ca56e8354dab_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5ebb645f5e3746168957a7ff7640900b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iff64a4df71714cc2b301cd15fa17cac9_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i15463bcc9ee04802abd38ead29ea3887_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i833ac88809664274ab22787623b8d238_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93fd01d998494aca846c6d58c36d0dcc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8240d35edaef41478472c5ad37bc778a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:BondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">advm:CashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a217f3fdd144ea6b634832732d7d3db_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i342bf0ef26dc49da8828fe5944816454_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iedc52aa3b04946a0a0eef67548681e3e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i707559898d544e9bb307731a2ae13d5f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70e71d13a2174d099753799db973fd83_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i621486e661ba4c8b85b23a96dfe63109_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8729f4de91b34c2d919e7cf785fff591_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i01f564a1a87d437f9d0b3f17d3bac012_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i83fefcb42e1542bd867592dab7eee895_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="idce7caa83b044c50a6c225417896fd78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie6384f75152d49f38ebf15724aca6383_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifa66768ec34c4f83b89a84a802763883_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11acc5e392074f6aa619a7caf4b0e38b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i747bceb18b5d4106adeb8f39000b9982_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0dff8015a05449eda49c8fb0645749d9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ife518f866ce14a03be135a52d4f9429c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5e6e4fe498c24ec5abb76f172e87c141_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i64910ab1df99412c876858849bf70e6f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib286c4189e9142e595e64dd9e87b795b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id78c5e96cfeb4a7ba9d2f8f09386b78f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i067845b9bbc441dca466c83c3266762f_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2550dd60ce2c49f19a995e351a4d4e99_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3ebb3283ddf14932b74fbf553fe5f243_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2be7ba555c8443369db8b32a5b5a90b0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i73b815ac0dad4ea7937de1d62295b3f1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advm:TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="ib89a5f94a6544269b3729160754cd23d_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501756</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">advm:TrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV80LTEtMS0xLTA_06ecddaa-0918-4429-96f0-8fa68005c7a0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV82LTEtMS0xLTA_7e304b32-ef21-4903-b217-5839690777d9">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV83LTEtMS0xLTA_1eb30538-08d3-40ce-a780-3be4f08fb2e2">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV8xMC0xLTEtMS0w_215e18ce-e9f1-4433-849e-1bbc684c6359">0001501756</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80L2ZyYWc6MjgxZDBmOGQ1MGM2NDg4ZDhmM2Q2ZmMxZDI5Njc0NjEvdGFibGU6ZjM1ZjhmOTkzNzgzNDZiNzg5MTVjMzhiOWRkNWQyODUvdGFibGVyYW5nZTpmMzVmOGY5OTM3ODM0NmI3ODkxNWMzOGI5ZGQ1ZDI4NV8xMS0xLTEtMS0w_fc4fdb89-8588-48be-9c05-13b1415fa547">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i7a217f3fdd144ea6b634832732d7d3db_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM0Nw_17c69df5-37f9-4e40-b044-a43f7f4fa76d">P1Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <dei:DocumentType
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM1_032c5a79-1869-4f80-b6f5-921891331526">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MDAzMmQ4NTNhMTFhNGIxMzkwNGVmZGUyMDcwMjRhNjcvdGFibGVyYW5nZTowMDMyZDg1M2ExMWE0YjEzOTA0ZWZkZTIwNzAyNGE2N18wLTAtMS0xLTEyNDY_2df007cd-c468-4e65-bc99-d92ca2284a67">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM18xMDk5NTExNjMwMjU4_2c665882-7ddd-4681-8c4c-d4f3f70a4b2f">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6YzM3YTg3NDIyMzcwNDkwODk4ZTkwMWQ5ZWZhZjFjYzYvdGFibGVyYW5nZTpjMzdhODc0MjIzNzA0OTA4OThlOTAxZDllZmFmMWNjNl8wLTAtMS0xLTEyNDg_896ef8f8-50ed-4025-96cd-8a38f4d66c7d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDUw_f5728d29-562a-4ea1-ba63-e253afb62cc2">001-36579</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM2_1d001eb4-6d1e-4120-8902-d1d847e363ff">Adverum Biotechnologies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MzY2ZjE5NTZkYzRhNDdiMWFhYzZkMzI5YmUwZDU1OGUvdGFibGVyYW5nZTozNjZmMTk1NmRjNGE0N2IxYWFjNmQzMjliZTBkNTU4ZV8wLTAtMS0xLTExOTg_cacbf85f-15b6-446c-a868-2a9f8d0471cf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MzY2ZjE5NTZkYzRhNDdiMWFhYzZkMzI5YmUwZDU1OGUvdGFibGVyYW5nZTozNjZmMTk1NmRjNGE0N2IxYWFjNmQzMjliZTBkNTU4ZV8wLTItMS0xLTExOTk_61dab842-4343-4c6f-a27e-3df334daf8e5">20-5258327</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDUx_e7017e20-0b85-46e1-b235-b2ea33277816">800 Saginaw Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180Mzk4MDQ2NTEzNzM5_0da3548c-ef7b-4eba-8cd8-0618fc8f7873">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU1_54fafea0-3c08-4ec9-ab67-e25e4291b16e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDM4_238593cb-0ae0-4e41-926a-354e374c5260">94063</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDQ1_fabc4ee0-ac4f-4d92-9b0d-ffc5cd301a31">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDQ5_815ba500-d98f-46be-ab25-caa2fe67fb16">656-9323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTAtMS0xLTEyMjA_9023f726-3502-4872-ab7d-5d65731a4158">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTEtMS0xLTEyMjI_ab16952c-2ee7-417a-9f73-8694777848f6">ADVM</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6NmZlZmU2YjljYTA5NDE3ZmI3M2U5MmMyNjllNTUwOTAvdGFibGVyYW5nZTo2ZmVmZTZiOWNhMDk0MTdmYjczZTkyYzI2OWU1NTA5MF8xLTItMS0xLTEyMjM_1fb16e40-8451-42fc-9148-21d71e8220be">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU2_43cb6c58-440b-44f2-bbc6-96377987d520">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU3_cbe43331-f58c-4575-9434-344ca22ae26a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8wLTMtMS0xLTEyNDI_b76e7019-0497-468e-b15d-45a34da8fa5a">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8xLTQtMS0xLTEyMzY_02435210-2fb8-49ac-940b-482f74196c5a">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGFibGU6MmMzMDBiZGRjZmE5NDE1ZmIyNWM3MDEwZmE1MGFkNWQvdGFibGVyYW5nZToyYzMwMGJkZGNmYTk0MTVmYjI1YzcwMTBmYTUwYWQ1ZF8yLTQtMS0xLTEyNDQ_a5b9e0f8-a02c-426b-a663-30a52daf0d9e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NTgw_6488e276-dd65-403a-8ddc-c1eebdd8f2d3">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib3b5cb04ce03418782a7afb3b064fa24_I20200522"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xL2ZyYWc6MWZmNTc1ZjMyZjU5NDA0NjlmYjBhYjYxYzBmNGUxMjMvdGV4dHJlZ2lvbjoxZmY1NzVmMzJmNTk0MDQ2OWZiMGFiNjFjMGY0ZTEyM180OTQ3ODAyMzI3NDU5_451ebfb7-7b5a-4807-b551-cc1876d8627c"
      unitRef="shares">80295560</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMy0xLTEtMS0w_ae2770ad-4131-456c-b43c-6f4d97b9bc4d"
      unitRef="usd">130162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMy0zLTEtMS0w_8397d4a1-0ecd-437c-9911-2d4bf1b31de1"
      unitRef="usd">65897000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNC0xLTEtMS0w_e89419e0-9b18-4629-bf59-654e797cb494"
      unitRef="usd">166904000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNC0zLTEtMS0w_e701f616-09a4-40df-bee4-d33ee6bb89c3"
      unitRef="usd">100138000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNS0xLTEtMS0w_c09b0d24-c6e2-4f5b-bc1b-27f498cb7ede"
      unitRef="usd">3382000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNS0zLTEtMS0w_83b8602e-674e-48d5-bb4c-cdeb654314f8"
      unitRef="usd">9835000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNi0xLTEtMS0w_0c41daf1-f1af-41d5-b33c-c798097cb1f1"
      unitRef="usd">300448000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNi0zLTEtMS0w_95ea5ddc-d8dc-464b-ba73-078cac247fe6"
      unitRef="usd">175870000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNy0xLTEtMS0w_d225ec48-007a-43d8-a919-a8e1e0c6bb42"
      unitRef="usd">20406000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfNy0zLTEtMS0w_5c6619a1-1b41-41eb-965e-178406d9e12a"
      unitRef="usd">20963000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOC0xLTEtMS0w_87594c57-cf6b-47a8-b9a0-5cd25ab25e16"
      unitRef="usd">26727000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOC0zLTEtMS0w_c5c96a46-4a96-4b6d-85f6-eaae605cd077"
      unitRef="usd">24884000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOS0xLTEtMS0w_da745cc4-3c9f-49fb-bbfb-c4dc9e3d18cc"
      unitRef="usd">999000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfOS0zLTEtMS0w_16a81349-41c9-4004-9ecb-b341897945bb"
      unitRef="usd">999000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTAtMS0xLTEtMA_db6037e2-484e-4532-a7b4-e7539db266b7"
      unitRef="usd">19000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTAtMy0xLTEtMA_2963378e-8089-4460-b9a9-227c65d86fc9"
      unitRef="usd">11000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTEtMS0xLTEtMA_f94c2d12-c786-4841-a867-516e7f50cb8a"
      unitRef="usd">348599000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTEtMy0xLTEtMA_fc3e76f4-b312-4d3c-ac0d-d7094df6214b"
      unitRef="usd">222727000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTQtMS0xLTEtMA_4496ee14-5466-4d56-b964-ace2868d421d"
      unitRef="usd">4663000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTQtMy0xLTEtMA_b7c6a8f5-e994-49f0-8f15-e419a6cd048e"
      unitRef="usd">4103000</us-gaap:AccountsPayableCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTUtMS0xLTEtMA_3c37184d-1090-4b4d-afe4-c173ff327839"
      unitRef="usd">8079000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTUtMy0xLTEtMA_e7c83ec2-037d-4b6d-941f-ead5edb5e35d"
      unitRef="usd">11271000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTYtMS0xLTEtMA_30b924e4-4fde-49e3-8456-313a049056f9"
      unitRef="usd">4025000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTYtMy0xLTEtMA_c04ce3c5-5f65-4101-b20f-d64ad651c269"
      unitRef="usd">4034000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTgtMS0xLTEtMA_9fa47114-655d-467e-91cb-837cc79df19c"
      unitRef="usd">16767000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMTgtMy0xLTEtMA_4da690cb-73a8-4cf7-a594-53d2efe41838"
      unitRef="usd">19408000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjAtMS0xLTEtMA_55389f6e-a720-4672-8dda-3d3f6fbf9437"
      unitRef="usd">27753000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjAtMy0xLTEtMA_b5da4aa1-e0ce-4756-a9ab-9870fdd1d9da"
      unitRef="usd">28214000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjEtMS0xLTEtMA_22a0fec1-3c66-485f-953f-009b2d5ad38c"
      unitRef="usd">126000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjEtMy0xLTEtMA_5530dd07-7e9e-4e6b-a597-e962faa6005a"
      unitRef="usd">148000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjItMS0xLTEtMA_fedca108-c483-453e-9c38-8655c33eea51"
      unitRef="usd">44646000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjItMy0xLTEtMA_17b519d6-4122-42eb-95ce-9f98de9a7fe5"
      unitRef="usd">47770000</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjUtMS0xLTEtMA_99ef0ca0-e403-4642-94f1-4b2111f32a6c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjUtMy0xLTEtMA_1c9d62cb-62f5-49b2-96a2-b0d21601434f"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjYtMS0xLTEtMA_6c9c4cfa-8f18-4e11-850a-a14e53c54b26"
      unitRef="usd">8000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjYtMy0xLTEtMA_d1c9df00-626b-4283-8417-376b8bde0000"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjctMS0xLTEtMA_897de7d8-276d-4f05-9482-50a73955369a"
      unitRef="usd">712713000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjctMy0xLTEtMA_34674bb4-10c8-453e-a0fd-5a914f67f811"
      unitRef="usd">560704000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjgtMS0xLTEtMA_bad6ad02-f885-4fec-a7ca-15d23a96b367"
      unitRef="usd">-833000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjgtMy0xLTEtMA_8acc055b-358d-4a54-afb5-ec672efa47cf"
      unitRef="usd">-725000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjktMS0xLTEtMA_32c6de5d-14d0-4a97-a2ae-c80e459c5924"
      unitRef="usd">-407935000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMjktMy0xLTEtMA_47d49429-a6e3-4832-b61e-961e0d1526fc"
      unitRef="usd">-385029000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzAtMS0xLTEtMA_4a75cf05-64b7-4b41-8d36-e69907519064"
      unitRef="usd">303953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzAtMy0xLTEtMA_739c3ce5-dd6c-472f-9ff0-691bc7663393"
      unitRef="usd">174957000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzEtMS0xLTEtMA_ac4a3313-9590-492d-9c69-b3002c21f12b"
      unitRef="usd">348599000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xNi9mcmFnOjdjMzIyMTk2YTZhNDRhNjc5Y2Q3ZWEyNzBjNGRlNDM2L3RhYmxlOjA2NDQ1MGZhNDlhZTRlNWQ5ZDRlNmE3NmI4YjFkNmMzL3RhYmxlcmFuZ2U6MDY0NDUwZmE0OWFlNGU1ZDlkNGU2YTc2YjhiMWQ2YzNfMzEtMy0xLTEtMA_9bafb627-2661-4e1d-a358-9d06a707c158"
      unitRef="usd">222727000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNS0xLTEtMS0w_82d14a36-36dc-4bb1-b1f7-b35186cd3a68"
      unitRef="usd">14751000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNS0zLTEtMS0w_79c3adc8-7974-44f0-a851-1bdc9bada42a"
      unitRef="usd">10131000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNi0xLTEtMS0w_ae7b3abc-0f28-47a5-830c-2ba5f4583133"
      unitRef="usd">9040000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfNi0zLTEtMS0w_7fc347a2-c854-49b7-9c4d-10887155cf1b"
      unitRef="usd">5576000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOC0xLTEtMS0w_0e7ea70f-fe2a-43f7-96ec-ee52bbff68bf"
      unitRef="usd">23791000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOC0zLTEtMS0w_3e9a8f13-05e7-4fdb-a16f-ab5fdcf06f97"
      unitRef="usd">15707000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOS0xLTEtMS0w_e37cd496-b2fd-49af-a077-cc1f3146a67b"
      unitRef="usd">-23791000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfOS0zLTEtMS0w_056c8e17-68f3-4f67-a29c-eaeedfd33aae"
      unitRef="usd">-15707000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTAtMS0xLTEtMA_74796613-c5d8-471a-bdc4-33a169136d2c"
      unitRef="usd">885000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTAtMy0xLTEtMA_2bef6822-f590-432e-a429-6df0180d5395"
      unitRef="usd">1218000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTMtMS0xLTEtMA_af2f1add-cfb5-49a9-a9df-2e1ef73fab3a"
      unitRef="usd">-22906000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTMtMy0xLTEtMA_c26c71b4-73db-4e9a-9cb7-29b0a8d86c7f"
      unitRef="usd">-14489000</us-gaap:NetIncomeLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTUtMS0xLTEtMA_f178c64a-c88e-4e8f-8493-e17d58f16516"
      unitRef="usd">-54000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTUtMy0xLTEtMA_f41975f0-4d14-4506-8a53-9169d85539d1"
      unitRef="usd">3000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTYtMS0xLTEtMA_47c2f6f3-27ab-49e0-bf2f-401cb2ea592a"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTYtMy0xLTEtMA_0caa177d-9a6e-4332-9d39-a0bb13ea1ff7"
      unitRef="usd">42000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTctMS0xLTEtMA_75c3528e-f9f3-41c8-b149-005629f82c75"
      unitRef="usd">-23014000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTctMy0xLTEtMA_fa1e408d-a713-4961-aaa6-5960403a0304"
      unitRef="usd">-14444000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTgtMS0xLTEtMA_b7eebfe7-fba0-4424-8220-f5a7ca21b940"
      unitRef="usdPerShare">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTgtMy0xLTEtMA_ac7b1b9a-9070-4995-bb7a-df744507b7df"
      unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTktMS0xLTEtMA_5a3af2bc-d52a-46da-9689-8ac2b9948d54"
      unitRef="shares">73797000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8xOS9mcmFnOmQxMjJlYzM1ZDgwODQwYjNhOWQyMTQ2Y2VjYzMyNGUxL3RhYmxlOmUzYzc1MDVjNjcyMTRkN2FiNDc1ODMyN2QyNWE1Y2VkL3RhYmxlcmFuZ2U6ZTNjNzUwNWM2NzIxNGQ3YWI0NzU4MzI3ZDI1YTVjZWRfMTktMy0xLTEtMA_e484ef95-19b6-4dd3-b789-1b6b3e96c452"
      unitRef="shares">63125000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0xLTEtMS0w_732601b2-6a45-4c5c-a2ed-6702ccea316d"
      unitRef="shares">67329000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ba3db0fe7cc40178a3c89ba677ed2d9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0zLTEtMS0w_21145d8f-e379-4a5c-9f75-b02de645cce3"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iacf2abccc1834cb1bdaab10d8de21ca0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi01LTEtMS0w_004fce56-3a6b-48ce-9482-db1ba81016b9"
      unitRef="usd">560704000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia816f302506f4971bff3c5020987ffa0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi03LTEtMS0w_da785afd-ba75-4e66-b248-37c7171a325b"
      unitRef="usd">-725000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i67edce6e02864aa48bab4d1c16e87715_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi05LTEtMS0w_d7038570-e049-4e71-9791-5a1f8b767d2f"
      unitRef="usd">-385029000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMi0xMS0xLTEtMA_11c981e8-23ac-45a6-88ac-6d7dfb438f53"
      unitRef="usd">174957000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMy01LTEtMS0w_482e2cec-0aaa-447e-97c7-f1c766537edb"
      unitRef="usd">3409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMy0xMS0xLTEtMA_6bc5d5ca-79ab-41dd-a100-426cf1d20115"
      unitRef="usd">3409000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0wLTEtMS0xNjYwL3RleHRyZWdpb246YzcxZGNkZDUzYjg2NDIyODhjNzYwNDMwMWM5NmE2NWFfNDk0NzgwMjMyNTA1NA_0a4f548f-8551-4a18-8324-895a5276d01a"
      unitRef="usd">332000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xLTEtMS0xNjc5_24a5d928-ce28-4bd4-a45f-6ce75c157391"
      unitRef="shares">10925000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0zLTEtMS0xNjc5_75943967-e08d-4a81-ad21-b584b2eba56c"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC01LTEtMS0xNjc5_2cb70d17-3f14-45f6-b825-7128fb5b1f64"
      unitRef="usd">140872000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xMS0xLTEtMTY3OQ_b707834a-cb5a-4ebf-b846-cbd725941b71"
      unitRef="usd">140873000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xLTEtMS0w_3d803367-272d-4e08-92d7-e1cb02e13d04"
      unitRef="shares">1310000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC01LTEtMS0w_c6495b47-849f-4bba-bdc4-221559d8a9f3"
      unitRef="usd">9650000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNC0xMS0xLTEtMA_e8d86afd-352e-4c4d-8916-127f3f411866"
      unitRef="usd">9650000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xLTEtMS0yMjQy_f3f14321-558a-44b6-9a96-9c63413ffe7b"
      unitRef="shares">7000</advm:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNS0xLTEtMS0w_3d849306-ac4a-4621-8a37-74ce2ade51e5"
      unitRef="shares">462000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="icca9bf46023b4215bf0a6c150f42866d_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xLTEtMS0w_972f1e87-1fee-4c77-a3b8-3bb68056f8e9"
      unitRef="shares">155000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <advm:StockPaidValueForTaxWithholdingForShareBasedCompensation
      contextRef="i7321fa80e56a46d986877106f9f44748_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi01LTEtMS0w_d08c990d-9cb3-4caa-92e0-18e6bc81a34d"
      unitRef="usd">1922000</advm:StockPaidValueForTaxWithholdingForShareBasedCompensation>
    <advm:StockPaidValueForTaxWithholdingForShareBasedCompensation
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfNi0xMS0xLTEtMA_06e3c7ff-4bed-4ef3-8f8f-e1cbf5ec050f"
      unitRef="usd">1922000</advm:StockPaidValueForTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOC03LTEtMS0w_40c16113-14ff-46d6-a3b9-48b12befcd04"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOC0xMS0xLTEtMA_a6a558f6-e56b-405a-a113-71dccfb14947"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ic055023ee5144f7ab091f27aa6efefe6_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOS03LTEtMS0w_4ef01261-9a26-4a84-a5bc-7b77e83afddd"
      unitRef="usd">-54000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfOS0xMS0xLTEtMA_2a8d7d3f-1c39-4cc7-b676-9e4761ac0d5f"
      unitRef="usd">-54000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4c01bdf8459643d8a68ef8c51b769185_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTAtOS0xLTEtMA_3d0278f5-eb56-4f60-8578-6f9c92ef2f75"
      unitRef="usd">-22906000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTAtMTEtMS0xLTA_69cbd87b-0e65-4f88-910d-f5d7c1e66ff7"
      unitRef="usd">-22906000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i093bc26ce2354e49aecd7233bb878cbd_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMS0xLTEtMA_c10f8098-aa4e-4bc0-b3c9-bcbf1d808432"
      unitRef="shares">79878000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i093bc26ce2354e49aecd7233bb878cbd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMy0xLTEtMA_1b4313d5-35a4-424f-9510-a2a29dca6b80"
      unitRef="usd">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i24e8cce64cab4c6e9d91184e4d15997c_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtNS0xLTEtMA_10603458-f60b-4a36-8cbd-0a980829ad11"
      unitRef="usd">712713000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4a23c9af1b9940d09d585b851026690a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtNy0xLTEtMA_3b847605-1d9f-499f-91b4-daf13f898c24"
      unitRef="usd">-833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idaf6e1fd67294be9a4ce6f1605da8ebf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtOS0xLTEtMA_a305b062-36d2-474a-ae08-57bf012ba4f1"
      unitRef="usd">-407935000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjUyOTUzNGZkZGUxNjRlYmRhYTY4YTRhNWVjMzQ3NDgzL3RhYmxlcmFuZ2U6NTI5NTM0ZmRkZTE2NGViZGFhNjhhNGE1ZWMzNDc0ODNfMTEtMTEtMS0xLTA_a2fd9f3a-f7d6-412f-8f23-b58e752db676"
      unitRef="usd">303953000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0xLTEtMS0w_c7165eca-a1d7-4e45-bff0-9a6824603f1a"
      unitRef="shares">62965000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58b80fc0b5cd40838a962d7e7e4b0a40_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0zLTEtMS0w_da734e4d-3e9c-41db-a874-672b21a339e8"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05a0800f62f84a1f83badb8e82cff328_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi01LTEtMS0w_774defef-ede3-4a43-bb6b-2612f174c685"
      unitRef="usd">522503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ieecaee0157b64ef9ba48e56e97f43459_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi03LTEtMS0w_c8599c85-6048-4c0c-b011-b3456b945c8d"
      unitRef="usd">-799000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3969f7d77a94b91b93ebc11fb4d9a86_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi05LTEtMS0w_96b3a653-9c1c-4b23-8564-40671655a273"
      unitRef="usd">-320543000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMi0xMS0xLTEtMA_6c6d9fb7-ff62-446f-b7be-851effa5bc5a"
      unitRef="usd">201167000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMy01LTEtMS0w_6fd2717e-1ba6-4755-a291-3703a6bb8a30"
      unitRef="usd">1762000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMy0xMS0xLTEtMA_d99eb101-5ef1-4c69-80c8-8b8183d30a57"
      unitRef="usd">1762000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi0xLTEtMS0w_65b4034b-9fca-4e69-a8bd-eb3bc8481e00"
      unitRef="shares">119000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi01LTEtMS0w_7c2920f6-d174-4a28-b9b5-766d4b1ed5f5"
      unitRef="usd">162000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNi0xMS0xLTEtMA_cf7d4e87-ec87-455f-97fe-cbd4fd6f7f23"
      unitRef="usd">162000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfNy0xLTEtMS0w_f286b135-d1cd-433d-981f-41b79fbd26a4"
      unitRef="shares">397000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i9f28a777fd374eceb04e427ad51c1979_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOC0xLTEtMS0w_edca8979-55e3-4f50-b8e2-3e6ee607307d"
      unitRef="shares">145000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <advm:StockPaidValueForTaxWithholdingForShareBasedCompensation
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOC0xMS0xLTEtMA_bd2b10d2-b794-4dda-ae2d-4a8b077938b9"
      unitRef="usd">0</advm:StockPaidValueForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if3af85056b4748499467cf1ef1e1789e_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOS01LTEtMS0w_f762673c-816f-4dff-95d6-17e6e41e452b"
      unitRef="usd">504000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfOS0xMS0xLTEtMA_1c9aa557-c649-4112-b64c-75b5b0aedd0d"
      unitRef="usd">504000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTAtNy0xLTEtMA_b0e1e16b-8355-45ec-83fd-b5eaccd17750"
      unitRef="usd">42000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTAtMTEtMS0xLTA_b1912e92-7943-44b3-9719-267337e95587"
      unitRef="usd">42000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i7a78a1d5579c4bc7aa3e9ccc8c333325_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTEtNy0xLTEtMA_b4200914-6636-4d8f-a774-599b10f3ff3f"
      unitRef="usd">3000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTEtMTEtMS0xLTA_9ebd2ea7-c074-44a6-89f6-a67bb16de466"
      unitRef="usd">3000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie296a832075d46d2b88ab3bca1eecd12_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTItOS0xLTEtMA_865d45b9-9e52-4942-88d9-113555683ac2"
      unitRef="usd">-14489000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTItMTEtMS0xLTA_c4330857-bbc8-4f8d-a26d-7e693753178a"
      unitRef="usd">-14489000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="idefba8ae62c94026a09f3f5f81761591_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMS0xLTEtMA_b1ef46f1-601b-40ed-82e0-959251bab93d"
      unitRef="shares">63336000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idefba8ae62c94026a09f3f5f81761591_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMy0xLTEtMA_e4747633-a95f-4d2d-8260-eb933e06ad1c"
      unitRef="usd">6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib67d336e80f142c7ad1f135676f4b5f4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtNS0xLTEtMA_310a18ab-b210-44d1-ae96-1120455e06dd"
      unitRef="usd">523923000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0984d4527bd849dea64c0968d781c858_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtNy0xLTEtMA_25a7dac2-21eb-4fa0-866d-40d7bc2c1768"
      unitRef="usd">-754000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e2950d05d944066bb3c8f6b9541befb_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtOS0xLTEtMA_fd688192-1d4d-4645-a35e-4a56bd7e4f9a"
      unitRef="usd">-335032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ba61405a18e48f09259ca56e8354dab_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yNS9mcmFnOjBiZGZlYzZiZTNhMTRiMGNiY2NmZjQ5ZjZhYzM0N2YxL3RhYmxlOjlkZmFjYTA3NDIzODQxZGE4NGIzMGVjYWJkYTc1NTJiL3RhYmxlcmFuZ2U6OWRmYWNhMDc0MjM4NDFkYTg0YjMwZWNhYmRhNzU1MmJfMTMtMTEtMS0xLTA_86fd3ad7-5417-4e82-95cc-eab3a51e4658"
      unitRef="usd">188143000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMy0xLTEtMS0w_c4527d53-1399-4b60-b289-de17dd7e873d"
      unitRef="usd">-22906000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMy0zLTEtMS0w_1267f495-d69b-4027-aa60-5e3771cacc11"
      unitRef="usd">-14489000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNS0xLTEtMS0w_205670ca-a706-4628-8da2-8ed76c10d8ac"
      unitRef="usd">599000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNS0zLTEtMS0w_1fb7d53d-2404-4f33-b62b-2332f4c9667e"
      unitRef="usd">426000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNi0xLTEtMS0w_f1499d1a-b689-47f3-9a9e-6e861b1ee3ec"
      unitRef="usd">3409000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNi0zLTEtMS0w_c63c5a6d-3069-46b4-81b7-45c37f153db6"
      unitRef="usd">1762000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNy0xLTEtMS0w_02062a84-a563-4dc2-9d4e-49ac348c16cf"
      unitRef="usd">179000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfNy0zLTEtMS0w_6e9c3e88-c28f-4c26-9e26-f279d83a2fa2"
      unitRef="usd">129000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTAtMS0xLTEtMA_3070e035-b192-480d-bc10-999fcd0b7773"
      unitRef="usd">48000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTAtMy0xLTEtMA_0737d838-efd7-45d4-bd2c-170fc1fa51f5"
      unitRef="usd">-40000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMS0xLTEtMA_6767a071-abc7-4709-a004-964b3339b9e5"
      unitRef="usd">-6345000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMy0xLTEtMA_ff1ffbab-ca7f-456d-987d-96482c2ebc9a"
      unitRef="usd">91000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTEtMS0xLTEtMTQwMw_ce4ebe0a-0703-4359-9adb-6492e991d7d1"
      unitRef="usd">8000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTEtMy0xLTEtMTQwNQ_cc3a3b1b-83cf-4975-b22d-1f201d600e88"
      unitRef="usd">18000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMS0xLTEtMTM5OQ_6cd4cf9e-97ee-41d5-aa5f-9198363120f7"
      unitRef="usd">-557000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTItMy0xLTEtMTQwMA_4878794e-a2ca-460b-8560-040201f68e71"
      unitRef="usd">-539000</advm:IncreaseDecreaseOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTMtMS0xLTEtMA_0eb0617d-634c-44c0-83c1-519f06d11e04"
      unitRef="usd">2514000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTMtMy0xLTEtMA_33babb31-08e7-4b9f-ac9e-70d03489ac97"
      unitRef="usd">-136000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTQtMS0xLTEtMA_b903d5f6-8155-4f0e-837e-dbbc3aaac749"
      unitRef="usd">-3429000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTQtMy0xLTEtMA_45acda95-bfbb-4716-9def-5df2fd8cbdf2"
      unitRef="usd">-2363000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <advm:IncreaseDecreaseInLeaseLiabilities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTctMS0xLTEtMA_55818488-667e-451b-bffe-c06f43a61ccd"
      unitRef="usd">-470000</advm:IncreaseDecreaseInLeaseLiabilities>
    <advm:IncreaseDecreaseInLeaseLiabilities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTctMy0xLTEtMA_2022a6b3-1969-4ac7-afa9-773dc69b8eaf"
      unitRef="usd">1242000</advm:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTktMS0xLTEtMA_9770458a-29c1-47db-9cc0-15237854290a"
      unitRef="usd">-13616000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMTktMy0xLTEtMA_9c4790a2-a368-48af-b63f-a31f511c095f"
      unitRef="usd">-13217000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjEtMS0xLTEtMA_efc7ced1-e060-4ab2-abaf-dff0a8df12cc"
      unitRef="usd">127733000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjEtMy0xLTEtMA_00c8020f-2702-4b1c-b83c-08d64f393a3e"
      unitRef="usd">22454000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjItMS0xLTEtMA_76d86260-5ac1-412c-864b-ce2de3403a8e"
      unitRef="usd">61200000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjItMy0xLTEtMA_4968123e-91bc-4da7-9548-2404469f7887"
      unitRef="usd">27385000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjMtMS0xLTEtMA_84b20f66-3a6f-4498-aeec-e7341676ada8"
      unitRef="usd">4210000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjMtMy0xLTEtMA_58aa9010-e198-4e97-b1cc-44f79e41477c"
      unitRef="usd">2186000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjQtMS0xLTEtMA_036463c7-29b9-451b-96a0-23d4af3e92e2"
      unitRef="usd">-70743000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjQtMy0xLTEtMA_06f784e7-78c9-4aaf-a0c3-89cb12288c5b"
      unitRef="usd">2745000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjYtMS0xLTEtMA_8679620e-5c29-4105-96b8-a7896d491f83"
      unitRef="usd">140923000</advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts>
    <advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjYtMy0xLTEtMA_8ca645fb-9322-43d3-ad2f-3f96bf98a34b"
      unitRef="usd">0</advm:ProceedsFromOfferingsOfCommonStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjgtMS0xLTEtMA_841ab23c-eea6-4727-879d-1732fbaa0cae"
      unitRef="usd">9650000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjgtMy0xLTEtMA_594f15fa-c4c6-4a57-970f-ca4b7e91218a"
      unitRef="usd">162000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjktMS0xLTEtMA_a2ae7dd0-ed32-43ff-9deb-6565e1001fe8"
      unitRef="usd">1922000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMjktMy0xLTEtMA_0785cc55-2a3d-4a11-9b42-09629a63b8c5"
      unitRef="usd">504000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfDebt
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzItMS0xLTEtMA_abcf19a2-ba62-4d9d-ba9f-9c6033272195"
      unitRef="usd">27000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzItMy0xLTEtMA_d14efbd2-02e2-45c0-9419-247881fbb1b6"
      unitRef="usd">28000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzMtMS0xLTEtMA_f830435e-e213-4441-a3c3-72e2150d929d"
      unitRef="usd">148624000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzMtMy0xLTEtMA_c5bfb45e-b994-4260-b715-83bf72d98122"
      unitRef="usd">-370000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzQtMS0xLTEtMA_f722a0ff-7935-46e8-92a8-30b3d2660a0e"
      unitRef="usd">64265000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzQtMy0xLTEtMA_1481bb70-ef16-4710-8464-9fdfed1887e9"
      unitRef="usd">-10842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzUtMS0xLTEtMA_8b4755d6-71a5-4601-866f-8f1f9dfe36d2"
      unitRef="usd">66896000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie3c5a35c46a546968108e4b3bbb4d0dd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzUtMy0xLTEtMA_9d73d272-ff20-4104-9a85-bf0c57317057"
      unitRef="usd">155948000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzYtMS0xLTEtMA_7ba9243f-7d3e-46e2-871a-2ed114e57171"
      unitRef="usd">131161000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ba61405a18e48f09259ca56e8354dab_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzYtMy0xLTEtMA_33aa7adc-0565-4b42-ace3-027e4243a289"
      unitRef="usd">145106000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzgtMS0xLTEtMA_3c464626-7a6a-4eb7-9a9c-84a6be385868"
      unitRef="usd">3474000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8yOC9mcmFnOjA3MjE0N2QwNTdkYzRmODZhZmY0ZDQ3NjU3OTczOTczL3RhYmxlOmQ3ZTAwNjVkMzRlNzQxODk5NTlhNzUxZjZmYzgzNjE2L3RhYmxlcmFuZ2U6ZDdlMDA2NWQzNGU3NDE4OTk1OWE3NTFmNmZjODM2MTZfMzgtMy0xLTEtMA_a6a54522-9de2-4494-81d9-7ca9d5674306"
      unitRef="usd">413000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfMjcyMw_a1acbc94-b399-4108-b592-f38770252020">Organization and Basis of Presentation&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Adverum Biotechnologies, Inc. (the &#x201c;Company&#x201d; or "Adverum") is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. The Company&#x2019;s core capabilities include clinical development, novel vector discovery, and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) quality control. Since the Company&#x2019;s inception, it has devoted its efforts to performing research and development activities, filing patent applications, hiring personnel and raising capital to support these activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has not generated any revenue from the sale of products since its inception. The Company has experienced net losses since its inception and had an accumulated deficit of $407.9 million as of March&#160;31, 2020. The Company expects to incur losses and have negative net cash flows from operating activities as it engages in further research and development activities. The Company believes that it has sufficient funds to continue operations into 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2020, are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2019 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfOTgz_ef30d22d-cbc4-4343-aea1-d2389db994c9"
      unitRef="usd">-407900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNC9mcmFnOjhkYmY5YjU2MjQ1NTQ4ZjY4ZTFiZGYzMDljNjgwOTRlL3RleHRyZWdpb246OGRiZjliNTYyNDU1NDhmNjhlMWJkZjMwOWM2ODA5NGVfNDk0NzgwMjMyNzczNQ_ae0187a4-b0e8-43bc-9569-9b7f6b2979a9">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x2014;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#x2019;s consolidated financial information. The results of operations for the three months ended March&#160;31, 2020, are not necessarily indicative of the results to be expected for the full year or any other future period. The balance sheet as of December&#160;31, 2019 is derived from the audited consolidated financial statements at that date but does not include all of the information required by U.S. GAAP for complete consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The full extent to which the novel coronavirus disease ("COVID-19") pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition, including expenses and manufacturing, clinical trials and research and development costs, will depend on future developments that are highly uncertain at this time. &lt;/span&gt;&lt;/div&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 filed with the SEC</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfMzkxMA_f77bdbbc-d822-4f7c-9c72-9e0750b3b833">Summary of Significant Accounting Policies&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Topic 326&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the &lt;/span&gt;&lt;/div&gt;Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfMzkwNw_becc06c5-a719-4691-84d7-a960fb30ea8f">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the condensed consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF8zNy9mcmFnOjA4YzBkYWQ4NWJhNTRkMmRiMzI5ZTg5Zjk0NWYyNzVkL3RleHRyZWdpb246MDhjMGRhZDg1YmE1NGQyZGIzMjllODlmOTQ1ZjI3NWRfNDk0NzgwMjM0NDk2OA_cef5170f-7957-4909-9403-da601b8c5ded">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;In June 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-13, &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Financial Instruments &#x2013; Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (&#x201c;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Topic 326&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#x201d;) and also issued subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04, ASU 2019-05, and ASU 2019-11. The standard requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The measurement of expected credit losses is based on historical experience, current conditions, and reasonable and supportable forecasts that affect collectability. Topic 326 also eliminates the concept of &#x201c;other-than-temporary&#x201d; impairment when evaluating available-for-sale debt securities and instead focuses on determining whether any impairment is a result of a credit loss or other factors. An entity will recognize an allowance for credit losses on available-for-sale debt securities rather than an other-than-temporary impairment that reduces the cost basis of the investment. Topic 326 will become effective for the &lt;/span&gt;&lt;/div&gt;Company beginning after December 15, 2022 and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting Topic 326.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjg5Ng_9cfbff6b-5c09-4044-855b-9b0ffd70e579">Fair Value Measurements and Fair Value of Financial Instruments&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;:&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of March&#160;31, 2020, $20.3 million of marketable securities had remaining maturities between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM0Nw_17c69df5-37f9-4e40-b044-a43f7f4fa76d"&gt;one&lt;/span&gt; and two years. The remainder of the marketable securities have a remaining maturity of less than one year. As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company's consolidated balance sheet. Management regularly reviews all of the Company&#x2019;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#x2019;s marketable securities as of March&#160;31, 2020 were temporary in nature and none were in continuous loss position for 12 months or more. Therefore, none of the Company&#x2019;s marketable securities were other-than-temporarily impaired as of March&#160;31, 2020.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjg5Nw_164e64ad-854e-4f5f-b48f-b1fe490c4d00">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following is a summary of the Company&#x2019;s cash equivalents and short-term investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;86,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;171,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(124)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;286,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119,540)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(139)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;166,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Cost Basis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:center;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;"&gt;Level 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;37,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;87,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash equivalents and short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;151,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Less: cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(51,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC0xLTEtMS0w_f09fc678-6178-4def-b290-c6812c4c9d1d"
      unitRef="usd">18315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC0zLTEtMS0w_7b30689e-6f1f-4956-a785-fc09761bf4b9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC01LTEtMS0w_2021cc17-2eb5-4a14-b6de-cc53939764b5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ebb645f5e3746168957a7ff7640900b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNC03LTEtMS0w_8d03da1f-94bc-4923-ba0c-c732400504cd"
      unitRef="usd">18315000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi0xLTEtMS0w_2e003877-c86a-4757-87b5-d8f82ad3d9a5"
      unitRef="usd">86930000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi0zLTEtMS0w_d5236f75-1b81-4cb6-b6ef-c6ffe845c4d3"
      unitRef="usd">78000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi01LTEtMS0w_e5123da4-3cc2-43f6-bb9e-ae13825325c9"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8c4aab79a764b9999f6f5666e9dc77a_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNi03LTEtMS0w_29cf7043-029a-4f74-8824-1b0109e07221"
      unitRef="usd">87005000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy0xLTEtMS0w_af186158-8e44-4963-b77c-84c7c8c4c35e"
      unitRef="usd">171736000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy0zLTEtMS0w_4f7cb80e-b003-45d4-96c0-3bbf13fa531c"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy01LTEtMS0w_3195a25f-205d-475e-abf3-650acd5a67dc"
      unitRef="usd">121000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff64a4df71714cc2b301cd15fa17cac9_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfNy03LTEtMS0w_77a3cd7d-1a08-4d6f-afba-34a7e2b5f896"
      unitRef="usd">171624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC0xLTEtMS0w_5d71f400-0004-44fb-8cc4-1fc350d254ae"
      unitRef="usd">9499000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC0zLTEtMS0w_88d3451f-aafc-4b69-a99a-ac4029f7dad8"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC01LTEtMS0w_b2cbe766-bd9c-442f-998f-6be4ce3b62da"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15463bcc9ee04802abd38ead29ea3887_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOC03LTEtMS0w_5001f785-4de8-4cfe-b888-4e2293938274"
      unitRef="usd">9500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i833ac88809664274ab22787623b8d238_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS0xLTEtMS0w_beb3177f-b600-4b92-a147-fde4feaba435"
      unitRef="usd">286480000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i833ac88809664274ab22787623b8d238_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS0zLTEtMS0w_b1912df5-3ece-4ae1-864d-05b22a473502"
      unitRef="usd">88000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i833ac88809664274ab22787623b8d238_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS01LTEtMS0w_dd21be42-f622-46a9-b9db-65813f2bf6a5"
      unitRef="usd">124000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i833ac88809664274ab22787623b8d238_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfOS03LTEtMS0w_bf777db7-c4a2-4c6d-addf-6a24483e110a"
      unitRef="usd">286444000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtMS0xLTEtMA_285ccdb3-d66b-435a-a86f-99f4978e9b80"
      unitRef="usd">119540000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtMy0xLTEtMA_76a71796-4639-44a2-8510-0eea4ba9b837"
      unitRef="usd">15000</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtNS0xLTEtMA_08d4575c-8ad9-47e0-94eb-3d3a684a9c58"
      unitRef="usd">15000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTAtNy0xLTEtMA_371928f3-8157-416c-9be7-4440625df636"
      unitRef="usd">119540000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtMS0xLTEtMA_91211fbc-ad90-400f-9211-cec830bf9146"
      unitRef="usd">166940000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtMy0xLTEtMA_dd2df514-00d8-4bb1-84df-9d77df269b29"
      unitRef="usd">103000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtNS0xLTEtMA_c2696613-2838-4315-bf8d-2e76a8038744"
      unitRef="usd">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjE0NzA2NjU5M2Q2YTQ2Y2JiNTEzYzkwODk1NjUzNzE3L3RhYmxlcmFuZ2U6MTQ3MDY2NTkzZDZhNDZjYmI1MTNjOTA4OTU2NTM3MTdfMTEtNy0xLTEtMA_54e0db15-cd2e-4c6c-8ca0-dde23de1e8bd"
      unitRef="usd">166904000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC0xLTEtMS0w_1ff40325-6327-4422-98c3-f5ff37e1f38c"
      unitRef="usd">15056000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC0zLTEtMS0w_3ce6b443-15da-4b73-b6b7-804d0c78098c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC01LTEtMS0w_c4044d3d-db39-476b-9576-04232d14f8ef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc58f9eb2c7d40b1a75fa15f93ebcf7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNC03LTEtMS0w_165ae7e2-314d-4ff7-a282-efefc96370ed"
      unitRef="usd">15056000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi0xLTEtMS0w_399fe3c1-a552-455b-b5a7-1988207b9398"
      unitRef="usd">37974000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi0zLTEtMS0w_646e93db-72b1-4b63-94e2-c176b3faf4d7"
      unitRef="usd">14000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi01LTEtMS0w_8ee2ee23-a9f1-4e47-a3f4-4b470e7768c7"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93fd01d998494aca846c6d58c36d0dcc_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNi03LTEtMS0w_a2eb3515-b759-4e29-acfe-5b59256fd2b5"
      unitRef="usd">37986000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy0xLTEtMS0w_60b71511-1555-49c7-b4f9-5c2ad2b156a0"
      unitRef="usd">87983000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy0zLTEtMS0w_2c27f30d-9b7d-48be-a1ae-6e3606fb380e"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy01LTEtMS0w_0b2682cc-ef18-49ff-9888-bd9c76336036"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibd0f5dba738e477b9c5e5b880fa38bc1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfNy03LTEtMS0w_5c819f10-24ef-42b3-b9d6-c87f3de170dd"
      unitRef="usd">87983000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC0xLTEtMS0w_75a48627-1a6b-40fc-8fcb-af0575869f6f"
      unitRef="usd">10495000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC0zLTEtMS0w_37e24632-ceab-4187-8774-5ee70ea8e639"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC01LTEtMS0w_776886e6-4e17-4fbb-a355-d5d60e5d6a21"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8240d35edaef41478472c5ad37bc778a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfOC03LTEtMS0w_025d2730-96bb-4dd1-8c82-713703906f33"
      unitRef="usd">10501000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtMS0xLTEtMA_0ddd43b2-02f1-43e1-92f1-6e063c3a004b"
      unitRef="usd">151508000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtMy0xLTEtMA_eed03e2a-bb54-4f81-a961-8932fed8891e"
      unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtNS0xLTEtMA_dc2d624d-3d46-486a-a9e0-e18c698fb339"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1619c84a59d34651a88f57a0d3cd5cb8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTAtNy0xLTEtMA_cac910ca-f50d-49ef-b292-7d2d37c417d5"
      unitRef="usd">151526000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:CashAndCashEquivalentAmortizedCost
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtMS0xLTEtMA_6e0fab44-fd74-496f-a323-a10a3938534a"
      unitRef="usd">51391000</advm:CashAndCashEquivalentAmortizedCost>
    <advm:CashAndCashEquivalentGrossUnrealizedGain
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtMy0xLTEtMA_6b689b01-3f12-4432-b1eb-06810f4c0d91"
      unitRef="usd">0</advm:CashAndCashEquivalentGrossUnrealizedGain>
    <advm:CashAndCashEquivalentGrossUnrealizedLoss
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtNS0xLTEtMA_cf642fc0-b44e-4727-a1d7-3f78d32fdb19"
      unitRef="usd">3000</advm:CashAndCashEquivalentGrossUnrealizedLoss>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTEtNy0xLTEtMA_b46d0981-1934-44bb-b169-34d3983be0bf"
      unitRef="usd">51388000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItMS0xLTEtMA_2056e580-13b2-425d-935f-6f7866964127"
      unitRef="usd">100117000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItMy0xLTEtMA_1b4ff0ca-715e-4dd7-ad2a-ff3ea8006902"
      unitRef="usd">28000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItNS0xLTEtMA_d0b5d309-2334-4b44-903d-1e3433bf8a7f"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RhYmxlOjkzODM2ZGYxYmRmMDQ0MGZiNTgyYmJhN2ViOGQwZGQ1L3RhYmxlcmFuZ2U6OTM4MzZkZjFiZGYwNDQwZmI1ODJiYmE3ZWI4ZDBkZDVfMTItNy0xLTEtMA_a9af808f-39a7-4af2-8ea6-9204d61e71cc"
      unitRef="usd">100138000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMTA5OTUxMTYzNDEwNg_a911e08c-a326-490c-95e1-fd0c4aacdc18"
      unitRef="usd">20300000</advm:DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="i342bf0ef26dc49da8828fe5944816454_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM2NQ_3da6e154-fc64-4bfe-b542-be482645242d">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfMjgwOQ_05fb28de-71ac-4586-b9d8-7450c2710a54"
      unitRef="usd">0</advm:OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ3_d59ff891-04b6-4e48-a721-3916a7ac8e3b">Balance Sheet Components&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Depreciation and amortization expense related to property and equipment for the three months ended March&#160;31, 2020 and 2019 was $0.6 million, and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Accrued Expenses and Other Current Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued preclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ4_af76df42-7b75-4172-892d-df7c15a106d9">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;32,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(8,591)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(7,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iedc52aa3b04946a0a0eef67548681e3e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMi0xLTEtMS0w_fa9ed5c6-dcee-4bf8-b6c6-09f4349c0df8"
      unitRef="usd">825000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i707559898d544e9bb307731a2ae13d5f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMi0zLTEtMS0w_b12efee4-52e8-4191-8e8c-32534dc747f4"
      unitRef="usd">752000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i70e71d13a2174d099753799db973fd83_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMy0xLTEtMS0w_d954dd4f-a0a0-4e3e-a543-5000e8e4c9f6"
      unitRef="usd">7319000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i621486e661ba4c8b85b23a96dfe63109_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfMy0zLTEtMS0w_51f0e725-830f-4c2e-9f6a-36a940143d37"
      unitRef="usd">6291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8729f4de91b34c2d919e7cf785fff591_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNC0xLTEtMS0w_0c0f090c-ec67-46ea-a37c-45e4d11d97b3"
      unitRef="usd">678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i01f564a1a87d437f9d0b3f17d3bac012_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNC0zLTEtMS0w_333b0ede-5edd-46f2-9038-f81463ffa957"
      unitRef="usd">678000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i83fefcb42e1542bd867592dab7eee895_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNS0xLTEtMS0w_95c0f840-7b88-4a3a-bd91-d43548c7c18c"
      unitRef="usd">26263000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idce7caa83b044c50a6c225417896fd78_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNS0zLTEtMS0w_3be71d27-ec7c-4976-87ca-2584cc7c79ef"
      unitRef="usd">1602000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie6384f75152d49f38ebf15724aca6383_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNi0xLTEtMS0w_6e83148e-738f-4a7f-912d-ed802c84f39d"
      unitRef="usd">233000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifa66768ec34c4f83b89a84a802763883_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNi0zLTEtMS0w_3f610091-30cd-4871-994e-b28358f07e63"
      unitRef="usd">23553000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNy0xLTEtMS0w_b02ba02b-7135-47c9-a45c-723670356dfd"
      unitRef="usd">35318000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfNy0zLTEtMS0w_b6e5a01c-a85e-4ae7-99ae-1c809a7ccc71"
      unitRef="usd">32876000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOC0xLTEtMS0w_d2627421-1160-48b0-a504-0c8412096ea4"
      unitRef="usd">8591000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOC0zLTEtMS0w_eaca9fe9-aca9-4498-962d-e2e68f3a255d"
      unitRef="usd">7992000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOS0xLTEtMS0w_a8fc28bb-0bd0-4f6e-993f-055049800458"
      unitRef="usd">26727000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjYyYTY0MGNkMTY0NzQzMjA4Y2FkZmIzMzdjMjUxOTA5L3RhYmxlcmFuZ2U6NjJhNjQwY2QxNjQ3NDMyMDhjYWRmYjMzN2MyNTE5MDlfOS0zLTEtMS0w_124874ff-0c14-4d96-bc16-c64030b1cc9e"
      unitRef="usd">24884000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfMjMx_3a01fc7d-d79c-432f-9d98-5d2243d1d7e8"
      unitRef="usd">600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfMjM5_05985cce-9d40-4a49-8cf8-3d5d510f256b"
      unitRef="usd">400000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RleHRyZWdpb246MmZjZjgxYTYwMGQxNGNkNTk5YmNjN2UyYjI2MzJjMGZfNDQ2_c6aa7617-a851-47fb-922f-01ef5ce634e4">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.941%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Employee compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued preclinical, clinical and process development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Accrued professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfMy0xLTEtMS0w_3b37a692-7346-4a0c-ab00-2b702c8a3ac5"
      unitRef="usd">2299000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfMy0zLTEtMS0w_acfa4429-f28e-46bd-8f4b-0e0cdd2e3cc1"
      unitRef="usd">4055000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNC0xLTEtMS0w_e6e7aa34-5c42-4b18-9f14-888f7dff2fa0"
      unitRef="usd">1823000</advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts>
    <advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNC0zLTEtMS0w_dd626568-9dd5-4a2c-8e8b-0f2e9490fb0f"
      unitRef="usd">1973000</advm:AccruedPreclinicalClinicalAndDevelopmentProcessCosts>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0xLTEtMS0xODY1_969db906-6504-4873-8672-61b11ea6a853"
      unitRef="usd">1466000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0zLTEtMS0xODY1_8482ecc2-99fa-4251-9cbc-c381c786c822"
      unitRef="usd">2607000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0xLTEtMS0w_bffb8a4d-8254-4024-b372-df62cceb54c6"
      unitRef="usd">2491000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNS0zLTEtMS0w_242349e7-28de-4dae-812f-4401e8bc3f6c"
      unitRef="usd">2636000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNi0xLTEtMS0w_6e2ec41d-4131-420f-85fd-b22d0751d003"
      unitRef="usd">8079000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <advm:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82MS9mcmFnOjJmY2Y4MWE2MDBkMTRjZDU5OWJjYzdlMmIyNjMyYzBmL3RhYmxlOjg3OWQwNzE1NjNiODQ5MTI5NTI0ODZjMDI0MGIxZGM3L3RhYmxlcmFuZ2U6ODc5ZDA3MTU2M2I4NDkxMjk1MjQ4NmMwMjQwYjFkYzdfNi0zLTEtMS0w_c755bcaa-8f73-4ddf-8feb-b6ff0c412aa4"
      unitRef="usd">11271000</advm:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTAy_aee14956-4547-4913-a72d-bc7ff8142cf9">Equity Incentive Awards&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTAz_42c4b4dd-4440-4d96-83ec-7f987f2606f2">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s option activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of&lt;br/&gt;Options&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(207)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMS0xLTEtMS0w_60d266bd-c932-4314-9ca2-52f5cec8e92a"
      unitRef="shares">8995000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i74e35996fd934b90add7c64de848251a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMS0zLTEtMS0w_d9f03879-4165-4261-b8f4-9d24669d027d"
      unitRef="usdPerShare">7.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMi0xLTEtMS0w_62c94bd5-9df3-49d8-920c-6b489114128b"
      unitRef="shares">1594000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMi0zLTEtMS0w_119a5352-80d9-4b0f-973b-b5de6ca202d2"
      unitRef="usdPerShare">15.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMy0xLTEtMS0w_7081984d-b162-4bb4-90b5-0e5ab8cf9fc6"
      unitRef="shares">1310000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfMy0zLTEtMS0w_8c23160b-863a-4fc5-8532-0fb8d2ba6b34"
      unitRef="usdPerShare">7.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNC0xLTEtMS0w_fac45a6f-9cad-4807-b4e9-0f4e217d8bce"
      unitRef="shares">207000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNC0zLTEtMS0w_0070c1a5-a52c-4272-b465-90f0dbdd74c7"
      unitRef="usdPerShare">14.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNS0xLTEtMS0w_834ee66b-3862-4446-aa79-3678d26017a6"
      unitRef="shares">9072000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNS0zLTEtMS0w_1b24d7fd-4de0-4b84-a8bf-ea227cb88875"
      unitRef="usdPerShare">8.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNi0xLTEtMS0w_d9fc6faf-f50b-485c-ad77-b4048739c3d3"
      unitRef="shares">2785000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib7f03b30ae4e49ffbf09b800ef895809_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmU2MTE0YThiODFlMzQxMDQ5NzQ5ZmZkMDE3ZDJhNTI0L3RhYmxlcmFuZ2U6ZTYxMTRhOGI4MWUzNDEwNDk3NDlmZmQwMTdkMmE1MjRfNi0zLTEtMS0w_171cf4ca-5aee-486e-95a9-802acadab484"
      unitRef="usdPerShare">6.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTA0_081ec0ac-3874-41c8-9d9f-bd81607fb06b">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company&#x2019;s RSUs activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number of Units&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted-&lt;br/&gt;Average Grant-&lt;br/&gt;Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;15.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(462)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i11acc5e392074f6aa619a7caf4b0e38b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMS0xLTEtMS0w_1e4ae5bd-63a4-4c25-bdaa-38e1d96b44bf"
      unitRef="shares">1121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i11acc5e392074f6aa619a7caf4b0e38b_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMS0zLTEtMS0w_70fbcc7e-6ce3-48cc-8f9b-1a22e8fe9ab7"
      unitRef="usdPerShare">4.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMi0xLTEtMS0w_155d3177-1046-4988-856d-c672ff6fc243"
      unitRef="shares">104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMi0zLTEtMS0w_f3e3d744-cbfb-4e6f-928c-fdbc935c4158"
      unitRef="usdPerShare">15.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMy0xLTEtMS0w_781dd3ec-c76f-4a11-9a27-1b1921ac46df"
      unitRef="shares">462000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfMy0zLTEtMS0w_e4d36020-4b9d-4943-82c1-5c174f71ddd9"
      unitRef="usdPerShare">4.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNC0xLTEtMS0w_a41362f9-ad9f-45b6-b5fb-44a3f0d7bbef"
      unitRef="shares">28000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i75fdb672ad734ea9b42e410086fa4149_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNC0zLTEtMS0w_e75d3da8-003b-4fc5-8620-326b46531e13"
      unitRef="usdPerShare">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNS0xLTEtMS0w_2b313ea8-d33c-4ab7-9e7d-dae2133a3db3"
      unitRef="shares">735000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i747bceb18b5d4106adeb8f39000b9982_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmVkYWMwYjQzMGEzNDQ2NWRiYzc0OTJlZjIwYjM2NWRkL3RhYmxlcmFuZ2U6ZWRhYzBiNDMwYTM0NDY1ZGJjNzQ5MmVmMjBiMzY1ZGRfNS0zLTEtMS0w_0e8b8117-9721-4b84-b5f8-6de58c71e362"
      unitRef="usdPerShare">5.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RleHRyZWdpb246MTUxMWE0NTE4NzRlNDYzN2JkMzljY2ViYWNiYWNhMmRfOTA1_bc2b50b6-ddd3-450b-bc5b-eac9fd690e9a">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table presents, by operating expense, the Company&#x2019;s stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0dff8015a05449eda49c8fb0645749d9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfMy0xLTEtMS0w_2999b6d7-7da6-4b64-ba83-3e58721935d9"
      unitRef="usd">1248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife518f866ce14a03be135a52d4f9429c_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfMy0zLTEtMS0w_4a5ab0b3-2947-4a91-9c92-4126d7126bb0"
      unitRef="usd">631000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e6e4fe498c24ec5abb76f172e87c141_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNC0xLTEtMS0w_4e68154b-7014-499e-8545-a135b4aab90f"
      unitRef="usd">2161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i64910ab1df99412c876858849bf70e6f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNC0zLTEtMS0w_c5467e6c-264c-4894-b46e-a25df94af9b0"
      unitRef="usd">1131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNS0xLTEtMS0w_2aa3f82e-a1fb-4d89-9d07-7edf1271cb1c"
      unitRef="usd">3409000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF82Ny9mcmFnOjE1MTFhNDUxODc0ZTQ2MzdiZDM5Y2NlYmFjYmFjYTJkL3RhYmxlOmUxOTM5YzcxMWE0NzQ2ODU5ZjkyZTUyNTA4YmY5ZDhhL3RhYmxlcmFuZ2U6ZTE5MzljNzExYTQ3NDY4NTlmOTJlNTI1MDhiZjlkOGFfNS0zLTEtMS0w_da35dcab-f994-4204-90ff-81100c32d8ed"
      unitRef="usd">1762000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RleHRyZWdpb246NjVlNTEzZDI0ZWI1NGQxNjgxNDkxMzkxMjM3ZDI5ODZfNDk0NzgwMjMyNjU2MQ_46a9e667-b110-4f4c-be52-7df523ad8172">Net Loss per Share&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding for the period using the treasury stock method. Outstanding stock options, RSUs, rights under the employee stock purchase plan (&#x201c;ESPP&#x201d;) and warrants are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RleHRyZWdpb246NjVlNTEzZDI0ZWI1NGQxNjgxNDkxMzkxMjM3ZDI5ODZfNDk0NzgwMjMyNjU2Mg_ae8e3406-bb56-4c27-9ae7-f3c20a1004a3">&lt;div style="margin-top:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following common stock equivalents outstanding at the end of the periods presented were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.029%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.619%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.622%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,072&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,932&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"&gt;&lt;span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib286c4189e9142e595e64dd9e87b795b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNC0xLTEtMS0yOTQ2_a5338ec0-9e64-4ccb-9121-89b34859758d"
      unitRef="shares">9072000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id78c5e96cfeb4a7ba9d2f8f09386b78f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNC0zLTEtMS0yOTQ2_29a53143-4aca-4660-9846-165a8d98d7b3"
      unitRef="shares">7969000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i84b60a8a9cd44f408b4a87c18eb152cd_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNS0xLTEtMS0yOTQ2_2b313ea8-d33c-4ab7-9e7d-dae2133a3db3"
      unitRef="shares">735000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i067845b9bbc441dca466c83c3266762f_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNS0zLTEtMS0yOTQ2_e07bc6e2-8f2d-4f69-a9c1-21b9708894f8"
      unitRef="shares">1729000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2550dd60ce2c49f19a995e351a4d4e99_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNi0xLTEtMS0yOTQ2_1d0d0cf5-8b19-48a2-a5b5-c5e7e57056a6"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ebb3283ddf14932b74fbf553fe5f243_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNi0zLTEtMS0yOTQ2_6d0a7414-e435-4670-b3af-24e7643ed8f3"
      unitRef="shares">132000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2be7ba555c8443369db8b32a5b5a90b0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNy0xLTEtMS0yOTQ2_096f6af3-b799-4b4f-8d9a-119d2877dbc8"
      unitRef="shares">80000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i73b815ac0dad4ea7937de1d62295b3f1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfNy0zLTEtMS0yOTQ2_5244162f-2746-4e20-8ba8-1cd8c62d7010"
      unitRef="shares">90000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfOC0xLTEtMS0yOTQ2_f880c4ed-b89f-4c11-83e6-3b499fcedd75"
      unitRef="shares">9932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i232fb1da6851489a9993afcedd46b9cb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83MC9mcmFnOjY1ZTUxM2QyNGViNTRkMTY4MTQ5MTM5MTIzN2QyOTg2L3RhYmxlOjlhOWUxYzNlNWFkMjQ2MTlhZGZhMWNlMzMxYWJjNjhhL3RhYmxlcmFuZ2U6OWE5ZTFjM2U1YWQyNDYxOWFkZmExY2UzMzFhYmM2OGFfOC0zLTEtMS0yOTQ2_1a88761d-2d11-4608-b203-9f7420b75326"
      unitRef="shares">9920000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ia1c289aae9114e718b061d97eb326203_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfNDEy_a4ee57ec-ad2e-403e-abec-24086486545b">Related Party TransactionsIn February 2020, the Company entered into a common stock purchase agreement with James Scopa, a member of the Board, and Anne Kenner, as Trustees for the James P. Scopa and Anne E. Kenner Family Trust (the &#x201c;Trust&#x201d;), pursuant to which the Trust purchased an aggregate of 10,000 shares of the Company&#x2019;s common stock at a price of $13.75 per share, for an aggregate cash purchase price of $0.1 million.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfMzAy_e5c368af-4eac-47df-8416-d4276ff626d1"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ib89a5f94a6544269b3729160754cd23d_I20200229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfMzU2_5c50eb0d-f3a0-4ecf-8dc2-ddd01ca212be"
      unitRef="usdPerShare">13.75</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if3cc70262de5431e9151b30abf240ea9_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF83My9mcmFnOjkyM2FhMTZmZjhjNDQ2YzQ4YTE2MDE3NGJmODQ0NWZiL3RleHRyZWdpb246OTIzYWExNmZmOGM0NDZjNDhhMTYwMTc0YmY4NDQ1ZmJfNDEw_298b7d32-2a94-488d-a1b9-02835ee4b161"
      unitRef="usd">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781835360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price</a></td>
<td class="nump">$ 13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash purchase price</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advm_TrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=advm_TrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615820640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value Measurements and Fair Value of Financial Instruments<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The authoritative guidance on the fair value hierarchy for disclosure of fair value measurements is as follows:</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-indent:-36pt;padding-left:63pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">:&#160;Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. U.S. government and agency securities, commercial paper, corporate bond and certificates of deposit are valued primarily using market prices of comparable securities, bid/ask quotes, interest rate yields and prepayment spreads and are included in Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy.</span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following is a summary of the Company&#8217;s cash equivalents and short-term investments:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,315&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">86,930&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,005&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171,736&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(121)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">171,624&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,499&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,500&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,480&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">88&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">286,444&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,540)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(15)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119,540)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,940&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">103&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(139)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">166,904&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Amortized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Cost Basis</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unrealized</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Gains</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized<br/>Losses</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Estimated</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(In thousands)</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 1:</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds</span></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,056&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration: underline;">Level 2:</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">U.S. government and agency securities</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,974&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37,986&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Commercial paper</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">87,983&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Corporate bonds</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,495&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,501&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash equivalents and short-term investments</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,508&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">151,526&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Less: cash equivalents</span></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,391)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(51,388)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total short-term investments</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,117&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100,138&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>As of March&#160;31, 2020, $20.3 million of marketable securities had remaining maturities between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZjYzg0ZTQ2NmUyNDQxZGNiMDdiNDliNGM5ODAzYTZkL3NlYzo2Y2M4NGU0NjZlMjQ0MWRjYjA3YjQ5YjRjOTgwM2E2ZF80My9mcmFnOjBjN2UxYTc2NDU5YzRmMzk5N2FiNTExMTRlNTA1NmZiL3RleHRyZWdpb246MGM3ZTFhNzY0NTljNGYzOTk3YWI1MTExNGU1MDU2ZmJfNDk0NzgwMjMzMTM0Nw_17c69df5-37f9-4e40-b044-a43f7f4fa76d">one</span> and two years. The remainder of the marketable securities have a remaining maturity of less than one year. As the Company may sell these securities at any time for use in current operations even if the securities have not yet reached maturity, all marketable securities are classified as current assets in the Company's consolidated balance sheet. Management regularly reviews all of the Company&#8217;s investments for other-than-temporary declines in estimated fair value. Management determined that the gross unrealized losses on the Company&#8217;s marketable securities as of March&#160;31, 2020 were temporary in nature and none were in continuous loss position for 12 months or more. Therefore, none of the Company&#8217;s marketable securities were other-than-temporarily impaired as of March&#160;31, 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649940832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Fair Value of Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears', window );">Marketable securities</a></td>
<td class="nump">$ 20,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities', window );">Other than temporary impaired investments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Marketable securities term</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Maturity, Allocated and Single Maturity Date, After One Through Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_DebtSecuritiesAvailableForSaleMaturityAllocatedAndSingleMaturityDateAfterOneThroughTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporary impaired investments available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">advm_OtherThanTemporaryImpairedInvestmentsAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>advm_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6781662752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 22, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adverum Biotechnologies, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-5258327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 Saginaw Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">656-9323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADVM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,295,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6772219968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782253792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards - Summary of Stock Options Activity (Detail)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Options Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">8,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(1,310)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares) | shares</a></td>
<td class="num">(207)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">9,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares) | shares</a></td>
<td class="nump">2,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in USD per share) | $ / shares</a></td>
<td class="nump">$ 7.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in USD per share) | $ / shares</a></td>
<td class="nump">15.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in USD per share) | $ / shares</a></td>
<td class="nump">7.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in USD per share) | $ / shares</a></td>
<td class="nump">14.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in USD per share) | $ / shares</a></td>
<td class="nump">8.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in USD per share) | $ / shares</a></td>
<td class="nump">$ 6.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615801344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsIn February 2020, the Company entered into a common stock purchase agreement with James Scopa, a member of the Board, and Anne Kenner, as Trustees for the James P. Scopa and Anne E. Kenner Family Trust (the &#8220;Trust&#8221;), pursuant to which the Trust purchased an aggregate of 10,000 shares of the Company&#8217;s common stock at a price of $13.75 per share, for an aggregate cash purchase price of $0.1 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6766991328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Options Activity</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s option activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of<br/>Options<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.19&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,594&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,310)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.37&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(207)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14.05&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,072&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.41&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,785&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.89&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company&#8217;s RSUs activity and related information:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number of Units<br/>(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-<br/>Average Grant-<br/>Date Fair Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and released</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(462)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.75&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(28)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.39&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table presents, by operating expense, the Company&#8217;s stock-based compensation expense:</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.029%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:12.619%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.622%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(In thousands)</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">631&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,161&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation expense</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,409&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,762&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
